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ABSTRACT

DEVELOPMENTAL REGULATION OF THE MURINE CD4 GENE

by
Rhonda Kay Hansen

CD4 is a membrane bound glycoprotein that plays an important role in T cell
development and activation. An extensive analysis of the CD4 locus identified potential
transcriptional control elements located 5' of the promoter and within the first intron. Since
the molecular mechanism for the control of CD4 expression during T cell development had
not been determined, it is the focus of this dissertation. A series of recombinant DNA
constructs were made to determine the contribution of putative transcriptional control
elements in regard to CD4 expression, and to identify elements being used to control CD4
expression during T cell development. One of these control elements, located within the
first intron, was further characterized to determine the DNA sequence involved. In
addition, the 15 kb 5' of the promoter and the 9 kb first intron were sequenced and
analyzed for homology to previously identified control elements. Our results indicate that
there are multiple c/s-acting elements which control the expression of the murine CD4
gene. Elements that have a positive effect on the expression of the CD4 gene are located:
(1) about 13.5 kb 5' of the first exon; and (2) within the first intron. Elements that have a
negative effect on the expression of the CD4 gene are located: (1) near the 5' enhancer;
(2) between the promoter and 5' enhancer; (3) within the first intron about 2.5 kb 3' of the

promoter; and (4) within the first intron about 4 kb 3' of the promoter. In addition, the
enhancer located 13.5 kb 5' of the promoter stimulates transcription from the CD4
promoter when the enhancer is left in it’s native context as long as some of the intervening
DNA sequence is deleted. The negative element located within the first intron about 4 kb
3' of the promoter corresponds to a GATA repeat. Sequence analysis of the DNA regions
containing these positive and negative elements indicates regions of DNA that could be
responsible for the functional activity associated with particular regions.
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CHAPTER 1. INTRODUCTION

A.

CD4 GENE STRUCTURE AND FUNCTION
1.

Gene Function

The cluster determinant (CD) molecules CD4 and CDS are essential for normal
T cell functions and play an important role in T cell development and activation
(Parnes, 1989; Janeway, 1991; Julius et al., 1993). In mature T cells, CD4 is expressed on
cells that have a T cell receptor (TCR) specific for antigen associated with class II major
histocompatibility complex (MHC) molecules, while CDS is expressed on T cells that
recognize antigen bound to class I MHC molecules (Swain, 1983). Furthermore, CD4 is
usually expressed on the helper subset of mature T cells while CDS expression is found
primarily on cytotoxic T cells, although in less frequent cases, the opposite expression
pattern has been described (Krensky et al., 1982; Swain, 1981). CD4 and CDS are called
coreceptor molecules, because they play an active role in the activation, differentiation, and
effector functions of T cells (Janeway, 1991; Julius et al., 1993). They have two key
elements that endow them with the properties required of a coreceptor. First, their
extracellular domains bind to membrane-proximal regions of MHC molecules on
antigen-presenting cells (Cammarota et al., 1992; Konig et al., 1992). These interactions
permit simultaneous binding of both TCR and CD4 or CDS to the same MHC molecule, a
requirement for coreceptor function in development and in T cell activation (Wallace et al.,
1993). Second, both CD4 and CDS bind to the cytoplasmic protein tyrosine kinase Lck
through a cysteine-containing motif shared by their cytoplasmic domains (Veillette et al.,
1991). This interaction is essential for effective signal transduction at low antigen
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concentration in coreceptor-dependent systems (Glaichenhaus et al., 1991; Zamoyska et al.,
1989).
CD4 and CDS have symmetrical functions. They both act as coreceptors, although
CD4 augments MHC class II recognition and T cell activation and CDS augments MHC
class I recognition and T cell activation. They are both associated with the cytoskeleton in
resting peripheral T cells, and activation of T cells increases the proportion of CD4 and
CDS associated with the cytoskeleton (Geppert and Lipsky, 1991). Evidence further
indicates a large degree of overlap in the mechanism by which they act to amplify
TCR-mediated signals (Ledbetter et al., 1990). However, if signaling through either CD4
or CDS coreceptor contributes to the development of a thymocyte into either a mature
MHC class II restricted helper T cell or MHC class I restricted cytotoxic T cell, it is
imperative that there be differences in the signals generated by these molecules. Indeed,
despite their many similarities, differences have been found (Julius et al., 1993). However,
for the purpose of this dissertation, discussions will be confined to CD4.
Mutagenesis studies indicate that the extracellular domain of CD4 interacts with the
P2 domain of MHC class II molecules (Cammarota et al., 1992; Konig et al., 1992). In
particular, the complementarity determining region (CDR)l-like and CDR3-like loops of
CD4 are important for the interaction of the CD4 molecule with the MHC class II
molecules (Clayton et al., 1989; Fleury et al., 1991a). The crystal structure of the
extracellular portion of CD4 indicates that this interaction occurs along a surface involving
only one side of the CDRl-like and CDR3-like loops, and that each CD4 molecule can
bind only one MHC class II molecule (Ryu et al., 1990; Wang et al., 1990). This
interaction serves to increase the avidity between the class II restricted T cell and the antigen
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presenting cell (APC) (Doyle and Strominger, 1987) and suggests that CD4 serves as an
adhesion molecule important for T cell activation. However, the relative adhesive effect of
CD4 is minor compared to other adhesion molecules, such as CD2 and lymphocyte
function antigen-1 (LFA-1) (Gay et al., 1987; Ratnofsky et al., 1987). Thus, the strength
of the interaction might not be as important as positioning the CD4 molecule next to the
TCR complex (Janeway et al., 1991).
Several experiments have pointed directly to a close physical association between
CD4 and the TCR (Gallagher et al., 1989; Beyers et al., 1992; Saizawa et al., 1987; Kupfer
et al., 1987; Rojo et al., 1989; Takada and Engleman, 1987; Weyand et al., 1987; Anderson
et al., 1988; Mittler et al., 1989; Collins et al., 1992). Evidence for the physiological
relevance of the CD4/TCR interaction was provided by the demonstration that
non-polymorphic regions of MHC class II molecules are natural ligands for CD4 (Doyle
and Strominger, 1987; Gay et al., 1987). Association between CD4 and the TCR is barely
detectable before T cell activation, however, TCR triggering induces a greater degree of
association. Furthermore, when compared to aggregation of TCR/CD3 alone,
antibody-mediated coaggregation of TCR/CD3 with CD4 results in more robust T cell
activation (Emmrich et al., 1987; Eichmann et al., 1987). A maximum of two CD4
molecules can associate with each TCR (Saizawa et al., 1987). CD4 and the TCR
colocalize to the site of direct interaction between a T cell and an APC (Kupfer et al., 1987),
and comodulate from the cell surface following T cell activation (Weyand et al., 1987;
Anderson et al., 1988). A potential site of this interaction is a particular epitope on the TCR
molecule (Rojo et al., 1989; Dianzani et al., 1992). This epitope involves the site on the
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Cp subunit of the TCR bound by both the antibody H57-597 and the CD3e subunit
(Dianzani et al., 1991; Portoles and Janeway, 1987).
The idea that CD4 has signal transduction, as well as ligand-binding capabilities,
gained support with the finding that the cytoplasmic tail of CD4 is linked noncovalently
with the amino-terminal domain of the p56lck protein tyrosine kinase, a member of the Src
family (Rudd et al., 1988; Veillette et al., 1988; Shaw et al., 1989; Bolen et al., 1991).
Site-directed mutagenesis has established that two closely positioned cysteine residues in
the cytoplasmic tail of CD4 (positions 420 and 422) and two cysteines in the NJ^ terminus
of p56lck (positions 20 and 23) are essential for this CD4-p56lck interaction (Shaw et al.,
1990). Alkylating agents that interact with free sulfhydryls can block CD4-p56lck
association, suggesting that these cysteines may coordinate around a metal ion rather than
engaging in interchain disulfide bonds (Shaw et al., 1990).
The evidence that CD4 binds both MHC class II molecules and p56lck suggests that
CD4 fulfills its requirements as a coreceptor by participating in the activation or
differentiation of the cell through intracellular signaling. Models in which CD4 acts by
modulating the protein kinase activity of p56lck (Shaw et al., 1989) and by bringing p56 lek
into the antigen receptor complex at the time of antigen recognition (Weiss, 1993; Veillette
and Davidson, 1992b) have been proposed. However, studies performed using chimeric
CD4-p56lck molecules demonstrated that the catalytic activity of p56lck is not required for
coreceptor function (Xu and Liftman, 1993). p56lck is required to functionally couple the
TCR to signal transduction (Abraham et al., 1991a, b; Weiss, 1993; Haughn et al., 1992).
Therefore, p56lck appears to have two distinct functions in coreceptor-assisted T cell
activation. One of these functions, which may occur either with or without the coreceptor,
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involves localization of enzymatically active p56lck in close proximity to the TCR complex,
where it acts early in the signaling pathway (Anderson et al., 1994). The second function
of p56lck is to coordinate interaction of the TCR and coreceptor with a single MHC
molecule, possibly by helping to stabilize CD4 in the antigen receptor complex in a
kinase-independent fashion (Saizawa, 1987; Collins, 1992). While evidence indicates that
both CD4 and p56lck are critical components of early T cell differentiation, they do not
appear to require association with each other (Killeen and Liftman, 1993). Instead, p56lck
may mediate signaling from the TCR p chain and initiate allelic exclusion, expansion, and
maturation of immature thymocytes. The transmembrane and/or cytoplasmic domain of
CD4 may signal via other proteins (Anderson et al., 1994; Julius et al., 1993).
CD4 appears to have a number of other functions as well. Crosslinking of CD4
has been reported to result in increases in the production of inositol phosphates (Ledbetter
et al., 1988), in Ca2+ flux (Kanner et al., 1992), and in Fas antigen expression (Oyaizu et
al., 1994). Crosslinking of CD4 results in tyrosine phosphorylation of a number of
substrates, such as the £ chain (Veillette et al., 1989b) and p56lck (Veillette et al., 1989b).
CD4 crosslinking also results in an increased activity of the associated p56lck (Veillette et
al., 1989a, 1991; Luo and Sefton, 1990). In addition, CD4 crosslinking contributes to IL-2
down-regulation (Tamura et al., 1990; Takahashi et al., 1992; Corado et al., 1991; Ledbetter
et al., 1988) partially by inhibiting the binding activities of nuclear factors involved in IL-2
transcription (Jabado et al., 1994). Finally, CD4 either binds or associates with a complex
of proteins that bind an interleukin secreted by CD8+ T cells called lymphocyte
chemoattractant factor (LCF). The interaction of LCF with CD4 stimulates migration of
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CD4+ lymphocytes, monocytes, and eosinophils, and stimulates the growth of CD4+
T cells (Center et al., 1995; Cmikshank et al., 1994).
In summary, CD4 is an essential component of the normal functioning helper
T cell. It is found on the surface of T cells that recognize antigen bound to MHC class II
molecules on antigen presenting cells. Furthermore, it acts as a coreceptor by binding the
same MHC class II molecule as the TCR.
2.

Chromosomal Location, Gene Structure, and Polypeptide Structure

CD4 is encoded by a single gene located on chromosome 6 in the mouse (Field et
al., 1987) and chromosome 12 in the human (Kozbor et al., 1986; Isobe et al., 1986). This
portion of mouse chromosome 6 is considered syntenic to human chromosome 12
because these chromosomes contain segments composed of homologous genes (Nadeau,
1989). CD4 is located in a syntenic group that contains a number of different genes that
are important to the functioning of the immune system. These genes include TNFR,
FGF-6, KRAS-2 (Elliott and Moore, 1992), HCP (Yi et al., 1992b; Yi et al., 1992a),
CD27 (Loenen et al., 1992), and LAG-3 (Triebel et al., 1990). The organization of these
genes to the same chromosomal locus may be important in controlling their expression.
The cDNAs for the CD4 gene have been cloned from man (Maddon et al., 1985),
mouse (Tourvieille et al., 1986), chimpanzee, African green monkey, sooty mangabeys,
patas monkey, rhesus monkey, pig tail macaque (Fomsgaard et al., 1992), rabbit (Hague et
al., 1992), cat (Dumont-Drieux et al., 1992; Norimine et al., 1992), dog (Milde et al.,
1993), miniature swine (Gustafsson et al., 1993), and rat (Clark et al., 1987). Furthermore,
the genomic organization of the murine and human CD4 genes have been determined
(Gorman et al., 1987; Littman and Gettner, 1987; Maddon et al., 1987; Blum et al., 1993).
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Both genes are divided into ten exons spanning more than 25 kb. Rearrangement of the
CD4 gene is not required for expression (Maddon et al., 1985; Tourvieille et al., 1986).
The CD4 gene has a large non-coding region in the first and third intron. Numerous T celland non-T cell-specific DNase I hypersensitive (DH) sites have been mapped to both
introns (Sands and Nikolic-Zugic, 1992; Wong, 1991; Siu et al., 1994) suggesting that the
first and third introns may be involved in regulating the expression of CD4.
The CD4 molecule is a high mannose oligosaccharide glycoprotein with a
molecular weight of approximately 55 kDa. CD4, a member of the immunoglobulin (Ig)
superfamily, has four extracellular domains, a transmembrane domain, and a cytoplasmic
tail (Maddon et al., 1985). Amino acid sequence comparisons of CD4 from a number of
species demonstrate strong conservation within all domains of the molecule (Fleury et al.,
1991b). The extracellular portion of CD4 consists of four Ig-like domains (D1-D4), which
contain repeated sites of interactions with nonpolymorphic determinants of the p-chain of
MHC class II molecules (Cammarota et al., 1992; Konig et al., 1992). The first domain
resembles an Ig light chain variable domain, the second domain is similar to a constant
domain, and the third and fourth domains adopt an Ig-fold (Wang et al., 1990; Ryu et al.,
1990). Crystallographic analysis of the four domains has suggested that a segmental flex
could result from the presence of a flexible junction between domains 2 and 3 (Kwong et
al., 1990). The extracellular domains are followed by a hydrophobic transmembrane
segment, and a highly basic cytoplasmic tail (Maddon et al., 1985). The cytoplasmic tail is
linked to the p56lck protein tyrosine kinase (Bolen et al., 1991). The human CD4 molecule
has two potential N-linked glycosylation sites, while the mouse has four, the rat has three,
the rhesus has two, and the chimpanzee has two. Each of the five species listed has six
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cysteine residues external to the cell, which form three intrachain disulfide loops connecting
adjacent cysteines. The cytoplasmic tail is the most highly conserved domain of CD4
between man and other species, with 80 percent identical residues in mouse, 78 percent
identical residues in rat, 100 percent identical residues in rhesus, and 97 percent identical
residues in chimpanzee. The external domains share only 55 percent identical residues in
mouse, 51 percent identical residues in rat, 89 percent identical residues in rhesus, and
96 percent identical residues in chimpanzee (Fleury et al., 1991b).
Crystallographic studies indicate that CD4 exists as a rod-like structure of about
125 angstroms in length and 25 to 30 angstroms in width (Ryu et al., 1990; Wang et al.,
1990; Harrison et al., 1992; Capon and Ward, 1991). When expressed as a secreted
protein in mammalian cell culture, CD4 (1-375) is a rod-like, monomeric molecule
(Kwong et al., 1990). Structural analysis of a soluble fragment of CD4, consisting of the
two amino-terminus domains, D1 and D2, show that these areas resemble Ig domains,
consisting of nine and seven p strands, respectively (Capon and Ward, 1991).

B.

CD4 GENE REGULATION
I.

T Cell Progenitors

Yolk sac cells from mouse embryos at day 8 and 9 of gestation are able to
reconstitute lymphocyte-depleted fetal thymic lobes and acquire mature T cell
characteristics that include expression of CD3, TCR, CD4, and CDS (Liu and Auerbach,
1991). After day 11 of mouse gestation, the fetal liver is the major site of hematopoiesis
(Umiel, 1971). Shortly before birth, the bone marrow becomes the primary site of
hematopoiesis (Ikuta et al., 1992; Metcalf et al., 1971).

9
CD4 is expressed at low levels on murine hematopoietic stem cells, not yet
committed to the T cell differentiation pathway. The initial characterization of a
monoclonal antibody, GK1.5, showed that bone marrow derived cells express the CD4
molecule (Dialynas et al., 1983). Frederickson and Basch (1989) provided additional
evidence that CD4 was expressed on immature hematopoietic cells. They suggested that
CD4 was transiently expressed by most, if not all, hematopoietic precursors early in their
maturation. The earliest T-lineage precursors in the adult murine thymus express CD4
(Wu et al., 1991b). These CD4lD precursor cells can differentiate into B and T cells if
injected intravenously but will only differentiate into T cells if injected intrathymically (Wu
et al., 1991a). CD4l0 murine bone marrow cells can repopulate all hematopoietic lineages
(Onishi et al., 1993; Wineman et al., 1992).
2.

Thymic Development

a.

Entry (CD4|0CD8 )

The first major event in the thymic development of T cells occurs when
hematopoietic stem cells seed the thymus. From the various sites of hematopoiesis,
pre-T cells travel to the thymus via the circulation (Savagner et al., 1986). The thymus is
colonized in waves during fetal development (Le Douarin et al., 1984; Ritter, 1978). After
birth, there is a continual low level of seeding of the thymus by precursors that are derived
primarily from the bone marrow (Metcalf and Wakonig-Vaartaja, 1964).
Although pre-T cells lack the markers of mature lymphoid or myeloid cells, such
as TCR, CD3, B220, CDS, CD5, Gr-1, or Mac-1 (Balasubramaniam and Appasamy,
1994), data suggests they express CD4. As discussed above, hematopoietic stem cells
from murine bone marrow express low levels of CD4. These CD410 cells give rise to
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T cells, and dendritic cells, upon direct injection into the thymus (Wu et al., 1991a; Ardavin
et al., 1993). In the thymus, there is a small subpopulation of CD4lG immature thymocytes
and these cells appear to be the recent immigrants from the bone marrow (Wu et al.,
1991b). The early T cell and thymic dendritic cell precursors of humans do not express
CD4 (Sotzik etal., 1994).
b.

Early (CD4 CD8)

Within two days, the immature thymocytes become CD4 CD8' (Scollay et al..
1988). Double negative cells constitute only about five percent of the murine adult thymus
and can be subdivided into three groups with respect to expression of the TCR:
CD4 CD8 CD3-, CD4 CD8"TCRy5+, and CD4 CD8 TCRa(3+ (de la Hera et al., 1985; Lew
et al., 1986; Bluestone et al., 1987; Budd et al., 1987; Fowlkes et al., 1987; Crispe et al.,
1987). Most of the data from in vivo and in vitro studies are consistent with a model in
which the earliest CD4 CD8' thymocytes are also CD3‘, Pgp-1+, HSA‘, Thy-ll0, IL-2R,
CD5lG. These cells lose Pgp-1, gain HSA, and start to express high levels of Thy-1.
Subsequently, they transiently express the IL-2R. Prior to the CD4+CD8+ stage
thymocytes are again IL-2R' (Fowlkes and Pardoll, 1989). The CD4'CD8'CD3' triple
negative stage of development is characterized by extensive expansion and differentiation,
as these cells begin to rearrange and express TCR genes in conjunction with accessoiy
molecules such as CD3, CD4, and CDS (Scollay et al., 1988).
There are two separate groups of TCR-bearing cells: those that express the TCRocp
and TCRy5. Lymphocytes expressing the y5 T cell receptor are a unique subset of
T lymphocytes distinguished from otp T cells not only in the use of different TCR genes,
but by the absence of cell surface CD4 or CDS antigens on most y8 T cells (Pardoll et al..
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1987; Bank et al., 1986). Furthermore, yd T cells may utilize a unique mechanism for
recognition of antigen compared to aP T cells (Schild et al., 1994). It appears that
precursors for the otP and yd lineage are distinct populations (Winoto and Baltimore,
1989a; Winoto and Baltimore, 1989b), although there is some evidence that yS cells are
able to develop into otP cells (Thompson et al., 1991). The commitment to the ap T cell
lineage and the y5 T cell lineage both seem to occur at the triple negative stage of
thymocyte development (Godfrey et al., 1993).
c.

Transition to CD4+CD8+

The immature triple-negative thymocytes become CD4+CD8+ after 7 to 9 days.
These cells constitute approximately 80 to 84 percent of the adult murine thymocytes
(Fowlkes and Pardoll, 1989). The expression of TCRa and P appear to precede the
expression of CDS, CD4, and CDS (Petrie et al., 1992). The least mature CD4'CD8'CD3‘
IL-2R+ cells require 3 days to express CD4 and CDS, while the most mature CD4'CD8‘
CD3' IL-2R' cells require only one day to express CD4 and CDS (Petrie et al., 1990a).
Controversial evidence exists as to whether CD4 or CDS is expressed next (Nikolic-Zugic
et al., 1989, Guidos et al., 1989; Tatsumi et al., 1990; Hugo et al., 1990; Wilson et al.,
1989; Watanabe et al., 1992b; Matsumoto et al., 1991). Weissman (1994) suggests that in
humans, the next stage is predominantly CD4hlCD8 CD3', while in most mouse strains,
the predominant developmental intermediate is CD8hlCD4'CD3'. Perhaps a CD4l0CD8l0
cell is a more accurate way to describe the precursor to the CD4+CD8+ cell (Andjelic et al..
1993).
The independent expression of CD4 and CDS might be attributed to different
signals that could be required to up-regulate their expression. CD4 requires a thymocyte-
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stromal cell interaction (Brightman et al., 1989; Tatsumi et al., 1990; Palacios et al., 1989),
while the expression of CDS is inducible by thymic stromal cell derived cytokines such as
TGFp and TNFa (Tatsumi et al., 1990; Suda and Zlotnik, 1992). Furthermore, the
up-regulation of CD4 and CDS appear to be signaled through the CD3/TCRP complex that
is expressed on CD4 CD8' thymocytes (Levelt et al., 1993; Mombaerts et al., 1992;
Shinkai et al., 1993). This signaling appears to be through the p56lck molecule since mice
deficient for this tyrosine kinase are also blocked at the CD4 CD8' thymocyte stage
(Molina et al., 1992). Humans with a defect in the expression of the CD3y subunit have a
problem in maturing CD8+ T cells (Alarcon et al., 1990) while humans with a defect in the
expression of the CD3e subunit have defects in maturing CD4+ T cells (Thoenes et al.,
1992). Thymosin fraction 5 has been reported to be able to induce CD4 and CDS
expression on immature thymocytes (Panajotovova et al., 1989). Finally, IL-1 can induce
CD4 and CDS on thymocytes that have been selected by complement lysis using
antibodies to CD4, CDS, and CD3 (Zimecki and Wieczorek, 1989), but it is not clear if
these cells are CD4 CD8 or CD4l0CD8l0.
d.

Transition to CD4+CD8" and CD4'CD8+

The double positive T cells represent potentially all possible TCR specificities, and
undergo an inordinate amount of intrathymic cell death (McPhee et al., 1979). This cell
population undergoes selection processes during their development which shape the final
TCR repertoire (Weissman, 1994). Positive selection involves the selection for survival of
those maturing thymocytes that can recognize self-MHC, ensuring that mature peripheral
T cells will recognize antigenic peptides bound to self, not foreign, MHC proteins (von
Boehmer, 1994). Negative selection involves deletion of developing thymocytes
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expressing TCRs that are potentially autoreactive, presumably because they bind with a
high affinity to self-MHC proteins (Nossal, 1994). The result of these selection processes
are MHC class I restricted CD4‘CD8+ T cells and MHC class II restricted CD4+CD8'
T cells. Only a minority of the T cells survive these processes and egress into the
periphery (Egerton et al., 1990) where they provide an effective immune system able to
recognize most potential pathogens yet not able to respond to self antigens (Janeway and
Bottomly, 1994).
While the specificity and affinity of the TCR play a crucial role in both positive and
negative selection, the CD4 and CDS coreceptor molecules have also been shown to be
intimately involved in these processes. Indirect evidence for the role of CD4 in positive
selection comes from studies targeting the MHC class II molecule. Mice treated from birth
with anti-MHC class II mAb (Kruisbeek et al., 1983, 1985) and genetic knockouts of the
MHC class II locus (Cosgrove et al., 1991; Grusby et al., 1991) result in a lack of
development of mature, MHC class II restricted CD4+ T cells. More direct evidence for
the role of CD4 in positive selection comes from studies using anti-CD4 mAb. Mature
CD4+ cells are lacking when pregnant mice are treated with anti-CD4 (Zuniga-Pflucker et
al., 1989b), or when adult mice are treated with anti-CD4 (Ramsdell and Fowlkes, 1989).
In addition, the CD4 gene has been genetically knocked out by homologous recombination
resulting in a loss of MHC class II restricted helper function (Killeen et al ., 1993;
Rahemtulla et al., 1991). CD4 clearly plays an important role in the development of CD4+
T cells, possibly through an interaction with MHC class II molecules.
The role of CD4 in negative selection has been established primarily by studies
involving in vivo treatment of mice with anti-CD4 (Fowlkes et al., 1988; MacDonald et al.,
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1988b; Zuniga-Pflucker et al., 1989a). T cells expressing a particular TCR variable gene
segment,Vp, would normally be destroyed in these mice due to autoreactivity (Kappler et
al., 1987a, b; 1989; MacDonald et al., 1988a). However, treatment with anti-CD4 mAb
rescued these cells from thymic deletion, presumably by blocking both the interaction and
signaling of CD4. This suggests that CD4 plays an important role in the deletion of at least
some autoantigen- reactive T cells.
One of the remaining critical questions regarding the development of CD4 and
CDS T cells is how a double-positive thymocyte expressing an apTCR that recognizes
antigen presented by a MHC class II molecule differentiates into a CD4+ T cell, while one
expressing an otPTCR that recognizes antigen presented by a MHC class I molecule
differentiates into a CD8+ T cell. Furthermore, how is the helper T cell program linked to
CD4 while the cytotoxic T cell program is linked to CDS? Two basic models have been
suggested to explain this correlation (von Boehmer, 1986; Janeway, 1988; Robey et al.,
1991; Burgulya et al., 1991). The instructive model proposes that positive selection occurs
at the double-positive stage of thymocyte development. The down-regulation of CD4 is
the result of a signal generated by the interaction of a TCR with a MHC class I molecule,
while the down-regulation of CDS is the result of a signal generated by the interaction of a
TCR with a MHC class II molecule. Conversely, the stochastic or selective model
proposes that positive selection occurs at the single-positive stage. The down-regulation of
CD4 and CDS are random events and the resultant cell is rescued to be either a helper T cell
if the TCR can interact with a MHC class II molecule or a cytotoxic T cell if the TCR can
interact with a MHC class I molecule.
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Both the instructive and stochastic models propose important roles for CD4 and
CDS. The instructive model requires that double-positive thymocytes are the target of
positive selection before down-regulation of either coreceptor. This model is consistent
with experiments in which a CDS coreceptor, encoded by a transgene expressed in all
T cells, failed to rescue CD4+ cells with an MHC class I-restricted receptor from cell death
(Borgulya et al., 1991; Robey et al., 1990), and experiments in which a chimeric CD8/CD4
molecule, with transmembrane and cytoplasmic tail derived from CD4, led to the
accumulation of peripheral T cells which expressed endogenous CD4 and CDS as well as a
MHC class I restricted receptor (Seong et al., 1992). The instructive model is also
consistent with the evidence that CD4+CD8+ thymocytes up-regulate their TCR levels as a
result of positive selection (Ohashi et al., 1990; Borgulya et al., 1991). The
stochastic/selective model requires that single-positive thymocytes are the target of positive
selection, and predicts that cells that have made the wrong choice in coreceptor
down-regulation should be rescued from cell death by a transgene encoding a coreceptor
fitting the TCR and expressed in all mature T cells. While initial experiments of this kind
failed to support the stochastic/selective model (Robey et al., 1991; Borgulya et al., 1991),
more recent data from this type and other types of experiments are consistent with it (Chan
et al., 1993; Davis et al., 1993) although the population rescued by the transgenic
coreceptor was either small or the levels of the endogenous coreceptors were abnormal.
The stochastic/selective model is further supported by experiments in which mice lacking
CD4 or CDS were rescued by expression of transgenes defective in signaling (Locksley et
al., 1993; Killeen and Littman, 1993; Chan et al., 1993), and experiments in which cells

16
committed to either CD4 or CDS lineage were found in mice lacking either MHC class I or
class II molecules (Chan et al., 1993; van Meerwijk and Germain, 1993).
More recent data does not support the instructive or stochastic/selective models
(Marodon and Rocha, 1994). The data suggests that mature CD4 and CDS T cells derive
from different pathways of T cell differentiation in the thymus. Interaction with MHC
class I induces the up-regulation of TCR, which precedes the down-regulation of CD4.
Further differentiation results in CD4 down-regulation and the transition into CD4'CD8+
thymocytes. In contrast, interaction of CD4+CD8+ thymocytes with MHC class II leads to
the immediate down-regulation of CDS, which occurs simultaneously with an increase in
TCR expression, generating CD4+CD8' thymocytes. Thus signals mediated through the
CD4 coaccessory molecule may be involved in selection, at least at this stage of T cell
differentiation. These results are especially intriguing when considered together with what
is known about the signals required for production of CD4+ versus CD8+ T cells. When
CD4+CD8+ thymocytes are grown in culture, they only differentiate into CD4'CD8+ cells
(Petrie et al., 1993; Blue et al., 1985). In order for them to differentiate into CD4+CD8'
cells, they must come in contact with MHC class II antigen presenting cells (Kaye and
Ellenberger, 1992; Blue et al., 1985; Petrie et al., 1993). This again suggests that the
development of CD4+ T cells occurs through a different mechanism than the development
ofCD8+T cells.
An alternate model of thymocyte development (Marodon and Rocha, 1994) is that
repertoire selection is a continuous process that starts as soon as TCR is expressed by
thymocytes. The interactions of specific ligands in the thymus with the TCR that lead to
selection of certain T cell specificities are not restricted to particular phases of T cell
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differentiation. Instead, the process of positive and negative thymic selection is the result
of multi-hit interactions taking place during thymocyte differentiation, which lead to
progressive enrichment or elimination of certain T cell specificities.
3.

Extra-thymic Development

While the thymus is widely accepted as the major organ where progenitor T cells
differentiate to form the repertoires of mature T cells (Finkel et al., 1989; Kisielow et al.,
1988; Smith et al., 1989; Teh et al., 1988), T cells are also generated extrathymically
(Rocha et al., 1992). Extrathymic T cell differentiation occurs in the hepatic sinusoids
(Ohteki et al., 1990; Seki et al., 1990; Ohteki et al., 1991; Abo et al., 1991; Seki et al.,
1991a; Seki et al., 1991b; Masuda et al., 1991), intraepithelial sites in the intestine
(Ferguson and Parrott, 1972; Mosley et al., 1990a; De Geus et al., 1990; Ebert, 1990;
Mosley et al., 1990b; Bandeira et al., 1991; Guy-Grand et al., 1991b; Guy-Grand et al.,
1991a; Rocha et al., 1991), the mucosa in the uterus (Abo et al., 1993; Saito et al., 1993),
and the omentum (Ishikawa and Saito, 1980; Andreu-Sanchez et al., 1991). Although
extrathymic T cells are minor in numbers at a young age, they gradually become prominent
with aging (Ohteki et al., 1991; Ohteki et al., 1992; liai et al., 1992; Taylor et al., 1992;
Takimoto et al., 1992).
These extrathymic T cells display many properties distinct from those of thymic
derived T cells, especially in mice (Ohtsuka et al., 1994). They comprise a considerable
proportion of y5 T cells as well as ap T cells (De Geus et al., 1990; Bandeira et al., 1991;
Guy-Grand et al., 1991b; Rocha et al., 1991; Deusch et al., 1991), and contain double
negative (CD4'CD8 ) cells and double-positive (CD4+CD8+) cells (Mosley et al., 1991a;
Watanabe et al., 1992a; Fangmann et al., 1991). Extrathymic T cells seen in the liver and
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other immune organs, except the intestine, have TCR of intermediate density (Seki et al.,
1991a; Okuyama et al., 1992; Murosaki et al., 1991). Since these extrathymic T cells do
not undergo negative selection for self-reactive clones, they contain a significant proportion
of self-reactive clones (Abo et al., 1991; Okyuyama et al., 1992; Murosaki et al., 1991).
They also exhibit poor response to T cell mitogens (Ohteki et al., 1992; Ebert, 1989;
Harriman et al., 1992). Finally, they show a morphology of large granular lymphocytes
(LGL) similar to NK cells (Seki et al., 1990; Guy-Grand et al., 1991b; Takimoto et al.,
1992; Guy-Grand et al., 1978; Guy-Grand et al., 1974).
It is postulated that extrathymically-derived T cells play a complementary role to
thymus-derived T cells (Ohtsuka et al., 1994). They are activated under conditions of
aging (Ohteki et al., 1992), infections (Hirokawa, 1985; Hayashi et al., 1989), malignancies
(Seki et al., 1991b; Ohmori et al., 1993; liai et al., 1994), pregnancy (Okuyama et al., 1992;
Heybome et al., 1992; Saito et al., 1993), and some autoimmune diseases (Ohteki et al.,
1990; Seki et al., 1991a; Masuda et al., 1991). Thus, the activation of extrathymically
derived cells may occur when the thymus becomes involuted or atrophic, to compensate
for the time when the intrathymic pathway is inactivated (Ohtsuka et al., 1994).
4.

Post-thymic

a.

T Cell Activation

Triggering of resting T cells involves interaction with cells bearing the appropriate
antigen in the context of MHC molecules (Altman et al., 1990; Janeway and Bottomly,
1994). The binding event initiates a cascade of biochemical changes and generates signals
that are transmitted sequentially from the cell surface to the nucleus, where genes are
activated or inhibited. This gives rise to activated and differentiated T cells displaying
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genetically determined effector functions, such as secretion of immunoregulatory cytokines
by T helper cells and specific lysis of target cells by T cytotoxic cells.
The TCR/CD3 complex associated with CD4 or CDS constitutes a multimeric
complex through which this physiological activation occurs (Bierer et al., 1989; Micelli and
Fames, 1993). Although this complex of molecules is the natural target for stimulation
with antigen/MHC complex, artificial ligands such as monoclonal antibodies directed
against TCR or CD3 can mimic the activation signals. The direct consequence of T cell
activation by antigen, anti-CD3, or phorbol myristate acetate (PMA) is the internalization of
TCR/CD3 and the down-modulation of cell surface CD4 and CDS (Hoxie et al., 1986b;
Minami et al., 1987; Saizawa et al., 1987; Takada and Engleman, 1987; Weyand et al.,
1987). A suboptimal signal of activation (soluble anti-CD3 or PMA alone) results in a
slight up-modulation of TCR, CD4, and CDS mRNA, while a strong activation signal
(anti-CD3 + PMA or anti-CD2) results in a specific transient down-modulation of these
mRNAs followed by a gradual re-expression (Paillard et al., 1988). The down-modulation
of CD4 and CDS involves transcriptional inhibition and destabilization of the mRNA pools
(Paillard et al., 1990). The TCR/CD3 induced down-regulation of CD4 and CDS on the
surface of T cells can be blocked by cyclosporin A (CsA) (Paillard et al., 1992). CsA
blocks the transcriptional modulation but does not affect mRNA stability. Interestingly, the
net result of T cell activation is the increase of CD4 and CDS gene expression (Fierro et al.,
1982; Blue et al., 1985; Appleyard et al., 1983). Activated, and thus larger T cells, express
more CD4, and to some extent CDS, than unactivated T cells. CD3 expression does not
vary upon stimulation (Appleyard et al., 1983). The administration of antibodies to CD4
also causes a down-modulation of cell surface expression of CD4 (Horneff et al., 1993).
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Cell surface expression of CD4 is modulated via receptor-mediated endocytosis
(Wang et al., 1992). Endocytotic vesicles and vacuoles of different sizes and shapes
contain CD4 after the T cell is activated by IL-2. These vesicles are located near the cell
membrane and deep in the cell center. The internalized CD4 molecule can be targeted to be
degraded or the CD4 molecule can recycle to the cell surface (Pelchen-Matthews et al.,
1989). Interestingly, CD4 is internalized faster than it recycles to the surface until
approximately 30 percent to 40 percent of the total cellular CD4 pool resides inside the
cell.
About three percent of human peripheral T cells are CD4+CD8+ (Blue et al., 1985).
The number of mature T cells that express both CD4 and CDS can be driven to 60 percent
using concanavlin A (ConA). The co-expression of CD4 and CDS is transitory and
eventually the T cell reverts back to the single positive phenotype. IL-4 can induce CD8ot
expression of CD4+CD8' T cells (Hori et al., 1991; Ebisawa et al., 1991; Reason et al.,
1990). The up-regulation of CDS is only apparent in neonatal T cells (less than two years
old) (Ebisawa et al., 1991). If the neonatal CD4+CD8‘ T cells are administered IL-4 and
grown in culture, the CD4+CD8 cells become CD4'CD8+ via a CD4+CD8+ intermediate
(Reason et al., 1990).
b.

Alterations in Response to Chemical Agents

There are a number of chemical agents which mimic T cell activation and can
down-modulate the cell surface expression of CD4. Phorbol esters, such as phorbol
12-myristate 13-acetate (PMA) (Shin et al., 1990; Solback, 1982), induce the
internalization of CD4. Activation of protein kinase C (PKC) (Hamamoto et al., 1989) and
phosphorylation of CD4 (Blue et al., 1987) are central to phorbol ester induced CD4
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endocytosis. Activation of PKC induces CD4 to dissociate from p56lck (Hurley et al.,
1989) possibly through phosphorylation of three serine residues in the CD4 cytoplasmic
tail (Shin et al., 1990). Disruption of the CD4/p56lck complex is necessary for rapid
internalization of CD4 (Sleckman et al., 1992). To initiate disruption of the CD4/p56lck
complex, which precedes PMA-induced CD4 internalization, phosphorylation on serine
408 may be necessary (Sleckman et al., 1992; Hurley et al., 1989). In fact, p56lck may
delay or inhibit CD4 endocytosis by preventing entry of CD4 into coated pits (Yoshida et
al., 1992; Pelchen-Matthews et al., 1992). Interestingly, PMA down-modulates CD4 on
mature human T cells but not mature mouse T cells (Sleckman et al., 1989). PMA does
down-modulate CD4 on murine CD4+CD8+ thymocytes (Wang et al., 1987).
Bryostatins, macrocyclic lactones isolated from Bugula neritina (Pettit et al., 1982),
can down-modulate cell surface expression of CD4 (Esa et al., 1990; Boto et al., 1991).
Bryostatins are structurally distinct from phorbol esters, but can bind and activate protein
kinase C (PKC), the cellular receptor for phorbol esters, and elicit PKC-dependent cellular
functions (Berkow and Kraft, 1985; Hess et al., 1988). A commonly used bryostatin,
bryo-1, inhibits the glycosylation and expression of CD4 in a manner similar to that of
tunicamycin, an N-linked glycosylation inhibitor (Boto et al., 1991).
Gangliosides, sialic acid containing glycosphinglipids, are ubiquitous constituents
of cell membranes (Hakomori, 1990). In T lymphocytes they seem to play a role in
cell-cell interactions, antigen recognition, activation, and signal transduction (Whisler and
Yates, 1980). Some gangliosides, such as GM1, are virtually undetectable in the
lymphocyte plasma membrane, while others, like GM3, represent approximately
70 percent of the ganglioside content in these cells (Kiguchi et al., 1990). Treatment of
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CD4+ T lymphocytes with GM1, or ganglioside derivatives, reduces CD4 surface
expression (Offner et al., 1987; Kawaguchi et al., 1989; Grass! et al., 1990; Repke et al.,
1992; Saggioro et al., 1993). This effect on CD4 may be due to masking of CD4 epitopes
(Offner et al., 1987; Grassi et al., 1990; Chieco-Bianchi et al., 1989), shedding of CD4
(Morrison et al., 1991), or endocytosis (Offner et al., 1987; Kawaguchi et al., 1989; Repke
et al., 1992; Saggioro et al., 1993). GM3 induces down-modulation of cell surface CD4 by
endocytosis (Sorice et al., 1995). The actual mechanism of ganglioside induced CD4
endocytosis is unclear since both a serine phosphorylation independent pathway involving
dissociation of p56lck (Repke et al., 1992; Saggioro et al., 1993; Sorice et al., 1995) and a
pathway independent of p56lck (Sorio et al., 1993) have been implicated.
An inhibitor of DNA methylation, 5-azacytidine (5-azaC), hypomethylates newly
synthesized DNA and suppresses the expression of genes (Santi et al., 1984; Jones, 1984).
Hydroxyurea (HU), inhibits DNA synthesis but does not affect DNA methylation (Boehm
et al., 1982; Radford et al., 1982; Letvin et al., 1984). Expression of CD4 can be induced
on CD4'CD8+ cells by 5-azaC, but not HU. In contrast, 5-azaC does not induce CDS
expression on CD4+CD8‘ cells (Richardson et al., 1986). This suggests that the expression
of CD4 is directly inhibited by the methylation of the CD4 gene, or that a positive regulator
of CD4 is repressed by methylation of its gene.
c.

Alterations in Response to Infective Agents

Although a number of infective agents can modulate the expression of CD4, the
most cited example is the human immunodeficiency virus, HIV. HIV-associated
down-modulation of cell surface CD4 occurs following infection of CD4+ lymphocytes,
T cell lines, monocytic cell lines, and macrophages (Hoxie et al., 1986a; Salmon et al.,
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1988; Geleziunas et al., 1991; Yuille et al., 1988). Cell surface alteration of CD4 occurs
early in infection, during HTV-l structural protein expression, and during the expression of
auxiliary proteins (Bour et al., 1994). Factors that may cause HIV-1 associated cell surface
CD4 depletion include endocytosis (Amadori et al., 1992; Cefai et al., 1992; Garcia et al.,
1993), reductions in transcript levels of CD4 (Hoxie et al., 1986a; Salmon et al., 1988),
impaired translation of CD4 mRNA (Geleziunas et al., 1991; Yuille et al., 1988),
intracellular retention of CD4 (Bour et al., 1991; Crise and Rose, 1992; Jabbar and Nayak,
1990), and CD4 degradation (Willey et al., 1992; Chen et al., 1993).
Early in infection, CD4 is down-modulated after cell-surface binding of virions.
Soluble gp!20, or antigen-antibody complexes that involve gpl20, mask cell surface CD4
(Amadori et al., 1992). Furthermore, after binding of gpl20 antigen-antibody complexes
or gpl20 alone, CD4 is internalized by a serine phosphorylation independent pathway
(Amadori et al., 1992; Cefai et al., 1992). The loss of CD4 from the cell surface causes the
T cell response to antigen and to anti-CD3 activation to be impaired. CD4 is gradually
up-modulated when soluble gpl20 is removed (Cefai et al., 1992).
CD4 is associated intracellularly with gpl60 and sometimes with gpl20 in
productively infected cells (Bour et al., 1991; Hoxie et al., 1986a; Salmon et al., 1988;
Shahabuddin et al., 1992). Cell lines which express gpl60 not only have internal
CD4/gpl60 complexes, but also have a reduced level of cell surface CD4 (Stevenson et al.,
1988; Crise and Rose, 1992; Jabbar and Nayak, 1990). Furthermore, intracellular levels of
gpl60 are inversely correlated with cell surface CD4 levels (Stevenson et al., 1988; Koga et
al., 1990). In cells co-expressing CD4 and gpl60, maturation and transport of both
molecules are inhibited because CD4/gpl60 complexes are formed and retained in the
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endoplasmic reticulum (Hour et al., 1991; Crise and Rose, 1992). Retention in the
endoplasmic reticulum seems to depend on membrane anchorage, since CD4/gpl60
complexes can anchor via the COOH-terminal transmembrane segment of gp41, while
CD4/gpl20 complexes cannot anchor and are transported from the endoplasmic reticulum
(Crise and Rose, 1992).
CD4 down-regulation is also related to the expression of two HIV-1 proteins, Nef
and Vpu. Nef is expressed during the early regulatory phase of HIV-1 gene expression in
a Rev-independent fashion, whereas Vpu is expressed during the structural phase of HIV-1
gene expression in a Rev-dependent manner (Cullen, 1991). Nef expression in thymocytes
of transgenic mice or in CD4+ cell lines led to the down-regulation of CD4 surface
expression (Garcia et al., 1993; Skowronski et al., 1993), but did not affect levels of CD4
mRNA or protein. Furthermore, the effect of Nef does not appear species-specific, as it
occurs with human and murine CD4 (Garcia et al., 1993; Skowronski et al., 1993). The
down-regulation of CD4 by Nef requires the cytoplasmic tail of CD4, but does not involve
the cytoplasmic tail serine residues (Garcia et al., 1993), suggesting that the mechanism
may be serine-phosphorylation independent endocytosis. Vpu can induce degradation of
CD4 in the presence (Willey et al., 1992; Chen et al., 1993) or absence (Willey et al., 1992)
of gpl60. The target for Vpu-associated degradation of CD4 appears to be the cytoplasmic
domain of CD4, and involves the hydrophilic COOH terminus of Vpu (Chen et al., 1993).
So by degrading CD4, Vpu reduces the quantity of CD4/gpl60 complexes and enhances
gpl60 processing.
Human herpesvirus-7 (HHV-7), a T lymphotropic virus, down-regulates CD4
expression on the surface of CD4+ T cells, while HHV-6 causes a slight increase in CD4
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expression in these cells. Since neither HHV-7 nor HHV-6 alter mRNA levels or
intracytoplasmic levels of CD4 in CD4+ T cells, the mechanism is postulated to be posttranslational (Furukawa et al., 1994). HHV-6 has also been shown to up-regulate CD4 on
CD4‘CD8+ cytotoxic T cells (Lusso et al., 1991) and NK cells (Lusso et al., 1993), making
them susceptible to HIV infection. Furthermore, HHV-6 increases HTV-1 expression in
co-infected T cells by acting on a segment of the HTV enhancer which contains an NFICB
motif (Ensoli et al., 1989).
Moloney murine leukemia virus-based retroviral expression vectors have been used
to facilitate the introduction of various genes into human T cell lines (Koka et al., 1988).
Interestingly, the murine retroviral vector alone can up-regulate the transcription of CD4
(Koka et al., 1991). MuLV regions responsible for this effect are the 5' or 3' LTR, or
500 bases adjacent to and downstream of the 5' LTR.
Trypanasoma cruzi, a protozoan which causes Chagas disease, down-regulates cell
surface expression of CD4 on mitogen activated, but not resting CD4+ T cells. This
inhibitory effect occurs whether the cells are activated with PHA or anti-CD3. The
mechanism of down-regulation of CD4, transcriptional or post-transcriptional, has not
been determined (Sztein et al., 1990).
d.

Summary of CD4 Modulation

In summary, CD4 expression is modulated during T cell activation and also by a
number of chemical and infective agents. CD4 transcript levels are reduced by
anti-CD4 + PMA, while CD4 transcript levels are increased by anti-CD3 alone, PMA
alone, ConA, 5-azaC, HHV-6, and the 5’ or 3’ LTR of MuLV. Cell surface expression of

26
CD4 is reduced during T cell activation by antigen, anti-CD3 alone, PMA alone, anti-CD4
alone, bryostatins, gangliosides, HIV infection, gpl20, gpl60, Nef, and Vpu.
5.

Molecular Basis for CD4 Gene Regulation

As discussed in section A, the CD4 gene encodes a transmembrane glycoprotein
which is a member of the immunoglobulin gene superfamily. The CD4 molecule is
essential for normal T cell functions and plays a crucial role in T cell development and
activation. Although the sequence of the murine and human CD4 genes was identified
several years ago (Gorman et al., 1987; Littman and Gettner, 1987; Maddon et al., 1987;
Blum et al., 1993), little is known regarding the regulatory mechanism underlying the
expression of CD4, particularly during T cell differentiation in the thymus. The following
sections will summarize and discuss what we know about CD4 gene regulation.
a.

Transcriptional and Post-transcriptional Control

The CD4 gene is regulated by both transcriptional and post-transcriptional
mechanisms. Post-transcriptional regulation of CD4 expression is important during T cell
activation as well as early in T cell development. Human T cells stimulated with anti-CD3
and PMA show a pronounced transient decrease in the half-life of CD4 mRNA within one
hour following stimulation (Paillard et al., 1990). The mRNA half-life returns to normal
after 3 hours. CD4'CD8|0 fetal thymocytes do not express the CD4 protein on the cell
surface, although it is actively transcribed (Takahama and Singer, 1992). In addition,
incubation of T lymphoma cell lines with protein synthesis inhibitors rapidly increases the
steady state levels of CD4 mRNA (Wilkinson et al., 1991b). In the case of a double
positive cell line, this increase appears due to a post-transcriptional effect.
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Transcriptional repression contributes to the down-regulation of CD4 mRNA after
T cell stimulation by anti-CD3 and PMA (Paillard et al., 1990). Although CD4 is
transcribed in early CD4 CD810 fetal thymocytes, CD4 CD8' precursors lack newly initiated
transcripts (Takahama and Singer, 1992), suggesting that CD4 transcription is up-regulated
as the cell progresses from the double-negative stage. Petrie et al. (1990b) also
demonstrated that cells progessing from the double-negative to double-positive stage are
actively transcribing CD4. Hybrids formed between double-positive and double-negative
T lymphoma clones repress CD4 expression (Wilkinson et al., 1991a). This repression is
mediated at least in part at the transcriptional level. Nuclear run-on analysis of the
developmental progression of T cells from double-positive to single-positive indicates that
the major mechanism of down-regulation of CD4 during this stage of T cell development
is transcriptional (Siu et al., 1994). These results do not appear to conflict with previous
reports that post-transcriptional mechanisms play a role in the control of developmental
expression of the CD4 gene (Takahama and Singer, 1992), since the earlier reports
concerned cells progressing toward the double-positive stage.
b.

Initial Insights into CD4 Regulation

The first insight into the molecular mechanism of CD4 control was published by
Wilkinson et al. (1991a). Somatic cell hybrids were made between murine T cell lines to
analyze the transcriptional regulation of T cell-specific genes. These hybrids provided
evidence that immature thymocytes are actively repressing CD4. Furthermore, the reason
that CD4 is expressed in more mature thymocytes appears to be due to the absence of
repressors that are present earlier in thymocyte development. The nuclear array of T cellspecific /ra/w-acting factors changes as CD4+CD8+ thymocytes are selected to become
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either CD4+CD8' or CD4'CD8+ mature T cells (Paquette et al.,1992). This was
demonstrated by using the viral long terminal repeat (LTR) from a thymotropic murine
mammary tumor virus variant, DMBA-LV, to drive the expression of two reporter genes,
the murine c-myc gene and the human CD4 gene, in transgenic mice. Thymocytes
supported the expression of the reporter genes while mature T cells did not.
The locations of potential c/5-acting elements controlling CD4 expression were
published by Sands and Nikolic-Zugic (1992). They extensively analyzed 75 kb of
chromatin associated with the murine CD4 locus in four T cell lines, a B cell line, a
macrophage cell line, a fibroblast cell line, and a teratocarcinoma cell line using DNase I
hypersensitive (DH) site analysis. Twenty-three DH sites were found in 75 kb of
chromatin. Seven of these DH sites are T cell-specific, and five additional DH sites are
lymphocyte-specific. The T cell-specific sites are located approximately 3 kb 5' of the first
exon, 2.5 kb 3' of the first exon, 4 kb 3' of the first exon, near the second and third exons,
and 3' of the gene. There are also lymphoid, but non-T cell-specific, DH sites located in
the third intron about 10 kb to 13 kb 5' of the first exon. Two cell type-specific nuclear
matrix attachment regions are located 5' of the first exon. One repetitive element is located
about 7 kb to 10 kb 5' of the first exon and another is located in the third intron. Most of
the T cell-specific sites have been subcloned and each has T cell-specific protein/DNA
interactions associated with it. Their work suggests that the transcriptional regulation of
CD4 is complex and involves numerous protein/DNA interactions occurring 5' of the
gene, within the first and third introns, and perhaps even 3' of the gene.
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c.

CD4 Promoter

The DNA sequence and transcriptional start sites of the murine (Siu et al., 1992)
and human (Salmon et al., 1993) CD4 promoters have been determined. There are three
transcriptional start sites for the murine CD4 gene (Siu et al., 1992). An analysis of the
sequence immediately upstream of the start sites that contains the CD4 promoter elements
does not reveal a consensus TATA sequence, CAAT box, or GC-rich region, although a
pyrimidine rich region exists around the cap sites that is characteristic of Inr (Initiator)
sequences (Siu et al., 1992; Nakayama et al., 1993). In addition, a 172 bp fragment
containing the murine CD4 promoter was found, by in vitro transfection studies, to be
active through two adjacent Myb binding sites in mature CD4+CD8' T cell lines but not in
mature CD4'CD8+ or immature CD4+CD8+ T cell lines (Siu et al., 1992). The human
CD4 promoter is similar to the murine CD4 promoter (Salmon et al., 1993). There is one
major and four minor transcriptional start sites for the human CD4 gene. Sequence
analysis indicates no consensus sequences such as TATA box, CAAT box, or initiator in
the vicinity of the transcription start site. Of the six Myb consensus sequences described in
the murine CD4 promoter, only two are found in the corresponding human region.
Furthermore, the human CD4 promoter is activated by Ets proteins. In addition, the
human CD4 promoter has been shown to be sufficient to up-regulate CD4 expression in
mature murine T cells and macrophages in the absence of the T cell-specific enhancer
located 5' of the gene (Salmon et al., 1993; Hanna et al., 1994).
The tissue-specific expression of the CD4 promoter could depend on both Myb and
Ets proteins. Myb is expressed at high levels in immature CD4 CD8' and CD4+CD8
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thymocytes and at low levels in the more mature CD4+CD8' and CD4'CD8+ thymocytes
(Sheiness and Gardinier, 1984; Thompson et al., 1986). In addition, Myb is expressed at a
low level in mature T cells, but is induced upon mitogen or interleukin stumulation
(Lipsick and Boyle, 1987; Pauza, 1987; Reed et al., 1986; Stem and Smith, 1986; Torelli et
al., 1985). Ets-1 and Ets-2 are expressed at 10-fold higher levels in CD4+ thymocytes and
lymphocytes than in their CD8+ counterparts (Bhat et al., 1989). Furthermore, Ets-1, but
not Ets-2, is expressed at high levels in resting T cells and at very low levels after T cell
activation (Kaufmann et al., 1987). Ets factors have been shown to be able to interact
cooperatively with a variety of other transcription factors that include AP-1, Spl, core
binding factor, and Myb (Dudek et al., 1992; Gegonne et al., 1993; Wang et al., 1994;
Wasylyk et al., 1990). Both Myb and Ets are required for the expression of the Lck gene
in immature thymocytes (McCracken et al., 1994).
d.

T Cell-Specific Enhancer

Enhancers have been identified for the murine (Sawada and Littman, 1991;
Wurster et al., 1994) and human (Blum et al., 1993) CD4 genes. A distal murine enhancer
was identified 25 kb 5' of the CD4 gene (Wurster et al., 1994). This enhancer is not T cellspecific. Furthermore, while the distal enhancer is capable of stimulating the CD4
promoter, it more likely stimulates another gene that lies between the distal enhancer and
the proximal enhancer. A proximal murine minimal enhancer was mapped to a site
13.5 kb 5' of the transcriptional start site (Sawada and Littman, 1991). This element is
T cell-specific but not subclass-specific. It stimulates the CD4 promoter in a similar way
that the TCRp enhancer stimulates the activity of the CD4 promoter. It consists of three
sites, CD4-1, CD4-2, and CD4-3. The CD4-2 site was shown to interact with the
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TCF-loc/LEF-l protein. However, only mutations in the CD4-3 site resulted in significant
loss of enhancer activity, indicating the importance of the CD4-3 site and not the CD4-1 or
CD4-2 sites. CD4-3 contains two E-box motifs. Three nuclear protein complexes were
identified within the CD4-3 site, CD4-3A, CD4-3B, and CD4-3C (Sawada and Liftman,
1993). The CD4-3A site contains the 5' E-box and binds HEB and El2, or an E12-related
protein. The proximal human enhancer (Blum et al., 1993) is located 6.5 kb 5' of the
human gene. Sequence comparison between the human and murine enhancers reveals that
the CD4-3 site is the only conserved element of the three previously reported murine
protein/DNA binding sites. Although CD4-2, which interacts with TCF-la/LEF-1, was
stressed by Sawada and Liftman (1991) this site is not conserved in the human enhancer.
In addition, the human enhancer is homologous to regions outside the murine minimal
enhancer. This suggests that the DNA surrounding the murine minimal enhancer may also
be important to enhancer function. Finally, the human enhancer works the best with the
human CD4 promoter, as compared to the CD3 delta promoter.
One group was unable to confirm enhancer activity in vitro for the proximal murine
sequences (Siu et al., 1992), discussed in section B2g. However, studies in transgenic
mice confirmed the presence of the murine T cell-specific enhancer (Blum et al., 1993;
Killeen et al., 1993; Hanna et al., 1994). These reports indicate that the T cell-specific
enhancer is indeed capable of stimulating an increased level of T cell-specific transcription.
In addition, Hanna et al. (1994) demonstrated that the T cell-specific enhancer fragment is
required for activating CD4 expression in CD4+CD8+ thymocytes.
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e.

CD4 Silencer

While the work of Wilkinson et al . (1991a) illustrated the dominant aspects of
negative control of CD4, indication that the first intron might contain negative control
elements was provided by the work of Sands and Nikolic-Zugic (1992). They showed the
presence of two T cell-specific DNase I hypersensitive sites in the first intron. DNase
hypersensitivity site 9 (DH9) correlates with the absence of expression of CD4 in
thymocytes and mature T cells, while DNase I hypersensitivity site 10 (DH10) does not
vary once the pro-T cell enters the thymus. Experiments in transgenic mice have since
implicated the importance of the first intron in controlling CD4 expression. Only
transgenic constructs containing the first intron express reporter genes in a somewhat
normal fashion (Blum et al., 1993; Gillespie et al., 1993). Blum et al. (1993) used
constructs that contained all the exons and introns of the human CD4 gene except about
20 kb of the third intron. These constructs demonstrate subclass-specific expression of the
human CD4 gene throughout the process of T cell development in transgenic mice.
Gillespie et al. (1993), using human CD4 constructs containing 10 kb 5' of the first exon,
the first intron, second exon, second intron, and the 5' portion of the third exon of the
genomic DNA fused to the remaining coding regions of the cDNA, were also able to
obtain correct expression.
Recently, a transcriptional silencer was identified within the first intron (Sawada et
al., 1994; Siu et al., 1994). Sawada et al. (1994) identified the silencer on a 428 bp
fragment located approximately 2.5 kb 3' of the transcriptional start site. This element
corresponds to DH9 (Sands and Nikolic-Zugic, 1992). Siu et al. (1994) identified the
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silencer within a 6.0 kb region of the first intron. This fragment encompasses the 428 bp
fragment identified by Sawada et al. (1994), and includes DH9 and DH10 (Sands and
Nikolic-Zugic, 1992). The 428 bp fragment down-regulates CD4 expression in CD4 CD8
and CD4'CD8+ T cells, but does not appear to regulate CD4 in non-T cells. In contrast, the
6.0 kb fragment down-regulated CD4 expression in CD4 CD8' and CD4'CD8+ T cells as
well as non-T cells. Furthermore, careful examination of the data indicates that the
constructs using the 428 bp fragment do not confer complete subclass-specificity, while
those using the 6.0 kb fragment do. These experiments suggest that a larger region of the
intron, involving DH9 and DH10, is necessary for proper expression. The critical
sequences and/or binding sites within these regions have not been reported. In addition, a
human counterpart to the murine CD4 silencer has been identified (Donda et al., 1995).
f.

Other Transcriptional Control Elements

In addition to the elements discussed above, other elements participate in the control
of the CD4 gene. The differences in results concerning the silencer identified by Sawada et
al. (1994) and Siu et al. (1994) suggests that there are other components or regulatory
elements located in the first intron. Sawada et al. (1994) identified the silencer on a 428 bp
fragment using constructs with various deletions in the first intron which were tested in
transgenic mice. Careful analysis of their results indicates the presence of three other
potential elements. There is a negative element located approximately one kb 3' of the
428 bp fragment within a 1.1 kb SpeVBsfXl fragment corresponding to DH10 (Sands and
Nikolic-Zugic, 1992). A positive element appears to be located 3' of DH10 located within
a 3.5 kb SpellHindlW fragement. Another positive element appears to be located between
DH9 and DH10 within a 0.5 kb BstXUSpel fragment. These elements may constitute part
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of a larger regulatory element located within this region, which includes the 428 bp
silencer.
Another transcriptional control element is located 3' of the CD4 gene. DNA in this
region stimulates transcription from the CD4 promoter in B cells and appears to prevent
the CD4 promoter from functioning in T cells (Blum et al., 1993). A Northern blot
analysis of the region 3' of the murine CD4 gene for the presence of other genes indicates a
B cell/macrophage-specific gene is located in this region (Sands, unpublished results).
In addition, Sands and Nikolic-Zugic (1992) reported T cell-specific DH sites located 3' of
CD4 and proposed that these sites could be either involved in regulating CD4 or in
regulating the expression of a gene located 3' of CD4. The transgenic data from Blum et
al. (1993) are consistent with the hypothesis that the 3' T cell-specific DH sites are the
result of T cell-specific repressors binding to a B cell/macrophage-specific enhancer which
is able to stimulate the CD4 promoter to function in B cells.
There are also other control elements which repress the CD4 promoter in
thymocytes (Siu et al., 1992; Blum et al., 1993; Hanna et al., 1994). Siu et al. (1992)
demonstrated that the CD4 promoter functions poorly in CD4+ cell lines derived from the
thymus, but functions well in CD4+ cells derived from the periphery. Blum et al. (1993)
and Hanna et al. (1994) illustrated that when 3 kb of DNA 5' of the promoter is included in
constructs, along with the first intron, there is no expression in thymocytes, but there is
expression in peripheral CD4+ T cells. These experiments indicate that the mechanism of
CD4 expression differs in the thymus versus the periphery.
Another element represses CD4 expression in mouse macrophages. The human
CD4 gene is expressed in a variety of cells, including macrophages, while mouse CD4
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gene expression is mainly restricted to T cells. Hanna et al. (1994) suggested that the
endogenous mouse CD4 gene fails to be expressed in mouse macrophages because it lacks
the required macrophage-specific regulatory elements or contains a suppressor sequence
which inhibits transcription in macrophages. They suggest that these control sequences are
located within a 2.5 kb region 5' of the first exon. Their data suggests that the region
immediately 5' of the promoter may contain another element important for the control of
CD4 expression.
In summary, there appear to be numerous elements in addition to the 5' enhancer
and the intronic silencer which control CD4 expression. These are located within the first
intron, 3' of the CD4 gene, and around the promoter. In addition, DNA sequences 3' of
the murine enhancer may also contain a negative element. More refined analysis of these
regions are needed to identify and define the sequences responsible for these activities.
g-

Problems with the Published Molecular Analysis Data

Many of the CD4 gene regulation controversies relate to the enhancer and the role it
plays in the up-regulation of CD4. As discussed above, the T cell-specific enhancer was
identified for the murine CD4 gene within a 339 bp fragment located 13.5 kb 5' of the CD4
promoter (Sawada and Littman, 1991). Although the paper concerns the identification of
murine enhancer and the stimulation of the murine promoter, a combination of murine and
human cell lines were used to test these elements. In particular, the CD4 CD8 T cells used
in the analysis were human Jurkat cells. Three functional sites were identified within the
339 bp enhancer (Section 5d). Although mutations in the third site, CD4-3, decrease
enhancer activity by 90%, the main focus was placed on the characterization of the second
site which when mutated, only decreased the enhancers activity by 40%. Later,
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comparisons of the human and murine enhancers revealed that the third site and not the
second is conserved between the two species (Blum et al., 1993). Siu et al. (1992) stated
that no enhancer activity was found in the region identified by Sawada and Liftman (1991).
However, this discrepancy appears to result from using different amounts of DNA
attached to the enhancer region. In order for the enhancer to work efficiently, it must be a
small piece of DNA similar to the 339 bp fragment used by Sawada and Liftman (1991).
If an additional 350 bp 3' of the CD4-3 site is included, the enhancer functions only 35% to
60% as active as the 339 bp fragment. This suggests that the region 3' of the enhancer is
important to the enhancers regulation, and may contain a repressor element.
While the presence of the enhancer was later confirmed by other groups, the role it
plays in the up-regulation of CD4 remained questionable. Siu et al. (1992) indicated that
the murine CD4 promoter directs high levels of expression in mature CD4+CD8' T cell
lines but not in mature CD4'CD8+ T cell lines. In addition, they reported that the murine
CD4 promoter did not function in cloned immature CD4+CD8+ thymomas, unless linked
to the TCRP enhancer. Blum et al. (1993) showed a similar result using the human CD4
promoter. However, they demonstrated that the human promoter responds to the human
CD4 enhancer in mature CD4+ murine T cells. Similarly, Hanna et al. (1994) showed that
the addition of the murine enhancer to the human CD4 promoter increases expression of
CD4 in CD4+CD8' T cells and CD4+CD8+ thymocytes. Furthermore, they demonstrated
that the murine enhancer is required for up-regulation of the human CD4 promoter in
CD4+CD8+ murine thymocytes but not in mature murine CD4+CD8' peripheral T cells.
Interestingly, Killeen et al. (1993) stated that appropriate expression of CD4 in both
CD4+CD8+ and CD4+CD8‘ cells requires the T cell-specific enhancer, while they show no
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data to support this statement. Their last publication, however, supports this conclusion.
Finally, Sawada and Liftman (1991) reported that a CAT construct, driven by both the
murine CD4 promoter and murine enhancer, is active in CD4' as well as CD4+ cell lines.
Futhermore, they suggest that the enhancer is required to up-regulate CD4 expression in
both CD4+CD8+ and CD4+CD8‘ cells. So, whether the enhancer is required at the double
positive and single-positive stages or just at the double-positive stage remains disputed.
One solution to this discrepancy could be that the murine and human elements work
differently in controlling CD4 expression.
In addition to the controversy concerning the enhancer, there are other problems
related to the analysis of CD4 gene regulation. Although the human and murine CD4
genes are similar in structure and function, they are not identical. Human CD4 is
expressed on T cells and thymocytes, macrophages, and a number of other cells discussed
in section C. Murine CD4 is expressed mainly on T cells and thymocytes. Since human
CD4 and not murine CD4 is a receptor for HIV, experiments have been directed at
producing transgenic animals that express human CD4 in order to study AIDS (Gillespie
et al., 1993). Some of the control elements appear to be similar between human and
mouse CD4. For example, both genes have similar promoters which lack TATA and
CAAT elements (Siu et al., 1992; Salmon et al., 1993). Both genes have enhancers located
5' of the promoter (Sawada and Liftman, 1991; Blum et al., 1993) although the murine
enhancer is located further 5' than the human enhancer. The human CD4 gene can be
expressed in mouse macrophages indicating that the /ra«s-acting factors necessary for
macrophage expression are present in the mouse (Hanna et al., 1994). This also suggests
that the murine CD4 gene lacks important c/s-acting control elements required for
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macrophage expression, or that the murine CD4 gene contains negative control elements
that repress CD4 expression in macrophages. The differences between the human and
murine CD4 genes raises important questions concerning the comparisons of their
regulatory mechanisms. Is it valid to assume that these genes are so similar that mixing
and matching human and murine regulatory elements does not matter? Are the differences
between the human and murine systems at the heart of the problem concerning the
conflicting reports about the role various elements play?
Finally, another problem concerns the construction of vectors used to test various
elements. Both Blum et al. (1993) and Killeen et al. (1993) used similar constructs of the
human CD4 gene. The 1.3 CD4-1 construct used by Blum et al. (1993) contains
approximately 3.5 kb 5' of the first exon and 9.5 kb 3' of the last exon plus a 1.3 kb
restriction fragment located about 6.5 kb 5' of the first exon which contains the human
enhancer. Killeen et al. (1993) used a construct containing 3 kb 5' and 8 kb 3' plus a 4.5 kb
fragment from 13 kb 5' of the murine promoter which contains the murine enhancer.
Blum et al. (1993) shows that only 58% of CD4+ cells were expressing their transgene,
while Killeen et al. (1993) does not show data to indicate what percentage of CD4+ cells
were expressing their transgene. In both cases, however, the enhancer fragment was
removed from its position in the genome and placed closer to the promoter. In contrast,
Gillespie et al. (1993) used a human CD4 gene construct containing 14 kb upstream of the
first exon and DNA extending from the first exon to the middle of the third exon of the
human CD4 gene. This construct left the enhancer in its normal position, located 6.5 kb 5'
of the first exon. Their transgene was expressed in a tissue-specific manner in which all
CD4+ cells also expressed the transgene suggesting that the DNA between the promoter
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and the enhancer is important for control of CD4 expression. This is underscored by the
results discussed above, in which the function of the murine enhancer differs depending on
the size of fragment it is carried on (Sawada and Littman, 1991; Siu et al., 1992). It is
possible that experiments in which elements were removed from their normal location
resulted in the loss of other regulatory elements such as those discussed in section B2f. In
addition, this also results in the disruption of chromatin structure which may be important
to CD4 gene regulation (Sawada et al., 1994).
In summary, the regulation of the CD4 gene is a complex, tightly regulated
process. This system seems to be controlled by several regulatory elements in different
cell types. Some of these elements control expression in mature CD4+CD8‘ T cells, allow
expression in immature CD4+CD8+ T cells (such as the T cell-specific enhancer), direct
expression in macrophages, or down-regulate CD4 in CD4'CD8+, CD4‘CD8‘, and
non-T cells (such as the silencer). Some of the conflicting results obtained by different
groups may indicate that the context in which these various elements are assembled is of
great importance and that the murine and human systems are not identical. A more refined
analysis leading to the identification of these factors should explain some of the
discrepancies.

C.

NON-T CELL GENE EXPRESSION
The pattern of CD4 expression on non-T cells appears to be species-specific. In the

mouse, CD4 is expressed primarily on thymocytes and mature T lymphocytes. In
addition, CD4 expression has been reported on some thymic stromal cells (Tucek and
Boyd, 1990), while not on thymic dendritic or splenic dendritic cells (Ardavin and
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Shortman, 1992). Human cells express CD4 on thymocytes and mature T lymphocytes
(Maddon et al., 1987), monocytes (Moscicki et al., 1983; Wood et al., 1983), macrophages
(Maddon et al., 1987; Scoazec and Feldmann, 1990), Langerhans cells (Schmitt et al.,
1990), dendritic cells (Maddon et al., 1987), eosinophils (Maddon et al., 1987; Lucey et al.,
1989), megakaryocytes (Basch et al., 1990; Gewirtz et al., 1992), neurons and glial cells
(Sawada et al., 1992; Funke et al., 1987), granulocytes (Maddon et al., 1987), some colon
epithelial cells (Omary et al., 1991), hepatic sinusoidal endothelial cells (Scoazec and
Feldmann, 1990), and some B cells (Maddon et al., 1987). CD4 expression has been
reported in the brain, but this appears due to infiltrating macrophages or microglial cells
(Sawada et al., 1992; Koenig et al., 1986). Rat CD4 is expressed on macrophage (Jefferies
et al., 1985), and Langerhans cells, and alveolar dendritic cells (Simecka et al., 1992) in
addition to thymocytes and T cells. The cynomolgus monkey expresses CD4 on
monocytes and macrophages (Li et al., 1991). In mice, the lack of expression of CD4 in
macrophages appears due to a truncation in the 3' coding region of CD4 (Moore et al.,
1992).
The human cells listed above all bear CD4 receptors, which makes them potential
targets for infection with the human immunodeficiency virus (HIV-1). HIV-1 infects and
replicates efficiently in cells of the macrophage/monocyte lineage (Gartner et al., 1986b; Ho
et al., 1986). Furthermore, infection of macrophages seems dependent on the degree of
expression of CD4 at the moment of infection (Asjo et al., 1987; Dalgleish et al., 1984;
Klatzmann et al., 1984; Perno et al., 1990; Potts et al., 1990; Kazazi et al., 1989). Tissue
macrophages are a selective targets for HIV, as shown by infection of Langerhans cells of
the skin (Tschachler et al., 1987), Kupffer cells of the liver (Hoda and Gerber, 1991),

41
alveolar macrophages of the lung (Salahuddin et al., 1986; Plata et al., 1987), and
reticuloendothelial cells in lymph nodes (Armstrong and Home, 1984). More importantly,
macrophage-like cells account for the large majority of cells infected by HIV in the central
nervous system. Macrophage infection and neuronal dysfunction in the brain play a crucial
role in the pathogenesis of HTV-related dementia complex (Koenig et al., 1986; Gabuzda
and Hirsch, 1987; Gartner et al., 1986a). Studies have shown that blood dendritic cells can
be infected by HIV (Macatonia et al., 1990; Patterson et al., 1991; Langhoff et al., 1991).
However, it is not clear whether this occurs at a high level in vivo (Cameron et al., 1992),
or whether it is dependent on CD4 expression (Chehimi et al., 1993). Eosinophils can
bind gpl20 (Lucey et al., 1989) and support HTV replication (Freedman et al., 1991). It
has been suggested that a degree of eosinophilia may be advantageous for survival in
advanced HIV infection (Smith et al., 1994). HIV-1 infection of colon epithelial cells
occurs independently of CD4 (Omary et al., 1991; Phillips and Bourinbaiar, 1992; Yahi et
al., 1992; Asmuth et al., 1994). Instead, galactosylceramide (galactocerebroside, GalCer)
is an alternate receptor in these cells (Yahi et al., 1992; Fantini et al., 1993). GalCer is also
abundant in the brain and appears to mediate HIV-l entry into some neural cells (Harouse
et al., 1991). Finally, although some B cells express CD4, it has been shown that an
alternate receptor for HTV in these cells are membrane immunoglobulins of the VH3
family (Berberian et al., 1993). So, while HTV can infect CD4+ non-T cells, their role in
AIDS pathogenesis is not clear.
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D.

OBJECTIVES
Prior to 1991, very little was known about the molecular mechanism of CD4 gene

regulation. The human and murine cDNAs had been isolated (Maddon et al., 1985;
Tourveille et al., 1986), and the genomic organization of these genes had been determined
(Gorman et al., 1987; Liftman and Gettner, 1987; Maddon et al., 1987). In addition, we
knew that CD4 gene expression was regulated by both transcriptional and
post-transcriptional mechanisms, at least following T cell stimulation (Paillard et al., 1990).
Then, in 1991, two papers were published which provided additional insights into
CD4 control. Wilkinson et al. (1991a) provided evidence of repression in T lymphoma
cells early in development, suggesting a mechanism for the down-regulation of CD4 in
immature thymocytes. Sawada and Liftman (1991) identified an enhancer 5' of the murine
CD4 gene, providing a mechanism for the up-regulation of CD4 in thymocytes and
peripheral T cells.
Also, in 1991, John F. Sands came to Loma Linda University and I joined his
laboratory. He had been studying the murine CD4 gene, and was in the process of
publishing a paper (Sands and Nikolic-Zugic, 1992). His work involved an extensive
analysis of the CD4 locus that identified possible transcriptional control elements. A
summary of those results is presented in Figure 1.1. DH sites 7 through 11, 17, and 18 are
T cell-specific. DH sites 3 through 6, 13, and 15 are lymphoid-specific or are present in
cells that are pluripotent (F9). Most of the T cell-specific sites had been subcloned. Each
T cell-specific site has associated with it a T cell-specific protein/DNA interaction. The
cell-specificity of these DH sites and the correlation of the various sites with the presence
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or absence of CD4 expression suggested that the protein/DNA interactions identified by
these DH sites are involved in the transcriptional regulation of the CD4 gene.
Therefore, the first goal of our work was to determine the transcriptional function
associated with the putative c/s-acting elements located 5' of the CD4 promoter and within
the first intron (Chapter 3). We made numerous recombinant DNA constructs to
determine the contribution that these putative transcriptional control elements provide with
regard to the regulation of CD4 expression. Our results indicate that there are multiple
positive and negative cA-acting elements within the 15 kb 5' of the promoter and the first
intron that control the expression of the murine CD4 gene. This work provided the basis
for the experiments in Chapters 4 through 6.
One of the important negative control regions indicated by the deletion analysis was
located within the first intron, in a 1.6 kb Xba\ fragment which contained OHIO. The
second goal of our work was to identify and characterize this negative control element
(Chapter 4). The T cell-specific protein/DNA interaction corresponding to DH10 was
mapped to a 280 bp fragment within the 1.6 kb region. This smaller fragment was used in
minigene expression constructs involving the enhancer and CD4 promoter to determine its
effect on CD4 gene expression. In addition, the protein/DNA interaction was studied using
nuclear extracts from various T lymphoma cell lines, and mapped to a repeated sequence
within the 280 bp fragment.
Studies of the cA-acting elements identified 5' of the CD4 promoter and within the
first intron in Chapter 3 suggested that large regions of DNA were involved in controlling
CD4 expression. We decided to investigate these control regions by first sequencing 15 kb
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Figure 1.1. Summary of DH sites, MARs, and REPs found at the CD4 locus. The
DNase I hypersensitive sites (DH sites) are indicated by arrows and labeled with Arabic
numerals. The nuclear matrix attachment regions (MARs) are indicated as hatched
boxes. The repetitive elements (REPs) are indicated as open boxes. The CD4 exons are
indicated as solid boxes. The break between DH20 and DH21 in the line representing the
DNA is 15 kb long.
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5' of the CD4 promoter and the entire first intron. Subsequent sequence analysis revealed
homology to numerous elements which could contribute to the functional activities
described in Chapter 3.
Finally, the fourth goal of our work was to identify which of the control elements
were being used to regulate the expression of CD4 during the various stages of T cell
differentiation. We used a set of T lymphoma cell lines genetically determined to represent
various stages of thymocyte development to study the putative transcriptional control
elements described in Chapter 3. Our results indicate that multiple elements control the
expression of CD4 during thymocyte development. While some are important negativeregulators, others are important positive-regulators.
In summary, our long term goal is to define the transcriptional control elements
responsible for the regulation of CD4 gene expression during T cell development.
Numerous T cell-specific protein/DNA interactions occurring 5', within the gene, and 3' of
the CD4 gene had been identified previously (Sands and Nikolic-Zugic, 1992). We
propose that many of these T cell-specific DNA interactions contribute to the
developmental regulation of the CD4 gene. Therefore, the specific aims of this thesis were:
A.

Determine the transcriptional function associated with the putative
cis-acting elements located 5' of the murine CD4 gene and within the
first intron.

B.

Characterize the negative cis-acting element located 4 kb 3' of the
promoter, within the first intron.
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C.

Sequence the 5' flanking region between the T cell specific enhancer
and promoter and sequence the entire first intron.

D.

Identify elements being used to control the expression of CD4 during
the various stages of thymocyte development.

CHAPTER 2. MATERIALS AND METHODS

A.

MATERIALS
Culture flasks, polypropylene tubes, polystyrene pipettes, nylon disposable filter

systems, and cryogenic vials were obtained from Coming Glass Works (Corning, NY).
RPMI, L-glutamine, penicillin, and streptomycin were obtained from Mediatech, Inc.
(Washington, DC). Newborn calf and fetal bovine serum were purchased from Gemini
(Calabasas, CA). Restriction enzymes, buffers, modification enzymes, and linkers were from
Promega Corp. (Madison, WI) with the exception of Not\, Sfi\, Ascl, £c/136II enzymes, and
Ascl and Sail linkers which were obtained from New England Biolabs (Beverly, MA) and the
Notl linker which was from Stratagene (La Jolla, CA). pSLl 180 was from Pharmacia LKB
Biotechnology Inc. (Piscataway, NJ), Bluescript II pKS+ was from Stratagene (La Jolla, CA),
and pCAT basic, pCAT promoter, and pCAT control were from Promega Corp. (Madison,
WI). Molecular biology grade agarose was obtained from Promega Corp. (Madison, WI) and
NuSieve low melting temperature agarose was from FMC BioProducts (Rockland, ME).
Electrophoresis grade ethidium bromide for staining gels and for cesium chloride-ethidium
bromide purification of plasmid DNA and cesium chloride were from Fisher Scientific (Fair
Lawn, NJ). Geneclean II and Mermaid kits were purchased from Bio 101 (La Jolla, CA).
Bactotryptone, agar, and bacto yeast extract were from Difco (Detroit, MI). Ampicillin was
from Boeringher Mannheim (Indianapolis, IN). Petri dishes and pasteur pipettes were
purchased from Fisher Scientific Co. (Irvine, CA). Polyallomer quick-seal ultracentrifuge
tubes were from Beckman Instruments Inc. (Palo Alto, CA). Pipetman tips were from VWR
Scientific (West Chester, PA) and microcentrifuge tubes were from USA Scientific Plastics
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(Ocala, FL). Disposable syringes and needles were from Becton Dickinson and Company
(Franklin Lakes, NJ). Reporter Lysis 5X buffer for CAT assays was obtained from Promega
Corp. (Madison, WI). N-butyryl coenzyme A was from Sigma Chemical Co. (St. Louis,
MO). Cytoscint scintillation fluid, 14C-chloramphenicol, and [y-32P]ATP were from ICN
Biomedicals Inc. (Irvine, CA). The BCA and BCA Protein Assay Reagent Kit was purchased
from Pierce Chemical Company (Rockford, IL). Magic PCR Prep was from Promega Corp.
(Madison, WI). Qiagen Plasmid Kit was obtained from Qiagen Inc. (Chatsworth, CA). The
PRISM Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit was from Applied
Biosystems, Inc. (Foster City, CA). Centri-Sep columns were from Princeton Separations,
Inc. (Adelphia, NJ). All other chemicals were molecular biology grade and were from Sigma
Chemical Co. (St. Louis, MO) or Fisher Scientific Co. (Irvine, CA).

B.

METHODS

1.

Cells and Cell Lines
a.

Cell Growth and Maintenance

The murine T lymphoma cell lines shown in Table 2.1 were grown in complete RPMI
media (RPMI supplemented with 10% newborn calf serum, 2 mM L-glutamine, 100 U of
penicillin per ml, and 100 pg of streptomycin per ml), with the exception of SL12.1 and
SL12.3 which were grown in 10% fetal bovine serum. The cells were cultured at 37°C in a
water-saturated atmosphere of 5% C02. SAKRTLS12.1 (CD4+CD8~), TB2.1 (CD4'CD8+),
and AKR1.G.1 (CD4+CD8+) were obtained from Dr. R. Hyman (Salk Institute, La Jolla, CA).
All other cell lines were obtained from Dr. C. MacLeod (University of California, San Diego,
CA).
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Table 2.1. The phenotype of T lymphoma cell lines
Name

Other Phenotypic Markers

£M

SL12.1

CDS' Thyl+ Pgpl+ HSA+ T200+

SL12.3

CDS Thyl+ Pgpl+ HSA+ T200+

SL12.4

lo

lo

CDS Thyl+ Pgpl HSA+ T200+

AKR1.G.1

+

+

CD3+ Thyl+ Pgpl HSA+ Ly-1

SAKRTLS12.1

+

TB2.1

CD3+ Thyl+ Pgpl+ HSA+ T200+

+

CD3+ Thyl+ Pgpl HSA+ Ly-1
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b.

Preparation of Culture Media

Supplements were added to the RPMI media prior to use. Complete RPMI media was
prepared in 1 liter batches and stored at 4°C. However, RPMI supplemented with 10% fetal
bovine serum was prepared fresh before each use. Serum was purchased in 100 ml bottles
which were heat inactivated at 50°C for 45 to 60 minutes. This serum was then either used
directly or frozen at -20°C in 10 ml aliquots. Other media components were purchased in
100 ml bottles which were thawed at room temperature and 10 ml or 50 ml frozen at -20°C.
c.

Freezing and Thawing Cells

Freezing media (for cells grown in fetal bovine serum, 90% fetal calf serum, 10%
DMSO; for cells grown in newborn calf serum, 10% newborn calf serum, 10% DMSO,
80% RPMI) was made in advance and stored at -20°C until use. Cells were counted using
a hemocytometer, then transferred to a sterile 50 ml tube and centrifuged at 3,500 rpm for
4 minutes at 24°C in a Beckman table-top centrifuge. The cell pellet was resuspended in
freezing media to a cell concentration of 5 x 106 cells/milliliter. One milliliter quantities
were transferred to plastic cryogenic vials and frozen at -70°C. Half of the vials were later
transferred to liquid nitrogen for long term storage at -196°C.
To thaw the cells, a tube was removed from -70°C and thawed rapidly at 37°C. The
freezing mixture was diluted out slowly by adding warm complete media dropwise over
1 to 2 minutes for a total volume of 15 milliliters, thereby preventing osmotic damage to
the cells. The cell suspension was then transferred to a sterile 15 milliliter tube and
centrifuged at 3,500 rpm for 4 minutes at room temperature in a Beckman table-top
centrifuge. The cell pellet was resuspended in 7 to 15 milliliters of complete media (or at a
10-fold higher concentration than usual after routine subculture) and transferred to a small
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flask for growth overnight. The following day, cell viability was determined using a
hemocytometer, and the cells diluted for 3 days of growth.
d.

Determining Cell Count and Viability

Total cell count and determination of viability was done using a Neubauer
hemocytometer (Fisher Scientific Co.) and a PhotoZoom Inverted Microscope (Cambridge
Instruments). For total cell count, 10 pi of the cells from a culture flask were loaded onto
the hemocytometer. The cells were counted for each of 5 grids and the total number of
cells/ml (N) calculated as: N = (Total number of cells in 5 grids/5) x 104.
Viability counts were done in a similar manner using the dye exclusion test. Ten
microliters of cells was added to an equal volume of trypan blue (0.4% in dH20, filtered
through 0.45 pm filter), mixed, and left for 1 to 2 minutes. The cells were introduced onto
the hemocytometer and the total number of cells unstained and stained were counted. The
total number of cells/ml (T) was calculated as: T = (Total number of cells in 5 grids/5) x 2
x 104. Percent viability (V) was calculated as: V = (Number of cells unstained/Total
number of cells) x 100.
2.

Construction of Expression Vectors
a.

Construction of the 5' Deletion Series

The DNA extending from the Xho\ site in the first exon to 15 kb 5' of the first exon
was initially subcloned as three restriction fragments. A SaWXbal restriction fragment
extending from the Sail site in the linker cloning region of RL5 (Sands and Nikolic-Zugic,
1992) to the Xba\ site located approximately 4.5 kb 5' of the first exon of CD4 was subcloned
into pSLl 180 and called \)SL-SallXba. pSL-prom was constructed by subcloning the 487 bp
XbaVXhol fragment containing 416 bp of sequence upstream of the transcriptional start site of
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CD4 and 71 bp of the 5' untranslated (UT) region into the XbaUXhol sites of ySL-SaUXba. A
derivative of Bluescript II pKS+ was constructed where the Xhol site was destroyed by filling
in the four base sticky end with Klenow. This derivative was used to clone the 4 kb Xbal
fragment immediately downstream of the DNA sequence contained in ySL-SallXba. The
resulting vector was named pKS-Afa. The Xhol site within the 4 kb Xbal insert was destroyed
by filling in the four base sticky end with Klenow and religating the blunted vector to itself
resulting in pKSAATio. The Xbal fragment of pKSAATio was subcloned into the Xbal site of
pSL-prom resulting in pMSl. pMSl contains an intact region of DNA encompassing 15 kb
5' of the CD4 gene and 71 bp into the first exon with the only modification being the addition
of 4 bp at the filled in Xhol site approximately 4 kb upstream of the promoter. The 5' Sail
restriction site of pMSl was changed to a Notl restriction site by filling in the Sail site with T4
DNA polymerase and ligating a Notl linker to the blunted site. The Sfil site within the
pSLl 180 portion of pMSl was blunted with T4 DNA polymerase and an Ascl linker ligated to
the blunted site. This final vector, pABl, contained the 15 kb of CD4 sequence flanked by
unique Notl/Ascl sites.
The Sad 5' deletions of pAB2, pAB3 and pAB4 were made by partially digesting
pABl with Sad, gel isolating the fragments and religating. The pAB5 5' deletion was made
by completely digesting pABl with EcoRl, which digests within the pSLl 180 linker and at a
site 6 kb upstream of the CD4 promoter, and then religating the cut vector to itself.
b.

Construction of the Intronic Deletion Series

The 3' end of the first intron was subcloned into pSLl 180 by isolating a Hindlll/Sad
restriction fragment from RL5 that encompassed the 1.8 kb first intron terminus, the first
intron splice acceptor and 26 bp of the 5' UT of the second exon, but is 13 bp upstream of the
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sequence representing the translational start codon of the CD4 gene. The Sad site of this
construct was T4 DNA polymerase blunted and a Sail linker was ligated to it. This construct
was called pB2. A pKS+ derivative was constructed which had its Xba\ site converted to an
Asd site by filling in with Klenow and linker ligation. This pKS+ derivative was ligated to the
HindAWJEcoRl fragment of pB2 generating pB3. A 7 kb XhoUHindlYL restriction fragment
extending from the Xho\ restriction site within the first exon to the HMYH restriction site in the
first intron was isolated from RL5 and subcloned into the Xhol and Hin&XW sites of pB3. This
clone is called pBCl and contains the first exon, the full first intron, the first intron splice donor
and acceptor and most of the 5' UT but does not contain the translational start codon of the
CD4 gene. The pBCl clone was digested with Xba\ and religated to itself to delete the 1.6 kb
Xba\ restriction fragment that exists in the first intron thus making pBC2.
The pAC4d was constructed by digesting pBC 1 with Pst\ and then religating the cut
vector to itself to make pBCAPs/. The pBCAPs/ clone was digested with Xhol and Asd, the
2.5 kb first intron/CAT fragment gel purified, and then ligated to pAB4 that had been cut with
Xhol and Asd to make pAC4d. The pAC4c clone was created by first converting the 5' Sad
site of pAB4 to a Sail site by digesting pAB4 with Sad, blunting with T4 DNA polymerase
and then adding a Sail linker to make pAB4/&?/. The pXBAISal clone was digested with Xhol
and Asd and ligated to the gel purified XhoUAsd first intronic/CAT fragment of pBCl to make
pAC4ASar/. The pAC4ASa/ clone was digested with Sad and then religated to itself to make
pAC4c.
c.

Addition of the CAT Reporter Gene

The CAT gene was obtained from the vector, pCAT basic (Promega Corp.). The
pCAT basic vector was digested with BamlAA, filled in with T4 DNA polymerase, and an Asd
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linker ligated to the filled in site. The CAT gene was removed from this altered pCAT basic
vector (pBCl .2) as a Sa/I/AscI restriction fragment and subcloned into the Sa/I and AscI sites
of pBCl and pBC2 to make pBCl.O and pBCl. 1 respectively. The JflioI/AscI fragments of
pBC 1.0 and pBC 1.1 were gel isolated and ligated to the Afrol and AscI sites of the
pABl-pAB5 series described above. The Sa/I/AscI fragment of pBCl .2 containing the CAT
gene without intronic sequences, was also ligated to the pABl-pAB5 series by fusing with the
XhoI/AscI restriction sites in these constructs. The final CD4 subclones make up the pAC 1 pAC5 series shown in Chapters 3 and 6.
d.

Construction of the Promoter and Promoter/Enhancer Series

The 900 bp PsiUXhol CD4 promoter fragment was ligated into the PsiUSatl sites of
pCAT basic resulting in p900, while the 500 bp XbaUXhol CD4 promoter fragment was
ligated into the XbaHSaW sites of pCAT basic resulting in p500. The T cell-specific enhancer,
isolated as a 339 bp BstXUAvaW fragment, was blunted with T4 DNA polymerase and ligated
into the blunted Sphl site of p900 and p500, resulting in pEPCl and pEPCO.5, respectively.
The 900 bp PstUXhoI CD4 promoter fragment was also ligated into the PstUSaB sites of
pCAT enhancer, which contains the SV40 enhancer, resulting in pSEPCl.
e.

Construction of Intron Element Series

The recombinant DNA constructs to test the intronic element were constructed
using the p900 and pEPCl vectors. The intronic element, cloned as a 280 bp
///>?cII/Ec/136II fragment, was placed into the blunted AscI site of p900 and pEPCl. This
produced constructs with 2 copies of the insert in either the forward or reverse orientation
(eg. p900M or p900MR, and pEPCl M or pEPCl MR). The 2.2 kb or 6 kb Sad
fragments located 10 kb to 12.2 kb or 4 kb to 10 kb 5' of the first exon, respectively, were
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also ligated into various pEPCIMR constructs (eg. p2.2MR, p6MR). These fragments
were blunted into the filled in Hin&H\ site of the respective vectors as £c/136H fragments.
The constructs containing a heterologous promoter and enhancer were made using
the pCAT control vector (Promega Corp.), which was called pSV40. In this case, the 280
bp intronic fragment was ligated into the reciepient vector as a //7>icII/£c/136II fragment
(e.g. pSV40M).
3.

Preparation and Transformation of Competent E. coli
a.

Preparation of Fresh and Frozen Competent E. coli

1.

Preparation using T Salts

A minimal medium plate (5X M9 salts (24 mM Na2HP04 • 7H20, 11 mM
KTLjPO^ 4 mM NaCl, 9 mM NH4C1), 20% dextrose, 12 pg of tetracycline per ml) was
streaked with E. coli XL1 blue cells and grown overnight at 37°C. This plate was used to
inoculate a 10 ml starter culture (LB, 30% dextrose, and 12 pg of tetracycline per ml)
(Maniatis et al., 1989) which was grown overnight at 30°C with vigorous shaking. A
100 ml culture of LB was then inoculated from the starter culture and grown for 2 hours at
30°C. This culture was quick-cooled in an ice slurry for 2 hours, with gentle swirling
every 15 minutes. The cells were pelleted by centrifugation at 2,500 rpm for 5 minutes at
4°C. The pellet was gently resuspended in 25 ml T-salts (0.1 M CaCl2, 70 mM MnCl2,
40 mM NaOAc pH 5.5) and incubated on ice for 30 minutes. The cell suspension was
centrifuged again at 2,500 rpm for 5 minutes at 4°C and the pellet resuspended in 5 ml
T-salts plus 900 pi 100% glycerol. The cells were quick frozen in liquid nitrogen in 50 pi
aliquots, then transferred to -70°C for storage.
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2.

Preparation using Calcium Chloride

Competent E. coli cells were also prepared using calcium chloride as described by
Cohen (1972). Bacterial cells (DH5a, XL1 Blue) (Maniatis et al., 1989) were used to
inoculate 100 ml of LB and grown at 37°C with vigorous shaking until the OD590 reached
0.2-0.4. The cells were transferred to a sterile 50 ml tube and centrifuged at 3,000 rpm for
10 minutes at 4°C. The bacterial pellet was resuspended in 50 ml of cold 100 mM CaCl2
and incubated on ice for 30 minutes. This was followed by centrifugation at 3,000 rpm for
10 minutes at 4°C. The pellet was then resuspended in 5 ml of cold 100 mM CaCl2 and
25% glycerol. 50 fil aliquots of the cells were quick frozen in liquid nitrogen and stored at
-70°C or used directly to transform.
3.

Preparation for Electro-transformation

This is a method originally used to introduce DNA into eukaryotic cells, but was
adapted for high level transformation of E. coli (Dower et al. 1988, Taketo 1988). A
50 ml volume of LB was inoculated with NM477 cells from a fresh overnight culture. The
cells were grown at 37°C with vigorous shaking to an OD600 of 0.5-0.8. The flask was
then chilled on ice for 15 to 30 minutes and centrifuged in a cold rotor at 10,000 rpm for
5 minutes. The pellets were resuspended in a total of 50 ml of cold water and centrifuged
again, followed by resuspension in 25 ml cold water and further centrifugation. Next the
pellet was resuspended in 1 ml of 10% glycerol and recentrifiiged. Finally, the cells were
resuspended in 150 pi of 10% glycerol. The cells were quick frozen in liquid nitrogen and
stored at -70°C.
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b.

Transformation of Competent Cells

1.

T-salt or Calcium Chloride Methods

This method was used to introduce DNA into bacterial cells through heat shock
(Cohen et al., 1972). An aliquot of recombinant DNA (100 to 250 ng) was added to 50 til
of competent E. coli cells. The tubes were gently swirled for several seconds to mix their
contents, and incubated on ice for 30 minutes. The tubes were then transferred to a heating
block that had been preheated to 42°C and heat shocked for 40 seconds, followed by
transfer to ice. After 1 minute, 800 pi of LB medium was added to each tube. The cultures
were incubated for 1 hour at 37°C to allow the bacteria to recover and to express the
ampicillin resistance (AmpR) marker encoded by the plasmid. Appropriate volumes (20 to
200 pi per 100-mm plate) of transformed competent cells were transferred onto agar LB
medium containing 100 pg of ampicillin per milliliter. A sterile bent glass rod was used to
gently spread the transformed cells over the surface of the agar plate. The plates were left
at room temperature until the liquid had been absorbed, then inverted and incubated at 37°C
overnight.
2.

Electro-transformation

This method was used for the high-efficiency transformation of NM477 E. coli
cells. The cuvettes and the sliding cuvette holder were pre-chilled on ice, and the Gene
Pulser apparatus (BioRad Laboratories, Hercules, CA) was set to 25 pF capacitance,
2.5 kV, and the Pulse Controller Unit (BioRad Laboratories) to 200Q The electrocompetent cells were gently thawed at room temperature and placed on ice. Plasmid DNA
(100 to 500 ng) was added to the cells and incubated on ice for 1 minute. The mixture of
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cells and DNA was then transferred to a cold 0.2 cm electroporation cuvette. One pulse
was applied to the cells. This was immediately followed by the addition of 1 ml of LB
medium directly to the cuvette. The cell suspension was then transferred to an eppendorf
tube and incubated at 37°C for 1 hour. The cells (20 to 200 pi) were plated on LB agar
plates supplemented with 100 pg of ampicillin per ml and incubated overnight at 37°C.
4.

Extraction of Plasmid DNA
a.

Small-scale Preparation

This protocol was used to isolate small amounts of plasmid DNA from bacterial
cells for the purpose of screening large amount of colonies for a desired clone (Birnboim
and Doly, 1979; Ish-Horowicz and Burke, 1981). A single bacterial colony from a
transformation plate was transferred into 2 ml of LB medium containing 100 pg of
ampicillin per ml in a loosely capped 15-ml tube. The culture was incubated overnight at
37°C with vigorous shaking. Approximately 1.5 ml of the culture was poured into a
labeled microfuge tube, and centrifuged at 13,000 rpm for 2 minutes at room temperature
in a Baxter Biofuge 13 microcentrifuge (Baxter Diagnostics Inc. Scientific Products
Division, McGaw Park, IL). The remainder of the culture was stored at 4°C. The medium
was removed by aspiration, and the bacterial pellet washed with 1 ml of solution 1 (50 mM
glucose, 25 mM Tris pH 8.0, 10 mM EDTA pH 8.0) followed by centrifugation at
13,000 rpm for 2 minutes. The bacterial pellet was then resuspended in 150 pi of cold
solution 1 plus 5 pi of RNase A (10 mg/ml). After a 5 minute incubation on ice, 350 pi of
solution 2 (1% SDS, 0.05 N NaOH) was added and mixed by inverting the tube 5 times.
The tube was incubated on ice for 15 minutes, followed by the addition of 250 pi of cold
solution 3 (3 M potassium, 5 M acetate). Again the tube was mixed by inverting 5 times
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and incubated on ice 20 minutes. The tube was centrifuged at 13,000 rpm for 10 minutes
at 4°C in a microfuge and the supernatant transferred to a fresh tube containing 400 pi of
isopropanol to precipitate the DNA. After 5 minutes at room temperature, the tube was
centrifuged at 13,000 rpm for 5 minutes at room temperature. The supernatant was
removed by gentle aspiration and the DNA pellet washed with 1 ml 70% ethanol.
Following centrifugation at 13,000 rpm for 1 minute at room temperature, the pellet was
dried using a Savant Speed Vac Concentrator (Savant Instruments, Inc., Farmingdale,
NY). The DNA was then resuspended in 20 pi of sterile dF^O, digested with the
appropriate enzymes, and run on an agarose gel.
b.

Large-scale Preparation

This procedure was used to isolate large amounts of plasmid DNA (Bimboim and
Doly, 1979; Ish-Horowicz and Burke, 1981). A one liter flask of LB containing 100 pg of
ampicillin per ml was inoculated from a plate streaked with a clone selected in the
small-scale plasmid preparation. This culture was incubated overnight at 37°C with
vigorous shaking. The bacterial cells were harvested by centrifugation of a 500 ml bottle at
5,000 rpm for 10 minutes in a Sorvall GS3 (Dupont Co.) rotor at room temperature using
a Sorvall RC5C centrifuge (Dupont Co.). The supernatant was discarded and the bottle
filled with the remaining 500 ml culture and centrifuged again. After discarding the
supernatant and allowing the bottle to drain, the bacterial pellet was resuspended in 25 ml
of solution 1 (50 mM glucose, 25 mM Tris pH 8.0, 10 mM EDTA). Then 60 ml of
solution 2 (1% SDS, 0.05 N NaOH) was added, and the bottle mixed by inverting 3 times.
After incubation on ice for 10 minutes, 45 ml of solution 3 (3 M potassium, 5 M acetate)
was added and the bottle inverted again 3 times and incubated on ice 10 minutes. The
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bacterial lysate was centrifuged at 5,000 rpm for 10 minutes in a Sorvall GS3 rotor at 4°C.
The supernatant was filtered through three layers of Kimwipes (Fisher Scientific Co.) into
a 250 ml bottle. Approximately 0.75 volumes of isopropanol was added, mixed by
inversion, and incubated for 10 minutes at room temperature. The nucleic acids were
recovered by centrifugation at 5,000 rpm for 20 minutes at room temperature in a Sorvall
GSA rotor (Dupont Co.). The supernatant was decanted carefully and the bottle was
allowed to drain inverted for 10 minutes. This was followed by drying in a speed vacuum
for 10 minutes. The nucleic acid pellet was resuspended in dFLp and purified by
centrifugation in CsCl-ethidium bromide gradient. Typical yield was 300 to 500 (xg of
plasmid DNA.
c.

Qiagen Preparation

The Qiagen Plasmid Purification procedure (Qiagen Inc.) was performed as per kit
protocol and used to isolate and purify plasmid DNA for automated sequencing. The
following procedure was for the Qiagen-tip 500. Bacterial cells were grown in an
overnight culture of 250 ml of LB. The cells were harvested when they reached A600 = 1.0
to 1.5 by centrifugation at 4°C for 15 minutes at 6000 rpm in a Sorvall GSA rotor. The
pellet was resuspended in 10 ml of buffer PI (100 jxg RNase A per ml, 50 mM Tris/HCl,
10 mM EDTA pH 8.0). This was followed by the addition of 10 ml of buffer P2
(200 mM NaOH, 1% SDS). The suspension was mixed gently by inversion 5 times and
incubated at room temperature for 5 minutes, after which 10 ml of chilled buffer P3
(3.0 M KAc pH 5.5) was added. Again the solution was mixed immediately but gently by
inversion 5 times. After incubation on ice for 20 minutes, the sample was mixed again just
prior to centrifugation at 4°C for 30 minutes at 16,000 rpm in a Sorvall SS-34 rotor
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(Dupont Co.). The supernatant was filtered through 3 layers of Kimwipes, then loaded
onto a Qiagen-tip 500 which had be equilibrated with 10 ml QBT (750 mM NaCl, 50 mM
MOPS, 15 % ethanol pH 7.0, 0.15% Triton X-100). The Qiagen-tip was washed with 2 x
30 ml buffer QC (1.0 M NaCl, 50 mM MOPS, 15% ethanol pH 7.0), then the DNA eluted
from the column with 15 ml buffer QF (1.25 M NaCl, 50 mM Tris/HCl, 15% ethanol pH
8.5). The DNA was precipitated with 0.7 volumes of isopropanol, centrifuged at 4°C to
9,500 rpm in a Sorvall HB-4 rotor (Dupont Co.) for 30 minutes. The supernatant was
carefully removed and the pellet washed with 15 ml of cold 70% ethanol, air dried, and
resuspended in sterile dF^O. Typical yield was 300 to 500 fig of plasmid DNA.
5.

Purification of Plasmid DNA
a.

Cesium Chloride-Ethidium Bromide Gradient

The cesium chloride-ethidium bromide purification procedure was performed as
described (Radloff et al., 1967) and used to purify large amounts of plasmid DNA for use
in cloning and transient transfections. The nucleic acid pellet from the large-scale plasmid
preparation (300 to 500 pg of plasmid DNA) was resuspended in 5 ml of sterile d^O in a
15 ml disposable conical tube, 5.5 g CsCl added, and the contents mixed gently until the
salt was dissolved. Then 350 pi of EtBr (40 mg/ml in water) was added and the tube
mixed by careful inversion. Following incubation at 4°C for 15 minutes, the tube was
centrifuged in a Beckman Acuspin FR table-top centrifuge (Beckman Instruments, Inc.) at
5,000 rpm for 15 minutes at 4°C. The supernatant was transferred to self-sealing tubes and
heat-sealed using a Beckman Quick Seal Tube Sealer (Beckman Instruments, Inc ). The
tube was then placed in a VTi90 ultracentrifuge rotor (Beckman Instruments, Inc.), and
centrifuged at 85,000 rpm for 3 hours at 20°C in a Beckman XL-90 ultracentrifuge
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(Beckman Instruments, Inc.). The plasmid band was removed from the tube using a 5 cc
syringe equipped with a 19.5 gauge needle. The EtBr was extracted with 10 ml of butanol
3 to 5 times. The plasmid DNA was diluted 5- to 10-fold with sterile df^O and
precipitated with 2 volumes of 95% ethanol overnight at -20°C. This was followed by
centrifugation at 5,000 rpm for 25 minutes in a Beckman table-top centrifuge (Beckman
Instruments, Inc.) at 4°C. The DNA pellet was washed once with 70% ethanol, dried in a
speed vacuum, and resuspended in 500 pi of sterile dH20. Typical yield was 300 to
500 pg of plasmid DNA.
b.

Sucrose Gradient

Approximately 500 pg of plasmid DNA from cesium chloride purification (Section
5a) for use in the DNase I footprinting assay was further purified by sucrose gradient
centrifugation to remove residual RNA (Schans and Aten, 1969). The gradient was
prepared using a 5% sucrose solution (5% sucrose, 100 mM NaCl, 10 mM Tris pH 7.4,
1 mM EDTA pH 8.0) and a 20% sucrose solution (20% sucrose, 100 mM NaCl, 10 mM
Tris pH 7.4, 1 mM EDTA pH 8.0). DNA samples were added to the gradient and
centrifuged in an SW27 rotor at 24,164 rpm for 15 hours. The samples were collected
using a Micro Fractionator (Gilson Medical Electronics, Inc., Middleton, WI) and a sample
of the individual fractions run on an agarose gel to assess purity. The pure samples were
combined, precipitated overnight using 1/10 volume NaOAc and 2 volumes ethanol at
-20°C. The DNA was then collected by centrifugation, washed once with 70% ethanol,
and resuspended in sterile dF^O. The sucrose-purified plasmids were cut with a restriction
enzyme at one end, dephosphorylated with calf intestinal phosphatase, end labeled with
[y-32P]ATP and T4 polynucleotide kinase to a specific activity of 1 x 106 cpm/pmol, then
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cut with a restriction enzyme at the other end to remove the desired fragment. The
fragment was separated from unincorporated label by agarose gel electrophoresis. The
target band was excised from the gel and the DNA recovered by either electroelution or
Magic PCR Prep.
6.

Dephosphoryation and Labeling DNA Fragments
The procedure used for labeling the 5' end of fragments for use in the

electrophoretic mobility shift assay and DNase I footprinting assay was performed as
described previously (Maxam and Gilbert, 1980).
a.

Dephosphorylation

This reaction was set up to remove the 5' terminal phosphate from DNA fragments
prior to labeling with [y-32P]ATP and T4 polynucleotide kinase. The following was added
to 1 to 20 pmol of DNA termini: 1 [i\ calf intestine phosphatase (1000 U/ml), 10 pi 10X
phosphatase buffer (IX concentration: 50 mM Tris-HCl, pH 9.3, 1 mM MgCl2, 0.1 mM
ZnCl2, 1 mM spermidine), and sterile df^O for a final volume of 100 pi. The reaction
mixture was incubated at 37°C for 2 hours and stopped by extracting twice with equal
volumes of phenol and chloroform. This was followed by extracting once with an equal
volume of chloroform and precipitating the dephosphorylated DNA with 1/25 volume
NaOAc and 2 volumes of 95% ethanol overnight at -20°C. The sample was centrifuged
for 30 minutes at 13,000 rpm, washed twice with 70% ethanol, and resuspended in 30 pi
of sterile dfTO.
b.

Labeling the 5' Ends

The dephosphorylated DNA was labeled using [y-32P]ATP and T4 polynucleotide
kinase in the following reaction: 30 pi DNA (1 to 20 pmol), 1 pi T4 polynucleotide kinase
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(10 U/jil), 5 |al 10X kinase buffer (IX concentration: 70 mM Tris-HCl, pH 7.6, 10 mM
MgCl2, 5 mM DTT), 5 pi [y-32P]ATP (160 mCi/ml), and sterile df^O for a final volume
of 50 pi. The reaction mixture was incubated at 37°C for 1 hour and stopped by adding
2 pi of 0.5 M EDTA. This was followed by an extraction using equal volumes of phenol
and chloroform, followed by another extraction with an equal volume of chloroform. The
sample was then precipitated using 1 pi tRNA (20 mg/ml), 1 pi 5 M NaCl, and 125 pi cold
95% ethanol. After 30 minutes at -70°C, the sample was centrifuged at 13,000 rpm at 4°C
and washed two times with 1 ml of 70% ethanol.
c.

Labeling one end

Two methods were used to label one end of a DNA fragment. The PCR method
was used to generate labeled fragments from regions of the DNA where there wasn’t a
convenient restriction enzyme site. Both methods resulted in a product that was labeled at
only one end.
1.

PCR Method

Primers were made to the region of interest and labeled at the 5' end using
[y-32P]ATP and T4 polynucleotide kinase. The completed reaction was extracted once with
phenol. The unincorporated nucleotides were removed by ethanol precipitation with
10 mM MgCl2, 0.3 M sodium acetate, and 2.5 volumes of 100% ethanol, followed by one
wash with 70% ethanol. The samples were dried and resuspended in sterile dH20. The
PCR reactions were then set up in a 500 pi tube as follows: 250 ng template DNA, 20 pi
10X PCR buffer (IX concentration: 50 mM KC1, 10 mM Tris-HCl pH 8.3, 2.5 mM
MgCl2, 0.01% gelatin w/v), 50 pmol end-labeled primer A, 50 pmol primer B, 3 pi of
10 mM dNTPs (all four dNTPs at 10 mM each), 5 units Taq DNA polymerase, and dl-^O
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to a final volume of 200 [i\. The cycling reactions were performed in a Ericomp
Twinblock System EZ Cycler (Ericomp, Inc., San Diego, CA) as follows: rapid thermal
ramp to 94°C, 94°C for 60 seconds, rapid thermal ramp to 37°C, 37°C for 40 seconds,
rapid thermal ramp to 72°C, 72°C for 60 seconds. This was done for a total of 20 to 25
cycles. The reactions were extracted once with chloroform, then ammonium
acetate/ethanol precipitated. The samples were then run on an agarose gel and isolated
using the Magic PCR Prep described below.
2.

Restriction Enzyme Method

The plasmid vector was cut at one site, labeled with [y-32P]ATP and
T4 polynucleotide kinase, and cut at another restriction site to remove the fragment from
the vector. The fragments were then separated on a low-melting temperature agarose gel,
the specified fragment excised from the gel and purified by either electroelution or Magic
PCR Prep described below.
7.

Purification of DNA Fragments
a.

G-25 Sephadex Column

DNA fragments labeled for use in the electrophoretic mobility shift assay were
purified over a G-25 sephadex column. The column was prepared by plugging the bottom
of a 1 ml syringe with glass wool, and adding hydrated G-25 sephadex to the column until
full. The prepared column was centrifuged in a swinging bucket rotor at 800 rpm for
2 minutes at room temperature. The sample was carefully applied to the top of the column
and centrifuged again at 800 rpm for 2 minutes. This was followed by elution of the
labeled fragment using an equal volume of TE and recentrifuging twice. One pd of each
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elution was counted in a scintillation counter and run on a 7.5% acrylamide gel to assess
the degree to which the G-25 sephadex column had removed the unincorporated label.
b.

Electroelution from Agarose

DNA fragments of a specified size were separated from fragments of other sizes
and from unincorporated label by agarose gel electrophoresis by a modification of a
method first described by Wienand et al. (1978). The agarose band was excised and placed
in a sealed dialysis bag filled with 0.1 X TBE. The DNA was electroeluted for 2 to 5 hr at
350 to 500 V using a horizontal gel electrophoresis apparatus. After electroelution was
complete, the polarity of the electrodes was reversed for 20 to 30 seconds. The bag was
opened carefully and the TBE buffer collected into a 15-ml disposable tube. The bag was
then rinsed with 500 pi of 0.1 M NaCl which was also placed in the 15-ml tube. The DNA
was concentrated to 250 to 500 pi using butanol extractions, and precipitated with
2 volumes of ethanol. After overnight incubation at -20°C, the DNA was collected by
centrifugation at 5,000 rpm in a table-top centrifuge for 30 minutes at 4°C. The sample
was then washed once with 70% ethanol, dried in a Speed-Vac, and rehydrated with sterile
dH20.
c.

Magic PCR Prep from Agarose

The Magic PCR Prep (Promega Corp.) was used as per protocol to purify labeled
DNA fragments from an agarose gel. The agarose band was excised from a low melting
temperature agarose gel, transferred to a 1.5 ml microcentrifuge tube, and incubated at
70°C until the agarose was completely melted. One ml of Magic PCR Preps Resin was
added and the tube vortexed for 20 seconds to mix. A 3 ml syringe without the plunger
was attached to a Magic Minicolumn and the resin/DNA mix pipetted into the syringe
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barrel. The plunger was inserted slowly and used to push the slurry into the Minicolumn.
The column was then rinsed with 2 ml of 80% isopropanol. This was followed by
centrifugation of the column for 1 minute at 13,000 rpm to dry the resin. The DNA was
eluted by adding 50 pi to the column and centrifuging again for 1 minute at 13,000 rpm.
d.

Geneclean II Kit Purification

The Geneclean II Kit (Bio 101) was used to remove and purify DNA from
agarose, and purify DNA between enzymatic reactions as per protocol. When the DNA
was contained in agarose, 3 volumes of Nal was added to a tube containing the excised
band and incubated at 45°C to 55°C until the agarose was melted. When the DNA was
purified from an enzymatic solution, melting was not necessary and 3 volumes of Nal
were added to the tube. The Glassmilk suspension was added to the Nal/DNA solution
(5 pi Glassmilk for < 5 pg DNA and 1 pi Glassmilk per 0.5 pg DNA above 5 pg), and
incubated at room temperature with gentle shaking for 10 to 15 minutes. A 1.5 ml
microcentrifuge tube was centrifuged at room temperature at 13,000 rpm for 1 minute or a
15 ml conical tube was centrifuged at room temperature at 5,000 rpm for 4 minutes to
pellet the Glassmilk. The pellet was then washed 3 times with New Wash followed by
centrifugation. The DNA eluted into 10 to 20 pi sterile df^O twice by incubation at 55°C
for 10 minutes and centrifugation.
8.

Transient Transfections and CAT Assays
The cells were fed 24 hours prior to transfection so they were in the log phase of

growth (1 x 103 cells per ml). The transfections were then performed by harvesting
2 x 107 cells and resuspending them in 1 ml of RPMI without additives (serum, glutamine,
penicillin, streptomycin). An aliquot of 100 pi of these cells, 2 x 106 cells, was incubated

69
on ice with 7 x 10'12 moles of supercoiled DNA for 5 minutes. Each recombinant DNA
construct was assayed 2 to 4 times in an experiment. The cells were electroporated using a
Gene Pulser (BioRad Laboratories) set at 250 volts and a Capacitance Extender (BioRad
Laboratories) set at 500 pF. The pulse was followed by incubation on ice for another
5 minutes. The cells were then transferred to 3 ml of complete RPMI and incubated at
37°C in a C02 incubator for 48 hours.
After the 48 hour incubation, the cells were harvested and resuspended in 100 pi of
IX Reporter Lysis Buffer (Promega Corp ). Cells were incubated for 15 minutes at 4°C,
and the soluble cellular extract was removed from the cellular debris by centrifugation. The
supernatant was transferred to a new tube and heat inactivated at 60°C for 10 minutes.
Chloramphenicol acetyltransferase (CAT) assays were performed as described previously
(Seed and Sheen, 1988; Promega, 1994). The cellular extract was combined with 5 pi
n-butyryl coenzyme A (5 mg/ml), 65 pi 0.25 M Tris-HCl pH 8.0, and 0.5 pi
14C-chloramphenicol (0.025 mC/ml). The reaction mixture was incubated at 37°C
overnight. The reaction products were extracted using 300 pi xylene and back-extracted
twice with 100 pi 0.25 M Tris-HCl pH 8.0. The final sample was mixed with 5 ml
scintillation cocktail and the radioactivity was counted using a Beckman LS3801 Liquid
Scintillation System (Beckman Instruments, Inc ). The relative activity of each CD4
construct reflects the average of 3 to 8 transfections from 2 to 4 independent experiments.
9.

Nuclear Extract Preparation
Nuclear extracts from cultured thymocytes were prepared as described previously

(Dignam et al., 1983). Cells (1 x 109) were harvested at the end of the log phase of
growth. They were washed once with 5 volumes of cold PBS and once with 5 volumes of
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cold Buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KC1, 0.5 mM DTT).
The cells were then resuspended in 2 volumes (approximately 10 ml) of cold Buffer A and
lysed using 10 strokes of a glass B-type pipette pestle and a Dounce homogenizer. The
nuclei were pelleted at 3,300-4,000 rpm for 5-10 minutes and resuspended in 3 ml of
Buffer C (20 mM HEPES pH 7.9, 25% glycerol, 0.42 M KC1, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM PMSF, 0.5 mM DTT). Salt concentration was adjusted to 0.4 M KC1 by
the addition of 2.5 M KC1 and the nuclei lysed using a glass A-type pipette pestle with the
Dounce homogenizer (Coming Glass Works). The broken nuclei were transferred to an
ultracentrifuge tube and rocked for 30 minutes at 4°C, followed by centrifugation at
15,000 rpm for 30 minutes in a 90Ti rotor. The supernatant was dialyzed using 10 mm
standard dialysis tubing with a molecular weight cut-off of 12,000 to 14,000 daltons
(Spectrum Medical Industries, Inc., Los Angeles, CA) against 2 changes of 50 volumes of
Buffer D (20 mM HEPES pH 7.9, 20% glycerol, 0.1 M KC1, 0.2 mM EDTA, 0.5 mM
PMSF, 0.5 mM DTT) for 5 hours at 4°C. The dialyzed extracts were then centrifuged at
20,000 rpm for 30 minutes at 4°C in a 90Ti rotor, and aliquots of the supernatant stored at
-70°C.

10.

Quantitation of Nuclear Proteins
The amount of protein in the nuclear extracts was quantitated using the BCA and

BCA Protein Assay Reagent Kit (Pierce Chemical Company). A set of protein standards
of known concentration were prepared by diluting a stock solution of bovine serum
albumin (BSA) in water. Three dilutions were made for each unknown protein sample
(1:4, 1:10, 1:35). An aliquot of 100 pi of each of the known and unknown protein
dilutions was transferred to separate labeled tubes, then 2.0 ml of BCA Working Reagent
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was added to each tube and the contents mixed. All tubes were incubated at 37°C for
30 minutes, then allowed to cool to room temperature. The absorbance was measured at
562 nm for each tube vs. a water reference. The absorbance of the blank was subtracted
from the value for the standards or unknowns. A standard curve was prepared by plotting
the net (blank corrected) absorbance at 562 nm vs. protein concentration. Using this
standard curve, the protein concentration for each unknown protein sample was
determined.
11.

Electrophoretic Mobility Shift Assay (EMSA).
The reaction conditions for the gel shift assay were as described (Singh et al.,

1986). Briefly, 1 pi of 1 mg/ml poly dldC (Pharmacia LKB Biotechnology Inc.) and 20 pi
IX AS (10% glycerol, 0.5 mM EDTA, 1 mM DTT, 20 mM HEPES pH 7.9, 50 mM
KC1, 2 mM MgCl2) were added to tubes containing 200 ng of nuclear protein and
incubated on ice for 10 minutes. One pi of end-labeled double-stranded oligonucleotide
probe (10,000 cpm/ pi), produced using T4 polynucleotide kinase, was added to this tube
and the reaction mixture incubated at room temperature for 20 minutes. Following
binding, the mixture was electrophoresed through a native low-ionic-strength gel (4%
acrylamide, 0.05% bisacrylamide, 2.5% glycerol, 50 mM Tris base, 380 mM glycine,
2 mM EDTA). Electrophoresis was carried out at 120 volts for 3 hours at room
temperature. The gel was dried and autoradiographed using RX Fuji Medical X-Ray Film
(Fisher Scientific Co.) with an Optex Lightening Plus intensifying screen (M. D.
McCaulay Co., Ontario, CA) at -70°C. For competition experiments, specific and
nonspecific competitor DNAs (50 to 200 pmol excess) were incubated in the mixture prior
to addition of the nuclear extracts.
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12.

DNase I Footprint Analysis
Sequencing was performed on DNA fragments to be used in the DNase I footprint

analysis by the chemical cleavage method (Maxam and Gilbert, 1980). The DNA samples
were end-labeled with [y-32P]ATP prior to sequencing. The amount of radioactivity was
determined by spotting 1 pi of the material on a small piece of Whatman paper and
counting in a scintillation vial without fluid.
a.

Maxam-Gilbert Sequencing
Reaction Specificity

Component

1.

A+G G
pi
pi

T+C

pi

Prepare the DNA samples.
Salmon sperm DNA (1 mg/ml)

1

1

1

1

^P labeled DNA (100,000 cpm)

10

5

5

10

DMS reaction buffer
dH20

200
10

5 M NaCl
2.

C
pi

15

Perform the base-specific modification reactions.
Piperdine formate

2

1

DMS
Hydrazine
Time (min) at 20°C

30

6

30

30

3.5

3
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3.

Stop the reactions by diluting with stop buffer and -20°C 100% ethanol, and
immersing in a bath of dry ice/ethanol for 5 minutes.
DMS stop buffer

50

Hydrazine stop buffer

200

200

750

750

750

0.3 M NaOAc

250

250

250

100% ethanol

750

750

750

100% ethanol
Collect DNA by centrifuging 5 minutes at 13,000 rpm.
4.

Remove any remaining reagents by reprecipitation.

Collect DNA by centrifuging 5 minutes at 13,000 rpm. Rinse twice with 70%
ethanol and drain.
5.

Perform the cleavage reactions by incubating 30 minutes at 90°C with 1 M
piperidine; then remove the piperidine by drying under vacuum.
1 M piperidine

6.

100

100

100

100

Remove traces of piperidine by evaporating the sample twice from water.
Sterile dRjO

50

50

50

50

DMS reaction buffer (50 mM sodium cacodylate pH 8.0, 1 mM EDTA)
DMS stop buffer (1.5 M sodium acetate pH 7.0, 1.0 M {3-mercaptoethanol, filter sterilized
then added 100 ug tRNA/ml)
Hydrazine stop buffer (0.3 M sodium acetate pH 7.0, 0.1 mM EDTA, filter sterilized then
added 25 pg tRNA/ml).
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b.

DNase I Footprinting

DNase I footprint analysis was performed as described (Galas and Schmitz, 1978).
The DNA fragment was isolated from a recombinant plasmid containing a 250 bp
DraUBamHl restriction fragment, encompassing DH10, cloned into the SmallBamYR sites
of pUC 19. The isolated fragment was labeled at one end, using T4 polynucleotide kinase
and [y-32P]ATP. As described above, pre-binding involving poly-dldC, IX AS, and
nuclear protein was performed on ice for 10 minutes. End-labeled fragment (15,000 cpm)
was then added to this tube and the reaction mixture incubated at room temperature for
1 minute. Following incubation 5 pJ of 100 mM MgCl2 and 5 U of DNase I were added
and the mixture incubated for another 5 to 10 seconds at room temperature. The reaction
was stopped with 112 pi of STE (0.1 M NaCl, 10 mM Tris, pH8.0, 1 mM EDTA,
pH8.0), followed by the addition of 300 pi phenol-chloroform and vigorously vortexed.
DNA was then ethanol precipitated.
Both the sequencing and footprinting reactions were run on a 6% acrylamide
sequencing gel. Electrophoresis was carried out at 3,000 volts at room temperature. The
gel was dried and autoradiographed using RX Fuji Medical X-Ray Film (Fisher Scientific
Co.) with an Optex Lightening Plus intensifying screen (M. D. McCaulay Co.) at -70°C.
13.

Automated DNA Sequencing
Sequencing was performed using the PRISM Ready Reaction DyeDeoxy

Terminator Cycle Sequencing Kit (Applied Biosystems, Inc.). The 15 kb 5' region and the
first intron of the CD4 gene were subcloned as BamYR, Kpnl, and Pstl fragments in
pUC19 or pBS+. These double-stranded templates were grown and prepared using the
large-scale plasmid preparation, and purified by cesium chloride or Qiagen Plasmid Kit.
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The templates were supplied at a concentration of 0.2 pig per ul. The reaction components
were mixed in a 0.6 ml microcentrifuge tube (9.5 pi terminator premix, 5.0 pi ds DNA
template, 3.2 pmol ds DNA primer) for a total volume of 20 pi. The tubes were then
placed in a Perkin-Elmer Cetus Model 9600 thermal cycler (Perkin-Elmer Cetus, Norwalk,
CN) preheated to 96°C. Thermal cycling was performed as follows: rapid thermal ramp
to 96°C, 96°C for 10 seconds, rapid thermal ramp to 50°C, 50°C for 5 seconds, rapid
thermal ramp to 60°C, 60°C for 4 minutes. This was done for a total of 25 cycles,
followed by a rapid thermal ramp to 4°C. The samples were then purified using
Centri-Sep columns. The columns were prepared for use by pre-hydrating with 800 pi of
dH2Q at least 30 minutes prior to use. After centrifuging the column at 750 x g for 2
minutes to remove dF^O, the samples were loaded carefully onto the surface. This was
followed by centrifuging again at 750 x g for 2 minutes and collection of the sample into a
sterile 1.5 ml microcentrifuge tube. The samples were then dried in a vacuum centrifuge.
Prior to loading on a 6% acrylamide gel, the samples were rehydrated with 4 pi of loading
buffer (5 pi deionized form amide, 1 pi 50 mM EDTA, pH 8.0), heat denatured at 90°C for
2 minutes, and transferred to ice. The samples were then loaded onto an Applied
Biosystems 373A DNA sequencer (Applied Biosystems, Inc.). The first round of
sequencing was performed using the Universal (-40 primer)
5'GGGTTTTCCCAGTCACGACG3' and Reverse (-48 primer)
5,AGCGGATAACAATTTCACACACAGGA3\ Subsequent sequencing runs involved
synthesizing unique primers and walking down the clones. The entire nucleotide sequence
was determined from both strands, and all sites used for cloning were crossed in the
sequencing runs.
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14.

Sequence Analysis
Sequence alignments and homology and motifs searches were performed with

Sequencher 2.1 from Gene Codes Corporation (Ann Arbor, MI), MacVector 4.5 from
International Biotechnologies, Inc. (New Haven, CT), PC/Gene from IntelliGenetics, Inc.
(Mountain View, CA), and BLAST from the National Center for Biotechnology
Information (Bethesda, MD). Alignment results in Chapter 5 are depicted in four groups.
The first region includes bases 1 through 2875. This region includes the T cell-specific
enhancer (Sawada and Littman, 1991). The second region includes bases 2876 through
10935, and corresponds to the sequence from the first &zcl site to the third Sad site. This
region is between the T cell-specific enhancer and CD4 promoter. The third region
includes bases 10936 through 14639, and corresponds to the third Sad site through the
transcriptional start site to the Xho\ site located in the first exon. The fourth region includes
bases 14640 through 23108 and coresponds to sequence from the Xhol site in the first
exon to a Sad site in the second exon.
Sequencher 2.1 was used to identify and remove vector sequences, create
contiguous sequences (contigs), edit contigs based on computer-generated chromatograms,
and create a consensus sequence. Sequences were assembled into contigs using the
Automatic alignment method of the program, which is based on an exhaustive search-andcompare algorithm. Assembly parameters used with this algorithm were a Minimum
Match of 65 to 95 percent and a Minimum Overlap of 20 bases. Sequence edits were
performed by comparing chromatograms for a specific base and eliminating ambiguities
and discrepancies. The consensus was then produced from these edited contiguous
sequences.
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MacVector 4.5 was used to locate restriction enzyme cut sites and to scan for
known consensus sequences and motifs. The entire sequence was analyzed using this
program.
PC/Gene was used to analyze the DNA sequence for helical distortions and hairpin
loops. DNAHELIX (Calladine, 1982; Dickerson, 1983; Shapiro et al., 1986) found the
distortions of a DNA double helix due to steric hindrance between adjacent purines on
opposite strands. In addition, HAIRPIN (Tinoco et al., 1973) was used to find hairpin
loops in the DNA sequence. The minimum stem length chosen for the hairpins was
7 bases and the number of unpaired nucleotides that formed the head of the hairpin was
5 to 20.

BLAST searches were performed to find homologies between known sequences
and the murine CD4 gene (Altschul et al., 1990). Databases searched were the following:
Brookhaven Protein Data Bank (pdb); GenBank (gb); GenBank update (gbupdate); EMBL
Data Library (embl); and EMBL update (emblu); Eukaryotic Promoter Database (epd);
Repbase database of human and other primate Alu repeat sequences (repbase); Rabat’s
database of sequences of immunological interest (kabat). The sequence was submitted to
BLAST in four parts: Part 1 (bases 1 to 6899), Part 2 (bases 6900 to 13797), Part 3
(bases 13798 to 20695) and Part 4 (bases 20696 to 23157). In addition, portions of the
sequence were resubmitted in smaller pieces for reanalysis using the various databases.

CHAPTER 3. MULTIPLE C/A-ACTING ELEMENTS CONTROL
EXPRESSION OF THE MURINE CD4 GENE

Extensive analysis of the CD4 locus indicated putative regions of transcriptional
control. These sites were located 5' of the CD4 promoter and within the first intron. In this
chapter, we analyze these regions using recombinant DNA constructs.

A.

RESULTS
1.

Explanation of Constructs

The pACl series of constructs contains sequence extending 15.7 kb upstream of the
CD4 promoter. The pAC2 series encompasses a similar region, with the exception of a
deletion of a 2.2 kb Sac\ fragment located 10 kb to 12.2 kb 5' of the promoter. The pAC3
series extends out to the 15.7 kb region, but deletes a 6 kb Sad fragment located 4 kb to 10 kb
upstream of the promoter. The pAC4 series contains a 3.5 kb fragment located 12.2 kb to
15 .7 kb upstream of the promoter and 4 kb of sequence upstream of the promoter, deleting the
2.2 kb and 6 kb Sad fragments concurrently. The pAC5 series contains about 6 kb of
sequence 5' of the CD4 promoter.
The members of each series are further broken down with respect to the sequence
located 3' of the promoter. The designations following the series number indicate the
presence or absence of sequence within the first intron of CD4. Vectors containing 8.9 kb
of the first exon, the first intron, and the 5' portion of the second exon are given the suffix,
"a", e g. pACla. The constructs containing the same region but deleting a 1.6 kb Xba\
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fragment located 2.2 kb to 3.8 kb downstream of the CD4 promoter are given the suffix, "b",
e.g. pAClb. The presence of only 70 bp downstream of the CD4 transcriptional start site is
denoted by the suffix, "e", e.g. pACle. Each of the sequence combinations located 5' of the
CD4 promoter have been fused to the three different intronic sequence alternatives described
above (a, b, and e) (Figure 3.1). In addition, the pAC4 5' sequence was cloned upstream of
two additional intronic sequences: "c"- which removes the 4.2 kb Sad fragment from the
intron and "d"-which removes the 8.15 kb of Psil fragments from the intron. The smallest
promoter construct discussed, p900, contains a 900 bp fragment extending 70 bp downstream
of the start site. A 339 bp fragment containing a previously identified T cell-specific enhancer
(Sawada and Littman, 1991) was ligated immediately upstream of the 900 bp promoter
fragment and is called pEPC 1. The positive and negative control vectors used in these
experiments were pCAT control, containing the SV40 promoter and enhancer, and pCAT
basic, which does not contain a eukaryotic promoter or enhancer sequence. All constructs
contain the reporter cassette, CAT, for sensitive quantitation of expression.
The 3.5 kb NotVSad fragment located in the extreme 5' of the CD4 sequence is the
location of two DH sites (DH4 and DH5) and the most 5' matrix attachment region (MARI)
(Sands and Nikolic-Zugic, 1992). The DH5 site corresponds to the previously identified
T cell-specific enhancer which interacts with the LEF-l/TCF-la (Sawada and Littman, 1991),
HEB (Sawada and Littman, 1993), and E12-related transcription factors (Sawada and Littman,
1993). The 2.2 kb Sad fragment, immediately 3' of the 3.5 kb NotVSad fragment, contains
another DH site (DH6) as well as the 5' portion of a repetitive element (Sands and NikolicZugic, 1992). The 6 kb Sad fragment immediately downstream contains the 3' portion of the
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Figure 3.1. CD4/CAT recombinant constructs, (a) Description of the CD4 5'
deletions. DNase I hypersensitive sites (DH sites) are denoted by numbered vertical
arrows directly above the region in which they are located. Matrix attachment regions are
represented by the cross hatched boxes and the repetitive element is represented by the
black striped box. The horizontal arrow at DH site 8 shows the start of transcription. The
letters directly below the line are the positions of relevant restriction sites used in making
the deletion constructs: N-Notl, S-SacI, E-EcoRl and H-Xhol. pAC is the designation
for the large vectors. The 5' region of DNA used in a given series (1-5) is shown by the
solid black lines next to each vector name, e.g. pACl contains the full 15 kb 5' sequence.
The p900 construct contains a 900 bp promoter fragment. pEPCl is identical to p900 but
also includes the 5' minimal 339 bp T cell-specific enhancer positioned immediate
upstream of the 900 bp promoter fragment, (b) Description of the first intron deletions.
As described for panel (a), the numbered vertical arrows indicate the position of DNase I
hypersensitive sites (DH sites). The letters directly beneath the top line denote restriction
sites used in making the deletion constructs: M-Xhol, P-Pstl, S-Sacl, X-Xbal, L-Sall.
The intronic DNA region included in a given construct is shown by the solid black lines
next to each lower case letter, e.g. "a" contains the full 8.9 kb first intronic fragment.
Lower case "e" represents vectors that do not contain any first intronic DNA. The
constructs are named by combining the appropriate 5' deletion construct designation with
the intronic deletion construct, e.g. pAC4d contains the 5' DNA region up to the EcoRl
site ligated to the sequence remaining after the 8.15 kb Pstl intronic fragment is removed.
The 8.9 kb first intron was fused to the 15 kb 5’ flanking region at the Xhol site (H).
(c) Description of the CAT reporter vector. The CAT reporter vector contains the CAT
gene (CAT), SV40 small T antigen (SV40), and (3-lactamase (AmpR) coding region. The
CAT gene was fused to the 3' end of each construct containing a 5’ flanking region and
first intron at the Sail site (L). In constructs with no first intron, the Sail site of the vector
was fused to the Xhol site (H) of the 5’ flanking region. A detailed description is found
in Chapter 2.
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repetitive element. The 6 kb 5' of the CD4 promoter contains another nuclear matrix
attachment region, MAR2, and two DH sites, DH7 located approximately 3 kb 5' of the
promoter and DH8 located at or near the start of transcription (Sands and Nikolic-Zugic,
1992). The 9 kb region located downstream of the CD4 promoter contains the 5' UT first
exon, the splice donor, the first intron which contains the DH9 and OHIO sites (Sands and
Nikolic-Zugic, 1992), the splice acceptor, and the 5' portion of the second exon. The second
exon contains the rest of the 5' UT down to a Sad restriction site within the second exon
(Gorman et al., 1987) which was converted to a Sail restriction site.
2.

The CD4 Promoter in SAKRTLS12.1

The clone, pAC5e, contains approximately 5.5 kb 5' of the CD4 promoter, the minimal
CD4 promoter and 71 bp of the 5' untranslated region without any intronic sequence. p900
has a 900 bp PstVXhol CD4 promoter fragment and contains the same 3' endpoint as pAC5e.
pEPCl has the same 900 bp promoter fragment with the minimal enhancer ligated
immediately upstream. In order to obtain baseline data on the CD4 promoter, pACla, pAC5e,
p900 and pEPCl were transfected into SAKRTLS12.1. When the 23 kb region is left intact
(pACla), the CD4 promoter functions poorly. The expression from pACla is consistently the
lowest of the transfected constructs and is used as the base value to which most of the
transfection results are compared. As Figure 3.2 illustrates, pAC5e expresses the CAT
reporter gene 5-fold better than pACla while p900 expresses CAT 50-fold better pACla. This
data illustrates that the DNA region immediately 5' of the 900 bp PstVXhol fragment exerts a
negative effect on transcription originating from the CD4 promoter. When the enhancer is
added upstream of the p900 promoter fragment, pEPCl, the expression is 675-fold higher
than pACla. Therefore the promoter elements within the 900 bp fragment respond strongly to
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Figure 3. 2. CAT assay data to determine baseline levels of the CD4 promoter.
Equi-molar amounts of pACla, pAC5e, p900, and pEPCl were transiently transfected
into SAKRTLS12.1. pACla contains the full 5' and first intronic sequences used in our
constructs and is used as the base value to which all other constructs are compared.
pAC5e contains about 6 kb of sequence 5' of the CD4 promoter and no intronic
sequence. p900 contains the 900 bp promoter, and pEPCl contains the 900 bp promoter
and 339 bp minimal T cell-specific enhancer. Each result represents the mean; the error
bars show the standard error of the mean (± SEM) for 3-8 separate determinations (n =
3-8).

84

pAC1a-

1

pAC5e-

p900

pEPC1

Fold Activity Over pAC1a

85
the minimal T cell-specific enhancer derived from sequence located 13.5 kb 5r of the first exon
and is consistent with other reports that have been published (Sawada and Littman, 1991;
Sawada and Littman, 1993).
3.

Multiple Regulatory Elements Located 5' of the CD4 Promoter

Activation of the CD4 promoter can be achieved by deleting various 5' regions
(Figure 3.3). pAC2a deletes the 2.2 kb Sad restriction fragment located 10 kb to 12.2 kb 5' of
the first exon of CD4. Expression of the CD4 promoter is increased 75-fold over that
observed when pACla is transfected. pAC3a contains a 6 kb Sad deletion located 4 kb to
10 kb 5' of the first exon of CD4. This construct shows an increase of 56-fold over pACla.
When the 2.2 kb and 6 kb fragments are deleted simultaneously, pAC4a, expression is 86-fold
higher than pAC 1 a. These data indicate that both the 2.2 kb and 6 kb fragments contain
negative regulatory elements (NREs) that affect the CD4 promoter. pAC5a contains sequence
6 kb 5' of the CD4 transcriptional start site. This construct had a 2-fold increase in expression
over pACla but this increase was significantly less than that seen by the constructs above
which have deleted some of the same 5' sequences. One notable difference between pAC5a
and the pAC2a - pAC4a clones is the deletion of the most 5' 3.5 kb fragment, known to
contain a T cell-specific enhancer (Sawada and Littman, 1991).
4.

Negative Effect of the First Intron

Relief from repression can also be seen if the 1.6 kb Xba\ fragment within the first
intron is deleted and expression using these constructs is compared to those constructs
containing the complete intronic fragment. This increase in activity, ranging from 8- to
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Figure 3.3. Deletion analysis of the 5' flanking region. Equi-molar amounts of each
construct were transiently transfected into SAKRTLS12.1. The constructs contain
varying amounts of the 5' flanking region with the complete first intron. pACla contains
the full 5' and is used as the base value to which all the other constructs are compared.
pAC2a has a deletion of a 2.2 kb Sad fragment, while pAC3a has a deletion of a 6 kb
Sad fragment. pAC5a contains about 6 kb of sequence 5' of the CD4 promoter. Each
result represents the mean ± SEM (n = 3-8). The values for pAC2a, pAC3a, and pAC4a
are not significantly different from one another.
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281-fold, holds for all 5' deletion sets (pACl - pAC5) containing the AM fragment deletion,
e.g. pACla vs. pAClb (Figure 3.4). Both the pAC2 and pAC4 sets of constructs delete the 5'
2.2 kb Sad fragment and show the most dramatic increase in activity when comparing vectors
with the complete intron and those containing the intronic deletion. The pAC3 constructs show
the same trend but the increase in expression of pAC3b compared to pAC3a is not
significantly different. Constructs which do not contain the 5' enhancer fragment, pAC5a/b,
show this same relationship, but at a greatly diminished level.
An additional set of deletion constructs was made to further investigate the contribution
of the first intron to the control of CD4 expression. The pAC4 series deletes two 5' Sad
fragments which remove a total of 8.2 kb of sequence. pAC4 is used as the base for the
vectors described below (Figure 3.1). pAC4c deletes the Xbal fragment and sequences
flanking it using a 4.2 kb Sad deletion that removes both the DH sites, DH9 and DH10. This
deletion has the greatest expression of all the vectors assayed, indicating that an additional
negative element other than the one present in the 1.6 kb Xbal fragment has been removed
(Figure 3.5).
5.

Positive Effect of the First Intron

The net effect of having a complete intronic fragment present is positive as
demonstrated by a comparison of pAC4a (86-fold) and pAC4e (19-fold). Inclusion of an
intronic fragment deleting the 1.6 kb Xbal fragment also increases expression over those
vectors having no intronic sequences. As shown in Figure 3.6, all 5' deletion sets show a drop
in activity when no intron is present as compared to 5' deletion sets that include intronic
fragments without the 1.6 kb Xbal fragment, e.g. pAC3b (67-fold) vs. pAC3e (24-fold). The
greatest increase in activity is seen when the 5' 2.2 kb .Sad fragment is also deleted

89

Figure 3.4. Comparison of constructs containing the full First intron with those
lacking the 1.6 kb Xbal intronic fragment. Equi-molar amounts of each construct
were transiently transfected into SAKRTLS12.1. The “a” constructs contain the full first
intron (pAC l-5a), while the “b” constructs contain the first intron with a deletion of the
1.6 kb Xba\ fragment (pAC 1 -5b). pAC la is used as the base value to which all the other
constructs are compared. Each result represents the mean ± SEM (n = 3-8).
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Figure 3.5. Comparison of deletions within the first intron in constructs derived
from the pAC4 series. Equi-molar amounts of each construct were transiently
transfected into SAKRTLS12.1. These deletion constructs contain the same 5' regions
(pAC4) and successively remove larger fragments of DNA from the first intron, starting
with the 1.6 kb Xba\ fragment (pAC4b). pAC4e, which contains no intronic sequence, is
used as the base value to which all other constructs are compared. Each result represents
the mean ± SEM (n = 3-8).
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Figure 3.6. Comparison of constructs containing the intron without the Xba\
fragment with those having no intronic sequences. Equi-molar amounts of each
construct were transiently transfected into SAKRTLS12.1. The “b” constructs contain
the first intron with a deletion of the 1.6 kb Xbal fragment (pACl-5b), while the “e”
constructs contain no intronic sequence (pACl-5e). pACla is used as the base value to
which all the other constructs are compared. Each result represents the mean ± SEM
(n = 3-8).
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e.g. pAC2b/e and pAC4b/e. Only a slight increase is seen when these same fragments are
deleted and the 5' enhancer has been removed (pAC5b/e). This again confirms the NRE
within the Sad 5' deletion and best exemplifies the positive activity of the intronic and far 5'
DNA regions.
The pAC4d construct deletes 8.15 kb of the first intron, leaving only 450 bp of the
most 5' end of the first intron including the splice donor and 250 bp of the most V end of the
first intron with the splice acceptor. pAC4d expresses 16-fold better than the pAC4e construct
indicating that the small amount of intronic sequence left confers a positive activity when
compared to the absence of intronic sequences. pAC4d expresses less than pAC4c which
deletes only the 4.2 kb intronic Sad fragment. The lower expression of pAC4d compared to
pAC4c suggests that a positive control element has been removed by deleting the Pstl intronic
fragments.
6.

Multiple Cis-Acting Elements

When the 6 kb or 2.2 kb Sad fragments in the CD4 5' region are deleted individually, a
stimulation of approximately 56- to 75-fold is seen, respectively. If the 6 kb fragment is
deleted simultaneously with the 1.6 kb Xbal fragment in the first intron, pAC3b, the
stimulation increases up to 67-fold. Concurrent deletion of the 5' 2.2 kb Sad fragment and the
1.6 kb Xbal fragment in the first intron, pAC2b, results in an increase of 202-fold.
Furthermore, the larger 5' deletion which also removes the 2.2 kb fragment, pAC4b, results in
a 281-fold increase, confirming that deletion of the 2.2 kb fragment in conjunction with the
1.6 kb fragment is permitting this large increase in activity. The above data reveals the
existence of a cooperative repression occurring between the negative elements that exist in
these locations. The remaining sequences are able to direct high levels of activity implicating
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two stimulatory regions, one located within the 3.5 kb fragment in the far 5' and the other
within the first intron. If either of these two stimulatory regions is excluded, the stimulatory
activity is greatly diminished. This observation is best typified by the constructs pAC5b and
pAC4e which only express 8-fold and 19-fold better than pACla respectively, even though
they do not contain the 2.2 kb, 6 kb, or 1.6 kb NREs. In addition, other regions show a
negative effect on transcription. One is the 5 kb of sequence located immediately upstream of
the promoter fragment as evidenced by the vector, pAC5e. pAC5e expresses at 5-fold better
than pACla while the construct containing the 900 bp promoter fragment expresses at 50-fold
better than pACla. Another negative element is located within the Sad fragments of the first
intron and is demonstrated when the levels from pAC4b and pAC4c are compared. pAC4b
contains the Sad fragment (minus the Xbal fragment) and is expressed at 13-fold than pAC4e
while pAC4c deletes the Sad fragment and is expressed at 22-fold over pAC4e. The NRE
being detected by these construct may coincide with the intronic silencer that has been
previously identified (Sawada et al., 1994; Siu et al., 1994).

B.

DISCUSSION
1.

Importance of Proper CD4 Expression

Appropriate expression of CD4 is an important aspect of how the immune system
develops. Much of the developmental regulation of CD4 is at the transcriptional level (Siu et
al., 1994). If CD4 fails to be expressed during thymocyte maturation, the result is the lack of
development of helper T cells and a suppression of the ability to make antibodies in response
to foreign antigen (Rahemtulla et al., 1991). The inappropriate expression of CD4 on mature
cytotoxic T cells has a significant impact on the immune system's functions. The coexpression
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of CD4 and CDS on mature T cells alters the MHC-specificity of the T cells (Robey et al.,
1991) while overexpression of CD4 in thymocytes disrupts the CD8-dependent negative and
positive selection of thymocytes (van Oers et al., 1992).
2.

Control Regions Implicated from Transgenic Experiments

Transgenic mice have been used to analyze which regions of DNA are necessary for
regulating the expression of CD4 in a developmental context (Killeen et al., 1993; Blum et al.,
1993; Hanna et al., 1994; Siu et al., 1994; Sawada et al., 1994; Gillespie et al., 1993). The
following regions of DNA are implicated in the control of CD4: (1) AT cell-specific
enhancer has been located 13.5 kb 5' of the murine CD4 promoter (Sawada and Littman,
1991) and

6.5 kb 5' of the human CD4 promoter (Blum et al., 1993). These enhancers are

necessary for the CD4 promoter to function during the CD4+CD8+ stage of thymocyte
development (Blum et al., 1993; Hanna et al., 1994). (2) The first intron is implicated in
controlling CD4 expression (Blum et al., 1993; Sawada et al., 1994; Gillespie et al., 1993;
Sands and Nikolic-Zugic, 1992; Siu et al., 1994; Hanna et al., 1994). One of the functions of
DNA sequences within the first intron is to down-regulate the expression of the CD4 gene in
cells not expressing CD4 (Sawada et al., 1994; Siu et al., 1994). (3) The CD4 promoter can
be up-regulated in mature T cells in the absence of the T cell-specific enhancer located 5' of the
CD4 gene (Blum et al., 1993; Siu et al., 1992; Salmon et al., 1993; Hanna et al., 1994).
3.

Negative Control Elements Functioning in CD4+ Thymocytes

The presence of negative c/s-acting elements that function in CD4+ thymocytes or cell
lines derived from the thymus has been documented. Siu et al. (1992) demonstrated that the
CD4 promoter functions poorly in CD4+ cell lines derived from the thymus but works well in
CD4+ cells derived from the periphery. Furthermore, they could not detect the presence of a 5'
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enhancer activity using large DNA pieces in an enhancer trap assay. The definition of the
proximal minimal enhancer also provided evidence that the DNA regions around the minimal
enhancer had a negative effect on the stimulation from the enhancer (Sawada and Liftman,
1991). The presence of negative elements functioning in CD4+ cells during thymocyte
development is also apparent from transgenic experiments using various CD4 constructs
(Blum et al., 1993; Hanna et al., 1994). When 3 kb of DNA 5' of the promoter was included,
along with the first intron, the reporter was not expressed in thymocytes but was expressed in
peripheral CD4+ T cells. When the 5' enhancer was included in their constructs, the CD4 gene
was also expressed in the thymus. CD4 gene expression appears to be controlled by different
mechanisms in peripheral T cells than in developing thymocytes. Apparently, in thymocytes,
the CD4 promoter is in a repressed state. The 5' enhancer is essential to overcome this
negative influence that is present in developing thymoctytes. When we tested our deletion
constructs in thymic derived T cell lines, we found that the CD4' cells would only express
reporter constructs that contained a small region of DNA around the CD4 promoter or that
contained the CD4 promoter and the minimal enhancer located 13.5 kb 5' of the promoter
(Chapter 6). Whenever more DNA was included in the reporter constructs (especially those
without the minimal enhancer), the repression of CD4 was so efficient that we were not able to
obtain high enough expression to monitor any changes in activity due to the addition or
deletion of different fragments. Interestingly, we found that the CD4+ cell lines expressed the
reporter genes well enough for us to detect the presence of negative c/s-acting elements over a
large region of DNA. Our results are consistent with those previously published, which
indicate the existence of negative regulatory elements in CD4+ cells (Sawada and Liftman,
1991; Blum et al., 1993; Siu et al., 1992; Hanna et al., 1994).
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4.

Multiple Negative and Positive Control Elements Regulate CD4

Expression
Taken together, the transgenic and transient transfection data indicate a complex system
for the control of CD4 expression involving multiple levels and regions of regulation. In the
simplest situation, a gene could be turned off by either the expression of negative /raws-acting
factors, or the lack of positive factors. There is data that suggests that both kinds of regulation
are occurring in developing and mature T cells. Wilkinson et al. (1991a) provided evidence for
the role of dominant negative /rarts-acting factors in down-regulating CD4 early in thymocyte
development. The lack of high enough concentrations of positive /ram'-acting factors is
suggested by Salmon et al. (1993) where they show that over expression of the Ets-1 protein
up-regulates CD4 expression. The concentration of the Ets-1 protein is 10-fold greater in
CD4+ thymocytes than in CD4' thymocytes (Bhat et al., 1989).
There are at least two DNA regions that appear to positively influence the transcription
originating from the CD4 promoter. One positive control element is located about 13.5 kb 5'
of the first exon and corresponds to the T cell-specific enhancer located in this area (Sawada
and Littman, 1991; Hanna et al., 1994). The other is located within the flanking sequences of
the first intron and the nature of this element remains to be defined. There are numerous
regions of DNA that have a negative effect on transcription originating from the CD4
promoter. Five of the negative control regions appear to cooperatively repress transcription
and correspond to DH sites 4, 6, 7, 9 and 10 (Sands and Nikolic-Zugic, 1992). Furthermore,
the sequence within the 5' 6 kb Sad fragment contains a NRE and correlates with the presence
of a large repetitive sequence.
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5.

Possible Involvement of MARs in Controlling CD4 Expression

Our data suggests that there may be another transcriptional control mechanism
regulating CD4 expression. When the 5' enhancer is positioned near the CD4 promoter, it acts
to stimulate the CD4 promoter. However, when DNA is included between the promoter and
enhancer, expression from the CD4 promoter decreases. How are the intervening negative
control elements overcome thereby enabling the enhancer to stimulate the promoter in CD4+
cells when the sequences are in their normal context? One explanation is that there is a
topological change in the conformation of the DNA, e.g. looping. When the normal chromatin
configuration is preserved and the enhancer is positioned 5' of the CD4 gene, the activation
provided by the enhancer would require a mechanism that essentially loops out the negative
region between the enhancer and the CD4 promoter. Furthermore, this looping mechanism
must be present when the enhancer is needed to up-regulate the CD4 promoter during
thymocyte development. Possible c/s-acting elements that could perform this function are the
MARs located 5' of the CD4 gene (Sands and Nikolic-Zugic, 1992). Recently, a SAR/MAR
binding protein expressed primarily in thymocytes has been identified (Wilkinson et al., 1991a;
Dickinson et al., 1992; Nakagomi et al., 1994). This SAR/MAR binding protein is expressed
primarily in CD4+CD8+ thymocytes. Thus it is possible that the interaction of the MARs
located 5' of CD4 and the thymocyte-specific MAR/SAR binding protein could be the
mechanism whereby the CD4+ thymocytes are able to position the 5' enhancer next to the CD4
promoter. This would allow the CD4 promoter to be up-regulated during the CD4+CD8+ stage
of thymocyte development.
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6.

Possible Role of REPs in Controlling CD4 Expression

An examination of the DNA regions between the two MARs also suggests a possible
candidate for the negative regulatory element that exists in this region of DNA. The primary
DNA feature that has been identified between the two 5' MARs is a repetitive element (Sands
and Nikolic-Zugic, 1992). The usual transcriptional effect of a repetitive element is repression
(Thorey et al., 1993; Laimins et al., 1986; Saffer and Thurston, 1989; Perelygina et al., 1987;
Wu et al., 1990; Hambor et al., 1993) and appears to function by some sort of transcriptional
interference, occlusion or insulation. A repetitive element often contains a transcriptional unit
of its own. When this unit is positioned between a promoter and an enhancer, it essentially
directs the activity of the enhancer to the promoter contained within the repetitive element
thereby reducing the effect of the enhancer on a downstream promoter. If this is what is
happening 5' of CD4, there exists the possibility that there are numerous silencing sites
between the two MARs that could be interfering with the action of the enhancer on the CD4
promoter since the NREs are so spread out in this region.
7.

A Model for CD4 Gene Regulation

We propose the following model for CD4 gene regulation during thymocyte
development. The presence of multiple negative elements adjacent to the CD4 promoter
causes its native state to be repressed. This repression is overcome through the use of the 5'
T cell specific enhancer and the SAR/MAR binding protein that is upregulated during the
double positive stage of thymocyte development. As the thymocyte progresses through
lineage commitment, the enhancer and the SAR/MAR binding protein are no longer functional
and one of two pathways are possible for the cell to take. If the helper cell phenotype is
“chosen”, a mechanism which uses different positive control elements upregulates the CD4
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promoter again overriding the NREs present within the promoter’s flanking sequence. If the
cytotoxic T cell pathway is adopted, the 5' T cell specific enhancer becomes nonfunctional and
thus there is no positive signal to overcome the NREs around the CD4 locus and the gene is
turned off.
8.

Summary

In summary, we propose that within the 15 kb of DNA 5' of the CD4 promoter
and the 9 kb of the first intron are numerous positive and negative elements that are
responsible for regulating CD4 transcription. It is likely that several mechanisms are at
work to properly regulate this gene, e.g. cis- and /raws-acting factors, transcriptional
insulation, looping, and altered chromatin structure.

CHAPTER 4. CHARACTERIZATION OF A SECOND NEGATIVE
REGULATORY ELEMENT WITHIN THE FIRST INTRON
OF THE MURINE CD4 GENE

In Chapter 3, we showed that the regulation of CD4 expression is complex and
involves numerous c/s'-acting regulatory elements that are located 5' of the CD4 promoter
and within the first intron. The first intron contains both negative and positive
transcriptional control elements. In this chapter we analyze one of the negative elements,
located 4 kb 3f of the CD4 promoter, which corresponds to DNase I hypersensitive site 10.

A.

RESULTS
1.

The First Intron Contains Regions of DNA that Negatively Effect the

CD4 Promoter
Two T cell-specific DNase I hypersensitive sites have been identified within the
first intron of the murine CD4 gene (Sands and Nikolic-Zugic, 1992). An important
negative regulatory element was determined to be present within a 1.6 kb region within the
first intron (Chapter 3). This 1.6 kb region did not include the silencer that has previously
been localized within the first intron (Sawada et al., 1994; Siu et al., 1994). Therefore, we
screened this region for a sequence that had a T cell-specific protein/DNA interaction, and
localized it to a 280 bp DraVBamHl fragment (Sands and Nikolic-Zugic, 1992). Based on
these findings, we constructed a mini-gene expression system where the CAT gene was
driven by the CD4 promoter, or a combination of the 5' T cell-specific enhancer and the
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CD4 promoter. The putative negative regulatory element, M, was then added to these
constructs (Figure 4.1a-d).
The 280 bp DrollBarnHl fragment containing M was tested for its ability to downregulate the CD4 promoter. The construct p900, has a 900 bp CD4 promoter driving the
expression of the CAT gene. The 280 bp intronic sequence, M, was added to this construct
in two copies and in either forward or reverse orientation (Figure 4. la). The results of
transient transfections in SAKRTLS12.1 using these constructs are shown in Figure 4.2.
When two copies are added in the forward orientation, there is a 64% decrease in relative
CAT activity. When two copies are added in the reverse orientation, the decrease is 82%.
These results indicate that the Dral/BamYR fragment from the first intron has a negative
effect on the CD4 promoter. Since the intronic sequence was placed outside of the
transcriptional unit, this element appears to have a transcriptional rather than
post-transcriptional effect on CD4 expression.
To determine if the 280 bp fragment could repress expression in the presence of the
T cell-specific enhancer, a 339 bp restriction fragment containing the minimal CD4
enhancer was added to the p900 series of constructs, producing the pEPCl series. The
intronic sequence was included with each construct in two copies and two orientations
(Figure 4.1b). Adding the enhancer boosts the level of CAT activity 315% (Figures 4.2
and 4.3). When two copies of the intronic element are included in either orientation, a
decrease is observed (Figure 4.3). This repressive effect is between 28% and 57%, which
is less than that observed when no enhancer is included in the constructs. However, the
trend remains that the intronic element can repress expression from the CD4 promoter
even in the presence of a strong enhancer.
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Figure 4.1. Intronic fragment/CAT recombinant constructs. The diagram at the top
of the figure shows the 15 kb of CD4 5' sequence and 8.9 kb of CD4 sequence 3' of the
promoter. DNase I hypersensitive sites (DH sites) are denoted by numbered vertical
arrows directly above the region in which they are located. The horizontal arrow at DH
site 8 shows the start of transcription. The letters directly below the line are the positions
of relevant restriction sites: N-Afo/I,
E-EcoRl, H-ATjoI, E-Psil, X-Xbal, and
L-Sall. Boxes below the line denote the restriction fragments used in the construction of
the vectors in a-e. The first box corresponds to the 5' minimal 339 bp T cell-specific
enhancer located within the NotUSacl fragment. The second box corresponds to the entire
2.2 kb Sad fragment, while the third box corresponds to the entire 6 kb Sad fragment 3'
of the 2.2 kb fragment. The box located at the promoter corresponds to a 900 bp
fragment. The boxes found in the first intron correspond to a 280 bp fragment
corresponding to DH10. The black box in the first intron denotes forward orientation,
while the white box in the first intron indicates reverse orientation. The constructs in a-d
all contain the 900 bp promoter fragment, and constructs in b-d contain the 339 bp
enhancer fragment, (a) Two copies of the 280 bp intronic fragment were added to the
p900 construct in forward and reverse orientation, p900M and p900MR, respectively.
(b) Two copies of the 280 bp intronic fragment were added to the pEPC 1 construct in
forward and reverse orientation, pEPCIM and pEPC 1 MR, respectively, (c) The
enhancer/promoter/CAT cassette from (b) was reversed to place the intronic fragments 5'
of the cassette. The reversed construct is called pR, and two orientations of M are pRM
and pRMR. (d) One copy of the 2.2 kb Sad and 6 kb Sad fragments were added to the
pEPCIMR construct shown in (b), to produce p2.2MR and p6MR, respectively.
(e) One copy of the intronic fragment was added to a construct containing the SV40
enhancer and promoter. The SV40 promoter and enhancer construct is called pSV40,
while the construct containing M is called pSV40M. The CAT gene is fused immediately
3' of the promoter in each construct (a-e). A detailed description is found in Chapter 2.
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Figure 4.2. Effect of the intronic fragment on the 900 bp promoter. Equi-molar
amounts of each construct were transiently transfected into SAKRTLS12.1. Two copies
of the 280 bp intronic fragment were added to the 900 bp promoter construct in forward
(p900M) and reverse (p900MR) orientation. Each result represents the mean ± SEM
(n = 4).
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Figure 4.3. Effect of the intronic fragment on the 900 bp promoter and 339 bp
minimal enhancer. Equi-molar amounts of each construct were transiently transfected
into SAKRTLS12.1. Two copies of the 280 bp intronic fragment in forward (pEPC 1M)
and reverse (pEPCIMR) orientation were added to a construct containing the 339 bp
5' minimal T cell-specific enhancer and 900 bp promoter. Each result represents the
mean ± SEM (n = 4).
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The previous constructs had the intronic element placed 3' of the expression
cassette. To determine the effect of placing it immediately 5' of the T cell-specific
enhancer, the enhancer/promoter/CAT portion of the constructs was inverted to produce pR
(Figure 4.1c). When the cartridge is reversed, there is a vector effect resulting in decreased
relative CAT activity, but the intronic element still has a repressive effect on the level of
transcription (Figure 4.4). The addition of multiple copies of the 280 bp fragment results
in a 46% to 54% repression. Thus, the intronic element is capable of repressing CD4
expression in the presence or absence of the T cell-specific enhancer. Furthermore, the
element is able to act in either forward or reverse orientation, and either 5' or 3' of the CD4
promoter.
2.

DNA 5' of the Promoter has a Negative Effect on the CD4 Promoter

Previously, we demonstrated that there are multiple negative regulatory elements
located 5' of the CD4 promoter, within the 2.2 kb and 6 kb Sac\ fragments (Chapter 3).
Therefore, the series of constructs listed in Figure 4. Id were made to further investigate
this repressive event. The p2.2MR and p6MR constructs have the 2.2 kb and 6 kb Sad
fragments included in the pEPCIMR constructs, respectively. When two copies of M
were included in a construct with one copy of the 2.2 kb Sad fragment, there was a slight,
but not significant, decrease of 24%, whereas adding one copy of the 6 kb Sad fragment
resulted in a decrease of 80% (Figure 4.5). Therefore, adding a piece of 5' DNA, which
has been shown to be highly repressive, is enough to decrease activity from the CD4
promoter. Adding the 6 kb fragment reduced CAT activity to a level comparable to that
observed when the promoter alone was used in constructs with the intronic element. This
fragment has the ability to block the effect of the enhancer on the promoter.
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Figure 4.4. Effect of placing the intronic fragment 5' of the 900 bp promoter and
339 bp minimal enhancer. Equi-molar amounts of each construct were transiently
transfected into SAKRTLS12.1. The enhancer/promoter/CAT cassette was flipped to
place two copies of the 280 bp intronic fragment in forward (pRM) and reverse (pRMR)
orientation 5' of the cassette. Each result represents the mean ± SEM (n = 4).
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Figure 4.5. Effect of adding DNA from the region between the enhancer and
promoter. Equi-molar amounts of each construct were transiently transfected into
SAKRTLS12.1. One copy of the 2.2 kb Sac\ (p2.2MR) or 6 kb Sac\ (p6MR) fragments
were added to constructs containing the 339 bp enhancer, 900 bp promoter, and two
copies of the intronic fragment in the reverse orientation. Each result represents the mean
± SEM (n = 4).
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3.

The Intronic Fragment Functions with a Heterologous Promoter and

Enhancer
To determine the effect of the intronic fragment on a heterologous promoter and
enhancer, the 280 bp sequence was placed in CAT constructs driven by the SV40 promoter
and enhancer (Figure 4. le). Figure 4.6 shows the results of transfections using
heterologous constructs containing one copy of M in the forward orientation. With the
SV40 promoter and enhancer, M was able to repress levels of CAT expression 55%.
4.

T Cell-Specific Protein/DNA Binding Complexes

The cA-acting element in the DraVBamHl fragment, corresponding to DH10, is
T cell-specific (Sands and Nikolic-Zugic, 1992). To study the binding interaction,
electrophoretic mobility shift assays (EMSA) were performed using the 280 bp fragment
and nuclear extracts purified from T lymphoma cell lines (Figure 4.7a-f). The
T lymphoma cell lines represent various stages of thymocyte development, from the
immature CD4 CD8" cells to the more mature CD4+CD8' and CD4'CD8+ cells. These
experiments identified at least two different complexes, B and C. In addition, there is a
third complex, A, located near the top of the gel, just below the loading well. The
CD4 CD8' cell lines have mainly the B protein/DNA complex, the CD4loCD8l0 and
CD4+CD8' cell lines have the B and C complexes, and the CD4+CD8+ and CD4'CD8+ cell
lines have all three complexes. Complexes A-C disappear at the same time when the
nuclear extract is serially diluted. Furthermore, formation of all three complexes are
inhibited in cold competition experiments (Figure 4.8a and b). Only M successfully
competes for binding. Taken together, these data indicate that a specific protein/DNA
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Figure 4.6. Effect of the intronic fragment on a heterologous enhancer and
promoter. Equi-molar amounts of each construct were transiently transfected into
SAKRTLS 12.1. One copy of the intronic fragment in forward orientation (pS V40M)
was placed in a construct containing the SV40 enhancer and SV40 promoter. Each result
represents the mean ± SEM (n = 4).
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Figure 4.7. Analysis of the protein/DNA binding complexes occurring at DH10.
The end-labeled, double-stranded 280 bp Dral/BamHl intronic fragment was used in
electrophoretic mobility shift assays (EMSA) with nuclear proteins extracted from
T lymphoma cell lines. Gel lanes (1-8) contain different amounts of protein extract
added: lane 1, no extract; lane 2, 3 pi; lane 3, 1 pi; lane 4, 1/2 pi; lane 5, 1/5 pi; lane 6,
1/10 pi, lane 7, 1/20 pi; lane 8, 1/30 pi. Protein concentration in each extract are: SL12.1,
4.74 mg/ml; SL12.3, 4.47 mg/ml; SL12.4, 2.95 mg/ml; AKR1.G.1, 9.3 mg/ml;
SAKRTLS12.1, 6.46 mg/ml; TB2.1, 3.43 mg/ml. The letters A-C indicate the separate
binding complexes formed. W corresponds to the loading well, and F corresponds to
free labeled probe. The cell lines from which the nuclear extracts were made are:
(a) SL12.1 is CD4 CD8', and the most immature of cell lines analyzed; (b) SL12.3 is
CD4'CD8', and is more mature than SL12.1; (c) SL12.4 is CD4l0CD8l0;
(d) AKR1.G.1 is CD4+CD8+; (e) SAKRTLS12.1 is CD4+CD8'; (f) TB2.1 is
CD4'CD8+.
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Figure 4.8. Competition of the intronic fragment with other DNA fragments. The
end-label, double-stranded 280 bp Dral/BamHl intronic fragment was used in cold
competition EMSA with unlabeled DNA fragments from the CD4 locus (M-Q) and an
unlabeled fragment from pUC19 (R). Competitions were performed using nuclear
extracts from AKR1.G.1 (CD4+CD8+) in (a) and SAKRTLS12.1 (CD4+CD8 ) in (b).
Unlabeled fragments used in the competitions were the following: M, a 280 bp
DrollBamHI fragment containing DH10; N, a 243 bp XbaUNlalN fragment located
immediately 5' of the CD4 promoter; O, a 275 bp HincXUXhol fragment containing the
CD4 promoter (DH8); P, a 226 bp PstUHindWl fragment containing DH7; Q, a 340 bp
DdellSmal fragment containing DH16; R, a 253 bp BgHJPvul fragment from pUC19.
Numbers across the top of each gel indicate separate lanes and correspond to different
amounts (molar excess) of cold competitor added: lane 1, 0; lane 2, 0; lane 3, 50; lane 4,
100; lane 5, 500; lane 6, 50; lane 7, 500; lane 8, 50; lane 9, 500; lane 10, 50; lane 11, 500;
lane 12, 50; lane 13, 500; lane 14, 50; lane 15, 500. Lane 1 also lacked any nuclear
protein extract.
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interaction is occurring in the DraVBamHi fragment, and that it binds T cell-specific
nuclear proteins.
5.

Protein/DNA Binding Corresponds to a TATC repeat

DNase I footprint analysis using crude T cell nuclear extracts was performed to
identify specific nuclear protein binding sites in the intronic fragment (Figures 4.9 and
4.10). Figure 4.9 shows the 3' end of the footprint, while Figure 4.10 shows both the 5'
and 3' ends of the footprint. One region was reproducibly protected from DNase I
digestion on both strands. As illustrated in the EMSA assay, binding occurred with
protein extracts from T lymphoma cells representing various stages of T cell development.
The degree of protection varied depending on the extract, with the greatest protection
shown using nuclear extract from CD4+CD8+ cells and the weakest protection given using
nuclear extract from CD4+CD8' cells. DNA sequence analysis of the region bound by
protein revealed that it is a TATC repeat (Figure 4.11). The 5' boundary of the footprint is
just 5' of the TATC repeat, while the 3' boundary is immediately 3' of the TATC repeat.

B.

DISCUSSION
1.

A Second Negative Control Element is Located at DH10

The first intron of the CD4 gene is important for subclass-specific expression of
CD4 (Blum et al., 1993; Hanna et al., 1994; Gillespie et al., 1993; Killeen et al., 1993;
Sawada et al., 1994; Siu et al., 1994). A silencer, which appears to down-regulate CD4
expression in developing thymocytes, mature T cells, and non-T cells, has been identified
in the first intron of the murine (Sawada et al., 1994; Siu et al., 1994) and human (Donda et
al., 1995) genes. The murine silencer appears to correspond to the DNase I hypersensitive
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Figure 4.9. DNase I footprint analysis of nuclear protein binding within the
intronic fragment showing the 3' end of the footprint. The 280 bp DraVBamYQ
intronic fragment was end-labeled at the EcoRl cloning site directly upstream from the
Dra\ genomic site. The labeled fragment was analyzed by DNase I footprinting with
nuclear extracts from AKR1.G.1 (CD4+CD8+), SAKRTLS12.1 (CD4+CD8 ), and TB2.1
(CD4'CD8+). Lanes: 1, AKR1.G.1; 2, no protein control; 3, Maxam-Gilbert A reaction;
4, Maxam-Gilbert G reaction; 5, Maxam-Gilbert T reaction; 6, Maxam-Gilbert C
reaction; 7, SAKRTLS12.1; 8, TB2.1; 9, BSA control; 10, Maxam-Gilbert G reaction;
11, Maxam-Gilbert A reaction. The bracketed region on the left corresponds to the
nuclear protein binding site. Nucleotide positions are indicated on the right and
correspond to the sequence in Figure 4.11.
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Figure 4.10. DNase I footprint analysis of nuclear protein binding within the
intronic fragment showing the 5' end of the footprint. The 280 bp DraVBamHl
intronic fragment was end-labeled at the Spel genomic site located 66 bp 5' of the Oral
genomic site. The labeled fragment was analyzed by DNase I footprinting with nuclear
extracts from AKR1.G.1 (CD4+CD8+), SAKRTLS12.1 (CD4+CD8 ), and TB2.1
(CD4 CD8+). Lanes: 1, AKR1.G.1; 2, no protein control; 3, Maxam-Gilbert A reaction;
4, Maxam-Gilbert G reaction; 5, Maxam-Gilbert T reaction; 6, Maxam-Gilbert C
reaction; 7, SAKRTLS12.1; 8, TB2.1. The bracketed region on the left corresponds to
the nuclear protein binding site. Nucleotide positions are indicated on the right and
correspond to the sequence in Figure 4.11.
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Figure 4.11. Nucleotide sequence of the 350 bp SpeUBamHl intronic restriction
fragment, (a) The diagram indicates the position of the SpellBamYU. fragment relative to
the Xbal sites shown in Figure 4.1. (b) Nucleotide sequence of the SpellBamYQ
fragment. Protected sequences are in large bold type. Nucleotide positions which
correspond to Figures 4.9 and 4.10 are shown above the nucleotide.
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site, DH9, identified by Sands and Nikolic-Zugic (1992). The murine silencer transgenic
analysis also provides data that the DH10 site affects the expression of CD4 in CD4+ cells.
Our data is consistent with this finding and points to a second NRE located at DH10. This
element decreased the level of CAT expression in transient transfections of T lymphoma
cells 24% to 88%. While this is not a high level of repression, our results consistently
show a repressive trend. The DNA/protein interaction associated with this repression is
T cell-specific, and involves a TATC (or GATA) repetitive sequence.
2.

TATC Repeats are Associated with Repression

At the level of transcriptional regulation, both general and sequence-specific
mechanisms for repression complement the methods of positive control. Of particular
interest are negative regulatory elements that have enhancer-like properties of orientationand position-independence as well as the ability to affect heterologous promoters. The
element that we have identified at DH10 shares these properties with a number of known
silencer and/or silencer-like elements (Brand et al., 1985; Laimins et al., 1986; Muglia and
Rothman-Denes, 1986; Remmers et al., 1986; Rosen et al., 1985; Saffer and Thurston,
1989). One T cell-specific silencer dementis the Rpt-1 silencer (Patarca et al., 1988). The
Rpt-1 (regulatory protein T-lymphocyte-1) gene specifies an intranuclear protein expressed
in CD4+ T cells that regulates expression of the interleukin-2 receptor a-subunit. Rpt-1
itself is regulated by a silencer element, the Rpt-1 silencer, which is located in its
3'-untranslated region. This silencer contains a TATC (or GATA) repeat similar to the
sequence of the CD4 OHIO element. Furthermore, the protein(s) that bind the Rpt-1
silencer is T cell-specific, similar to the CD4 intronic element. Unfortunately, little has
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been reported concerning the identification and/or purification of these factors (Patarca et
al., 1989).
3.

Members of the GATA Family are Probably Not Mediating the

Repression
There are numerous reports linking the GATA sequence to regulatory activities.
The GATA family of /rara-acting factors specifically interacts with the GATA motif
present in regulatory elements. These GATA proteins have been identified in vertebrates
as lineage-specific transcriptional regulatory proteins (Martin and Orkin, 1990; Romeo et
al., 1990; Ho et al., 1991). They contain a highly conserved amino-acid domain which
binds the GATA sequence motif through a unique C4 zinc-finger structure (Yamamoto et
al., 1990; Romeo et al., 1990; Martin et al., 1990). One of the GATA proteins, GATA-3,
is abundantly expressed in the T lymphocyte lineage. However, while the GATA family
of proteins have been associated with both stimulatory and repressive activities, GATA-3
is mainly associated with binding to T cell-specific enhancers (Lambastie et al., 1994). The
possibility that GATA-3 regulates CD4 expression through binding the CD4 intronic
element is attractive. However, this is unlikely since GATA-3 preferentially binds solitary
GATA consesus sites rather than tandem repeats of this sequence (Ho et al., 1991).
4.

TATC Repeats are Associated with Altering Chromatin Structure

Highly repetitive GATA sequences were originally recovered from the
W chromosome of the banded krait Bungarus fasciatus and called Bkm sequences
(banded krait ininor satillite DNA). These sequences, originally thought to be organized in
a sex-specific fashion, are phylogenetically conserved and found in a broad spectrum of
eukaryotes (Jones and Singh, 1981). Recently, a protein that binds specifically to the
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GATA repeats of Bkm was identified and called BBP (Bkm binding protein) (Singh et al
1994b). This sex- and tissue-specific binding protein has been compared to the GATA
protein family discussed above because of its sequence specificity. However, it differs
from GATA proteins in a couple of important ways. BBP preferentially binds large
stretches of GATA repeats (GATA)16, rather than single or clustered sites. Furthermore,
while the addition of metal chelators abolishes the ability of the GATA family to bind to
DNA (Evans and Hollenberg, 1988), it does not affect the binding ability of BBP.
Bkm-related sequences are scattered throughout the genome of all the species
studied so far, and may be involved in some aspect of generalized gene control. One
possibility is that Bkm sequences are involved in the condensation/decondensation of
chromatin (Singh et al., 1994a). The Bkm GATA repeats are flanked by SAR motifs.
These SARs may form loops which are anchored to the nuclear scaffold at the SAR,
delimiting the ends of active chromatin. Looping of DNA may bring the SARs and
GATA repeats in close proximity at the matrix. Furthermore, histone HI may bring about
additional DNA compaction by preferential binding to SAR motifs resulting in highly
condensed chromatin (Singh et al., 1994a; Singh et al., 1994b). So, the CD4 intronic
element may be involved in altering the chromatin structure at the CD4 locus and the
repressive effects observed in our assays may be due to local effects on the DNA in the
region of the TATC repeat.
5.

Summary

The CD4 gene appears to be regulated in part by an enhancer (Sawada and Littman,
1991; Blum et al., 1993), a silencer (Sawada et al., 1994; Siu et al., 1994), and a promoter
that does not contain consensus sequences often associated with promoters (such as TATA
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or CAAT) (Siu et al., 1992; Nakayama et al., 1993; Salmon et al., 1993). In addition, its
regulation may also involve elements which alter the chromatin state (Sawada et al., 1994).
Negative regulation of gene expression can involve multiple mechanisms, such as the
inactivation of silencing factors, competition for binding to the silencer sequence, or new
protein-protein interactions that alter the repressive state of the chromatin (Levine and
Manley, 1989; Jackson, 1991). Because of the proximity of the CD4 DH10 element to the
previously identified CD4 DH9 silencer element (Siu et al., 1994; Sawada et al., 1994)
these elements may actually be components of a larger array of regulatory elements which
work together to control CD4 expression. Conversely, the DH10 element may play a
separate, but complementary role to the silencer in regulating CD4 expression. It may
work similarly to the RPT-1 silencer or GATA family of proteins by binding a cell typespecific factor which regulates gene expression, or it may act in a more global fashion, on
chromatin structure, similar to what has been suggested for Bkm sequences. Since there is
protein/DNA binding activity associated with this site at all stages of T cell development,
this element probably does not completely eliminate expression, but instead may simply
reduce it.
As mentioned before, the regulation of the CD4 gene is a complex, and tightly
controlled process (Fowlkes and Pardoll, 1989). Thymocytes and mature T cells must be
able to control genes by more than an all-or-nothing mechanism. There is evidence of
negative regulation in cells that are CD4+ as well as CD4' (Chapter 3). The reducer element
identified in the first intron at DH10 may play a role in the fine-regulation of CD4 gene
expression in both types of cells.

CHAPTER 5. SEQUENCE ANALYSIS OF THE 5' FLANKING
REGION AND FIRST INTRON OF THE MURINE CD4 GENE

Functional analysis of the region 15 kb 5' of the murine CD4 promoter and the first
intron indicated multiple positive and negative regions of regulation (Chapter 3). Based on
these results, we sequenced these regions and analyzed the sequence for possible regulatory
elements. In this chapter we discuss elements identified by the sequence analysis and their
potential relationship to the regulation of the murine CD4 gene.

A.

RESULTS
1.

DNA Sequence and Analysis

Previously, 75 kb of chromatin associated with the murine CD4 locus was
analyzed for the presence of DNase I hypersensitivity sites (DH), nuclear matrix
attachment regions (MARs), and repetitive elements (REPs) (Sands and Nikolic-Zugic,
1992). Based on this analysis, we proposed that the primary elements controlling the
expression of the murine CD4 gene are located in 15 kb 5' of the transcription start site and
within the first intron. Our functional analysis of these two regions indicated the existence
of multiple positive and negative control elements (Chapter 3). There are two regions
containing positive c/s-acting elements, a DNA region located about 13 kb 5' of the first
exon and sequences within the first intron. There are also four regions of DNA that have a
negative effect on CD4 gene expression: (1) a DNA region located near the 5' enhancer;
(2) a large portion of the DNA located between the promoter and the 5' enhancer; (3) a
DNA sequence located within the first intron about 2.5 kb 3' of the promoter; and (4) a
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DNA sequence located within the first intron about 4 kb 3' of the promoter. Based on
these results, we sequenced the entire region 15 kb 5' and the first intron and analyzed these
sequences for possible regulatory elements that could be mediating these effects.
The murine CD4 gene 5' flanking region, exon 1, intron 1, and 5' end of exon 2
were subcloned as previously described (Sands and Nikolic-Zugic, 1992). Sequence of the
subclones was performed using an ABI automated sequencing system, and sequence
editing was done using Sequencer 2.1. The complete DNA sequence is 23108 bases and is
numbered from 1 to 23108 (Figure 5.1). The three transcription start sites identified for the
murine CD4 gene (Siu et al., 1992) are located at bases 14561,14564, and 14569.
Therefore, the sequence extends approximately 14560 bp 5' and 8539 bp 3' of the
transcriptional start sites. Figure 5.2 gives the locations of commercially available hexamer
cutting restriction enzymes that recognized less than 16 sites in the sequence. The entire
sequence was analyzed using MacVector, PC/Gene, and BLAST.
MacVector was used to scan for known consensus sequences and motifs. The
entire sequence was analyzed using this program.
PC/Gene was used to analyze the DNA sequence for helical distortions and hairpin
loops. DNAHELIX (Calladine, 1982; Dickerson, 1983; Shapiro et al., 1986) found the
distortions of a DNA double helix due to steric hindrance between adjacent purines on
opposite strands. The steric hindrance can be reduced by one of four angle changes. One
change decreases the propeller-like twist (on one or both of the base pairs). The twist
angle’s undistorted value is 24.3 degrees. Another angle change spreads the two purine
nucleotides farther apart by increasing the roll angle, the angle between the planes of
successive base pairs. Theoretically, this plane is perpendicular to the helix axis, but the
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Figure 5.1. DNA sequence of the 5' flanking region and first intron of the murine
CD4 gene. DNA sequencing was performed using an ABI automated sequencing
system. Sequence was determined on both strands. The sequence is numbered 1
through 23108 from 5' of the CD4 promoter to the untranslated region of the second
exon. Start sites of transcription are located at 14561, 14564, and 14569.

137

1

TCACCATCACCATCATCACCATCACCATCACCATCATCACCATCACCATCATCATAATGAT

62

GAGGAGATGGCTCAGCACATGCTTCGCAAGCCGGAGGACCTGAGTTCAGCTCCCCGGCACC

123

CGTATAAAAGTTAGGTGACTTCCAAAGACCCTTTAGGATATTGCTTTACAGTGCGCCTGTC

184

TCTGATCCCTCTTCCAGGGCCACTGGGTTTCCACCTGTGACAACCCAAGAGTCCCAGCCCT

245

GAACCCCAAACCTCAGAACATCAGATTGCCTTAAATGGCTGGGTATTCAGGCTTTGGGGAC

306

TCCCAGCACAAAATAATGGTGTCACTTTTCATTCTCTGTCCCCAAGTCTCTGTCCCCTCTG

367

TCTCCATAGAGATGGAGATCTTCAACCTCCTGTTTATGCTCAGGTACCAGTGTAGGGTGTT

428

TGTCACAGCTGTGTGTATGCCACCGTGAGACTCCTTCAGGCTCCCTTCCTCTTGGGGTCAC

489

TAATTTGCTCCCCTGTGCAGAGCTACAGCTCCCTGACAAACAGCAAGGGTCCAGGCTCCAC

550

CTTCATCACAGTGCAAGGTCTCAGGTCCTACCCCTTTGACTGAGGCACAGTGTGTTCTGCA

611

GGACCTCTGCTGAGGCCCTGCCTCAGGCCTTCTTTCCATGGCCTCAGGGGAGGCCACCATG

672

T T T TCACAAGGCAAGGAT T TCC T GGAAAGT T T T GT GGGT GGCAT TTTTTCCTTT GCAC TAG

733

ATAATAACCCATGCCCTTTGGGTTTGTGAGAGAAGTCACAGGCTCACCAAGGCTCCTGCAG

794

GGACTTCCCCACACTCTTTCATGAAGGGAACAGAGGCAGAGTAGAAGACCACCTTGGTCTT

855

CTGTCTCT CATAGAAGAT GT GT GAGGC CAGT GGCACAGAACACAAGACAGAGGGGT T GGCA

916

GCTTGTGTTGAACAGTGCATAGTTCATACAGAGCCCCACCCTCTTGCCAGCAGGATAACTT

977

CTAGCCCTTCCTTGCAGTGTGTGTCCTTGTTAGATCTCTGCGAGTTGGGTTAATTCGCTAG

1038

TTGTGTTCCCAAGTGGCTGTTTGTTTGGGTGTTTTGTTTTTTGTTTTTGTTTTTGTTTTTT

1099

TGTTTTTTTTAATGGCTTTGGAGTTTGAACCTAGGATCTCGGGTTTGTAGCAAATGTTCTA
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1160

CCAATGGGCTCCTCAGCCTGTTGACCAGTTAGTTTATCTGTAAACCAGTGCTCTGGACTGG

1221

GAGCCT GAAGGT GAAGGGAGCC T GAGAGGAGGCAAAT T GATCGGGGAGCT T TAGGGGT T GG

1282

GCAGGGGAGTCATCCCAGAAGCAAAGAATGTATATTATAGCTATCTATCACTGCACTTAAA

1343

AAAAAAAAAATCACCCCAGAACTGGGTAATCCCCTCCCAGGCAGAAATCAGGCTAGCAGAT

1404

CATGCTGGTACAGGGTTTGTCACGAGGCTGCTCTAATGTGTGGCCAAAGCTGTGGTCAAGG

1465

GGAAGCGAGGCCCGGGTTGAGGAATCTGTCTCTGAACAGGCTCGCTCACTTGGTCGAGGGC

1526

CAGAGGCCTCAGTTCTTCCTCTTTAGTGCCATGGCAACTGGCCTCTCTGTGGACAGGATGG

1587

ATGAGACAAAAGCACTCAGGCGTCATCACCTGATCTTGAAAGTGATAGGTCATCATTTCTG

1648

CCCCTGTCTGTAGATCACACAGGCCACTTGTGACACGGTATAGGAAATGCAAGATAAGGAT

1709

GTCAACCAAGGAAGGGGATTGCTGGGACCTCTTAGAGCCTGGCTGTCACAAGCTAGCAGTA

1770

CTTGAATGACAGACAGCCCAAGAAAGAGGAGGGGGCATCTCTGATTATCCGACATCTGTGC

1831

CCTTCTCACGGAATTGGCAGGCTCCTCCACTGTCAACTTTGCAGAAGTTCTGGAGGCTAAT

18 92

CAAGGCCAATCCTGCAGGTAGAAGGCTACCCGGTGGACCTCCAGACCCTTGGCTACTGCTC

1953

CTTCCACATATGAACTTGTTTACAGGGCTTCATGGCTCAGAACCTACCCAGAGAATTTTCT

2014

GTTCTACATCCCCAACCAAGCCAAGGTGTTGGGGTTCAAATTTGAGCCCCAGCTGTTAGCC

2075

CTCTGCAAAGAAAAAAAAAAAAAAAAAAGAACAAGGGGCCTAGATTTCCCTTCTGAGCCCC

2136

ACCCTAAGATGAAGCCTCTTCTTTCAAGGGAGTGGGGTTGGGGTGGAGGCGGATCCTGTCA

2197

GCTTTGCTCTCTCTGTGGCTGGCAGTTTCTCCAAAGGGTAACAGGTGTCAGCTGGCTGAGC

2258

CTAGCTGAACCCTGAGACATGCTACCTCTGTCTTCTCATGGCTGGAGGCAGCCTTTGTAAG
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2319

TCACAGAAAGTAGCTGAGGGGCTCTGGAAAAAAGACAGCCAGGGTGGAGGTAGATTGGTCC

2380

TTCTAGTTGCAGCTTCCAAGGTGCCGCCAGGGTCTGGGCGTTTCACCCCACACCAAGGAGA

2441

AGCCTTTGTAACCCAGCCCAGCTACCGACCCAAGCCCACCCCACAGCTATTTTGCGGGAGT

2502

TTCAGTGCTATAGCAGATGGTTTCTGTAACGAGTCACCACAGGCTGCACCTGGTGCTCCAC

2563

TTCCATCGTCCTCATCTCTAATACACTGGCCTCCTCTAGTGCTCTTTTGGCAGCCTCTCAC

2624

AGTGTCCGGGCCCCTGCTTCCTTTCTCCCATTTGGTCACCTTCCCCTCTTCTAGCTAGAAG

2685

CACAGAATATGGACAGCAAACATAGCTCCAAACAAGAACTAGGAATCTGCAAAAATCAGGC

2746

TCTAAGCTCACCTTCAGGGACCGGGGCAGACAGCCTGACTTCAGTTTCCTTTGTAAAATGA

2807

GGATAGCGAGCTGACCTCGGTGGCTCTTGCCTGTAGCCTTCCAACTCGGAGGCTGAGGCAG

2868

GAAGAGCTCTGCTTCCAGGCCAGGCAGAGCTACTTAGACTATCTCAATAAAGCAAACAAGA

2929

AGGTTTTACTTCTATGATACTCTCAGGATTGGAGCCAGGGTCTCACACAGAGATCCCGAGC

2990

AAGGAAAATGCTTTCCCATTGAGCTATCCTCAGCCGTATTTATTTATTCATTTATTTGGAG

3051

GCAGTGTCTAACTATGTAGTACAGGCTGGCCTACAACTCTCTTTCCTGTAGTCTGAGCCTC

3112

CCAAGGACT GGGGT TACAGGT GT GAGGGCACAACAGCCAGT T T CTAGT TC T TAGC T GATAT

3173

ATCAAAACATTAAATGCACTTATTAAACTAGGTGTGATGTCACAGGCCCTTAATCCCAGCA

3234

CTTGGGAGGTAGAGTCAGTGGATCTCTGTGAGTTCGAGGCCAGCTTGGTCTTACAGAGCAA

3295

GTTCCAGGATGGCCAGGGCTACACAAAGAAACCCTGTCTCAATTAATCAGAAAAAACCAAA

3356

TCCAATTATTTGTGGGACTATCTCCTGTGTAATGTATTGACACATGTATGCTATGTAATAT

3417

T T AAAT GGGCAAAT GGGAT TATAGC GT T GGC T CAGT GGT TAAGAGT GCTGGCTGCTTTCCC
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3478

AGCAGACCTGAGTTTGAATCCCAGCACTCAGAACCATCTGTGGCTCCAGTCCCAGGGATCC

3539

GAGGTCCTCTTCTGACCTCTGAGGGTACCAGGCATGCACACATTACACAGACATACATGCA

3600

GGAAAAAAAAAAACCTCACACATAAAACAATAAAAATAATAZ^ATCTAAATCAAGTTAACTA

3661

CCTACTCCAAAAATATCATTTCTTCATAGGGAACTTTTGTTTGTTTGTTTGTTTGTTTGTG

3722

CCTTTGCTGCCTTGAAGTTTGCTATTCAGACCAGTGTGGTCTCAGAGTCACAGAGATCCAC

3783

CTGCCATGGATTTCCAGGATCTGGGACTAAAGGCTTGTGCTGACACGTTGAGTCTCACAGT

3844

GTTTTCGGAGTCAGGGTATCTTACTGAGTCCTAGGCTTGTGTCTTAGATTAGGCTTGCTGG

3905

CCAGAATCTGAGGGTTCCTCCTATCTCTGTCCGCCTAGTGCTGGGGTTAAAAGTGTGCGCT

3966

AGTACACTAACTTTAATTACCTGGGCGAGGGGCCCAAACTCACAGCCTTATGCTTGCTTGC

4027

AAGCTCTTGATGGACAGAGCCATTTTCCTAGGCCCTTCAGCTCTAATTTCTAAAAGAATTT

4088

TGTTCTGCCCCAGTTTCCTTATCTCTGTTCCTGGGGAATGGCGTCTGAGCCCCCCTCCTCT

4149

TAT GAGGAT TAAATAAAGACAT CAAT CACATAACACC CAAAGC TATACCAT C T GT T CACCA

4210

CAAACCCTCCCTCTCTTCCTCTTTTTTTTTCCTCTCTGGAGATCCCCGAAGGAGGAGCTAG

4271

GC T C GT GAT GC C C T T GAT T T T CAGGT GCCAAT C T GCACAGGCAAT CACAAC CACACACACA

4332

CAGGCACACACACACACACACACACACACACACAGCCACACACACACAGAGACACACACAC

4393

ACAGCCACACACACACACACACACACACACACACAGTCAGAAGGCTGACTAGGTTCTTCTG

44 54

GCCCATAGTTTCCAAACTGGTGGATCTGAAGCTAGAGCCAGATTGCTTTGTTTGATCTACC

4515

CAGTGGTATTACCAAAACAZ\AACACCCAAAAACCAGAAGACAAAACCCCCAAAACCAAAAA

4576

AAAAAAAAAAZ^AAAAZ\ACAAAAAAAACAT T T CAT T GC C GT CAT TAAAATAAGGAGGTAT TA
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4637

CATAATCCTGGTTTTTTATTCTCTCCCAACATCTTTGCAGAGCTGGCAACTCTGGGCTCAT

4698

GTCCTATCATTCTGATAGAAGTTCTAGGATTGAGCAGGCCATGGCGCTGCAAACCTCTAGT

4759

CCCTGCACTCTGGAGATAGAAGGCATGATGGTGGGGAGTGGAAGGACAACCTGGTCTGTGG

4820

AGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAT AGT

4881

TCAAATCCAGCCCAGGCTGCATGAAACCTTGTCTGAACTAAACAAACATCTAAACCGGGCG

4942

TGGTGGCTCACGCCTTTAATCCCAGCACTCGGGAGGTAGAGGCAGGTGGATTTCTGAGTTG

5003

GAGGCCAGCCTGGTCTACAGAGTGAGCTCCAGGACAGCCAGGGCTATACAGAGAAACCCTG

5064

T C T C GAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGA

5125

AAGAAAGAAAGAAAGAAAGAAAGAAAGACCCTAAAACAAAAACAAAACACAAAAACAAAAC

5186

GCAACCAAACATCTACTGGCTCAGCTGGACCTCTAAAGATGACTTCTTCTCATCCTAGATG

5247

AGGTGGGTACCCTCTGGCTTTCCTCAATTCCCACCCTTCCCTATTATGTCATAGCCAGCCT

5308

GCTTTCTCACTTTACTGGACAGACTCCTAAAGGTAGTTAGGTCGGAAACCTGCTGCAGTAG

5369

GCCAGGCCTTTTCATTTCTTCATTATCAAATAGCTAGTAGCTAGTAATGCTTCCCACCTGC

54 30

CCCCAAGCATGAGCGCATGTGCGTGCGTGCGTGCGTGCGTGCGTGCGTGCGTGCGTGCGTG

5491

CGT GT GT GT GT GT GT GT GT GT GT GT GT GT GCT GT GT GTAAT TAT GGT GT T TAAT GAGACCA

5552

GAGAGT T TAGGT GGGGAAGGT GATAACAT T CCAGT GGC GGATAC T GGTAT T GAT GACACAA

5613

CCATGTTAGAGAAACTATCTAAGATTTCCTAAGTTTAATAGCAAGGGCCAGACAGTGGAGA

5674

AGACCAACAGGAGAAGCCATCAGTAGCAGCTATGTTGCCAAACCCACACCAGCAACACAGA

57 35

ACCACCCCACAGTTCGGAATGTATCCATCAAAAGTTTGACTCAATCAGCAGGTGGCTAACT
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5796

GACAGGAATTCCTGCATTTTGCTCTCAACTTAATCCAGAAACAAGTCTGTTCTCCTCATGG

5857

AGCTTCCTGTTCCAGAACTTTCCTCTCTTTGCTATCTCTTACCTCTCTTTTCAATGAGAAG

5918

CTTATATTTTCCTTCCTCAACCTTTGTTATAAAAAAACACTCTTGAGGCCTAGCATGGTGG

5979

TGCACACCTTTGAGTCCAGTCCTTTGGAGGCCGGGGCAGGCTGATCTCCGTGAGTTTGAGG

6040

ACAGCAGTTCTAGGCCAGCCACACAGAGAGACCCTGTCTAAAAAACAAAACCACGACAGAA

6101

AAACAAACAAACAAACAAACAAACAAACAAACCACC T GC T C T TAGACAT GAAAGAGCCAAG

6162

AAGGGGT GT GT GTGT GT GT GT GT GT GT GT GT GT GT GT GGAGGT GT GT GT GT GGAGGT GT GC

6223

CTCTGGGGTACTATACCTTATTTGGTGAGACAGCTCTCTCAATGAACCTTGCCATTCTTTA

6284

GGTTAGTTTCCAGTGATTTGGGGGTCTGTCTCTGTCCCCAACACTGGGGTTATAGGCACAC

6345

ACAGTTGTGTCCGGCTCTGCAAGTGCTGGTGGTTTGATAACTCACTTGGAGTTATCTTTCT

6406

TTCACGGCAAGTGCTGTGACCCATCTCCCCTCTCCCAGGGTAAAGCTTTTCTTTCTCGTTC

6467

CTTTCCTTTTCTTGCCTCCTCCATTTCCTCCTCTTCCTCCTTTACTTCCTCCTCCTTCTCA

6528

ATAT GAT TCAT GCC T GTAATCC TAZ^AAC T T GGCAGAGACAGGAGGAT T T C TATACAT T T TA

6589

GGTCATCCTGGCTACAGAATGAATTCCAGGCAACCAGGACACTGGATGTTCTTCCAGAGGC

6650

CCCTGGGTATTGATTCCCAGCACTCAAAAGGCAGTTCCACTCTCAGGGCATCTGATGCCCT

6711

CAT CT GGCC T CC TAGGGGGCT GCAT GGT CATACAT GCAAGCAAGACACCCACACATATAAG

6772

ATAGATCTTAAGAAAACCACCCAAAAAGCAGAGGTGTGATTGCCACATCTGTAGCTTAAGC

6833

AC T T GGGAGAGGGAGGTAGAAGGACCTAGAGT CAAAAGCCAGCC T T GAT TACAGGAGAGTT

6894

TGTGGTCGGTCTGAACTACATGAGACCTTGTTAAATTAAACAAAAAATGAAAACAATGATT
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6955

TTTTTTTTTTAAGTTCTTGGCTTGTAAGCCTAGTGGCCATATTTTCAAGCACTTTTTAGCT

7016

TTTGGCTGAAGATCTGGGGACTGTCCTCTTCCTTAGCAGGAGTTGGTAATGATTCAATAAA

7077

CCCTTTTCTTTCTGAACCTCTTGGTCTCAAGAGTTTTGCTTTAAGGTTTAACCACTACAGT

7138

GTGCCTCTAATCTCAGCGCTCGGGAGGCTGGGGTGGAGGGTTTAATCTTTTGTTTTGCTTT

7199

GCTTTTCAGCAGGGTCTCCTGTTCAGGATGGCCTCGAATTTGCTATAGGGTAACCTTGAAC

7260

TTCTGATCTTGCTGCTTGTACCTCCTAACTGATGGGACTACAGGCATGTGCCATCATGCCT

7321

AGCCTAGCAAAAGGAACTTTGGAGTAAGAAGCCAGTATAGGCTATGCACTGAGACTGTTTA

7382

AAAGGCAAAAGGAGTCGGGCATGGTGGTGCACGCCTTTAATCCCAGCATTTGGGAGGCAGA

7443

GGCAGGTGAATTTCTGAGTTCGAGGCCAGCCTGGTCTACAGAATGAGTTCCAGGACAGCCA

7504

GGT CT ACACAGAGAZVACCC T GT C TCAAAAAAACAAAAACAAAAACAAAAACAAAACAATAA

7565

AGGCAAAAGGTTTCAGTTCAACGTGGTAACTATACTTAACCTCACAGAGGTGTGGCTTTTC

7626

AAAT GT T T T CAAT GT T GGC T GGGATATAGC T CAGT GGTATAGC T CATAC T TACCAAGT GTT

7687

AGTTTTTGTGTTCAATCCTCAGGGTCAAAAATTAATATATAATTTTTAATGGTTTAGAGTT

7748

GGGTATGGCAGTACGTGCCTGTAATCCCAATCACTTGAGAGGCAGAGGGAGGAAGATTAAT

7809

ATATGAAGGCTGTCGTTGGCTATCTGACAAATTCAAGACCAGCCTGAGCCGGGCGTGGTGG

7870

CACACATCTTTAATCCCAGCACTTGGGAGGCAGAGACAGGCGGATTTCTGAGTTTGAGGCC

7931

AGCC T GGTC TACAAAGT GAGT TCCAGGACAGC TAGGGCTATACAGAGAAACCC TATC T C GA

7992

AAAACAAAACAAACAAATGAACAAGACCAGCCTGGGCTACCTGAGACCCTTTTATCTACAA

8053

AAAAAGT CAT TAC CAC CACAAGCAAAAAAAT AT AAGT GGC TAACAT GGTAAAC T T CAT GGT
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8114

ACGTATATTTTACCACAAGAAGTTTAATATCAATTTCACGTCAATTAATCTTAACATATAA

8175

AAATATATTTAACATATGGATATATGGATATAGGCCAGGAGTTGGGAAGTAGGAATTAATA

8236

AAACAAGGATCTGGGCAGT GGTAGGACACACCTCACAGCACTCC AGCAAAGGCAGAGGCTG

8297

CCAGGGCTCTGAATTCCAGGCTAGCCCGCTCTACAGAGCAAGACACTGATAAAATAAAACA

8358

AAACACTATCCTGGCCAGAGTCTGCAACAGCCCTTGTCCCTATGACCCAGGGTCACAACTC

8419

ATCCACCCAACACAGAGGAGGTACCTGTCTTAGTCAGGTTTCTATTCCTGCACAAACATCA

8480

TGACCACAAACAAATTGGGGAGGAAAGGATTTATTCAGCTTACACTTCCGCATTGCTGTTC

8541

ATCACCAAAGGAAGTCAGGACT GAAACTCAAGCAGATCAGGAAGCAGGAGCT GAT GCAGAG

8602

GCCTTGGAGGGGTGTTTCTTACTGGCTTGCCTCCCCTGGCTTGCTCAGCTTGCTCTCTTAT

8663

AGAACCCATGACTACCAGCCACAATGAGCCCTTCCCCTTCTTGATCACCAACTGAGAAAAT

8724

GCCCCACAGCTGGATCTCATAGAGGCACTTCCCCAGCTGAAGCTCCTTTCTCTGTGATAAC

8785

TGCAGCTCGTGTCAAGTTGACACACAAAACCAGCCAGTACAGTATCTATTGAAACTTGGAC

8846

TTGATTCTAAGAAAATAGCTCCTAATCCTGGAGAAAGCCTCTTCCTGTGAAGATGAGACCC

8907

T GAGAAAAGT T TAGT T C TAGCAC CAGGGT GAGAGC T TAGGCCAT GAAGAGC T TACC T CACC

8968

CATACAAGGACAT GAGT T CAGT CACCAGACCT GAGGTCC TAGC T GTACACAGT GTC T T GGA

9029

GGTATACTCTGTTCTTCTTTTGTTTGCTCCAAAAAGCCTGCCTATTCTTGCTGAATATCTT

9090

CGT GT GT GT GT GT GAATATATATAT AT ATATATATATATATATATATATATATATAT GT GT

9151

GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GTATATATACACACACACAAGATAGCCCAGG

9212

TTATTCTAAACTTGTAGCACTCCTTTTGCCTTAGTCTCCATTGGTATAGACATGTGTGCAC
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9273

CATCCTTGAATTTCTTTCTCCAAGGAAACCAAAAAAAAAAAAAAAAAAAAAATGGAGCCTG

9334

TTGTCTGGTAACATAGGTACTAGGTGTCTTTGCTGAGATCCTTGAGGTTGGGGGGGGGGGC

9395

TCAGGGCATCCAGTGCTAAATAAGGCACTAGCTACCACCATTGTGTTTAGTGAGGTGGACA

9456

GCAGCTAATAAATAT TTGGTTTTGGTT GAAAGAT GGC TACAGAGAAGAGGC GCAAGGCATC

9517

AATCGTTCCTTACATTAGGGZVAGTGTACTGCACCTGAAGAACTAGAGTGGCTACAGCCTCT

9578

GGGCAGAGGTCAAGAAATAAAAAAACAAGGATCCCAGCAGCCTCTTCTAGGCCCTGGAGTA

9639

GCTGGAGTAGCTGGAGTAGCTGGTGCTCCCTCCCAAAGAACCACCACCCTCGACATCTTTC

9700

TTATGAGGAACAAACTCTTCTTAGTCAAGCCAAGCAACTGTTTTGAATTTTCCTCCATTTG

9761

T C GCAGCATAGAAGC T C T T GATAC T TAACAATACAC T T GTAGT T GGCATAAGGC TAG T T T G

9822

TGGTAAGCTTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTGCTCTCCATGCTTTTCCT

9883

T T T GAAGT GCAT GCCAT T T GC GATAAGATCAT TCAT TAT GGACAT GT TACAACCCAAAGCT

9944

TGTGCGACCTAATCTGCTTTGATATTCACTATTACATATTCACGCTCACTGTTACACCCCC

10005

AACACGGACTAAAGTGGCTTGGTCTGGTGGATGCTTAACACTCTTTGAATATATGGATGGG

10066

TAGAT GGGT GGGTAGATAGGT GGGT GGGT GGCT GGATAGAT GGAT GGAT GGGT GGGT GGGT

10127

AGAT GAGTAGAT GGGT GGGT GGAT GGATAGGT GGT GTAAT GGT T T GTATAT GC T T GGC T CA

10188

GGAAGT GAGAGGAT T AGAAAGT GT GCCCCT GT T GGAGTAGGT GTGCCCTTGTT GGAGTAGG

10249

TTTGTGACTGTGGTGTGGGCTTTAATAACCTCATCCTAGCTGCCTGGAAGGCAGTACTCTG

10310

CTAATAACCTTCAGATGAAGATGGAGAACTCTCAGCTCTTTCTGCACCATACCTGACTGGA

10371

TGCTGCCATGTTCCCGCCTTGATGATAATGGACTGAATCTCTGACTGTGTAAGCCAGCCCT
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10432

AACTAAATGTTGATTTATAGGAGCTGCCTTGGTCATGGTGTCTGCTCACAGCAGTAAAACC

10493

CAGACTAAGACAGGTGGATGGATGGGAGGGTGGGTGGGTCTAGAGCACGGTCAAAAATTCA

10554

ATTGCCTACTGAAGCCTGCTAGGTAGTGCAAATGAGAAAGGAGGGCTGTCTATAAGTTATA

10615

CGGAAGGGTTTGCATAGCAGACTGTAAGAAAAGAAAGCCCCAGGCAGGGGAGTCAACACCT

10676

AGCTGCTTTTAAAGAGCAACTTTGAGGTTTTGTCTGACACGTTCACTTCAATTCATTCACA

10737

AAACTGAGTCACTTGGCCAGAATGACTGCAAAGAAAGCTTGGGAGTGTGTGTGTGCTATCT

10798

GGTTGCTAAAGGCTGGCCTGCAATTCCAGCTACTTGAGAGGAGGCAGGAGGATTGTCTGAG

10859

CCAGGAGTTGGAGATCAGGCTGGGCAGCATTGTAAGATTCCATCTCAAAATAAATAATCAA

10920

TAAAAAAAATTGAGCTCAGTTGAAATCTGTGAGTTCTGGGGCTAGGGAGATGGTTCAGTGG

10981

ATAAAGCATTTGCCTCGCAAGTGTGAGGGCTGGAATTTGGACCCCAGAACCTGCATAAAGC

11042

CAGCTAGAT GCAATAGTGAAT GTCT GT AACCTTAGCACTCCTATAAT GAGGT GAGAGGCAG

11103

AGACAGAGCAACCTAGCATGCTCATGGGCCCAGGATATACAGCAGAGGACAAGACACCCTT

11164

GTTCACCCGAGGAAGAAGGTGGAGACCAACACCACTCGAGATTGTCCTTTGATGTTGTCAT

11225

TGGCATGTGTGTCCCTTTACCCATACAGAATAACACCTCTTTCTCTCTTTCTCTCTCTCCC

11286

CCCTTACACACACACACAGATGATAAAAAACGAGGGGGGGGGCTCTATTAGTAAGAAGAAA

11347

GAGAAAACCAAAT T GAGACATAGC TAAATAAAAC T GATAGC TAGGC T C TAAAGAAT GAATA

11408

AAGGGTCCCCTAGATTTGTGGTTCCCAGCGTATAAGTGTGGCCCGTGGATCCCTAAGAGAC

11469

CCTGAAACCTTAAAGGGCAAGCCAGCTTTATTAAGGCAACAGGACTCCATCTGCCCGTTGC

11530

T GT CC TAAATCC CAGC GGGGC T GCAAAAGC T T CCT GGGT GAAACAGCT GCC T CAGCACAAA

147
Figure 5.1 (continued)
11591

GCGAGGTGGTGTCAGGAAAATGCACCCTGGTCCTTCACTGCCAGGCACTTGCCATTTTCAA

11652

AAACATGCCCATATTTTACTGAGCAATGTCTTTGGTTGAAACAATAAAATTTAATTTTATT

11713

AAAATGCAACCTTTGGGAACACCGTGTTGTGAAACAGGAAGCTGCAGAGAGCACTTGTGGT

11774

GCAGATGGGGTTGGGATGTTCGTCGTGAGTAGAAACTCGTGGGGGCCACAAGTCAAGCTAC

11835

ACTTTTAACATCTCTCGTTTCTTCTTACCATTGTAATAATTTGTTTATTTTTGCTGCCAGT

11896

ACTCTTAACTGCTGAGCTATCTCCCCAGCCCATTATTGTTTAAAGTTAACATGCATAGCGA

1 1957

TGGGTTTCACACATGTATGTCATCACAGTGATGGCATCTTCATATGTATAGATTATTAAGC

12018

TTTGCTTTTATCTTATTCTTCCCGAGCCCCTATGCCCATCTTGCTGAAGCAGCCACTTTTT

12079

TTAGTTGTCTGTTTGTGTGTGTCTGTGTGTGTTTTGTTTTTCATTTGTTTGTTGTGTGTGA

12140

GCATTTTGCCTCCACATATGTTATGTACCTGGTGCCGGTGGGAGGCCAGAAGATGGGGCAG

12201

ATCCCCTGGTGCTGAAGTTACACACAGTTGTGAGCCACCAGGCAGGTGTTGGGAATAGAAC

12262

CTGGATCCTCTGGAAGAGCAGCCAGTGCTCTTAACCACTGAGCCATCTCTTTAGGCCCAGA

12323

ACCAGCCACTTTTTCAGAGTAGGGGGATGGCTAGAACACGTGTATACCTTTTAGTGATCAC

12384

TCTGGCTGCTGTGTGGAACATGACCTGGAGGAAAGCAGAAGACAGAGTGGGTACCCACCAG

12445

CCAT GGGTATCAAAGGCC T T GGCAGGGAGGGT GAT GGTAGCCAGAGACCCAAGAC T CT GGG

12506

TTCACCTCAAGACTAAACAATTTTGCCAGGTGTGGTGGTGCATGACTTTAATCCCAGCACT

12567

CAAGGGGCAGAGGCAGGAGGATTTCTATGACTCTGAGGCCAGCCTGGTCTATAAATGGAGT

12628

T CCAGGATAGCC TAGGC T GT T C T T CAGAGAGAAATAC T C T CAAGAACAAACAAACAGACAT

12689

GAACGGAGTTTGTTTTTCCTACCACTGTTTCTATATGGCTTCTCTAGCCACTAAGAGATTG
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12750

TTGTTGCAAGCAGCACTTGAATAAAGAGTGCCTTTGCCCCCTTATAAGAGTTCTTCCTGCC

12811

AAGCTCCCCTGACCTTGTGGCTTTGCTTGGCTCCAGAGGACATTCCTCCAAGGTTTTATCT

12872

GTGCTTGAAGTTTTCCAAAGTCAGGCAGTCATGGGGCTGCATCTGGGTCAGGATTTGTGCC

12933

CAATAAAGGAACAGC GAACCAT C T GGAT CCCAACAGGAGAGGCCAGGACAT GGGAGT TAGG

12994

GACTGGAGCCACCATGCCGGCATAGAATGGCAATGTCACCCTACGCTGACATAGTGGTTCA

13055

GAATGACCTAGAGAGATTTGAAAGACATTTAGAAGAATTTGTAAATAGATACATGACAGGG

13116

ATTGGGGACTGAGGAAGTAAAAGATTGCATTCAATGTGTTTGGCTTAGCTATCTTGCCGTC

13177

ACTCTGTAGAAAACTTGAGGCAAGGGCAGGCAGATGCTAAGTCTGTCCAGAACTAGTCTGA

13238

GAT T TAT GGAAAT T GC TAT GT GAAGAGACACAAT GACCAAGGCAAC T C T CAT GAAGGAAAC

13299

CATTTAATCGGGGACTTGCTTGCAGTTTCAGAGGGAGTCTATTATCTTCATGGTGCTGGAC

13360

CAGTAGC TAAGAGC TAGATCC T GAT CTGTGGGGGGGGGGTGT GGGGGGGGAGAACAGAGAG

13421

AGAGGGAAGGAGGGAGGGAAGAACAGAGAGAGAGAGAGAGAGAGGAAGGAGACTGGGCTTG

13482

GCATGGACTTTTAAAACCTCAAAGCCTTCCCCCAGTGATATACTTCCTCCAATAAGGCCAC

13543

ACTTCTTAGTCCTTATAATCCTTTCAAATAGTACTACTCTCTGGTGACTTAGCATTCAAAT

13604

ACATGAACCTATTAGGGCCATTCTTAGTCAAACCACCACAGTCTGCAGAGCTTAGGTGAGA

13665

TCTGGGCTAGAGGAGAATATGGGGAATGTTAGCAACAGACTGCTCCCTAGTCTCCAGTCAT

13726

TCCTGTCTTCTCAGATGTTCGTATTGCAGTCCAGGCCTCTCTGCCACAGCGAGTCAGATAT

13787

ACAGTCTGCTGATCACAGGCTGCACATTGCACAGATGCTCTCAGGGGTGTGTAATGAGAAG

13848

CCCTCAGAGGGATCACCACAGCTGCTCTCAAATTGTCACTAAAGGAAGTGTAGCGTGTTTG
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13909

CTTACCTGTCCAAAACAGTGGCCCTACTCTTCCTGTAAGATGGGCACACAGTCTGZ^ATGGC

13970

TTCTTTCTGCCTTCCCCATAGAGGAGACACACAAGGTTCTCATCATGCATGCTTTTTTGCA

14031

CCTTGGCCATGTGCTACCCACTCAATCTCCAGCAATGGAGTAAGGGAAAGCCAAACCACTA

14092

TGTCTTTAGCTGCCACAGAGCCGTGTTGACTCTTGCTGTTTCCCTATGGGCTCTTTGTCAT

14153

CTCTAGAACAGCCGACTTAGTGGATCTGTTGGGCAACGTAATCTAAATTTTCCATTGATTA

14214

AATTGCTAACTTTTTTTTTTAAAACATGGCATTACTGCATAGGCAGCCTAGTCTGGCCTTG

14275

AGCTTGTGATTTTTCTGCTAAATCACCCAGTGCTGGGGTTACAGTTACATGCCCGTGCCCG

14336

TGCCCGTGCCTGTAAGCCTTGCCTCACGTTGACCTAACCAGGCTGTTTCAGCTTTTTACGG

14397

CACCAAACAATAGTGACATTCCAGACTCCAGCTTGATTCTGCTCAGGCATTTTCAGTGACT

14458

TTGGCATTTTTAATTTTTCAACTTCCCCAACAACTGGGGGTGGGAGGGAGGGACTCCTGAG

14519

GGCTGGCTTACGTCCGCCGTGCAGAGGAGCCTCACGACCAGGCTTCCTGTCTTTTCATTTA

14580

CGAACATCTGTGAAGGCAAAGCAAGACTCTCTTCTTCACTAGGTACCTGTTTGCAAAGTCT

14641

C GAGCCC TCATATACACACACC T GT GCAAGAAGCAGAGT GAAGGAAGGACT GGCCAGAGGT

14702

AAGAGGGACGTGTTCAACTTTGTTCTTTCAAGGAGCTGGAAGGGGCAGCTAATGTGCCGGA

14763

ATGTTCTGGATGCAGTTCTCTGTTCTCAGTTGTGGCCTGGGGTTCTCCTGTATTCCTCTTA

14824

GAACGGGTCATGAACAGTGATCTCCCACTGGAATCATGAGCTTCGAAAGGCTCAGCAGTAA

14885

GCCCTTCTCATCTTTGCCTGCCCATGGCCCCAAGTATAGTTTAGTGCTCAGAGCAGTAGGT

14946

GCCCCCTTGAACCACCCCAGGAAGAATGCAAAGTCAGAGGGGTAGAAAGGCAGCTGGGACA

15007

T GGT GGGGT GT GGGGGCAATAGT GGGGAGT GGAAAGC T GGGGAGAGAGAAAATACAGAAAT

150
Figure 5.1 (continued)
15068

AAT T TAGCAGAGGACT GAAGAT TAG7\AA.GAGGAAAC T T T GAGAAT GGAAGAGACAC TAAAA

15129

CAAA?VCAACAACA?VCASAAAGAAACAGAAAACACAAGAAAAACAGAGT GGGC GATAT GCAA

15190

TTAAAAAAAAAAAACTTTCTTAAAAGTCTTCACCAAGGATCATGCAATCAAGAACACTGCA

15251

GGCCACATGGTCCATTTTGGGCTCGCTCAATTTCATTTGTGTTGACGTGAGCTGTTAAACT

15312

CTTGTTTTCTTCTGTGT^AGTTTTAGGGTTTTGGCTTGTTGTGTTTTGTTTCTGAGGTTTCA

15373

CTGTGTTGCCTGGGCTGGTCTCAATATCCTGGGCCCAGATGATATTATTGCTTCAGCTTCC

15434

CCAGTAGCTGGGACCAAGGCACATGCCACTCTGTCTGGGCTGATATTTAGGGTTTTTGAAA

15495

TGTTCTAAGGGGACTCTGTTTTAGTTACCCTGGGTTAGGAGTTGAGGAGGGGATTTTATCA

15556

GAAAATGTTAAAACTGGCCCCTTATCTATGAATTGCTGTAAAGGGACACTTTTTTTTTTAA

15617

AAGTAGACAT GT TAGAATAAT TAAT T C TAAGAGAAT TAGT C T T GGC TACAGAC CCCAGAGG

15678

GCTTGGTACAAAGCGGTCATAAGTCAGGACTCTATTTCTCAAGATGGGGTGAGCTTCCCTG

15739

TCTCCACACCCTCAGACCTTTCTCCTTCCCCAGAGCCACATGGTCTTGAAGTTATGTTGTG

15800

CCCCTGAGTGTCCTTCAGTTCATAGACTTGTTCCCAGACAGTGGTCTCCTGAGGTTCATTC

15861

TGACCCTTCAAAATAGAAAGGTTCCGTTGAGGTAATTCAAAAACTCTTCTGAGTGGAATAG

15922

CGGAATATCCTGGTCTCGTAGGGAACTCTTTTTGGAAGCAAGGCTGGGAGAACCCGATGAG

15983

GGAGGCCAGTGCTATTTAGTGTTCTGACCATTTCCGATGCTATCTTAGATTCTCTAGGTTA

16044

ATACAAAATGGCCGCCCTGAACCACTAAAGAAAGATCCTCCGAGGAGCCAGATACCTAGAA

16105

CCAGTTTTCCCTTTCAATCCGAGGCCCTCACAGAAGAGGCCTGCCTCTATGTACAGAGTCT

16166

TCCCCACGGTCAACCAGTTCTAGGAAGAGGCTCCAAGTGGCCTTCGGTCTCACTCTTGACC
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16227

GCAGTGGTTGGCACATTTTAGACACTTAATAAACATTTGTTGGGTTAAATACCTTGGATGG

16288

AGAT GGGAAAGGGGAT GACGGAAGGGAGGAT GTAGAT GT GTC T GTAGGGT GT GAAT GT T CA

16349

GTGCTGCTTACAGCATTGTTTAGACCTTTCTTTCTGAGTCAAGAGAAGCAGGGGTTACAGA

16410

GCTCCCACCCACTGCCACCCACCCGCTGCGTGTAGGCACCCGAGGCAAAGGAGAGGGTGGC

16471

AGAGGTTGCAGCCACTGAACCACAAGGGTCGCTTAGAGGGTCACATCTCTAGGAAGTTTAT

16532

ACGAAGCTAGGCAACAGAGGAAGGGTGTGTGGCGGGGGGCACATCCCACAACTGGGCTAGA

16593

GTGGGCTGACTGGGGGGCCATGAGGAGAAGATGAAAACGCATTCGGGACCACAGGCTGTCA

16654

CTGTGGTGGGGCTGCTGTGCTGGAACTGTGCCCTCCTCTCCCATCTCTGGGGGCCATGTGA

16715

GGGT GGCAGGAACCCCAAGTACCT TAAAAGGT GT GT GGT GT GTAC T GTCACT T GATAACAT

16776

CCCTTGTGTGGTCCCTCTCTTTGTTCTTTTGGTGTTGAGTTCTCTGCATGTATCTTGCCTT

16837

CTAGAGTCTCTTCATTCCTATGCCTCTCCTTCTGACATGTTCTTGTCATGTGTTGATGGAT

16898

CCTGTGAAGGGTGGTTGTTGCTTACTGACTTTTCTTTGTCCCTTTCTCTTTCGCTCCTGTC

16959

TTCCCTTGAGGCTTCTGTGGTTGGTTTGTTGTTGTTGTTGTTTGTTTGTTTGTTTGTTTTT

17020

TTCCAGAAAACATGTCCCCTCTCCCTCAACTCTGCAGCCAATTCCTCTCACATCCACCCTT

17081

CCGGTCCAGCCTATACTCCACAGCTTCCTGTCAGATCAAAGCTCCTGGAAGACCTACCAGA

17142

AGCCAGGCTACTTGTTTACAGGGTAGAAGGAACCAGAGATCTTGGTGTCATCTGAGGAGAG

17203

GAAAGGGGAGAAAGAGGAGAT AGGGGGCAC T CCAAGGGGAAGAGAACAC TAAAGGC TCCAG

17264

CTCAGAGGAAGACATCCAAGGAGCTGAAGGCCAAAGCCCAAGCATGGGGAAATAGATTGAG

17325

ATAT GCAGACAT GAGCAGAGAC GGGGGAGGGGGACAT T GCAGC CAGT CAGC T C T T GCAT CC
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17386

TTTCCCAGGGGTGACGTACACAGGATGCTGCGCTTACTCTTTATGAGATATAGCGCCTCTG

17447

GGGAGGCTGAGGATGTGGGAATCAAAGGCCAGGTCTCTGGGGTAGCAGCGGAAACCTGAAG

17508

CACCAATGCAGGCTGTGGCTGGAAACCCACAGCCTCCTCCACTGAGCCAATTCCCAGCGTG

17569

CGTTGGTGTGGGGCCAGGAGCTGGAGACAGACTCCAAGGTTGTACAGTGAGGGAGAGAAAG

17630

TGCCTACCCTCTGGGGAAGAGCCAGGAATGCCCTCGTTCCTCCAGCATCTTTATCAGAGCT

17691

ACGTGAATTTAGATCCCAAGGAGGAAGAGCCCAATAGAGACTTGGTTTCTCTGTTAACTTC

17752

TACTCACCAGGGACTGACACACCCGCTCATCAAGGTTTTCCATCTAGGGTAGGGACAGCAG

17813

GAAACCTTCTTGGGCCTAGGCTGCTCCTTCAACTCTTATCACCCCACACCCTTCCCTTAAA

17874

TGCTTTGCAGGCCCTGGCCCAAGTCAACTGTGCCAACTTGTAATCTCCTCTGTGACTATAA

17935

TGACTAGTCTCAGGCCTGCCTTCCCCAGAAACCTCTCTTTTGGCTATTTCTCTTTCTAGTT

17996

CTCTGTTTAAACCAAATTTATTCTATATATCTATCTATCTGTCTATCTATCTATCTATCTA

18057

TCTATCTATCTATCTATCTATCTATCATCTACTTATCATCTGTCTAGCCATTTGAAGCATC

18118

TTTGTGTTTTAGGTCCTGTTAGATTCTCCTTTCAGCCAGTGGAGGATCTGGACAGAGCTAT

18179

TTCTTAGCTTCCCCTAAGCCATGTTGTTAGAACGAATCCCCCACACCTCCTCTGAGTGCTA

18240

CGTCTCCGTCAAGAATTATGTATGTGGGATCCAGATGGCCCAGTGGATAAAACTGCAAGTG

18301

T CAT GACCAT GAG C T GAG T TCAAGGGAT T GT GTAGAAAGGGAGT TAT CACAGT GT GAGGGA

18362

CAGGGCTAAGGACACTAACCCGTATGTTGAGGGGCACAGACGCTAGCAACAACAGTGAAGT

18423

GT T TAAAAAGGCAAAAAT CAT GT T T C TAGAAGT CAGGAAGAGC C TAAC T T GT GGACAAGGA

18484

CCAACAGGCAGCAGT T GT TAT GGGGCAGGGCAGAGGGAGAGCGGACAC GCAGC T T T T GGCA
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18545

TCAAACACACCCAGAGTGTGGATAGAGAGTAGGGAAATACTCTAGTCTCTGGCTAGGATAC

18606

TCCCCTCTCTTTTTGACATTTCTCATTGGCAGCCCCAAGTGGTCACTGGAGAGCCAGGAAG

18667

CCTAAAGGACACAGTTAGTAGCAGCCAGCTCCTTTGGTGGAATTTTGGGGACATGGTGGGG

18728

TGACTTGGCTCTATCCAGGCCAGGGCTGGGTGTGAGTATACACTTAGTGACTGGCCTTCCT

18789

TCTCAGGTTCCCTCCTTCTCCCTCGCCCTTCTTTCCTTGAAGCTACATTTTTGTAATACTG

18850

AGGATAAGACCCAGGGCATGCAAAGCAGACCCTGTACCCCTGAGCTATGTCCTCGGCCTTC

18911

AGTGACCCATTTAAGGAACAGAATCCAGGTACTGCGTATAGGAAGATGCACCAATGAGGTA

18972

TTTGCCTCTGTTCATCCTATTTGGCTTAAATTAAACAGGGATATTATCCACTTCCACTGGT

19033

GCCAGCCTCGTGGTGGCTTAAGGCAGCTTGAGACTGTCATCTCTGTCCTTGTAGAGTTCAC

19094

GCTAGCGGGGGAAGGGATTATGTGAATCACTCTCGGTTAAGGTGGCAGAGGCGACATGGCC

19155

AAGAGAGCAT CAAGAGAGAAC T GAT T GAGT T CAGAAAGGGCAGAT T GC TACAGAGCAACAC

19216

AGCAGGGGT TAT T CAAGGGGACAGAAAAATCAGGC T T GGGATAAAGAATAATAAT TAAC TC

19277

TTCGTGAATATCTTGCCTCACCAGCTCTGGACCAGATTCCCTGTTGAGACTCACCCTTAAT

19338

AGTCACTTCCCTGAGCCCCACTTAGAGCCTGGGCCGCTGGGTTGCATTGCCTTCGTGCATG

19399

T GC GCAT GCCCGT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GTAT GT GT GT GT

19460

GTGTATGCGTGTGTAAATAACAGTGATTTCACTCATCACCAGAACCAATCTCAACTCTTCT

19521

AGCTTGCCTGTTAGGATTTATTGCCAGCCCCCAAATATGTTCCTATATATAGCCCCCTGTG

19582

CTGTGTTAGTTCTTAGCACTTCTAGCACACCCCGAAGGACTGAGAACGGTCCTCTGAGGAT

19643

GGCCTTGAACTCCCGATTTCCTGCCTCTTTCTACCTTCTGTGCAGGGATTATCAGTATACA
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19704

CCACCACAGCTCGGACCACTCCATGGCCGGTGCTCCTGAACCCATGGCCTCACACACACTA

19765

GGCAGATACTTACTAACCGAGCCACAGTCCCAAATGCTGCTTTTAATTTTTTTGGAAATTT

19826

TATATTAAAGCATTCCCATCCTTGCCACAGACGCAGAGTGGTGGATATAGCACTTGTCTAG

19887

TGTGTATGGCCCTGAGTTCGATCTCAACAGGAAGTTTTATCAAAAATGAATATACCCGGCT

19948

GGTGACACCTTACCTTATCTGGTAAAGGTGTCTGCTGCCAAGCCAAACCATCCCATTAGAT

20009

CCCTAAGCCCCAAAATGGTGGAAGGAGAGAACTGACTCCCACAAGTTGTCTTCCAACCTCC

20070

ACGAAAGTGTAACATTTGATAACCAAATACACAAATAATTAGATTTATAGATAAGTAAATG

20131

AATAAGTAAATAAGATGAAAAAAATTAATGAATAACAAGCTCTGCACTCGCCACTTCAGTA

20192

AGAGACGTGTTTTGCTTTCAGTTTGATGTTTTTCTCTTTCTTTCTTGAACATTTTATTTTT

20253

AGACAATTTGTATATCTGTAAATACATTCTGACTATTCAGCTCCCACCATCTTCTCTTTCT

20314

CCCGAGTTGTCAACCCTCCCCTTCCCTGCAAACCTTGCTTCCCCTTTTATGTCTTTTTTGG

20375

GTTTGTTCTTTCATGACCCATCCAGTTTAACTAGGGCAGCCCCAGTGCATGGGTACAGAGC

20436

GAT T CAGGGCAT GGGTACAGAGC GATCCAGGGCAC GGGCAAGACACCAGT GGCTAC GCCGC

20497

TGAATACCATGACTGTTCTTCTTCTAGCCACTGCCCGCTGTCTGCTGCCCACTGCCCGCTG

20558

CCCATAGTTGCTCGGGGAGAGGCGGGGCTGTGGCCTCCTGAGCTCCTGCCCATCCATGACT

20619

GGGCGCGGGGTCAGTGGTTTAAGGTTGGCAGGGGCCACAGCTTTCATTTGCCTTGCTTTTG

20680

GCCAGCAAGCAAGAGAT GCAT CAACACAAAAACAAAGAGC CAGGGGT C CAGT T CAGT GATA

20741

GAACGCTTGCCCGGCAGGCACACACGGGGGTTGTGTCTCTGGCACCATGAAATGAATAGAC

20802

AAGC CAAC TAG GCAGCCT T GGT GCAAGGTCCACCC GTAAACC TAACATAGTAAC TAT T T GA
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20863

AAATTACAGTTATCAGGGTTAGGAGTGTGGTTCAGTAGTAGAAGAACACATATCTGATGCA

20924

TGGGAATTTCTAGGTTATAGGCCCACTACTGGGGGAAAACAAACAAAAAAATTACAATATC

20985

AGTAAAGGT GATAT GAT T TATAGGT GAAATAAAGCTATC T GGAAAT GGT T TAG TACAGT T T

21 046

CTGAACTTGGACCTAAATGTGTGTGTGTATACATATAATTTTTATTTACATAAAATGTTGT

21107

CAGTCTATGCTTATACTTTACTTTTTGTTTATTTATTTATGTGTATGGATGTTTTGTCTCC

21168

ATGTGGGTCTGTGTGTCACATGCATACCCTGGGACTAAGTTCCATACAGGCCACCAGTAAG

21229

TGCTAAGTATTGAACCCAGATCCCCGGGAAGAGCAGCCAGTGCTCTTAAGGGCTGAGCCGT

21290

TGTTTCAGCCCCTGTTTCTACGTCTAACCAGAACAGACATCTCAAGTAACAAGAGATGTTT

21351

CTCTATATGGAGTCTAATGGTTTCTTTTATGAACTACTTGTCCAAAGCTTCAAATAATTAA

21412

CAAAACAACAAAACCCTTTCATAATATTGTCTCTTACAACTAGATTTGAGTGTATGTGAGT

21473

AT GTAT GT T T GAGATAGCATAT T T GT GT GT GAGTACATAT GT CCAGT TAGCAT GT T T GT GT

21534

GTGTGTCCATGCCAGCTTTTTGGGTGTGTGTTTGTATCCATGCCAACTTGCTCCAGAGATC

21595

ATTTGCATAGTAAACACTTTATCTTCTGACCATCTCTCCAGTTCAAAATTAGGTATTTCTT

21656

AAGCAAAGGCAGCAGTCTCTCTCTCTCTCTTTGCTTTTTGTTTTATGTTTTTTGTTTGGGT

21717

TGGTTTTGGTTTTTAGAGACAGGGTTTCTCTGCATAGCCCTAGCTGTTGTAGAACTTATGT

21778

AGAATAGGCTGACCTTGAGCATAGAGATCTACCTGGTTTTGCCTTCTGAGTGCTGGGATTA

21839

AAGAT GTAT GCCACCCAAGAAGACAGGAGTAGGT GGGAGAGCACCC T CATAGAGGCAGTAG

21900

GAGGAGAT GGAGTAGGGGGT T T C T GAAGGGGAGACC T GGAAAGGGGAAAACAT T T GAAACA

21961

TAAACAAT GAGAATAGC CAATAAAAAATAAAAAGAAACAGTATAT GTAT T TATAAAGAACA
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22022

CATTAGTGTGTATATATATACATGTATAAGCATGTTAAATTTGTGTGTGTTTGTAAATCTA

22083

CACATATATGTTCCATGAATATAATACTCTGCTGATAAACATTTAATGGTTGCCTCTCTAA

22144

AGCAAAACAAACAAAACACCCGATGGTCAATATTTGGCAACTTCCATGGTGTGAAGATTCC

22205

TGCTGAGGCTGCTTTACCAGGACCCCTCCTGGTGACATCACTCACTGTAGAGCTGGGGAGA

22266

AAACTGCATAATCAATTCTTGCCAATCACTGTGGAATGCTGCCAGTGCAGTGACAGATAAC

22327

ATACCTCCCCCAAAAGATGTGTGCCACCACCACCTGGCTATAATTTTATTAAAAGGCAAGT

22388

GGGTCCTTCTCCCCATACTTGAGATAGGGTCTTGTATAACCCAGGTTAGCCTTGAGCTTAC

22449

TATATAGCTGAGGCTGGCCTTGAACTGGGTGTTTGCCTGCATGTATGTACGCGTACCATGT

22510

GATTGGAGCCTGCTGAGGTCAGAAGAGGACACTGGATCCACAGTAATGGAATTACAGACAT

22571

ACCCATGTAGGATCTCGGAATCGAACCTGGGACCTCCACAGGAGGAACAAGTGCTCACAAC

22632

CCTTTAGTTTTATTTTTGAGATAGGGTTTCACAGTACAGTCCTTGCTGGCTTTGGACTCAT

22693

GGTCCTCCTGCCTTGGCCTCCTAGCTACTAAGAGTGTACACATATGCCTCTGTGCCAGGGT

22754

CGGAGACAATAACGGTGCACGTGAGGACCTA7\AACCGTAGTTTGTCTTTGACACCCAGGAA

22815

TATACTTATTTCTGGGTCTCTGTCATGCACTGCTGCTATTGCTCAGGATGTTTAAATTGCT

22876

CTTCAGCTACTGACATCACAGTCTTAGTTTGGCAGGACCTTTGGGGTGCATTACTGCAGGG

22937

TGCCCACTTTTGTGTATGCAGATAATGTTCTCTGGGTTGGTTATCAAGGTCCTGAGGAAGA

22998

GAAAGAGTTCTTGTGTGCCCCAGGCCCAAGGAATACCTGAAGACTGATGATTTCTATCTTC

23059

CTCCGCCCCTGACATTTTTGTAGGCTCAGATTCCCAACCAACAAGAGCTC
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Figure 5.2. Restriction enzyme recognition sites. Restriction enzymes listed are
commercially available, recognize 6 bp sites, and cut at less than 16 sites in the 23108 bp
sequence.
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plane can rotate around the long axis between both the nucleotides. The roll angle’s
undistorted value is -1.0 degrees. A third angle change slides the purines radially out from
the helix axis and the pyrimidines in toward the axis; this increases the torsion angle
between the carbon-carbon bonds at the carbon along the chain backbone to which the
purine nucleotide is attached and decreases the angle at the carbon to which the pyrimidine
is attached. The undistorted torsion angle value is 0 degrees. A fourth angle change
decreases the main helix twist or rotation angle, which is the angle at which the helix rotates
around the helix axis between base pairs. The undistorted twist of the helix is 35.6 degrees
per helix turn. In addition, HAIRPIN (Tinoco et al., 1973) was used to find hairpin loops
in the DNA sequence. The minimum stem length chosen for the hairpins was 7 bases and
the number of unpaired nucleotides that formed the head of the hairpin was 5 to 20. In
addition, T. Kohwi-Shigematsu (La Jolla Cancer Research Foundation, La Jolla, CA)
scanned the sequence for potential MARs.
Searches on BLAST were performed to find homologies between known
sequences and the murine CD4 gene (Altschul et al., 1990). The searches were done using
the following parameters: PROGRAM blastn; DATALIB nr, epd, repbase, or kabatnuc;
EXPECT 0.75. The PROGRAM directive was used to specify the nucleic acid BLAST
program. The DATALIB directive was used to indicate which database to search. For this
directive, non-redundant (nr) was used to search Brookhaven Protein Data Bank (pdb),
GenBank (gb), GenBank update (gbupdate), EMBL Data Library (embl), and EMBL
update (emblu). In addition, the Eukaryotic Promoter Database (epd), Repbase database of
human and other primate Alu repeat sequences (repbase), and Rabat’s database of
sequences of immunological interest (kabat) were also searched. The EXPECT directive
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was used to specify the statistical significance threshold for reporting matches against
database sequences. The default value is 10, such that 10 matches are expected to be found
merely by chance, according to the stochastic model of Karlin and Altschul (1990). The
value 0.75 was used because it defined a very stringent threshold. The sequence was
submitted to BLAST in four parts: Part 1 (bases 1 to 6899), Part 2 (bases 6900 to 13797),
Part 3 (bases 13798 to 20695) and Part 4 (bases 20696 to 23157). Each of these parts
were submitted as an nr, epd, repbase, and kabat search. In addition, portions of the
sequence were resubmitted in smaller pieces for reanalysis using the various databases.
Results of sequence analysis are presented based on the regions of DNA with
functional activity discussed above (Figure 5.3). Each region is presented in detail in the
figure indicated in Figure 5.3. The first region includes bases 1 through 2875. This region
contains the T cell-specific enhancer (Sawada and Littman, 1991). The second region
includes bases 2876 through 10935, and corresponds to the sequence from the first Sac\
site to the third Sad site. This region is between the T cell-specific enhancer and CD4
promoter. The third region includes bases 10936 through 14639, and corresponds to the
third Sad site through the transcriptional start site to the second Xho\ site. The fourth
region includes bases 14640 through 23108 and corresponds to sequence from the second
Xhol site to a Sad site in the second exon.
2.

Analysis of T Cell-Specific Enhancer Region

The murine T cell-specific enhancer was originally identified 13.5 kb 5' of the CD4
promoter (Sawada and Littman, 1991). The minimal enhancer consists of three
protein/DNA binding sites, CD4-1, CD4-2, and CD4-3, with 90% of the activity of the
minimal enhancer attributed to CD4-3. Careful analysis of the transient transfection data
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Figure 5.3. Sequence analysis of the 5' flanking region and first intron of the
murine CD4 gene. Description of diagram showing the 15 kb of CD4 5' sequence and
8.9 kb first intron. DNase I hypersensitive sites (DH sites) are denoted by numbered
vertical arrows directly above the region in which they are located. Matrix attachment
regions are represented by the cross hatched boxes and the repetitive element is
represented by the black striped box. The horizontal arrow at DH site 8 shows the start of
transcription. The letters directly below the line are the positions of relevant restriction
sites used in making the deletion constructs discussed in Chapter 3: N-Notl, S-Sacl,
E-£coRI, W-Xhol, P-Ps/I, X-Xba\, L-Sati. Horizontal lines below the figure indicate
regions in which the sequence analysis is given in detail. Detailed diagrams are found in
the figure indicated at the left of each line.
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presented in the original paper indicates that the region surrounding the minimal enhancer,
specifically 81 bp 5' or 385 bp 3', decreases activity in transient transfections. As
discussed in Chapter 3, our results also indicate that the region encompassing the enhancer
may contain a NRE. In addition, our data indicates that the region 5' of the minimal
enhancer has enhancer activity. Therefore, the minimal T cell-specific enhancer may be
one part of a larger regulatory unit, consisting of both positive and negative activities.
Our sequence analysis indicates there are regions of homology to the human CD4
enhancer (Blum et al., 1993) within and 5' of the minimal murine CD4 enhancer
(Figure 5.4). The human enhancer has 73% homology to CD4-3 (2169-2258) and
homology to three regions 5' of the murine CD4 enhancer. Region 1 (1617-1673) is 75%
homologous, region 2 (1732-1758) is 81% homologous, and region 3 (1852-1900) is 71%
homologous. This suggests that although the minimal enhancer may be the core enhancer
element, sequences upstream may also be important to stimulatory activity. While the
murine CD4 silencer was identified in the first intron (Sawada et al., 1994), the sequence
immediately 3' of the murine T cell-specific enhancer has 50-60% homology to this
silencer (2405-2843). Since the region of highest sequence similarity, 60%, is within the
385 bp region previously mapped as negatively regulating, it may be responsible for the
repressive activity observed. There are two inverted repeats in this region, both upstream
of the minimal enhancer (893-900, 917-924; 2023-2029, 2041-2047). One of these
repeats lies directly upstream of the minimal enhancer, indicating the possibility of
additional factor binding sites. The murine enhancer also lies in a region predicted to form
non-B DNA (2055-2125). This is a feature which has been postulated to affect
transcription and may further contribute to the function of the enhancer.
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Figure 5.4. Summary of sequence analysis of bases 1 through 2875. This is a
summary of results of sequence analysis of the region containing the murine T cellspecific enhancer. The horizontal line corresponds to sequence 1 through 2875.
Restriction sites located below the line indicate cut sites at the ends of the fragment:
G-Hphl; S-Sacl. Boxes below the line indicate regions of homology and their location
within the sequence. The box size corresponds to the relative size of the homologous
region. Names of the elements are located at the left of the boxes. The T cell-specific
enhancer is referred to as the murine CD4 enhancer to distinguish it from the human CD4
enhancer. Homology to the human CD4 enhancer is located immediately 5' of the
murine enhancer, while homology to the murine CD4 silencer located in the first intron
and corresponding to DH9 is located immediately 3' of the murine enhancer.
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3.

Analysis of the Region Between the Enhancer and CD4 Promoter

The T cell-specific enhancer is necessary to up-regulate CD4 expression at the
double-positive stage of thymocyte development (Hanna et al., 1994). Previous work
from our laboratory indicates that the region between the enhancer and promoter
(consisting of 8.2 kb) contains a NRE (Chapter 3). Furthermore, in order for the enhancer
to work in transient transfections of T lymphoma cells, this region must be deleted. Sands
and Nikolic-Zugic (1992) identified two matrix attachment regions (MARI, MAR2) and a
repetitive element (REP1) in this region. MARI was localized to a region 10 to 12 kb 5',
MAR2 was localized to 2 to 5 kb 5', and REP1 corresponds to the region 6 to 9 kb 5' of
the transcriptional start site (Sands and Nikolic-Zugic, 1992). Our sequence analysis of
this region indicates homology to the following elements: (1) 5' flanking regions of
eukaryotic promoters; (2) sequences with the potential to bind the nuclear matrix (MARs);
(3) repetitive elements (REPs); (4) sequences with the potential to form non-B DNA;
(5) enhancer and silencer homologies; (6) inverted repeats (Figure 5.5).
There are two regions with homology to the flanking regions of eukaryotic
promoters. One of these regions is located in the first Sad fragment, while the other is
located in the second Sad fragment. The first region (3039-3461) involves approximately
250 bp of sequence, and the second region (7394-8051) involves 650 bp of sequence.
Sequence homology corresponds to a region 300 to 500 bp 5' of the transcriptional start
site of the various genes. Interestingly, these motifs are directly overlapping each other.
The promoters involved include mouse elastase II (73%, 3213-3253; 74%, 7399-7448;
75%, 7745-7776; 75%, 8016-8051) (Stevenson et al., 1986), mouse hypoxanthine
phosphoribosyltransferase (HPRT) (80%, 3206-3251; 90%, 7498-7562;
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Figure 5.5. Summary of sequence analysis of bases 2876 through 10935. This is a
summary of results of sequence analysis of the region between the T cell-specific
enhancer and CD4 promoter. The horizontal line corresponds to sequence 2876 through
10935. Restriction sites located below the line indicate cut sites within and at the ends of
the fragment: S-iSacI. Boxes below the line indicate regions of homology and their
location within the sequence. The box size corresponds to the relative size of the
homologous region. Names of the elements are located at the left of the boxes. The
T cell-specific enhancer is referred to as the murine CD4 enhancer. Regions of
overlapping homology to the 5' flanking regions of eukaryotic promoters are referred to
as promoter clusters. There are two clusters of overlapping homologies to the 5' flanking
regions of promoters. These promoter clusters are separated by a region with homology
to MARs and potential to adopt non-B DNA conformation. The second promoter cluster
is also in a region with homology to a number of other elements. These include MAR,
B1 and B2 repetitive elements, murine CD4 enhancer, murine CD4 silencer, and Alu
reducer. Homology to MARs and sequences with the potential to form non-B DNA are
found 3' of the second promoter cluster.
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86%, 7857-7948) (Melton et al., 1984; Melton et al., 1986), mouse interferon alpha
(IFNa) (74%, 3285-3354; 82%, 7936-8008) (Kelley and Pitha, 1985; Nagata et al, 1980),
c-ras^ (81%, 3300-3336; 87%, 7494-7540) (Muller et al, 1983; Hoffman et al, 1987),
human CD3y (72%, 7498-7562) (Tunnacliffe et al, 1987), and mouse renin-2 (69%,
3419-3461) (Field et al, 1984; Dreyfus et al, 1987). The HPRT gene promoter has been
mapped by deletions and found to contain cryptic upstream initiation sites in the region
homologous to the murine CD4 regions.
There are six MAR homology sites in this region (3601-3690, 4520-5480,
7710-7780, 8151-8180, 9090-9200, 9831 -9870). The first two sites listed correspond
roughly to MARI, while the sixth site corresponds to MAR2 (Sands and Nikolic-Zugic,
1992). Interestingly, the region between MARI and MAR2 also has the potential to bind
the nuclear matrix (sites three through five).
The region between the enhancer and promoter contains sequences with the
potential to form non-B DNA structures, or Z-DNA (Calladine, 1982; Dickerson, 1983;
Shapiro et al, 1986). These stretches of DNA are dinucleotide or trinucleotide repeats.
There are seven of these simple repeats in this region (4145-4430; 4813-4880; 5070-5150;
5420-5530; 6080-6160; 6460-6530; 9090-9200).
Sequence analysis indicates homology to three highly repetitive families in the 5'
flanking region, corresponding to the REP1 region (Sands and Nikolic-Zugic, 1992).
These elements are the mouse MT repetitive element (75-88%, 8453-8680; 87%, 86968824) (Bastien and Bourgaux, 1987), mouse (clone pIL8) B1 dispersed repeat (85%,
7372-7539; 91%, 7853-7998) (Vidal et al, 1993), mouse B1 ubiquotous repeat (copy b)
(84-87%, 7389-7563; 83-91%, 7833-8013) (Krayev et al, 1980), and mouse RNA
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polymerase Hi-associated B2 repeat (80-94%, 8544-8816) (Singh et al., 1985). The mouse
B1 family of sequences are found throughout the mouse genome and show considerable
homology to the human Alu family (Kalb, et al., 1983; Krayev et al., 1980). Alu repetitive
elements have been shown to act as NREs (Wu et al., 1990; Saffer and Thurston, 1989),
and as insulators (Thorey et al., 1993). The mouse MT family exhibits considerable
homology to the B2 family of repetitive sequences (Bastien and Bourgaux, 1987). These
elements have homology to the promoter for polymerase HI (Bastien and Bourgaux, 1987;
Singh et al., 1985). In addition, the MT family shows homology to the SV40 origin
(Bastien and Bourgaux, 1987). Our sequence analysis indicates homology to the
polymerase IH promoter B-box and the SV40 origin, but not the mandatory polymerase III
A-box, which is necessary for promoter function.
Interestingly, this region also contains homology to several enhancers and silencers.
There is 45-75% homology to the murine CD4 enhancer (7486-7830) (Sawada and
Littman, 1991), 49-73% homology to the murine CD4 silencer (7456-7764) (Sawada et
al., 1994), 56-71% and 69-83% homology to the Rpt-1 silencer (4763-4904); 9069-9245)
(Patarca et al., 1989), and 82% and 68-100% homology to the Alu reducer (7387-7421;
7845-7881) (Saffer and Thurston, 1989). In addition, there are six inverted repeats
scattered throughout this region (2872-2879, 2891-2898; 6380-6387, 6393-6400;
7301-7307, 7314-7320; 7713-7720, 7726-7733; 8098-8104, 8122-8128; 8730-8736,
8756-8762). Homology to the CD4 enhancer, CD4 silencer, and the Alu reducer is within
the region containing the second cluster of homologies to the flanking regions of
promoters, homology to B1 and B2 repetitive elements, and MAR homologies,
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constituting a “hot-spot” of potential control elements. The last four inverted repeats are
also located in this region.
In summary, the organization of the elements within the region between the
enhancer and promoter is very intriguing (Figure 5.5). There are “hot-spots” of sequence
where a number of homologies are located. The second cluster of homologies to the 5'
flanking regions of promoters in particular, is flanked by MARs and non-B DNA, and is
found within a region of highly repetitive DNA. This design may be important not only
for repression, but may also provide a way to circumvent this repression.
4.

Analysis of the Region Immediately 5' of the CD4 Promoter

Previous results indicated that the region immediately 5' of the CD4 promoter has a
repressive effect on gene expression (Chapter 3). This was based on comparison of a
construct containing 6 kb of DNA including the promoter, with a construct containing
0.9 kb of DNA including the promoter. The region implicated in this negative activity
includes DNA from the Pstl site located at 13650 to the EcoRl site at 8307. The EcoFl
site is located in the region discussed above in the previous section, and includes homology
to two MARs, one potential non-B DNA region, homology to the B2/MT repetitive
element, homology to the Rpt-1 silencer, and the sixth inverted repeat. Sequence analysis
of the region from the Sad at 10935 to the Pstl site at 13650 is shown in Figure 5.6. This
region includes the following: potential non-B DNA (11261-11301), homology to MARs
(11691-11940), a cluster of overlapping homologies to the 5' flanking regions of
promoters (12220-12592), homology to B1 repetitive elements (12526-12641), and five
inverted repeats. Sequence analysis of the region from the Pstl site at 13650 to the
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Figure 5.6. Summary of sequence analysis of bases 10936 through 13650. This is a
summary of results of sequence analysis of the region immediately 5' of the CD4
promoter. The horizontal line corresponds to sequence 10936 through 13650.
Restriction sites located below the line indicate cut sites at the ends of the fragment:
S-Sacl; P-Pstl. Boxes below the line indicate regions of homology and their location
within the sequence. The box size corresponds to the relative size of the homologous
region. Names of the elements are located at the left of the boxes. Regions of
overlapping homology to the 5' flanking regions of eukaryotic promoters are referred to
as promoter clusters. The promoter cluster is located 3' of regions with homology to
MARs and potential non-B DNA.
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transcription start site at 14569 did not indicate homology to any elements covered in this
analysis.
The region of overlapping homologies to the 5' flanking regions of eukaryotic
promoters involves approximately 370 bp, and corresponds to the following: mouse whey
acidic protein (77%, 12220-12319) (Campbell and Rosen, 1984; Motojima and Oka,
1983;, mouse renin-2 (76-87%, 12227-12319) (Field et al., 1984; Dreyfus et al., 1987);
mouse pmm-globin (73%, 12420-12461) (Cheng and Kazazian, 1977; Konkel et al., 1979;
Baralle and Brownlee, 1978); rat elastase II (64%, 12527-12588) (MacDonald et al., 1982);
mouse hypoxanthine phosphoribosyltransferase (HPRT) (85%, 12537-12592) (Melton et
al., 1984; Melton et al., 1986). The B1 repetitive element consists of mouse (clone pIL8)
B1 dispersed repeat (80%, 12526-12641) (Vidal et al., 1993), and mouse B1 ubiquotous
repeat (copy b) (80%. 12526-12641) (Krayev et al., 1980). There are five inverted repeats
located in this region (12275-12281, 12287-12293; 12645-12651, 12669-12675;
12672-12678, 12696-12702; 12675-12682, 12696-12703; 12808-12814, 12835-12841).
Three of the inverted repeats are clustered in the sequence immediately 3' of the B1 repeat.
The elements identified by sequence analysis in the 6 kb region 5' of the promoter
closely resemble those identified in the region further 5'. Furthermore, both regions have
been identified as negative elements. Therefore, it is possible that both are part of a large
region of DNA which is negative, and were identified as separate elements simply based
on the deletion construct design in Chapter 3.
5.

Analysis of the First Intron

The first intron is necessary for proper expression of the CD4 gene (Blum et al.,
1993; Hanna et al., 1994; Gillespie et al., 1993; Killeen et al., 1993). Our previous analysis
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of the first intron using transient transfections indicates that the first intron has both a
positive and negative effect on gene expression (Chapter 3). The positive element was
localized to the region 5' of the Sad site at 16412 or 3' of the Xbal site atl8447, while the
negative activity was localized to the region between Sad and Xbal. One of the negative
elements corresponds to the previously identified silencer (Sawada et al., 1994), while the
other negative element is located further downstream at a TATC repeat (Chapter 4).
Sequence analysis of the region containing the positive element indicates homology
to recognition sites for transcription factors at both the 5' and 3' ends of the first intron
(Figure 5.7). Sites included in these regions are Ap-2, Cre, E-box, Elf-1, Gata-3, Ikaros,
Lyf-ID-CD8, Mef-1, Myc/Max, NF-E1, NF-CD4, Oct-1, Sox-4/TCF-l, and TCR/Lef-1.
Furthermore, there are two regions with homology to the murine adenosine deaminase
origin of replication (Virta-Pearlman et al., 1993). The first is 86% homologous (1850318524), while the second is 73-82% homologous (19376-19477). There is one region
with charactertistics postulated to be important for the formation of non-B DNA
(19410-19470), three regions with homology to MARs (20100-20165, 21058-21170,
21990-22120), and seven inverted repeats (15628-15634, 15640-15646; 19951-19958,
19972-19979; 20670-20677, 20686-20692; 21257-21263, 21269-21275; 21275-21284,
21294-21300; 21326-21332, 21342-21348; 21656-21663, 21684-21691). Six of these
inverted repeats are located in the region containing the MAR homologies.
The CD4 silencer (Sawada et al., 1994) corresponds to sequence at the 5' end of the
region containing negative elements (16408-16841) (Figure 5.8). The TATC repeat
(Chapter 4) is located 1174 bases 3' of the silencer (18015-18100). Sequence analysis
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Figure 5.7. Summary of sequence analysis of bases 14640 through 16412 and
18448 through 23108. This is a summary of results of sequence analysis of the positive
region within the first intron. The region is split into two parts: 14640 through 16412,
and 18448 through 23108. Analysis of the region between 16412 and 18448 is shown in
Figure 5.8. Restriction sites located below the line indicate cut sites within and at the ends
of the fragments: H-ATioI; S-Sacl; X-Xbal. Boxes below the line indicate regions of
homology and their location within the sequence. The box size corresponds to the relative
size of the homologous region. Names of the elements are located at the left of the boxes.
Regions with homology to a group of recognition sites for transciption factors are
referred to as consensus sites. These regions are located at the 5' and 3' ends of the first
intron. Regions of homology to an origin of replication, potential non-B DNA, and
MARs are located in the 3' region of the first intron, downstream of the region discussed
in Figure 5.8.
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Figure 5.8. Summary of sequence analysis of bases 16413 through 18447. This is a
summary of results of sequence analysis of the negative region within the first intron.
The horizontal line corresponds to sequence 16413 through 18447. Restriction sites
located below the line indicate cut sites within and at the ends of the fragment: S-SacI;
X-Xba\. Boxes below the line indicate regions of homology and their location within the
sequence. The box size corresponds to the relative size of the homologous region.
Names of the elements are located at the left of the boxes. The CD4 silencer was mapped
to the SacVXbal fragment. Homology to MAR, Rpt-1 silencer, and origin of replication
correspond to the TATC repetitive region.
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indicates that the TATC repeat has 90-91% homology to the murine adenosine deaminase
origin of replication (17970-18130) (Virta-Pearlman et al., 1993), 68-75% homology to the
Rpt-1 silencer (18016-18166) (Patarca et al., 1989), and homology to MARs
(17970-18130). It is also the consenses site for GATA-3 (Yamamoto et al., 1990; Romeo
et al., 1990; Martin et al., 1990; Ho et al., 1991). There is an inverted repeat located in the
silencer (16640-16646, 16654-16660), and two inverted repeats in the region between the
silencer and the TATC repeat (17380-17386, 17407-17413; 17517-17525, 17534-17542).
The silencer and TATC negative elements may work independently, or be part of a larger
regulatory unit.

B.

DISCUSSION
1.

Complexity of CD4 Gene Regulation

The CD4 gene is regulated in a complex manner. There are multiple positive and
negative regulatory elements which control CD4 gene expression (Chapter 3). The murine
CD4 promoter (Siu et al., 1992), proximal (Sawada and Littman, 1991) and distal
(Wurster et al., 1994) enhancers, and a silencer (Sawada et al., 1994; Siu et al., 1994) have
been identified. However, investigations indicate that a level of regulation, involving
chromatin structure, is missing (Sawada et al., 1994). Since previous reports have shown
that the 5' flanking region and the first intron are all that are necessary for the proper
expression of CD4 (Gillespie et al., 1993; Blum et al., 1993), we sequenced this 23 kb
region. Our analysis indicates that the DNA 5' of the promoter and within the first intron
has homology to various enhancers, silencers, flanking regions of promoters, and has the
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potential to bind the nuclear matrix and form altered chromatin structures. These regions
may contribute to the tissue- and subclass-specific regulation of CD4 expression.
2.

The T Cell-Specific Enhancer May Be Part of a Larger Element

The DNA region encompassing the minimal 339 bp murine enhancer has been
associated with repressive as well as stimulatory activity (Sawada and Littman, 1991; Siu
et al, 1992; Chapter 3). Sequence analysis suggests that the minimal enhancer may be part
of a larger regulatory unit composed of adjacent or overlapping enhancer and silencer
elements. Overlapping enhancer/silencer elements have been observed for a number of
genes (Weissman and Singer, 1991; Ye et al., 1994). Although enhancers have been
extensively described, the role of negative regulation in gene expression is beginning to be
appreciated as more examples are described among eukaryotic gene systems. The
molecular mechanisms underlying negative regulation have been divided into four
categories: (1) competitive inhibition of enhancer factors by binding of a silencer factor to
a common sequence; (2) quenching of enhancer activity by binding of silencer factor to a
distinct but overlapping sequence; (3) direct repression of the promoter complex;
(4) squelching by sequestration of transcription factors by high concentrations of enhancer
factors (Levine and Manley, 1990). Of these, competitive inhibition and quenching appear
to be the most common, while direct repression and squelching have not been rigorously
demonstrated. The negative sequences 3' of the T cell-specific enhancer may
down-regulate expression by one of the mechanisms described above. Since the silencer
sequence 3' of the enhancer and within the first intron are homologous, these sites may
bind similar factors and function in a similar manner.
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3.

There are Elements Between the CD4 Promoter and Enhancer that

Could Interfere with the Stimulation of the Enhancer on the Promoter
The T cell-specific enhancer is necessary for CD4 expression at the double positive
stage of thymocyte development (Hanna et al., 1994). Prior to this stage, dominant
negative regulation prevents the expression of CD4 (Wilkinson et al., 1991a). The DNA
region between the enhancer and promoter contains a NRE (Chapter 3). Sequence analysis
indicates that there are a number of elements in this region which could contribute to this
repression. The region contains both B1 and B2/MT repetitive elements. The usual
transcriptional effect of a repetitive element is repression (Laimins et al., 1986; Saffer and
Thurston, 1989; Thorey et al., 1993; Perelygina et al., 1987; Wu et al., 1990; Hambor et al.,
1993). Furthermore, the repetitive elements are located 5' of the CD4 gene in a region
containing sequence similarity to the 5' flanking region of several eukaryotic promoters.
These flanking regions correspond to sequence 300 to 500 bp 5' of the corresponding
promoter, and overlap in a short segment of the CD4 locus. Since the homologous region
of the HPRT promoter contains cryptic promoters (Melton et al., 1986), the other genes
may also contain cryptic promoters. The unique clustering of the repetitive regions, which
may act as repressors, with potential cryptic promoters, suggests that this region may be
responsible for the observed repression in the region between the enhancer and promoter.
The mechanism by which this region of DNA is repressive may involve some sort of
transcriptional interference, whereby cryptic promoters attract the activity of the enhancer,
thereby reducing the effect of the enhancer on the CD4 promoter (Thorey et al., 1993; Wu
et al., 1990). Alternatively, since this region also contains homology to silencers,
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repressive activity could involve one of the negative regulatory mechanisms outlined
above.
4.

The Region Between the Enhancer and Promoter Contains MARs

and DNA Sequences that Could Alter the Chromatin of this Region
Sequence analysis further indicates that the region between the enhancer and
promoter contains homology to sequences shown to bind the nuclear matrix (MARs) and
sequences predicted to form non-B DNA. There are a number of models for how MARS
may be involved in transcriptional regulation: (1) formation of loops to isolate domains
containing single genes or clusters of genes; (2) formation of loops to bring together
otherwise distant cA-acting elements; (3) providing loci for relaxation of transcriptionally
generated supercoiling; (4) providing sites at which negative superhelical torsion is
generated (Zlatanova and Holde, 1992). In reality, however, MARs may function by a
mechanism that is a combination of those outlined above. Simple DNA sequences, like
those in the CD4 locus predicted to form non-B DNA, have been shown to assume
alternative DNA conformations (Z-DNA) (Gebhard and Zachau, 1983). These non-B, or
left-handed Z-DNA structures, appear at critical control regions of genes, and have been
proposed to play an important role in gene regulation (Rich et al., 1984; Tripathi and
Brahmachari, 1991; Wells, 1988; McLean and Wells, 1988). It has also been shown that
purine-pyrimidine tracts either in the B- (Gross et al., 1985) or Z-conformation (Nickol et
al., 1982; Miller et al., 1985) can form altered chromatin domains. These DNA sequences
are associated with repression of gene transcription (Naylor and Clark, 1990; Tae et al.,
1994), but the mechanism by which they function remains undetermined. It may be that
by adopting the Z-DNA conformation, these sequences act by one of the following
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mechanisms: (1) increase accessibility of the promoter and/or other c/'s-acting elements to
the polymerase and/or other transcription factors; (2) facilitate the unwinding of DNA;
(3) facilitate the binding of Z-DNA binding proteins (Yu and Edenberg, 1995). Therefore,
both MARs and non-B DNA regions have the capacity to alter chromatin conformation,
leading to a change in gene expression. Indeed, both may contribute to the regulation of
CD4, by changing the DNA to allow the enhancer access to the promoter and to bypass the
negative regulatory regions discussed above.
5.

There are Numerous Regions in the First Intron that Could Be

Involved in Controlling CD4 Expression
The first intron has both a positive and negative effect on CD4 expression
(Chapter 3). In the region associated with positive activity, there are clusters of
transcription factor consensus sites, homology to an origin of replication, homology to
MARs, and sequences predicted to adopt non-B DNA conformation. The transcription
factor clusters are located at the borders of intron 1 and the untranslated regions of exons 1
and 2, suggesting that these sites are important in transcription and/or splicing. Homology
to the origin of replication was located both in the positive and negative regulatory regions.
This replication origin sequence has a B1 repeat region and a polypurine repeat region. As
discussed above, B1 repeats are associated with repression. Polypurine repeats are
distributed non-randomly throughout the genome and can form triplex DNA and non-B
DNA structures, suggesting they play a role in gene regulation (Baran et al., 1991; Manor
et al., 1988; Wong et al., 1990). Within the region of the first intron associated with
negative activity, there is the CD4 silencer, and the TATC repeat. The CD4 silencer has
been identified functionally, and while it contains homology to a number of transcription
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factor binding sites, functionally important sites have not been defined (Sawada et al.,
1994). The TATC repeat is also the consensus site for a number of elements. These
elements include the Rpt-1 silencer (Patarca et al., 1989), GATA family of transcription
factors (Yamamoto et al., 1990; Romeo et al., 1990; Martin et al., 1990), BBP
(Bkm binding protein) (Singh et al., 1994b), and the adenosine deaminase origin of
replication (Virta-Pearlman et al., 1993). In addition, this sequence may also bind the
nuclear matrix. As discussed in Chapter 4, the TATC repetitive sequence may act through
destabilization of the chromatin. Origins of replication, MARs, and non-B DNA all
involve altered DNA conformation. The fact that sequences with homology to these
elements are located 3' of the silencer is intriguing, suggesting that altered chromatin
structure in the intron may also play a role in CD4 regulation.
6.

Summary

The overall theme seen from our sequence analysis is of DNA regions with the
potential to alter or disrupt the chromatin structure, and NREs. Chromatin structure is
important because it is dynamic. Changes can occur in the arrangements of histones and
DNA which will affect not only replication, but also transcription (Travers, 1992).
Recently, the picture of chromatin structure has changed from being viewed exclusively as
repressive, to one in which interactions between transcription factors and chromatin can be
required for gene activation (Lewin, 1994). It has been suggested that the string of
nucleosomes provide a “ground state” of chromatin, on which other proteins impose
(additional) repression or the potential to be activated. Some of the effects could be
provided by factors that act at discrete locations such as promoters or enhancers, while
others would require adjustment of chromatin structure over more extensive regions.
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Furthermore, larger loop domains could exist which insulate a particular region of a
chromosome and thus protect it from the regulatory mechanisms of neighboring domains.
The regulation of CD4 expression could be viewed in the same manner. There is a
“ground state” of chromatin structure in the CD4 locus. The enhancer and silencer impose
secondary positive and negative regulatory effects, respectively. In addition, MARs and
Z-DNA regions alter the chromatin to impose yet another level of regulation. The
combined effects of proteins that bind these regulatory elements may result in the
fine-tuned expression of CD4 required at specific stages in the life of the T cell.

CHAPTER 6. CD4 TRANSCRIPTIONAL CONTROL

ELEMENTS USED THROUGH T CELL DEVELOPMENT

In Chapter 3, we described the identification of numerous positive and negative ex
acting elements located within 15 kb 5' of the CD4 promoter and the first intron. This
chapter focuses on the identification of how these elements are used during T cell
development to regulate CD4 gene expression.

A.

RESULTS
1.

Explanation of T Lymphoma Cell Lines

We chose to study CD4 regulation during T cell development using murine
T lymphoma cell lines which represent various stages of development, based on
phenotypic markers (Figure 6.1). SL12.3 is CD4 CD8' and is the most immature of the
cells used by us for transfection (Wilkinson et al., 1991a). SL12.4 is CD4l0CD8l0, and
slightly more mature (Wilkinson et al., 1991a). The CD4+CD8+ cell line is AKR1.G.1.
Finally, two cell lines were chosen to represent single-positive thymocytes,
SAKRTLS12.1 is CD4+CD8' and TB2.1 is CD4'CD8+. A complete description of the cell
lines is found in Chapter 2.
2.

Explanation of Constructs

The constructs used in this study were designed such that cassettes made from the
sequence upstream of the CD4 promoter could be cloned in front of any of three
alternatives of the first intron (Figure 6.2). Because of this “modular” type of construction,
the name of a given vector also indicates the CD4 regions included. The

199

200

Figure 6.1. Description of cell lines. A complete description of the phenotypic markers
for each cell line are given in Chapter 2. The most immature line, SL12.3, is at the top of
the figure; each subsequent line represents a later stage in the developmental sequence.
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Figure 6.2. CD4/CAT recombinant constructs used to transfect the different cell
lines, a) Description of the 15 kb of CD4 5' sequence. DNase I hypersensitive sites
(DH sites) in both panels are denoted by numbered vertical arrows directly above the
region in which they are located. Matrix attachment regions are represented by the cross
hatched boxes and the repetitive element is represented by the black striped box. The
horizontal arrow at DH site 8 shows the start of transcription. The letters directly below
the solid line in both panels are the positions of relevant restriction sites used in making
the deletion constructs: N-Afo/I, S-A/cI, E-£coRI, W-Xhol, P-Ps/I, H-Xba\, L-Sati.
pAC is the designation for the large CD4 derived vectors. The 5' region of DNA used in
a given series (1-5) is shown by the solid black lines next to each vector name,
e.g. pAC 1 contains the full 15 kb sequence. The p900 constructs contain the 900 bp
PstVXhol promoter fragment and the p500 construct contains the 500 bp Xbal/Xhol
promoter fragment. pEPCl and pEPC0.5 contain the T cell-specific enhancer derived
from the CD4 5' flanking region. pSEPCl contains the SV40 enhancer, b) Description
of the 8.9 kb of intronic CD4 sequence used in the pAC constructs. The DNA included
in a given construct is shown by the solid black lines next to each lower case letter, e.g.
"a" contains the full 8.9 kb intronic fragment. Lower case "e" represents vectors that do
not contain intronic DNA. The constructs are named by combining the appropriate 5'
designation with the intronic designation, e.g. pAC4a contains the 5' DNA region from
the EeoRl site in the 5', fused to the entire intron containing fragment. The CAT gene is
the reporter used in each construct.
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pACl series of constructs contains DNA sequence extending 15.7 kb upstream of the
CD4 promoter. The pAC2 series encompasses a similar region, with the exception of a
deletion of a 2.2 kb Sad fragment located 10 kb 5' of the promoter. The pAC3 series
extends out to the 15.7 kb region, but deletes a 6.0 kb Sad fragment located 4 kb upstream
of the promoter. The pAC4 series extends 15.7 kb upstream of the CD4 promoter but
deletes both the 2.2 kb and 6 kb Sad fragments mentioned above. The pAC5 series
contains approximately 6 kb of sequence 5' of the CD4 promoter. Members of each series
are further broken down with respect to the sequence located 3' of the promoter. The
designations following the series number indicate the presence or absence of sequence
within the first intron of CD4. Vectors containing 8.9 kb of the first exon and first intron,
contiguous from the promoter, are given the suffix, "a", e.g. pACla. The constructs
containing the same region but deleting a 1.6 kb Xbal fragment located 2.4 kb downstream
of the CD4 promoter are given the suffix, "b", e.g. pAClb. The presence of only 70 bp
downstream of the CD4 transcriptional start site is denoted by the suffix, "e", e.g. pACle.
Four small constructs were also made to test the ability of the CD4 promoter to
transcribe and be stimulated by a T cell or heterologous enhancer. The smallest CD4
construct used contains a 500 bp XbaVXhol promoter fragment cloned downstream of a
339 bp fragment comprising the previously identified T cell-specific enhancer (Sawada
and Littman, 1991), pEPC0.5. Another small CD4 promoter construct, p900, contains a
900 bp Pstl/Xhol fragment extending 70 bp downstream of the transcription start site.
This vector was used as the base to which the T cell-specific and SV40 enhancers were
cloned, pEPCl and pSEPCl, respectively. All constructs contain the reporter cassette.
CAT, for sensitive quantitation of expression.
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3.

Analysis of Expression in SL12.3

Transient transfection of the double negative SL12.3 lymphoma cell line with p900
indicates that the CD4 promoter is functional in these immature cells (Figure 6.3).
Furthermore, the promoter is capable of being stimulated by the heterologous enhancer
(pSEPCl), but not by the T cell-specific enhancer (pEPCl). This result suggests that
CD4 CD8' cells do not contain the factors necessary for use of this T cell-specific
enhancer. When the cell line is transfected with the pAC panel of constructs, none of these
vectors are expressed well, irrespective of the deletion used (pACl-5). Since CD4 is not
expressed in these cells, this is not surprising. However, it may illustrate that CD4
expression in CD4 CD8' cells is not repressed by a single site, but by multiple sites of
negative regulation. This repression is not relieved unless most of the region is deleted
(p900).
4.

Analysis of Expression in SL12.4

The SL12.4 lymphoma cell line is more mature than SL12.3, and expresses CD4
and CDS at a low level. Transient transfection indicates that the promoter (p900) functions
at only a low level (Figure 6.4). In addition, the T cell-specific enhancer is capable of
stimulating the CD4 promoter (pEPCl). The 500 bp promoter fragment (pEPC0.5) is
expressed at a higher level than the 900 bp promoter fragment (pEPCl) when in
conjunction with the enhancer, confirming the presence of a

acting NRE within the

400 bp upstream of the Xba\ site (Chapter 3). Interestingly, the heterologous enhancer
stimulates the 900 bp promoter at a lower level than the T cell-specific enhancer in these
cells (pSEPCl versus pEPCl). When the large pAC constructs are used to transfect the
cells, there is a low level of expression from the constructs except pAC4a and
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Figure 6.3. Expression of constructs in SL12.3. Equi-molar quantities of CD4derived vectors were transiently transfected into SL12.3 (CD4 CD8 ). ND indicates
constructs for which results were not determined. Each result represents the mean of 1-2
separate determinations.
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Figure 6.4. Expression of constructs in SL12.4. Equi-molar quantities of CD4derived vectors were transiently transfected into SL12.4 (CD4l0CD8l0). ND indicates
constructs for which results were not determined. Each result represents the mean of 1-2
separate determinations.
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pAC4b. These constructs delete an 8.2 kb region (a 2.2 kb Sad fragment plus a 6 kb Sad
fragment) between the T cell-specific enhancer and the CD4 promoter. Since pAC4a and
pAC4b are expressed much better than the other pAC constructs, it suggests that the
element primarily responsible for repression in CD4l0CD8l0 T lymphoma cells is located
in the region between the enhancer and the promoter. Interestingly, when the fragments
which comprise the large 8.2 kb deletion in pAC4 are deleted individually, pAC2
(2.2 kb Sad fragment) and pAC3 (6 kb Sad fragment), the high level of expression is not
observed. Therefore, deletion of a large piece or domain of DNA, 8.2 kb, is necessary for
high activity. This deletion brings the endogenous T cell-specific enhancer within 4 kb of
the CD4 promoter (Figure 6.2). If the same 8.2 kb of DNA is deleted, but now the
deletion includes the 3.5 kb fragment located far 5', pAC5, the level of expression
decreases. The 3.5 kb DNA fragment contains the T cell-specific enhancer. These results
taken together with the results using pEPCl and pEPC0.5 suggest that the enhancer is
responsible for the enhanced expression of the pAC4 constructs.
5.

Analysis of Expression in AKR1.G.1

The AKR1 .G. 1. lymphoma cell line is CD4+CD8+. These cells express the CD4
promoter (p900), and are stimulated by both T cell-specific (pEPCl) and heterologous
(pSEPCl) enhancers (Figure 6.5). Like SL12.4, the 500 bp promoter fragment
(pEPC0.5) is expressed better than the 900 bp fragment (pEPCl), again demonstrating the
presence of a negative regulator 5' of the promoter. These double-positive lymphoma cells
express certain pAC constructs better than others. Similar to SL12.4, the large 8.2 kb
deletion allows high expression (pAC4). However, in AKR1 G.l, the component
sequences of the 8.2 kb deletion (2.2 kb Sad fragment and 6 kb Sad fragment) results in a
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Figure 6.5. Expression of constructs in AKR1.G.1. Equi-molar quantities of CD4derived vectors were transiently transfected into AKR1 .G. 1 (CD4+CD8+). Each result
represents the mean of 3-8 separate determinations.
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high level of expression as well. The pAC2b and pAC4b constructs both delete the same
2.2 kb Sad fragment in the 5' and the 1.6 kb Xbal fragment in the first intron, and are
expressed the best. Finally, if the far 5' fragment containing the T cell-specific enhancer is
deleted in conjunction with the 8.2 kb fragment, pAC5, activity drops, again demonstrating
the importance of the positive element located within the 3.5 kb fragment.
6.

Analysis of Expression in SAKRTLS12.1

The single-positive SAKRTLS12.1 lymphoma cell line is able to express the
900 bp promoter fragment (p900) at a low level, and is sensitive to stimulation by the
T cell-specific (pEPCl) and heterologous (pSEPCl) enhancers (Figure 6.6). The
pEPCO.5 construct is expressed better than pEPCl, again indicating the presence of a
negative regulator in the 400 bp region 5' of the promoter. Similar to AKR1 .G. 1, deletion
of the 8.2 kb fragment (pAC4) and deletion of the component fragments (pAC2 and
pAC3) results in an increase in expression. The highest activity from the large pAC
vectors is from those consructs which have simultaneously deleted the 2.2 kb Sad and
1.6 kb Xbal fragments. Also, when the fragment containing the T cell-specific enhancer is
deleted (pAC5), the level of activity drops.
7.

Analysis of Expression in TB2.1

The single-positive TB2.1 lymphoma cell line is able to express the 900 bp
promoter fragment (p900) (Figure 6.7). In addition, it is stimulated by both T cell-specific
(pEPCl) and heterolous enhancers (pSEPCl). The 500 bp promoter (pEPC0.5) is not
expressed better than the 900 bp promoter (pEPCl), suggesting that the negative element
located in this region does not function in CD4'CD8+ cells. In other respects, TB2.1 is
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Figure 6.6. Expression of constructs in SAKRTLS12.1. Equi-molar quantities of
CD4-derived vectors were transiently transfected into SAKRTLS12.1 (CD4+CD8 ).
Each result represents the mean of 3-8 separate determinations.
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Figure 6.7. Expression of constructs in TB2.1. Equi-molar quantities of CD4derived vectors were transiently transfected into TB2.1 (CD4'CD8+). Each result
represents the mean of 3-8 separate determinations.
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similar to SL12.3. None of the pAC construct are expressed well, irrespective of the
deletion used. This is again indicative of multiple repressors.

B.

DISCUSSION
1.

Regulation of CD4 Expression During T Cell Development

The aim of this study was to identify elements within 15 kb 5' of the CD4
promoter and in the first intron that are important to the regulation of CD4 during
thymocyte development. We used transient transfection of T lymphoma cell lines
representing various stages of thymocyte development with deletion constructs to
functionally dissect these regions. Our results illustrate the importance of both positive
and negative elements during these developmental stages.
2.

Elements that Control CD4 Gene Expression

The progression of a pre-T cell through development to a mature T cell is an
intricate process. In order to generate CD4+ T cells, both interaction with class IIMHC
molecules (Kruisbeek et al., 1983, 1985; Cosgrove et al., 1991; Grusby et al., 1991) and
expression of CD4 (Zuniga-Pflucker et al., 1989b; Ramsdell and Fowlkes, 1989; Killeen
et al., 1993; Rahemtulla et al., 1991) are required. Since CD4 expression is critical to the
development of these cells, its correct regulation is essential. Transcriptional control points
of CD4 expression consist of both positive and negative c/s-acting elements (Chapter 3;
Sawada and Liftman, 1991; Blum et al., 1993; Sawada et al., 1994; Siu et al., 1994), and
probably chromatin structure (Sawada et al., 1994; Chapter 3). While the precise
mechanism for how these elements work together is a mystery, we are beginning to define
regions of DNA and elements important at various stages during T cell development.
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Two elements that have been identified are the T cell-specific enhancer and CD4
silencer. The enhancer was located 13.5 kb 5' of the murine CD4 promoter (Sawada and
Littman, 1991) and 6.5 kb 5' of the human CD4 promoter (Blum et al., 1993). The
minimal enhancer is T cell-specific, but not subclass-specific, as it can up-regulate CD4
expression in all subclasses of thymocytes and mature CD4+ T cells (Sawada and Littman,
1991; Blum et al., 1993; Killeen et al., 1993; Hanna et al., 1994). Furthermore, while it is
required to up-regulate CD4 expression at the double-positive stage of thymocyte
development (Hanna et al., 1994), the CD4 promoter can up-regulate CD4 expression
without the T cell-specific enhancer in peripheral T cells and macrophages (Salmon et al.,
1993; Hanna et al., 1994). A silencer was identified within the first intron of the murine
CD4 gene (Sawada et al., 1994; Siu et al., 1994). An equivalent element has recently been
identified for the human CD4 gene (Donda et al., 1995). The murine silencer is reported
to down-regulate CD4 in non-T hematopoietic cells, CD4 CD8' thymocytes, and
CD4'CD8+ T cells. There is some discrepancy concerning the region of DNA within the
first intron necessary to achieve this regulation.
3.

Negative Elements are Functioning in CD4+ Thymocytes

In addition to elements that either markedly up-regulate or down-regulate CD4
expression in CD4+ and CD4' cells, respectively, a second level of finely modulated
negative regulation occurs in cells that express CD4. This negative regulation has been
illustrated both at the promoter (Blum et al., 1993; Siu et al., 1992; Hanna et al., 1994) and
the enhancer (Sawada and Littman, 1991). Clearly, more information is needed to define
other elements which participate in CD4 regulation, discern how these elements function,
and at what stages of thymocyte development the various elements are important.
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4.

Regulation of CD4 Expression in CD4 CD8' Thymocytes

In the mouse, the earliest precursors from the bone marrow express low levels of
CD4. After being in the thymus for a few days, these cells become CD4 CD8' (Wu et al.,
1991b). Wilkinson et al. (1991a) demonstrated that dominant negative regulation is
important in these CD4'CD8‘ cells. Our results in CD4 CD8' lymphoma cells, SL12.3,
indicate that the CD4 promoter works at a low level in these cells, and the minimal
enhancer is incapable of stimulating the promoter. The inability of the enhancer to work
could be due to a lack of necessary positive /raras-acting factors to bind this element, or
direct repression of the enhancer. Previously, a silencer was identified in the first intron of
the CD4 gene which is presumably the major factor for down-regulation of CD4 in early
thymocytes (Sawada et al., 1994; Siu et al., 1994). However, our results indicate that this
is not the only repressor acting in these immature cells, since no single deletion, including
the first intron relieved repression. The results in Chapter 3 indicate that other negative
elements are located 3' of the enhancer, between the enhancer and promoter, and 5' of the
promoter. Only by deleting all these regions could we get our CAT reporter constructs
expressed in CD4 CD8' cells.
5.

Regulation of CD4 Expression in CD4|0CD8|0 Thymocytes

Immature CD4 CD8' thymocytes are not in stasis. Although they do not express
CD4 or CDS, they undergo many changes in the expression of other surface molecules
(Fowlkes and Pardoll, 1989). This developmental stage is also characterized by extensive
expansion and differentiation, as the cells begin to rearrange and express the TCR (Scollay
et al., 1988). One way to describe double-negative cells as they progress to double
positive, is CD4l0CD8l0 (Andjelic et al., 1993), like SL12.4. As the cell transitions to the
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CD4+CD8+ stage, the T cell-specific enhancer is needed to up-regulate CD4 expression
(Hanna et al., 1994). Our results indicate that cells in this transitory stage from CD4 CD8'
to CD4+CD8+ are changing toward expressing CD4. Although the CD4 promoter works
at a low level, the minimal enhancer can now up-regulate expression. Furthermore, the
region between the enhancer and promoter blocks this positive effect. When the
intervening DNA is removed, expression from the CD4 promoter reaches a high level.
Finally, there is an element 5' of the promoter which acts to repress CD4 expression. This
element may be part of the NRE located between the enhancer and promoter, in the 8.2 kb
fragment. Alternatively, it may act independently.
6.

Regulation of CD4 Expression in CD4+CD8+ Thymocytes

The thymocytes expressing both CD4 and CDS are called double-positive. These
cells are the most numerous thymocytes in the adult thymus (Fowlkes and Pardoll, 1989).
While the promoter still works at a low level in CD4+CD8+ lymphoma cells, the T cellspecific enhancer stimulates expression to a high level. This stimulation is higher than that
in CD4l0CD8l0 cells. In addition, the region between the enhancer and promoter still has a
negative effect on CD4 expression. Unlike the CD4l0CD8l0 cells, however, deletion of
either the 2.2 or 6 kb Sad fragments present in this region relieves repression. This may
indicate that the enhancer has a stronger effect at this stage of development. Furthermore,
it may reflect other changes occurring in the cell as it progresses toward expressing either
CD4 or CDS, but not both.
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7.

Regulation of CD4 Expression in CD4+CD8' and CD4'CD8+

Thymocytes
Although most double-positive thymocytes undergo cell death (Egerton et al.,
1990), some differentiate into MHC class II restricted CD4+CD8' T cells or MHC class I
restricted CD4'CD8+ T cells (Swain, 1983). Our transient transfection results indicate that
CD4 regulation in CD4+CD8' thymocytes is similar to CD4+CD8+ thymocytes, while
CD4 regulation in CD4'CD8+ thymocytes is similar to CD4 CD8' thymocytes. In
CD4+CD8' lymphoma cells, the enhancer stimulates the CD4 promoter, there is repression
in the region 5' of the promoter, and the region between the enhancer and promoter
contains a NRE. The level of expression is lower than that in double-positive cells,
possibly indicating changes in thymocytes as they move to expressing CD4 at an
intermediate level during this developmental stage. In CD4'CD8+ cells, the CD4 promoter
is capable of directing expression of the gene, and the minimal enhancer stimulates the
promoter. The intronic silencer was reported to play an important role in down-regulating
CD4 expression in CD4'CD8+ cells (Sawada et al., 1994; Siu et al., 1994). However,
deletion of the first intron does not relieve repression. Deletion of the region between the
enhancer and promoter does not relieve repression either, indicating the presence of
multiple negative regulators acting in these cells. Additional repression may be due to the
region 3' of the enhancer or 5' of the promoter, as suggested in Chapter 3. However,
repression in the 400 bp region immediately 5' of the promoter is absent.
8.

A Model for CD4 Gene Regulation During T Cell Development

We propose that the following model of CD4 regulation is closer to what is really
happening in developing T cells. Hematopoietic stem cells enter the thymus expressing a
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low level of CD4 (Wu et al., 1991a, b). These cells are not committed to the T cell lineage,
and can differentiate into B cells if removed from the thymus. Therefore, the expression
of CD4 at this stage may be due to a lack of T cell-specific negative regulatory factors.
After two days, CD4 is down-regulated and the cell is CD4 CD8 (Fowlkes and Pardoll,
1989). Dominant negative regulation is responsible for the inability of the cell to express
CD4 (Wilkinson et al., 1991a). Specific sites of repressive action include the first intron
(Sawada et al., 1994; Siu et al., 1994; Chapter 4), the promoter (Siu et al., 1992), and
probably the DNA associated with the minimal enhancer (Chapter 3). Furthermore, the
enhancer is incapable of stimulating the promoter, probably due to a lack of factors
required for its function. Within seven to nine days, both CD4 and CDS are up-regulated
(Fowlkes and Pardoll, 1989). As the CD4 CD8' begins the transition to CD4+CD8+, there
are a number of changes. The enhancer is now capable of stimulating the promoter to a
high level of expression, however, its action is blocked by the region of DNA between the
enhancer and promoter (Chapter 3; Chapter 6). This repression may be due to repetitive
elements and cryptic promoters located in this region which act as a barrier to hinder the
ability of the enhancer to stimulate the promoter (Chapter 5). Since the enhancer is
required for up-regulation of CD4 at this stage (Hanna et al., 1994), this repression must
be overcome. The intronic silencer also appears to lose its dominant role in these cells
(Sawada et al., 1994; Siu et al., 1994). The increased expresssion of CD4 at the
pre-double-positive stage may involve chromatin changes in both the region surrounding
the silencer (Sawada et al., 1994; Chapter 4; Chapter 5), and in the region separating the
enhancer and promoter (Chapter 3; Chapter 5). In the first intron, these changes may be
precipitated by the TATC repetitive element (Chapter 4; Chapter 5), while in the 5' region,
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the changes may involve nuclear matrix attachment regions and regions of non-B DNA
(Sands and Nikolic-Zugic, 1992; Chapter 5). The result of these structural changes is the
increased expression of CD4, and may be at least partially due to positioning the enhancer
next to the promoter. Following selection processes, the cell becomes either CD4+CD8' or
CD4'CD8+. In either case, the enhancer is capable of stimulating the CD4 promoter, but is
blocked from acting. In the CD4+CD8‘ cells, this is mainly due to repression by the region
between the enhancer and promoter (Chapter 3; Chapter 6). In the CD4'CD8+ cells, this
repression is due to multiple negative regulators, including the intronic silencer (Sawada et
al., 1994; Siu et al., 1994; Chapter 6).
Additional support for this model is provided by the identification of a MAR
binding protein, Tia/SATBl, which is expressed primarily in CD4+CD8+ thymocytes
(Dickinson et al., 1992; Nakagomi et al., 1994; Wilkinson et al., 1991a). Wilkinson et al.
(1991a) provides data indicating that the Tia/SATBl protein increases in concentration at
the transition from the double negative stage of thymocyte development to the double
positive stage of thymocyte development. This suggests that the interaction of the MAR
binding protein with MARs located 5' of the murine CD4 promoter may be an important
regulator involved in the expression of CD4, possibly by altering the chromatin to allow
the T cell-specific enhancer to up-regulate expression from the CD4 promoter.
9.

Summary

This model emphasizes some important points about CD4 regulation. The CD4
gene is not regulated by a simple on/off switch involving the T cell-specific enhancer and
intronic silencer. Instead, in order to accomodate expression at low, high, intermediate,
and off levels, multiple methods of regulation are used. These may involve c/s-acting
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elements, /raws-acting factors, and changes in chromatin structure. Furthermore, the
context in which these various elements are assembled and studied is of great importance.
A basic understanding of the interactions between these elements is necessary to control
CD4 in a cell type-specific, stage-specific, and species-specific manner.
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CHAPTER 7. OVERVIEW AND FUTURE DIRECTIONS

A.

OVERVIEW
1.

Importance of Proper CD4 Regulation

The appropriate regulation of CD4 expression is important for the immune system
to properly develop. If CD4 is not expressed, MHC class II restricted helper T cells fail to
develop (Zuniga-Pflucker et al., 1989b; Ramsdell and Fowlkes, 1989; Killeen et al., 1993;
Rahemtulla et al., 1991) and thus the humoral branch of the immune system does not
function (Rahemtulla et al., 1991). If CD4 is inappropriately expressed, the specificity of
the CD8+ cytotoxic T cells is altered (Robey et al., 1991) and self-reactive T cells can
escape into the periphery (van Oers et al., 1992). Furthermore, the expression of CD4 can
be altered by infective agents to apparently avoid immune surveillance. Infective agents
take advantage of alterations in CD4 expression to further complicate the disease they
cause; for example, human herpes virus 6 (HHV-6) up-regulates CD4 in cytotoxic T cells
making them susceptible to HIV infection (Lusso et al., 1991).
2.

Complexity of CD4 Gene Regulation

The regulation of CD4 expression is complex. The CD4 gene is actively repressed
by dominant /raws-acting factors early in thymocyte development (Wilkinson et al.,
1991a). In order for the repression of the CD4 gene to be relieved, a thymocyte-stromal
cell interaction is necessary (Brightman et al., 1989; Tatsumi et al., 1990). The upregulation of CD4 at the CD4+CD8+ stage of thymocyte development requires the
stimulation of a T cell-specific enhancer located 5' of the murine (Sawada and Littman,
1991) and human (Blum et al., 1993) CD4 genes. The down-regulation of CD4
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expression in mature cytotoxic CD8+ T cells requires a silencer present within the first
intron (Sawada et al., 1994; Siu et al., 1994). The /ra/ts'-acting factors necessary to initiate
transcription at the CD4 promoter are present in cells that are transcriptionally repressing
the expression of CD4, as illustrated by the fact that the minimal enhancer stimulates the
CD4 promoter in CD4‘ cells (Sawada and Littman, 1991). Furthermore, negative control
elements are functioning in CD4+ thymocytes, as demonstrated by the need for the 5'
enhancer to overcome the repression of the promoter in CD4+ cells and by the fact that a
larger enhancer fragment is not as functional as the minimal enhancer (Sawada and
Littman, 1991; Blum et al., 1993; Siu et al., 1992; Hanna et al., 1994). During T cell
activation, CD4, CDS, and TCR are down-regulated at the level of transcription with later
recovery to previous levels of expression (Paillard et al., 1990). The murine and human
CD4 promoters have been analyzed and the /raw-acting factors Myb (Siu et al., 1992;
Nakayama et al., 1993) and Ets-related proteins (Salmon et al., 1993) are implicated in
regulating CD4 expression. T cell-specific enhancers, located 13.5 kb (Sawada and
Littman, 1991) and 25 kb 5' of the murine CD4 gene (Wurster et al., 1994) and 6.5 kb 5'
of the human CD4 gene (Blum et al., 1993), act through the /ram-acting factors
TCF-la/LEF-1 (Sawada and Littman, 1991), HEB (Sawada and Littman, 1993), an
E12-related protein (Sawada and Littman, 1993), and Elf-1 (Wurster et al., 1994) to
stimulate the CD4 promoter.
3.

Molecular Mechanism of CD4 Gene Regulation

When I started my dissertation research very little was known about the molecular
mechanism of CD4 gene regulation. Wilkinson et al. (1991a) had provided evidence that
dominant negative regulation plays an important role in the control of CD4 expression in
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developing thymocytes. Sawada and Liftman (1991) had just identified an enhancer 5' of
the murine CD4 gene, providing evidence of a positive regulator of CD4 expression.
However, the constitutive nature of the minimal enhancer in cell lines (Sawada and
Liftman, 1991), and the information described above, suggested that there might be more
involved in the regulation of CD4 than simply an enhancer that up-regulates the CD4 gene
at one stage of T cell development. At this time, Dr. John Sands was publishing work
identifying potential czs-acting elements by analyzing 75 kb of chromatin at the CD4 locus.
Based on the locations of the T cell-specific DH sites identified by Dr. Sands, we predicted
that numerous negative and positive cA-acting elements were located within the first intron
and within a 15 kb region 5' of the CD4 promoter. We therefore set out to address what
role these DNA regions play in regulating the expression of CD4 during T cell
development by designing a set of deletion constructs to be tested in T lymphoma cell
lines. We chose to work on a large scale rather than approach this project on a small scale
in order to more efficiently examine the large DNA regions that were implicated by the DH
site work. The construct design was not easy at first, but we finally became proficient in
dealing with the various problems that working with large fragments of DNA presents.
Following examination of the large DNA regions we characterized one of the negative
regulatory elements located in the first intron. We found that the c/s-acting element was a
TATC repeat that has a negative effect on promoter function. In addition, we sequenced
the entire region, and analyzed the sequence to get an idea of the locations of the negative
and positive control elements we had functionally identified using the large deletion
constructs. Our data complements the transgenic data that is now present in the literature
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and has provided many new insights into CD4 gene regulation that would be difficult to
achieve using transgenic mice.
4.

Regulatory Elements that Control CD4 Expression

a.

T Cell-Specific Enhancer

The proximal murine minimal enhancer was identified as a 339 bp fragment
located 13.5 kb 5' of the murine CD4 promoter (Sawada and Littman, 1991). This
minimal enhancer stimulates CD4 expression in a T cell-specific, but not subclass-specific
manner. Furthermore, the enhancer was reported to work in a constitutive manner. Our
results using transient transfections of the minimal enhancer in T lymphoma cell lines
supports this data. However, we also find that if the DNA surrounding the enhancer is left
intact, the enhancer has a degree of subclass-specificity. Our work suggests that the 339 bp
enhancer is actually part of a larger regulatory element. Although they did not address this
point, Sawada and Littman (1991) actually showed this by using a construct with 81 bp 5'
and 385 bp 3' which lost over 50% of its activity. The data reported by Siu et al. (1992)
also supports the idea of a larger regulatory element. The large size of the fragments they
used in their enhancer-trap studies may be the reason they were unable to detect an
enhancer in this region. The available data suggests that the core minimal enhancer is
constitutive but is only one part of a larger array of control elements. Furthermore, the
enhancer is associated with one of the negative control elements implicated by Wilkinson et
al. (1991).
b.

Region Between the Enhancer and CD4 Promoter

The enhancer was shown to play an important role in the up-regulation of CD4
expression at the CD4+CD8+ developmental stage (Hanna et al., 1994). Our data indicates
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that the region of DNA between the enhancer and promoter must be deleted in order for the
enhancer to work properly in these cells. Furthermore, it suggests that the position of the
enhancer may be important to its function. This explains another problem with the
published molecular analysis data. Both Blum et al. (1993) and Killeen et al. (1993) used
constructs in which they deleted the region of DNA between enhancer and promoter. In
both cases, they got partial expression of their reporters in the correct cell types. Gillespie
et al. (1993), on the other hand, left the enhancer in its natural position and got correct
expression. The differences in results of these transgenic experiments suggests that the
region of DNA between the enhancer and promoter is important to the regulation of the
CD4 gene. Our sequence analysis of this region indicates elements that may participate in
subclass-specific regulation of CD4. The primary function of this region appears to be the
down-regulation of the effect of the enhancer on the promoter, possibly by some sort of
interference mechanism. When we remove the negative intervening sequence, the
enhancer’s ability to stimulate the promoter increases by at least two to three orders of
magnitude. Furthermore, the degree of stimulation increases as the cells acquire a more
mature (CD4+CD8+) phenotype. Apparently, more immature thymocytes are negatively
controlling the enhancer itself, while as the cells mature, repression of the enhancer is
gradually relieved. It is especially intriguing that the increase in the concentration of a
nuclear matrix binding protein correlates to the ability of the enhancer to stimulate the
promoter. Sands and Nikolic-Zugic (1992) found CD4+CD8+ nuclear attachment regions
between the promoter and enhancer. Our sequence analysis indicates that the nuclear
matrix attachment regions between the enhancer and promoter may be even more extensive
than the previous analysis indicated. These results all suggest that the CD4+CD8+-enriched
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nuclear matrix attachment protein may be facilitating the ability of the enhancer to upregulate the promoter by creating an “artificial deletion” of the DNA region between the
enhancer and the promoter. This would allow the enhancer to be repositioned near the
promoter, circumventing the NRE.
c.

CD4 Promoter and Region 5' of the Promoter

The murine CD4 promoter is T cell-specific but is not subclass-specific in
thymocytes, while it does have subclass-specificity in peripheral T cells (Siu et al., 1992).
Furthermore, the human CD4 promoter up-regulates CD4 expression in peripheral T cells
without the assistance of the enhancer (Salmon et al., 1993; Hanna et al., 1994). Our
results indicate that the CD4 promoter functions at a low level in cells representing all
stages of thymocyte development. The region immediately 5' of the promoter appears to
contain a negative regulatory element, that has a direct effect on the promoter without
simply interfering with the ability of the enhancer to stimulate the promoter (Siu et al .,
1993; Hanna et al., 1994). Furthermore, the DNA 5' of the promoter inhibits expression in
thymocytes, but not peripheral T cells. This region may contain a regulatory element that
inhibits CD4 expression in mouse macrophages (Hanna et al., 1994). The region 5' of the
promoter appears to provide a degree of subclass- and tissue-specific regulation to the
promoter.
d.

First Intron

Some of the most intriguing work from both our laboratory and others concerns
the role of the first intron in the regulation of the CD4 gene. We knew from Sands and
Nikolic-Zugic (1992) that the first intron contained two T cell-specific DH sites. Their
work suggested that the first intron might be functioning to down-regulate the CD4 gene in
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CD4"CD8+ cells, since DH9 correlated with the absence of CD4 expression in both
thymocytes and peripheral T cells. We were analyzing this region when two reports were
published that a transcriptional silencer had been identified within the first intron (Sawada
et al, 1994; Siu et al, 1994). Sawada et al. (1994) identified the silencer within a DNA
fragment located approximately 2.5 kb 3' of the transcriptional start site, corresponding to
DH9. Siu et al. (1994) identified the silencer within a larger DNA fragment, which
includes DH9 and DH10. Careful examination of the data from these experiments
suggested that DH10 was also affecting CD4 gene expression, but in CD4+CD8' T cells.
Our data indicates that there is a second regulatory element corresponding to DH10, which
has a negative effect, especially in CD4+ cells. Our analysis of this second negative
regulatory element located in the first intron indicates that it involves a T cell-specific
protein/DNA binding interaction which corresponds to a TATC (or GATA) repeat. Since
this sequence is repetitive and not just a single GATA site, the potential function of this
region could be different than simply a reducer or silencer element. GATA repeats have
been implicated in altering chromatin structure so that genes can be properly regulated
(Singh et al., 1994a; Singh et al., 1994b). This idea was proposed by Dr. J. Sands when he
first identified OHIO in his analysis of the CD4 locus. He suggested that this region of
DNA might function as a transcriptional “flag” to allow the CD4 gene to be regulated in
T cells. Sawada et al. (1994) also proposed that the region of DNA in the first intron may
be involved in the alteration of chromatin structure.
The first intron is not only important for negative control of CD4 expression but is
important for positive control as well. Transgenic analysis illustrated the importance of the
first intron in CD4 gene expression (Blum et al., 1993; Gillespie et al., 1993; Hanna et al,
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1994; Sawada et al, 1994; Killeen et al, 1993; Siu et al, 1994). Only constructs that
contained the first intron were expressed in a somewhat normal fashion. Our analysis in
transient transfections indicates that the inclusion of the first intron, or part of the first
intron, is necessary for good expression of our reporter gene. We trimmed down the first
intron so that only 450 bp was left downstream of the 5' splice donor site and 250 bp left
upstream of the 3' splice accceptor site and found that this small amount of DNA was
sufficient to confer much of the positive effect. This suggests that the first intron may be
involved in post-transcriptional regulation of CD4, possibly by providing a means to
regulate the processing and transport of the CD4 mRNA from the nucleus. This coincides
with reports that post-transcriptional regulation also plays a role in the regulation of the
CD4 gene (Paillard et al., 1990; Takahama and Singer, 1992; Wilkinson et al., 1991b).
5.

Developmental Implications

a.

Regulation of CD4 Expression in CD4 CD8' Thymocytes

In the mouse, the earliest precursors from the bone marrow express low levels of
CD4. After being in the thymus for a few days, these cells become CD4 CD8' (Wu et al.,
1991b). One of the predominant themes of CD4 gene regulation is repression. Repression
of a gene can be accomplished by either direct or indirect mechanisms. Direct mechanisms
involve negative /raw-acting factors which act on a c/.v-acting element to somehow
negatively influence the promoter of a gene. Indirect mechanisms involve repressing a
positive factor that acts on a region that up-regulates the expression of a gene or making the
chromatin inaccessable to positive factors. Early in T cell development the positive trans
acting factors that stimulate the CD4 promoter are not present in a significant amount, and
the CD4 gene is being repressed by an indirect mechanism. Data to support this
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conclusion includes the following: (1) The T cell-specific enhancer cannot stimulate the
CD4 promoter in early CD4 CD8' cells (Figure 6.3). (2) We have no indication that the
intronic silencer (DH9) is playing a significant role before the CD4+CD8+ stage, since
deletions of various portions of the first intron have no effect on expression in these cells
(Figures 6.3 and 6.4). Furthermore, the presence of DH9 in early thymocytes is greatly
reduced as compared to its presence later in development when CD4 is not expressed
(Sands and Nikolic-Zugic, 1992). Both these facts contradict the models proposed by Siu
et al. (1994) and Sawada et al. (1994) concerning how the enhancer and silencer interact at
the double negative stage of thymocyte development. These groups propose that the
silencer somehow blocks the positive effect of a constitutive enhancer. (3) The
involvement of DH10 in down-regulating CD4 expression is minimal in CD4 CD8' cells,
as indicated from both the transient tranfection data where deletions of this region have no
effect (Figure 6.3), and EMSA data where only one of the three protein/DNA complexes
form (Figure 4.7). (4) The 5 kb 5’ of the CD4 promoter contains a NRE that is able to
silence the promoter in double-negative cells. These data indicate that the dominant
negative /ram-acting factors identified by Wilkinson et al. (1991a) may not be acting
directly on the CD4 gene but may be acting to repress a positive factor that is necessary for
CD4 gene expression. Alternatively, these negative /ra/is-acting factors may bind the NRE
located immediately 5’ of the promoter.
b.

Regulation of CD4 Expression in CD4|0CD8|0 Thymocytes

One way to describe CD4 CD8' cells as they progress to the CD4+CD8+ stage, is
CD4loCD8l0 (Andjelic et al., 1993). The cells in this transitory stage express characteristics
of both double-negative and double-positive cells. This idea is supported by the following
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data: (1) The T cell-specific enhancer is functional in CD4l0CD8l0 cells (Figure 6.4),
although not to the degree that is seen in CD4+CD8+ cells (Figure 6.5). This correlates
with the work by Paquette et al. (1992) which indicates that the CD4l0CD8l0 stage of
thymocyte development is similar to the CD4+CD8+ stage with respect to the composition
of nuclear /raws-acting factors that are present in these cell types. (2) The primary
repression of CD4 expression at the CD4l0CD8l0 stage of development is contributed by
the NRE(s) located in the region between the T cell-specific enhancer and the CD4
promoter (Figure 6.4). (3) The first intron does not exert a significant negative effect at
this stage (Figure 6.4). (4) Our data correlates with Wilkinson et al. (1991a) where they
show that the CD4loCD8l0 cells are unable to repress the expression of CD4 in fusions with
CD4+CD8+ cells, while fusions between the CD4 CD8' cells and the CD4l0CD8l0 cells do
down-regulate a set of T cell-specific genes. Since the enhancer is functional at the
CD4loCD8l0 stage, why is it unable to stimulate the promoter? The DNA between the
enhancer and promoter contains potential c/s-acting elements that could interfere with the
enhancer’s interaction with the promoter. The regions of DNA that have homology to
cryptic promoters are especially intriguing since these promoter motifs could be directing
the T cell-specific enhancer to themselves rather than permitting the enhancer to act on the
CD4 promoter. Furthermore, there exists the possibility that, in CD4l0CD8l0 cells,
whatever causes the enhancer to ignore these sites is not present, but at the next stage of
thymocyte development this factor is present. A good candidate for this factor is
Tia/SATBl (Wilkinson et al., 1991a; Dickinson et al., 1992; Nakagomi et al., 1994). An
interesting piece of preliminary data is the correlation of different forms of Tia/SATBl in
CD4l0CD8l0 versus CD4+CD8+ cells (Sands and Kohwi-Shigematsu, unpublished data).
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Western blots of proteins isolated from the cells used in this dissertation were probed with
antibodies to Tia/SATB 1. The results indicate that the Tia/SATB 1 protein is found in two
molecular forms, a 120 kDa protein and a 66 kDa protein, in cells not expressing CD4, and
a single form of 103 kDa in cells expressing CD4. The different forms of Tia/SATB 1
may explain why the enhancer cannot stimulate the promoter at a developmental stage
when the enhancer is able to function. One form of Tia/SATB 1 may be repressive, while
the other is stimulatory. The stimulatory form of Tia/SATB 1 could permit the chromatin
of this region to be altered so that the enhancer recognizes the promoter, while the
inhibitory form of Tia/SATB 1 would not permit this to occur.
c.

Regulation of CD4 Expression in CD4+CD8+ Thymocytes

Thymocytes expressing both CD4 and CDS are called double-positive, or
CD4+CD8+. The high level of CD4 expression in these cells is dependent on the function
of the T cell-specific enhancer. Data to support this conclusion includes the following:
(1) The enhancer is highly stimulatory for the CD4 promoter in CD4+CD8+ cells (Figure
6.5). Apparently the positive /raws-acting factors binding the enhancer are increasing in
concentration, since the activity of the enhancer increases as the thymocytes develop. The
increased stimulatory effect of the enhancer on the promoter correlates with transgenic
work which indicates that CD4 expression in CD4+CD8+ cells requires the T cell-specific
enhancer (Blum et al., 1993; Killeen et al., 1993; Hanna et al., 1994). (2) The promoter
itself still functions at a low level, suggesting that it has no inherent strength without the
T cell-specific enhancer. Our results support the conclusion of Siu et al. (1992) in their
initial analysis of the murine CD4 promoter. They provided evidence that the CD4
promoter does not function well in CD4+CD8+ cells. (3) The NREs located in the region
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between the T cell-specific enhancer and CD4 promoter have a decreased cumulative
negative effect, since less of this intervening region needs to be deleted in order to get
expression of our CAT reporter in CD4+CD8+ cells (Figure 6.5). Alternatively, there may
be a /raws-acting factor that effectively eliminates the negative effects of these NREs and is
now expressed at a high level in CD4+CD8+ cells. One candidate for this additional
positive /raws-acting factor is Tia/SATBl (Wilkinson et al., 1991a; Dickinson et al., 1992;
Nakagomi et al., 1994). This nuclear matrix binding protein is expressed at high levels in
CD4+CD8+ cells. The concentration of Tia/SATBl in CD4+CD8+ cells may be high
enough for its effect to be apparent even in our transient transfection assays. The
involvement of a nuclear matrix binding protein in regulating CD4 is supported by data
which indicates that the chromatin at the CD4 locus in CD4+CD8+ cells is in the most open
configuration of all the cells investigated (Sands, unpublished data), and by evidence that
the MARs at the CD4 locus were only able to be identified using nuclear matrix
preparations from CD4+CD8+ cells (Sands and Nikolic-Zugic, 1992). Whereas the
enhancer is critical to CD4 expression in CD4+CD8+ cells, Tia/SATBl may facilitate its
activity by allowing the T cell-specific enhancer to be positioned so that it can interact with
the CD4 promoter. This model predicts that CD4 expression can be quickly downregulated by simply removing /ra^s-acting factors that bind the enhancer or by altering the
molecular form of Tia/SATB 1. (4) The negative /ram-acting factors present at earlier
stages of development are not completely absent in double-positive cells. This is supported
by the low level of promoter activity at this stage of development (Figure 6.5; Siu et al.,
1992; Hanna et al., 1994), and by the CD4+CD8+ EMSA data in which the protein/DNA
complexes formed using recombinant DNA fragments corresponding to DH7-10 are
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almost identical to the complexes formed when using nuclear extracts from CD4'CD8+
cells rather than CD4+CD8' cells (Sands and Nikolic-Zugic, 1992).
d.

Regulation of CD4 Expression in CD4+CD8' Thymocytes

Following selection, some double-positive cells are chosen to differentiate into
CD4+CD8' T cells (Swain, 1983). The positive and negative foms-acting factors are both
down-regulated at this stage of development. Data that supports this conclusion includes
the following: (1) The enhancer is still functional (Figure 6.6), but at a lower level than in
CD4+CD8+ cells (Figure 6.5). (2) The NREs located between the T cell-specific enhancer
and the CD4 promoter have a similar effect as they do in CD4+CD8+ cells. (3) The
chromatin at the CD4 locus is less open as compared to CD4+CD8+ cells (Sands,
unpublished data). (4) In addition, the MARs were not discemable using nuclear matrix
preparations from these cells (Sands and Nikolic-Zugic, 1992). Although the form of
Tia/SATBl found in CD4+CD8' cells correlates with the form found in CD4+CD8+ cells,
Tia/SATBl expression is down-regulated once the cells leave the cortex and move to the
medulla (Sands and Kohwi-Shigematsu, unpublished data). The combination of these
results suggests that Tia/SATBl is not playing as predominant a role in CD4+CD8' cells as
in CD4+CD8+ cells. (5) The transition to the CD4+CD8' stage appears to involve downregulation of one or more repressors that down-regulate CD4 expression, as indicated by
the EMSA data (Sands and Nikolic-Zugic, 1992). There is a significant difference
between CD4+CD8' and CD4+CD8+ cells as shown by the DNase I footprint and EMSA
data at DH10 (Figures 4.7, 4.9, 4.10) as well as the EMSA data at other DH sites (Sands
and Nikolic-Zugic, 1992). In order to get CD4 expression to remain up-regulated in the
mature CD4+CD8' helper T cell, the repressors that are present in CD4+CD8+ thymocytes
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must be down-regulated. The down-regulation of these repressors may be what is the end
result of the CD4/p56lck signaling that is necessary to keep CD4 up-regulated once a
thymocyte has been selected to be a helper T cell (Micelli and Fames, 1993).
e.

Regulation of CD4 Expression in CD4'CD8+ Thymocytes

Finally, some double-positive cells are also chosen to differentiate into CD4 CD8+
T cells (Swain, 1983). CD4 expression is down-regulated at this stage of development
because the T cell-specific enhancer is blocked from stimulating the CD4 promoter. The
supporting data for this conclusion includes the following: (1) The enhancer is still
functional in these cells (Figure 6.7). (2) EMSA data shows strong protein/DNA binding
interactions at or near the promoter, while the DNase I hypersensitivity assay could not
detect this binding (Sands and Nikolic-Zugic, 1992). The chromatin at the promoter
appears to have changed so that the /raws-acting factors present in the CD4'CD8+ cells can
no longer bind the CD4 promoter. (3) The repression in these CD4 CD8+ cells seems to
be due to multiple NREs, since no single deletion relieves repression (Figure 6.7).
Furthermore, the form of Tia/SATBl is similar to that found in CD4l0CD8l0 cells, not
CD4+CD8+ or CD4+CD8' cells (Sands and Kohwi-Shigematsu, unpublished data).
(4) We have no strong evidence that the intron is important, or unimportant, at this stage
of development, although elements in the first intron have been shown to be important in
the transition from double-positive to single-positive (Blum et al., 1993; Gillespie et al.,
1993; Hanna et al, 1994; Sawada et al, 1994; Killeen et al, 1993; Siu et al, 1994). If we are
correct about how CD4 is down-regulated, there are two indirect means of repressing CD4
expression in addition to the multiple NREs that control CD4 expression: (1) removing
the /ram-acting factors binding the enhancer; (2) changing the molecular form of
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Tia/SATBl. In the CD4'CD8+ cells that we examined, the altered molecular form of
Tia/SATBl seems to be the more likely cause for the down-regulation of CD4 expression.
6.

Murine and Human CD4 Genes

Expression of the murine and human CD4 genes differs in a number of respects.
The murine CD4 gene is expressed mainly on the surface of T-lineage cells, while the
human CD4 gene is expressed on the surface of many other cells, including macrophages
(Chapter 1). Furthermore, murine hematopoietic cells express low levels of CD4 (Wu et
al., 1991b), while human hematopoietic cells do not (Sotzik et al., 1994). These
differences in expression may correspond to differences in the elements used to control
CD4 expression or differences in gene structure, and not the /ram-acting factors available,
since the human CD4 gene can be expressed in murine macrophages (Hanna et al., 1994).
Hanna et al. (1994) suggested that the negative control element which prevents murine
CD4 expression in macrophages is located 5' of the promoter. Our data also suggests that
there is a negative element in this region. These results become especially intriguing when
the distance between the murine enhancer and promoter, 13.5 kb, and the distance between
the human enhancer and promoter, 6.5 kb, is considered. The greater distance between the
enhancer and promoter in the mouse appears to correlate with the tighter control of murine
CD4 gene expression compared to the expression of the human CD4 gene. So, while the
murine and human genes are expressed in a similar manner, the differences between the
two systems may warrent careful attention.
10.

Summary

In summary, the focus of this dissertation is the regulation of the murine CD4 gene
during T cell development. Our work has pointed to the fact that the CD4 gene is regulated
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in a much more complex manner than simply by an enhancer located 13.5 kb 5' of the
gene that up-regulates the CD4 promoter in CD4+ cells and a silencer located 2.5 kb 3' of
the first exon that down-regulates the CD4 promoter in CD4' cells. Our data indicates the
following additional control elements:
a.

Region Containing the T Cell-Specific Enhancer

The 5' minimal enhancer is only a part of larger regulatory element that contains
additional positive elements located 5' of the minimal enhancer and negative elements
located 3' of the minimal enhancer.
b.

Region Between the Enhancer and CD4 Promoter

The region between the enhancer and the promoter has a profound negative effect
on the ability of the enhancer to stimulate the promoter. This negative effect is due to a
combination of silencer-like elements and interfering elements. The mechanism by which
these elements act may involve promoter-like sequences that attract the stimulatory activity
of the enhancer, thus preventing the enhancer from stimulating the CD4 promoter. If this
is what is happening, at some stage of T cell development there must also be a mechanism
for the enhancer to circumvent this interference. The numerous nuclear matrix attachment
regions and regions that have the potential to form non-B DNA that exist between the
promoter and the enhancer may constitute the mechanism that the developing T cell uses to
overcome the negative effect of this region.
c.

Region Immediately 5' of the Promoter

The region 500 bp to 6 kb 5' of the promoter also has a negative effect on the ability
of the CD4 promoter to function. This repressive effect is independent of any interference
that this region may have on the stimulation coming from the enhancer.
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d.

Region Corresponding to the Negative Effect of the First Intron

The first intron contains a complex negative element that involves multiple
components. One of these components corresponds to a TATC (or GATA) repeat. This
element may bind /ra/w-acting factors that are involved in altering the chromatin of the
CD4 locus so that the CD4 gene can be effectively regulated by the different positive and
negative /ra/is-acting factors.
e.

Region Corresponding to the Positive Effect of the First Intron

The first intron has a positive effect on CD4 gene expression. This positive effect
may involve some sort of T cell-specific splicing that facilitates the expression of the CD4
gene.

The combination of functional analysis, sequencing, and sequence analysis should
be invaluable for future experiments. I will deal with each of the above regions to explain
how my work can be extended by those who come after me.

B.

FUTURE DIRECTIONS
1.

Region Containing the T Cell-Specific Enhancer

The 5' T cell-specific enhancer has been defined as a 339 bp region of DNA that
can stimulate the CD4 promoter (Sawada and Littman, 1991). The existing data from our
laboratory and from others suggests that there are additional positive elements 5' of the
minimal enhancer and negative elements 3' of the minimal enhancer. Furthermore, our
data suggests that some of these additional elements may contribute to subclass-specific
control of the enhancer in T cells, especially during thymocyte development. The enhancer
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could be investigated further by creating an enhancer trap vector containing the 900 bp CD4
promoter fragment driving the CAT gene. This vector would have a poly linker located 5'
of the promoter fragment that could be used to insert DNA fragments containing different
amounts of DNA from the enhancer region. These constructs should then be tested in
T lymphoma cell lines that represent the different stages of thymocyte development.
2.

Region Between the Enhancer and CD4 Promoter

The region between the enhancer and the promoter has a negative effect on the
ability of the enhancer to stimulate the promoter. This negative effect can be effectively
dissected by using the sequence data provided in this dissertation. The regions of DNA
that have homology to either silencers, reducers, or the flanking regions of promoters
should be subcloned and inserted in a “silencer-trap” vector. This vector should include
the following: the 900 bp CD4 promoter fragment; the 5' enhancer (not just the minimal
enhancer); the CAT gene as a reporter; and a polylinker located between the enhancer and
the promoter for inserting the DNA to be analyzed. These constructs should be tested in
T lymphoma cell lines that represent the different stages of thymocyte development.
The region between the enhancer and the promoter also contains sites that are
potential nuclear matrix attachment regions (MARs). These sites need to be more carefully
defined to determine which sites actually function in this capacity. Furthermore, the sites
need to be investigated to determine if they bind the thymocyte-enriched Tia/SATBl
protein. We have preliminary data from a collaboration with T. Kohwi-Shigematsu (La
Jolla Cancer Research Foundation, La Jolla, CA) indicating that the Tia/SATBl protein
may be in different forms depending on whether CD4 is expressed or repressed. These
results suggest that this protein may play a dual rule in controlling CD4 expression. The
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MARs can be defined to small regions of DNA by using the classical MAR analysis.
Tia/SATBl binding can be investigated by using purified Tia/SATBl in electrophoretic
mobility shift assays. In addition, Tia/SATBl expression can be correlated with CD4
expression by isolation of RNA and concurrently probing with Tia/SATB 1 and CD4
cDNAs. Once the MARs and Tia/SATB 1 binding sites have been well characterized using
in vitro approaches, the involvement of the MARs in regulation of CD4 expression should
be undertaken. This can be done by antisense studies using cDNAs that encode the
Tia/SATBl gene. If Tia/SATBl expression is an important determinant of CD4
expression, the down-regulation of Tia/SATBl in CD4+ cells should have an affect on
CD4 expression. Conversely, if Tia/SATBl is over-expressed in CD4l0 or CD4' cells CD4
expression should be up-regulated. Tia/SATBl knock-outs could also be made in cell lines
or in transgenic mice in order to analyze the involvement of this protein in CD4 expression.
Finally, analysis of the function of the MARs in regulating CD4 expression could be done
by selectively deleting different MARs from constructs and then making stable
transfectants and transgenic mice with these constructs and determining the effect on CD4
expression.
3.

Region Immediately 5' of the Promoter

The region immediately 5' of the 500 bp CD4 promoter fragment has a negative
effect on promoter function. This negative effect needs to be more clearly defined. This
could be done using deletion analysis of this region. The deletions should be generated
starting at the EcoRl site located 6 kb 5' of the promoter and then progressively removing
more DNA until the minimal promoter is destroyed and no CAT activity is discernable.
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These constructs should be tested in the different cell lines that represent different stages of
thymocyte development.
4.

Region Corresponding to the Negative Effect of the First Intron

The silencing activity in the first intron has been characterized by a number of
groups including ours. I think that we should place our emphasis on the silencer I have
characterized, located 4 kb 5' of the first exon corresponding to DH10. At the same time, a
more careful analysis should be done to determine how the intronic silencing elements
work together to silence CD4 expression. The TATC repeat is especially intriguing since it
has been associated with altering chromatin structure, possibly by the action of the proteins
that bind to this region. The best way to test the altered chromatin structure hypothesis is
by using transgenic animals which have nearly identical regions of the CD4 locus left intact
but that delete the TATC repeat. In vitro studies could also be pursued to determine what
protein binds to this region. A good candidate to test would be the Bkm-binding protein
(BBP). The silencer located 2.5 kb 3' of the first intron should be more carefully defined,
but I suspect that D. Littman’s group is well on their way with this analysis.
5.

Region Corresponding to the Positive Effect of the First Intron

The first intron has a positive effect on CD4 gene expression when 450 bp 3' of the
splice donor site and 250 bp 5' of the splice acceptor site are included in constructs. The
positive effect of this region could be associated with an enhancer-like sequence or could be
associated with a splicing related phenomenon. The 450 bp and the 250 bp, described
above, should be analyzed further. This can be accomplished using Bal31 deletions that
progressively remove DNA from the 5' and 3' regions. The resultant constructs should be
tested in cell lines to determine the minimal requirements for the positive effect. Another
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approach that could be taken is to replace the normal first intron splice donor and splice
acceptor with another intron that contains a non-T cell-specific splice donor and acceptor,
such as the SV40 intron that exists 3' of the CAT gene in all our constructs. This
construction would indicate if the CD4 first intron has been tailor-made for CD4 gene
expression and thus is probably using T cell-specific splicing factors to enhance the
expression of CD4.
6.

Region 3' of the CD4 Gene

The region 3' of the CD4 gene is intriguing because of the presence of a
B cell/macrophage-specific gene and strong T cell-specific DNase I hypersensitive sites in
this region. Cells that enter the thymus to become T cells can also become B cells. Once
in the thymus for a short time, the only option is to be a T cell. Could the DH sites 3' of
CD4 represent repressor binding sites that are part of this differentiation step? The analysis
of the promoter/enhancer/silencer regulation of the 3' gene could provide some interesting
insights into how the B cell lineage is lost at this stage. This problem could be analyzed in
a similar fashion to what we have done with the CD4 promoter and enhancer. The
transcriptional start site would have to be determined and then constructs could be made
that include various amounts of the DNA between the first exon of this gene and the last
exon of CD4. The constructs should be tested in various T cell, B cell, and macrophage
cell lines. An attempt should also be made to determine if different factors from B cells
and T cells compete for the same (enhancer/silencer) sequence.
7.

Murine and Human Mechanisms of CD4 Gene Regulation

An important question concerning the regulation of the CD4 gene involves
comparisons between the murine and human genes. Are the elements that have been
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identified truly similar? Are similar /raws-acting factors present in both organisms?
Analysis of this problem could begin by testing the various murine deletion constructs in
human cell lines.

CHAPTERS. LITERATURE CITED

Abo, T., H. Watanabe, and H. Sekikawa. 1993. Multiplicity of sites for extrathymic T-cell
differentiation. Acta Med. Biol. 41:59-79.
Abo, T., T. Ohteki, S. Seki, N. Koyamada, Y. Yoshikai, T. Masuda, H. Rikiishi, and K.
Kumagai. 1991. The appearance of T cells bearing self-reactive T cell receptor in
the livers of mice injected with bacteria. J. Exp. Med. 174:417-424.
Abraham, K. M., S. D. Levin, J. D. Marth, K. A. Forbush, and R. M. Perlmutter. 1991a.
Delayed thymocyte development induced by augmented expression of p56lck. J.
Exp. Med. 173:1421-1432.
Abraham, K. M., S. D. Levin, J. D. Marth, K. A. Forbush, and R. M. Perlmutter. 1991b.
Thymic tumorigenesis induced by overexpression of p56lck. Proc. Natl. Acad. Sci.
USA 88:3977-3981.
Alarcon, B., C. Terhorst, A. Arnaiz-Villena, P. Perez-Aciego, and J. Ramon-Regueiro.
1990. Congenital T-cell receptor immunodeficiencies in man. Immunodefic. Rev.
2:1-16.
Altman, A., K. M. Coggeshall, and T. Mustelin. 1990. Molecular events mediating T cell
activation. Adv. Immunol. 48:227-360.
Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local
alignment search tool. J. Mol. Biol. 215:403-410.
Amadori, A., G. De Silvestro, R. Zamarchi, M. L. Veronese, M. R. Mazza, G. Schiavo,
M. Panozzo, A. De Rossi, L. Ometo, J. Mous, A. Barelli, A. Borri, L. Salmaso,
and L. Chieco-Bianchi. 1992. CD4 epitope masking by gpl20/anti-gpl20
antibody complexes. A potential mechanism for CD4+ cell function downregulation in AIDS patients. J. Immunol. 148:2709-2716.
Anderson, P., M. L. Blue, and S. F. Schlossman. 1988. Comodulation of CD3 and CD4.
Evidence for a specific association between CD4 and approximately 5% of the
CD3 :T cell receptor complexes on helper T lymphocytes. J. Immunol. 140:17321737.
Anderson, S. J., S. D. Levin, and R. M. Perlmutter. 1994. Involvement of the protein
kinase p56lck in T cell signaling and thymocyte development. Adv. Immunol.
56:151-178.

248

249
Andjelic, S., N. Jain, and J. Nikolic-Zugic. 1993. Ontogeny of fetal CD8l0CD4l0
thymocytes: expression of CD44, CD25, and early expression of TcR alpha
mRNA. Eur. J. Immunol. 23:2109-2115.
Andreu-Sanchez, J. L., I. M. Moreno de Alboran, M. A. Marcos, A. Sanchez-Movilla, A.
C. Martinez, and G. Kroemer. 1991. Interleukin 2 abrogates the nonresponsive
state of T cells expressing a forbidden T cell receptor repertoire and induces
autoimmune disease in neonatally thymectomized mice. J. Exp. Med. 173:13231329.
Appleyard, J., J. C. Scomik, R. C. Braylan, and N. A. Benson. 1983. Distinctive
expression of the T4 antigen in normal and stimulated lymphocytes. Cell.
Immunol. 76:171-188.
Ardavin, C., and K. Shortman. 1992. Cell surface marker analysis of mouse thymic
dendritic cells. Eur. J. Immunol. 22:859-862.
Ardavin, C., L. Wu, C. L. Li, and K. Shortman. 1993. Thymic dentritic cells and T cells
develop simultaneously in the thymus from a common precursor population.
Nature 362:761-763.
Armstrong, J. A., and P. Horne. 1984. Follicular dendritic cells and virus-like particles in
AIDS-related lymphadenopathy. Lancet 2:370-372.
Asjo, B., I. Ivhed, M. Gidlund, S. Fuerstenberg, E. M. Fenyo, K. Nilsson, and H. Wigzell.
1987. Susceptibility to infection by human immunodeficiency virus (HIV)
correlates with T4 expression in a parental monocytoid cell line and its subclones.
Virology 157:359-365.
Asmuth, D. M., S. M. Hammer, and C. A. Wanke. 1994. Physiological effects of HIV
infection on human intestinal epithelial cells: an in vitro model for HIV
enteropathy. AIDS 8:205-211.
Balasubramaniam, V., and P. M. Appasamy. 1994. Development of murine pre-T cells
into y5 T-cell receptor bearing cells. Dev. Comp. Immunol. 18:179-191.
Bandeira, A., S. Itohara, M. Bonneville, O. Burlen-Defranoux, T. Mota-Santos, A.
Coutinho, and S. Tonegawa. 1991. Extrathymic origin of intestinal intraepithelial
lymphocytes bearing T-cell antigen receptor y6. Proc. Natl. Acad. Sci. USA
88:43-47.
Bank, I., R. A. DePinho, M. B. Brenner, J. Cassimeris, F. W. Alt, and L. Chess. 1986. A
functional T3 molecule associated with a novel heterodimer on the surface of
immature human thymocytes. Nature 322:179-181.

250

Baralle, F. E., and G. G. Brownlee. 1978. AUG is the only recognizable signal sequence
in the 5'non-coding regions of eukaryotic mRNA. Nature 274:84-87.
Baran, N., A. Lapidot, and H. Manor. 1991. Formation of DNA triplexes accounts for
arrests of DNA synthesis at d(TC)n and d(GA)n tracts. Proc. Natl. Acad. Sci. USA
88:507-511.
Basch, R. S., Y. H. Kouri, and S. Karpatkin. 1990. Expression of CD4 by human
megakaryocytes. Proc. Natl. Acad. Sci. USA 87:8085-8089.
Bastien, L., and P. Bourgaux. 1987. The MT family of mouse DNA is made of short
interspersed repeated elements. Gene 57:81-88.
Berberian, L., L. Goodglick, T. J. Kipps, and J. Braun. 1993. Immunoglobulin VH3
products: natural ligands for HTV gp 120. Science 261:1588-1591.
Berkow, R. L., and A. S. Kraft. 1985. Bryostatin, a non phorbol ester lactone, activates
intact human polymorphonuclear leukocytes and binds to the phorbol ester
receptor. Biochem. Biophys. Res. Commun. 131:1109-1116.
Beyers, A. D., L. L. Spruyt, and A. F. Williams. 1992. Molecular associations between
the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or
CDS and CD5. Proc. Natl. Acad. Sci. USA 9:2945-2949.
Bhat, N. K., K. L. Komschlies, S. Fujiwara, R. J. Fisher, B. J. Mathieson, T. A. Gregorio,
H. A. Young, J. W. Kasik, K. Ozato, and T. S. Papas. 1989. Expression of Ets
genes in mouse thymocyte subsets and T cells. J. Immunol. 142:672-678.
Bierer, B. E., B. P. Sleckman, S. E. Ratnofsky, and S. J. Burakoff 1989. The biologic
roles of CD2, CD4, and CDS in T-cell activation. Annu. Rev. Immunol. 7:579599.
Bimboim, H. C., and J. Doly. 1979. A rapid alkaline extraction procedure for screening
recombinant plasmid DNA. Nucleic Acids Res. 7:1513-1523.
Blue, M. L., J. F. Daley, H. Levine, and S. F. Schlossman. 1985. Coexpression of T4 and
T8 on peripheral blood T cells demonstrated by two-color fluorescence flow
cytometry. J. Immunol. 134:2281-2286.
Blue, M. L., D. A. Hafler, K. A. Craig, H. Levine, and S. F. Schlossman. 1987.
Phosphorylation of CD4 and CDS molecules following T cell triggering.
J. Immunol. 139:3949-3954.

251
Bluestone, J. A., D. Pardoll, S. O. Sharrow, and B. J. Fowlkes. 1987. Characterization of
murine thymocytes with CD3-associated T-cell receptor structures. Nature
326:82-84.
Blum, M. D., G. T. Wong, K. M. Higgins, M. J. Sunshine, and E. Lacy. 1993.
Reconstitution of the subclass-specific expression of CD4 in thymocytes and
peripheral T cells of transgenic mice: identification of a human CD4 enhancer.
J. Exp. Med. 177:1343-1358.
Boehm, T. L., W. Kreis, and D. Drahovsky. 1982. Inhibition of thymidylate synthase by
hydroxyurea in rapidly proliferating P815 mastocytoma cells. Biochim. Biophys.
Acta 696:52-56.
Bolen, J. B., P. A. Thompson, E. Eiseman, and I. D. Horak. 1991. Expression and
interactions of the Src family of tyrosine protein kinases in T-lymphocytes. Adv.
Cancer Res. 57:103-149.
Borgulya, P., H. Kishi, U. Muller, J. Kirberg, and H. von Boehmer. 1991. Development
of the CD4 and CDS lineage of T cells: instruction versus selection. EMBO J.
10:913-918.
Boto, W. M., L. Brown, J. Chrest, and W. H. Adler. 1991. Distinct modulatory effects of
bryostatin 1 and staurosporine on the biosynthesis and expression of the HIV
receptor protein (CD4) by T cells. Cell. Reg. 2:95-103.
Bour, S., F. Boulerice, and M. A. Wainberg. 1991. Inhibition of gpl60 and CD4
maturation in U937 cells after both defective and productive infections by human
immunodeficiency virus type 1. J. Virol. 65:6387-6396.
Bour, S., R. Geleziunas, and M. A. Wainberg. 1994. The role of CD4 and its
downmodulation in establishment and maintenance of HIV-1 infection. Immunol.
Rev. 140:147-171.
Brand, A. M., L. Breeden, J. Abraham, R. Sternglanz, and K. Nasmyth. 1985.
Characterization of a “silencer” in yeast: a DNA sequence with properties opposite
to those of a transcriptional enhancer. Cell 41:41-48.
Brightman, B. K., K. G. Chandy, R. H. Spencer, and H. Fan. 1989. A T lymphoid cell
line responds to a thymic stromal cell line by expression of Thy-1 and CD4.
J. Immunol. 143:2775-2782.
Budd, R. C., G. C. Miescher, R. C. Howe, R. K. Lees, C. Bron, and H. R. MacDonald.
1987. Developmentally regulated expression of T cell receptor beta chain variable
domains in immature thymocytes. J. Exp. Med. 166:577-582.

252

Calladine, C. R. 1982. Mechanics of sequence-dependent stacking of bases in B-DNA.
J. Mol. Biol. 161:343-352.
Cameron, P. U., U. Forsum, H. Teppler, A. Granelli-Pipemo, and R. M. Steinman. 1992.
During HTV-l infection most blood dendritic cells are not productively infected and
can function normally in clonal expansion of CD4+ T cells. Clin. Exp. Immunol.
88:226-236.
Cammarota, G., A. Scheirle, B. Takacs, D. M. Doran, R. Knorr, W. Bannwarth, J.
Guardiola, and F. Sinigaglia. 1992. Identification of a CD4 binding site on the beta
2 domain of HLA-DR molecules. Nature 356:799-801.
Campbell, S. M., and J. M. Rosen. 1984. Comparison of the whey acidic protein genes of
the rat and mouse. Nucleic Acids Res. 12:8685-8696.
Capon, D. J., and R. H. R. Ward. 1991. The CD4-gpl20 interaction and AIDS
pathogenesis. Annu. Rev. Immunol. 9:649-678.
Cefai, D., M. Ferrer, N. Serpente, T. Idziorek, A. Dautry-Varsat, P. Debre, and G.
Bismuth. 1992. Internalization of HIV glycoprotein gpl20 is associated with
down-modulation of membrane CD4 and p56 ck together with impairment of T cell
activation. J. Immunol. 149:285-294.
Center, D. M., J. S. Berman, H. Kornfeld, A. C. Theodore, and W. W. Cruikshank. 1995.
The lymphocyte chemoattractant factor. J. Lab. Clin. Med. 125:167-172.
Chan, I. T., A. Limmer, M. C. Louie, E. D. Bullock, W. P. Fung-Leung, T. W. Mak, and
D. Y. Loh. 1993. Thymic selection of cytotoxic T cells independent of CD8a-Lck
association. Science 261:1581-1584.
Chan, S. H., D. Cosgrove, C. Waltzinger, C. Benoist, and D. Mathis. 1993. Another view
of the selective model of thymocyte selection. Cell 73:225-236.
Chehimi, J., K. Prakash, V. Shanmugam, R. Collman, S. J. Jackson, S. Bandyopadhyay,
and S. E. Starr. 1993. CD4-independent infection of human blood dentritic cells
with isolates of human immunodeficiency virus type 1. J. Gen.Virol. 74:12771285.
Chen, M. Y., R. Maldarelli, M. K. Karczewski, R. L. Willey, and K. Strebel. 1993.
Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in
vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J. Virol.
67:3877-3884.
Cheng, T. C., and H. H. Kazazian, Jr. 1977. The S'-terminal structures of murine a- and
p-globin messenger RNA. J. Biol. Chem. 252:1758-1763.

253

Chieco-Bianchi, L., M. L. Calabro, M. Panozzo, A. De Rossi, A. Amadori, L. Callegaro,
and A Siccardi. 1989. CD4 modulation and inhibition of HIV-1 infectivity
induced by monosialoganglioside GM1 in vitro. AIDS 3:501-507.
Clark, S. J., W. A. Jefferies, A. N. Barclay, J. Gagnon, and A. F. Williams. 1987.
Peptide and nucleotide sequences of rat CD4 (W3/25) antigen: evidence for
derivation from a structure with four immunoglogulin-related domains. Proc. Natl.
Acad. Sci. USA 84:1649-1653.
Classon, B. J., J. Tsagaratos, I. F. McKenzie, and I. D. Walker. 1986. Partial primary
structure of the T4 antigens of mouse and sheep: assignment of intrachain disulfide
bonds. Proc. Natl. Acad. Sci. USA 83:4499-4503.
Clayton, L. K., M. Sieh, D. A. Pious, and E. L. Reinherz. 1989. Identification of human
CD4 residues affecting class IIMHC versus HTV-l gpl20 binding. Nature
339:548-551.
Cohen, S. N., A. C. Y. Chang, and L. Hsu. 1972. Nonchromosomal antibiotic resistance
in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc.
Natl. Acad. Sci. USA 69:2110-2114.
Collins, T. L., S. Uniyal, J. Shin, J. L. Strominger, R. S. Mittler, and S. J. Burakoff. 1992.
p56lck association with CD4 is required for the interaction between CD4 and the
TCR/CD3 complex and for optimal antigen stimulation. J. Immunol. 148:21592162.
Corado, J., F. Mazerolles, F. Le-Deist, C. Barbat. M. Kaczorek, and A. Fischer. 1991.
Inhibition of CD4+ T cell activation and adhesion by peptides derived from the
gpl60. J. Immunol. 147:475-482.
Cosgrove, D., D. Gray, A. Dierich, J. Kaufman, M. Lemeur, C. Benoist, and D. Mathis.
1991. Mice lacking MHC class II molecules. Cell 66:1051-1066.
Crise, B., and J. K. Rose. 1992. Human immunodeficiency virus type 1 glycoprotein
precursor retains a CD4-p56lck complex in the endoplasmic reticulum. J. Virol.
66:2296-2301.
Crispe, I. N., M. W. Moore, L. A. Husmann, L. Smith, M. J. Bevan, and R. P.
Shimonkevitz. 1987. Differentiation potential of subsets of CD4'8' thymocytes.
Nature 329:336-339.

254

Cruikshank, W. W., D. M. Center, N. Nisar, M. Wu, B. Natke, A. C. Theodore, and H.
Komfeld. 1994. Molecular and functional analysis of a lymphocyte
chemoattractant factor: association of biologic function with CD4 expression.
Proc. Natl. Acad. Sci. USA 91:5109-5113.
Cullen, B. R. 1991. Regulation of human immunodeficiency virus replication. Annu.
Rev. Microbiol. 45:219-250.
Dalgleish, A. G., P. C. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves, and R.
A. Weiss. 1984. The CD4 (T4) antigen is an essential component of the receptor
for the AIDS retrovirus. Nature 312:763-767.
Davis, C. B., N. Killeen, M. E. C. Crooks, D. Raulet, and D. R. Littman. 1993. Evidence
on a stochastic mechanism in the differentiation of mature subsets of T
lymphocytes. Cell 73:237-247.
De Geus, B., M. Van den Enden, C. Coolen, L. Nagelkerken, P. Van den Heijden, and
J. Rozing. 1990. Phenotype of intraepithelial lymphocytes in euthymic and
athymic mice: implications for differentiation of cells bearing a CD3-associated y5
T cell receptor. Eur. J. Immunol. 20:291-298.
Deusch, K., F. Luling, K. Reich, M. Classen, H. Wagner, and K. Pfeffer. 1991. A major
fraction of human intraepithelial lymphocytes simultaneously expresses the y/5
T cell receptor, the CDS accessory molecule and preferentially uses the V61 gene
segment. Eur. J. Immunol. 21:1053-1059.
Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres,
and F. W. Fitch. 1983. Characterization of the murine T cell surface molecule,
designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to
the human Leu-3/T4 molecule. J. Immunol. 131:2445-2451.
Dianzani, U., A. Shaw, B. K. al Ramadi, R. T. Kubo, and C. A. Janeway, Jr. 1991.
Physical association of CD4 with the T cell receptor. J. Immunol. 148:678-688.
Dianzani, U., A. Shaw, B. K. al Ramadi, R. T. Kubo, and C. A. Janeway, Jr. 1992.
Physical association of CD4 with the T cell receptor. J. Immunol. 148:678-688.
Dickerson, R. E. 1983. Base sequence and helix structure variation in B and A DNA.
J. Mol. Biol. 166:419-441.
Dickinson, L. A., T. Joh, Y. Kohwi, and T. Kohwi-Shigematsu. 1992. A tissue-specific
MAR/SAR DNA-binding protein with unusual binding site recognition. Cell
70:631-645.

255

Dignam, J. D., R. M. Lebowitz, and R. G. Roeder. 1983. Accurate transcription initiation
by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res. 11:1475-1489.
Donda, A., K. Karjalainen, M. Schulz, K. Burki, G. De Libero, and Y. Uematsu. 1995.
Identification of a human CD4 silencer element, p. 723, 4291. Abstr. 9th
International Congress of Immunology. 1995. American Association of
Immunologists, San Francisco, CA.
Dower, W. J., J. F. Miller, and C. W. Ragsdale. 1988. High efficiency transformation of
E. coli by high voltage electroporation. Nucleic Acids Res. 16:6127-6145.
Doyle, C., and J. L. Strominger. 1987. Interaction between CD4 and class IIMHC
molecules mediates cell adhesion. Nature 330:256-259.
Dreyfus, M., N. Doyen, and F. Rougeon. 1987. The conserved decanucleotide from the
immunoglobulin heavy chain promoter induces a very high transcriptional activity
in B-cells when introduced into an heterologous promoter. EMBO J. 6:16851690.
Dudek, H., R. V. Tantravahi, V. N. Rao, E. S. Reddy, and E. P. Reddy. 1992. Myb and
Ets proteins cooperate in transcriptional activation of the mim-1 promoter. Proc.
Natl. Acad. Sci. USA 89:1291-1295.
Dumont-Drieux, A. M., A. De Parseval, M. Heiber, P. Salmon, G. Pancino, P. Sonigo,
and D. Klatzmann. 1992. Unusual amino acid sequence of the second Ig-like
domain of the feline CD4 protein. AIDS Res. Hum. Retroviruses 8:1581-1591.
Ebert, E. C. 1989. Proliferative responses of human intraepithelial lymphocytes to various
T-cell stimuli. Gastroenterology 97:1372-1381.
Ebert, E. C. 1990. Intra-epithelial lymphocytes: interferon-gamma production and
suppressor/cytotoxic activities. Clin. Exp. Immunol. 82:81-85.
Ebisawa, M., D. C. Reason, H. Saito, S. Nakano, K. Seo, K. Kawamura, and Y. likura.
1991. Ann. Allergy 67:612-614.
Egerton, M., R. Scollay, and K. Shortman. 1990. Kinetics of mature T-cell development
in the thymus. Proc. Natl. Acad. Sci. USA 87:2579-2582.
Eichmann, K., J. Jonsson, I. Falk, and F. Emmrich. 1987. Effective activation of resting
mouse T lymphocytes by crosslinking submitogenic concentrations of the T cell
antigen receptor with either Lyt-2 or L3T4. Eur. J. Immunol. 17:643-650.

256
Elliott, R. W., and K. J. Moore. 1992. Mouse chromosome 6. Mamm. Genome 3:S81S103.
Emmrich, R., L. Kantz, and K. Eichmann. 1987. Cross-linking of the T cell receptor
complex with the subset-specific differentiation antigen stimulates interleukin 2
receptor expression in human CD4 and CDS T cells. Eur. J. Immunol. 17:529534.
Ensoli, B., P. Lusso, F. Schachter, S. F. Josephs, J. Rappaport, F. Negro, R. C. Gallo, and
F. Wong-Staal. 1989. Human herpes virus-6 increases HIV-1 expression in
co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J.
8:3019-3027.
Esa, A. H., W. O. Boto, W. H. Adler, W. S. May, and A. D. Hess. 1990. Activation of T
cells by bryostatins: induction of the IL-2 receptor gene transcription and downmodulation of surface receptors. Int. J. Immunopharmacol. 12:481-490.
Evans, R. M., and S. M. Hollenberg. 1988. Zinc fingers: gilt by association. Cell
52:1-3.
Fangmann, J., R. Schwinzer, and K Wonigeit. 1991. Unusual phenotype of intestinal
intraepithelial lymphocytes in the rat: predominance of T cell receptor oc/(37CD2'
cells and high expression of the RT6 alloantigen. Eur. J. Immunol. 21:753-760.
Fantini, J., D. G. Cook, N. Nathanson, S. L. Spitalnik, and F. Gonzalez-Scarano. 1993.
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus
(HIV-1) is associated with cell surface expression of galactosyl ceramide, a
potential alternative gpl20 receptor. Proc. Nad. Acad. Aci. USA 90:2700-2704.
Ferguson, A., and D. M. V. Parrott. 1972. The effect of antigen deprivation on thymusdependent and thymus-independent lymphocytes in the small intestine of the
mouse. Clin. Exp. Immunol. 12:477-488.
Field, E. H., B. Tourvieille, P. D’Eustachio, and J. R. Parnes. 1987. The gene encoding
the mouse T cell differentiation antigen L3T4 is located on chromosome 6.
J. Immunol. 138:1968-1970.
Field, L. J., W. M. Philbrick, P. N. Howies, D. P. Dickinson, R. A. McGowan, and K. W.
Gross. 1984. Expression of tissue-specific Ren-1 and Ren-2 genes of mice:
comparative analysis of 5'-proximal flanking regions. Mol. Cell. Biol. 4:23212331.
Fierro, M. T., M. C. Giubellino, P. Lusso, M. L. Ferrando, and R. Foa. 1982. OK Tpositivity in stimulated T-lymphocytes. Boll. Soc. Ital. Biol. Sper. 58:311-314.

257

Finkel, T. H., J. C. Cambier, R. T. Kubo, W. K. Bom, P. Marrack, and J. W. Kappler.
1989. The thymus has two functionally distinct populations of immature aP+
T cells: one population is deleted by ligation of a(3 TCR. Cell 58:1047-1054.
Fleury, S., D. Lamarre, S. Meloche, S. E. Ryu, C. Cantin, W. A. Hendrickson, and R. P.
Sekaly. 1991a. Mutational analysis of the interaction between CD4 and class II
MHC: class II antigens contact CD4 on a surface opposite the gp 120-binding site.
Cell 66:1037-1049.
Fleury, S. G., G. Croteau, and R. P. Sekaly. 1991b. CD4 and CDS recognition of class II
and class I molecules of the major histocompatibility complex. Semin. Immunol.
3:177-185.
Fowlkes, B. J., and D. M. Pardoll. 1989. Molecular and cellular events of T cell
development. Adv. Immunol. 44:207-264.
Fredrickson, G. G., and R. S. Basch. 1989. L3T4 antigen expression on hemopoietic
precursor cells. J. Exp. Med. 169:1473-1478.
Freedman, A. R., F. M. Gibson, S. C. Fleming, C. J. Spry, and G. E. Griffin. 1991.
Human immunodeficiency vims infection of eosinophils in human bone marrow
cultures. J. Exp. Med. 174:1661-1664.
Fomsgaard, A., V. M. Hirsch, and P. R. Johnson. 1992. Cloning and sequences of
primate CD4 molecules: diversity of the cellular receptor for simian
immunodeficiency vims/human immunodeficiency vims. Eur. J. Immunol.
22:2973-2981.
Fowlkes, B. J., A. M. Kmisbeek, H. Ton-That, M. A. Weston, J. E. Coligan, R. H.
Schwartz, and D. M. Pardoll. 1987. A novel population of T-cell receptor alpha
beta-bearing thymocytes which predominantly expresses a single V beta gene
family. Nature 329:251-254.
Fowlkes, B. J., R. H. Schwartz, and D. M. Pardoll. 1988. Deletion of self-reactive
thymocytes occurs at a CD4+8+ precursor stage. Nature 334:620-623.
Funke, I., A. Hahn, E. P. Rieber, E. Weiss, and G. Riethmuller. 1987. The cellular
receptor (CD4) of the human immunodeficiency vims is expressed on neurons and
glial cells in human brain. J. Exp. Med. 165:1230-1235.
Fumkawa, M., M. Yasukawa, Y. Yakushijin, and S. Fujita. 1994. Distinct effects of
human herpesvims 6 and human herpesvims 7 on surface molecule expression and
function of CD4+ T cells. J. Immunology 152:5768-5775.

258
Gabuzda, D. H., and M. S. Hirsch. 1987. Neurologic manifestations of infection with
human immunodeficiency virus. Clinical features and pathogenesis. Ann. Intern.
Med. 107:383-391.
Galas, D., and A. Schmitz. 1978. DNase footprinting: a simple method for the detection
of protein-DNA binding specificity. Nucleic Acids Res. 5:3157-3170.
Gallagher, P. F., B. F. de St. Growth, and J. F. Miller. 1989. CD4 and CDS molecules
can physically associate with the same T-cell receptor. Proc. Natl. Acad. Sci. USA
86:10044-10048.
Garcia, J. V., J. Alfano, and A. D. Miller. 1993. The negative effect of human
immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species
specific and requires the cytoplasmic domain of CD4. J. Virol. 67:1511-1516.
Gartner, S., P. Markovits, D. M. Markovitz, R. F. Betts, and N. Papovic. 1986a. Virus
isolation from and identification of HTLV-III/LAV-producing cells in brain tissue
from a patient with AIDS. JAMA 256:2365.
Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic.
1986b. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science
233:215-219.
Gay, D., P. Maddon, R. Sekaly, M. A. Talle, M. Godfrey, E. Long, G. Goldstein, L.
Chess, R. Axel, J. Kappler, and P. Marrack. 1987. Functional interaction between
human T cell protein CD4 and the major histocompatibility complex HLA-DR
antigen. Nature 328:626-629.
Gebhard, W., and H. G. Zachau. 1983. Simple DNA sequences and dispersed repetitive
elements in the vicinity of mouse immunoglobulin K light chain genes. J. Mol.
Biol. 170:567-573.
Gegonne, A., R. Bosselut, R. A. Bailly, and J. Ghysdael. 1993. Synergistic activation of
the HTLV1 LTR Ets-responsive region by transcription factors Etsl and Spl.
EMBOJ. 12:1169-1178.
Geleziunas, R., S. Bour, F. Boulerice, J. Hiscott, and M. A. Wainberg. 1991. Diminution
of CD4 surface protein but not CD4 messenger RNA levels in monocytic cells
infected by HIV-1. AIDS 5:29-33.
Geppert, T. D., and P. E. Lipsky. 1991. Association of various T cell-surface molecules
with the cytoskeleton. J. Immunol. 146:3298-3305.

259
Gewirtz, A. M, L. Boghosian-Sell, L. Catani, M. Z. Ratajczak, Y. M. Shen, A. D.
Schreiber. 1992. Expression of Fc gamma RH and CD4 receptors by normal
human megakaryocytes. Exp. Hematol. 20:512-516.
Gillespie, F. P., L. Doros, J. Vitale, C. Blackwell, J. Gosselin, B. W. Snyder, and S. C.
Wadsworth. 1993. Tissue-specific expression of human CD4 in transgenic mice.
Mol. Cell. Biol. 13:2952-2958.
Glaichenhaus, N., N. Shastri, D. R. Littman, and J. M. Turner. 1991. Requirement for
association of p56lck with CD4 in antigen-specific signal transduction in T cells.
Cell 64:511-520.
Godfrey, D. I., J. Kennedy, T. Suda, and A. Zlotnik. 1993. A developmental pathway
involving four phenotypically and functionally distinct subsets of CD3'CD4'CD8'
triple-negative adult mouse thymocytes defined by CD44 and CD25 expression.
J. Immunol. 150:4244-4252.
Gorman, S. D., B. Tourvieille, and J. R. Fames. 1987. Structure of the mouse gene
encoding CD4 and an unusual transcript in the brain. Proc. Natl. Acad. Sci. USA
84:7644-7648.
Grassi, F., L. Lopalco, P. Lanza, F. Ciccomascolo, F. Cazzola, A. Di Martino, G.
Kirschner, L. Callegaro, L. Chieco-Bianchi, and A. G. Siccardi. 1990. Chemical
residues of ganglioside molecules involved in interactions with lymphocyte surface
targets leading to CD4 masking and inhibition of mitogenic proliferation. Eur. J.
Immunol. 20:145-150.
Gross, D. S., S. Y. Huang, and W. T. Garrard. 1985. Chromatin structure of the potential
Z-forming sequence (dT-dG)n x (dC-dA)n. Evidence for an “altemating-B”
conformation. J. Mol. Biol. 183:251-265.
Grusby, M. J., R. S. Johnson, V. E. Papaioannou, and L. H. Glimcher. 1991. Depletion
of CD4+ T cells in major histocompatibility complex class II-deficient mice.
Science 253:1417-1420.
Guidos, C. J., I. L. Weissman, and B. Adkins. 1989. Intrathymic maturation of murine
T lymphocytes from CD8+ precursors. Proc. Natl. Acad. Sci. USA 86:75427546.
Gustafsson, K., S. Germana, T. M. Sundt 3rd, D. H. Sachs, and C. LeGuern. 1993.
Extensive allelic polymorphism in the CDR2-like region of the miniature swine
CD4 molecule. J. Immunol. 151:1365-1370.

260
Guy-Grand, D., N. Cerf-Bensussan, B. Malissen, M. Malassis-Seris, C. Briottet, and P.
Vassalli. 1991a. Two gut intraepithelial CD8+ lymphocyte populations with
different T cell receptors. A role for the gut epithelium in T cell differentiation.
J. Exp. Med. 173:471-481.
Guy-Grand, D., C. Griscelli, and P. Vassalli. 1974. The gut-associated lymphoid system:
nature and properties of the large dividing cells. Eur. J. Immunol. 4:435-443.
Guy-Grand, D., C. Griscelli, and P. Vassalli. 1978. The mouse gut T lymphocyte, a novel
type of T cell. Nature, origin, and traffic in mice in normal and graft-versus-host
condition. J. Exp. Med. 148:1664-1677.
Guy-Grand, D., M. Malassis-Seris, C. Briottet, and P. Vassalli. 1991b. Cytotoxic
differentiation of mouse gut thymodependent and independent intraepithelial T
lymphocytes is induced locally. Correlation between functional assays, presence of
perforin and granzyme transcripts, and cytoplasmic granules. J. Exp. Med.
173:1549-1552.
Hague, B. F., S. Sawasdikosol, T. J. Brown, K. Lee, D. P. Recker, and T. J. Kindt. 1992.
CD4 and its role in infection of rabbit cell lines by human immunodeficiency virus
type 1. Proc. Natl. Acad. Sci. USA 89:7963-7967.
Hakomori, S. 1990. Bifiinctional role of glycosphingolipids. J. Biol. Chem. 265:1871318716.
Hamamoto, Y., Y. Hayashida, S. Kobayashi, T. Tamaoki, N. Yamamoto, and N.
Kobayashi. 1989. Comparison of effects of protein kinase C inhibitors on phorbol
ester-induced CD4 down-regulation and augmentation of human
immunodeficiency virus replication in human T cell lines. Biochem. Biophys. Res.
Commun. 164:339-344.
Hambor, J. E., J. Mennone, M. E. Coon, J. H. Hanke, and P. Kavathas. 1993.
Identification and characterization of an Alu-containing, T-cell-specific enhancer
located in the last intron of the human CDS alpha gene. Mol. Cell. Biol. 13:70567070.
Hanna, Z., C. Simard, A. Laperriere, and P. Jolicoeur. 1994. Specific expression of the
human CD4 gene in mature CD4+CD8' and immature CD4+CD8+ T cells and in
macrophages of transgenic mice. Mol. Cell. Biol. 14:1084-1094.
Harouse, J. M., S. Bhat, S. L. Spitalnik, M. Laughlin, K. Stefano, D. H. Silberberg, and F.
Gonzalez-Scarano. 1991. Inhibition of entry of HIV-1 in neural cell lines by
antibodies against galactosyl ceramide. Science 253:320-323.

261
Harriman, G. R., E. Homqvist, and N. Y. Lycke. 1992. Antigen-specific and polyclonal
CD4+ lamina propria T-cell lines: phenotypic and functional characterization.
Immunology 75:66-73.
Harrison, S. C., J. Wang, Y. Yan, T. Garrett, J. Liu, U. Moebius, and E. Reinherz. 1992.
Structure and interactions of CD4. Cold Spring Harb. Symp. Quant. Biol.,
LVII:541-548.
Haughn, L., S. Gratton, L. Caron, R. P. Sekaly, A. Veillette, and M. Julius. 1992.
Asociation of tyrosine kinase p56lck with CD4 inhibits the induction of growth
through the ap T-cell receptor. Nature 358:328-331.
Hayashi, Y., M. Utsuyama, C. Karachima, and K. Hirokawa. 1989. Spontaneous
development of organ-spcific autoimmune lesions in aged C57BL/6 mice. Clin.
Exp. Immunol. 78:120-126.
Hera, A., de la, M. L. Toribio, C. Marquez, and C. Martinez. 1985. Interleukin 2
promotes growth and cytolotic activity in human T3+4'8‘ thymocytes. Proc. Natl.
Acad. Sci. USA 82:6268-6271.
Hess, A. D., M. K. Silanskis, A. H. Esa, G. R. Pettit, and W. S. May. 1988. Activation
of human T lymphocytes by bryostatin. J. Immunol. 141:3263-3269.
Heybome, K. D., R. L. Cranfill, S. R. Carding, W. K. Born, and R. L. O’Brien. 1992.
Characterization of y6 T lymphocytes at the maternal-fetal interface. J. Immunol.
149:2872-2878.
Hirokawa, K. 1985. Autoimmunity and aging. Concepts Immunopathol. 1:251-288.
Ho, D. D., T. R. Rota, and M. S. Hirsch. 1986. Infection of monocytes/macrophages by
human T lymphotropic virus type IE. J. Clin. Invest. 77:1712-1715.
Ho, I. C., P. Vorhees, N. Marin, B. K. Oakley, S. F. Tsai, S. H. Orkin, and J. M. Leiden.
1991. Human GATA-3: a lineage-restricted transcription factor that regulates the
expression of the T cell receptor alpha gene. EMBO J. 10:1187-1192.
Hoda, S. A., J. E. White, and M. A. Gerber. 1991. Immunohistochemical studies of
human immunodeficiency virus-1 in liver tissues of patients with AIDS. Mod.
Pathol. 4:578-581.
Hoffman, E. K., S. P. Trusko, N. Freeman, and D. L. George. 1987. Structural and
functional characterization of the promoter region of the mouse c-Ki-ras gene.
Mol. Cell. Biol. 7:2592-2596.

262
Hori, T., X. Paliard, R. de Waal Malefijt, M. Ranes, and H. Spits. 1991. Comparative
analysis of CDS expressed on mature CD4+CD8+ T cell clones cultured with IL-4
and that on CD8+ T cell clones: implication for functional significance of CDS
beta. Int. Immunol. 3:737-741.
Homeff, G., A. H. Guse, H. Schulze-Koops, J. R. Kalden, G. R. Bumester, and F.
Emmrich. 1993. Human CD4 modulation in vivo by antibody treatment. Clin.
Immunol. Immunopathol. 66:80-90.
Hoxie, J. A., J. D. Alpers, J. L. Rackowski, K. Huebner, B. S. Haggarty, A. J.
Cedarbaum, and J. C. Reed. 1986a. Alterations in T4 (CD4) protein and mRNA
synthesis in cells infected with HTV. Science 234:1123-1127.
Hoxie, J. A., D. M. Matthews, K. J. Callahan, D. L. Cassel, and R. A. Cooper. 1986b.
Transient modulation and internalization of T4 antigen induced by phorbol esters.
J. Immunol. 137:1194-1201.
Hugo, P., G. A. Waanders, R. Scollay, K. Shortman, and R. L. Boyd. 1990. Ontogeny of
a novel CD4+CD8'CD3 thymocyte subpopulation: a comparison with CD4'
CD8+CD3‘thymocytes. Int. Immunol. 2:209-218.
Hurley, T. R., K. Luo, and B. M. Sefton. 1989. Activators of protein kinase C induce
dissociation of CD4, but not CDS, from p56lck. Science 245:407-409.
liai, T., H. Watanabe, S. Seki, K. Sugiura, K. Hirokawa, M. Utsuyama, H. TakahashiIwanaga, T. Iwanaga, T. Ohteki, and T. Abo. 1992. Ontogeny and development of
extrathymic T cells in mouse liver. Immunology 77:556-563.
liai, T., H. Watanabe, T. Iwamoto, I. Nakashima, and T. Abo. 1994. Predominant
activation of extrathymic T cells during melanoma development of
metallothionein/ret transgenic mice. Cell. Immunol. 153:412-427.
Ikuta, I., N. Uchida, J. Friedman, and I. L. Weissman. 1992. Lymphocyte development
from stem cells. Annu. Rev. Immunol. 10:759-783.
Ish-Horowicz, D., and J. F. Burke. 1981. Rapid and efficient cosmid cloning. Nucleic
Acids Res. 9:2989-2998.
Ishikawa, H., and K. Saito. 1980. Congenitally athymic nude (nu/nu) mice have Thy-1bearing immunocompetent helper T cells in their peritoneal cavity. J. Exp. Med.
151:965-968.
Isobe, M., K. Heubner, P. J. Maddon, D. R. Littman, R. Axel, and C. M. Croce. 1986.
The gene encoding the T-cell surface protein T4 is located on human chromosome
12. Proc. Natl. Acad. Sci. USA 83:4399-4402.

263

Jabado, N., F. Le Deist, A. Fisher, and C. Hivroz. 1994. Interaction of HIV gp!20 and
anti-CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the
binding activity of NF-AT, NF-KB, and AP-1, three nuclear factors regulating
interleukin-2 gene enhancer activity. Eur. J. Immunol. 24:2646-2652.
Jabbar, M. A., and D. P. Nayak. 1990. Intracellular interaction of human
immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gpl60 with CD4
blocks the movement and maturation of CD4 to the plasma membrane. J. Virol.
64:6297-6304.
Jackson, M. E. 1991. Negative regulation of eukaryotic transcription. J. Cell Sci.
100:1-7.
Janeway, C. A., Jr. 1988. Accessories or coreceptors? Nature 335:208-210.
Janeway, C. A., Jr. 1991. The co-receptor function of CD4. Semin. Immunol.
3:153-160.
Janeway, C. A., Jr., and K. Bottomly. 1994. Signals and signs for lymphocyte responses.
Cell 76:275-285.
Jefferies, W. A., J. R. Green, and A. F. Williams. 1985. Authentic T helper CD4
(W3/25) antigen on rat peritonial macrophages. J. Exp. Med. 162:117-127.
Jones, K. W., and L. Singh. 1981. Conserved repeated DNA sequences in vertebrate sex
chromosomes. Hum. Genet. 58:46-53.
Jones, P. A. 1984. Gene activation by 5-azacytidine. p. 165. In A. Razin, H. Cedar, and
A. D. Riggs (ed.), DNA Methylation. Biochemistry and Biological Significance.
Springer-Verlag, New York.
Julius, M., C. R. Maroun, and L. Haughn. 1993. Distinct roles for CD4 and CDS as
co-receptors in antigen receptor signalling. Immunol. Today 14:177-183.
Kalb, V. F., S. Glasser, D. King, and J. B. Lingrel. 1983. A cluster of repetitive elements
within a 700 base pair region in the mouse genome. Nucleic Acids Res. 11:21772184.
Kanner, S. B., J. P. Deans, and J. A. Ledbetter. 1992. Regulation of CD3-induced
phospholipase C-gamma 1 (PLC gamma 1) tyrosine phosphorylation by CD4 and
CD45 receptors. Immunology 75:441-447.
Kappler, J. W., E. Kushnir, and P. Marrack. 1989. Analysis of V beta 17a expression in
new mouse strains bearing the V beta a haplotype. J. Exp. Med. 169:1533-1541.

264

Kappler, J. W., N. Roehm, and P. Marrack. 1987a. T cell tolerance by clonal elimination
in the thymus. Cell 49:273-283.
Kappler, J. W., T. Wade, J. White, E. Kushnir, M. Blackman, J. Bill, N. Roehm, and P.
Marrack. 1987b. A T cell receptor V beta segment that imparts reactivity to a class
II major histocompatibility complex product. Cell 49:263-271.
Karlin, S., and S. F. Altschul. 1990. Methods for assessing the statistical significance of
molecular sequence features by using general scoring schemes. Proc. Natl. Acad.
Sci. USA 87:2264-2268.
Kaufmann, T., T. Silverman, B. Levi, and K. Ozato. 1987. Induction of c-ets and c-fos
gene expression upon antigenic stimulation of a T cell hybridoma with inducible
cytolytic capacity. J. Exp. Med. 166:810-815.
Kawaguchi, T., H. Nakakuma, T. Kagimoto, K. Shirono, K. Horikawa, M. Hidaka, M.
Iwamori, Y. Nagai, and K. Takatsuki. 1989. Characteristic mode of action of
gangliosides in selective modulation of CD4 on human T lymphocytes. Biochem.
Biophys. Res. Commun. 158:1050-1059.
Kaye, J., and E. L. Ellenberger. 1992. Differentiation of an immature T cell line: a model
of thymic positive selection. Cell 71:423-435.
Kazazi, F., J. M. Mathijs, P. Foley, and A. L. Cunningham. 1989. Variations in CD4
expression by human monocytes and macrophages and their relationships to
infection with the human immunodeficiency virus. J. Gen. Virol. 70:2661-2672.
Kelley, K. A., and P. M. Pitha. 1985. Characterization of a mouse interferon gene locus I.
Isolation of a cluster of four a interferon genes. Nucleic Acids Res. 13:805-823.
Kiguchi, K., C. B. Henning-Chubb, and E. Huberman. 1990. Glycosphingolipid pattern
of peripheral blood lymphocytes, monocytes, and granulocytes are cell specific.
J. Biochem. 107:8-14.
Killeen, N., and D. R. Littman. 1993. Helper T-cell development in the absence of CD4p56lck association. Nature 364:729-732.
Killeen, N., S. Sawada, and D. R. Littman. 1993. Regulated expression of human CD4
rescues helper T cell development in mice lacking expression of endogenous CD4.
EMBOJ. 12:1547-1553.
Kisielow, P., H. Bluthmann, U. D. Staerz, M. Steimetz, and H. von Boehmer. 1988.
Tolerance in T-cell receptor transgenic mice involves deletion of nonmature
CD4+8+thymocytes. Nature 333:742-746.

265

Klatzmann, D., E. Champagne, S. Chamaret, J. Gruest, D. Guetard, T. Hercend, J. C.
Gluckman, and L. Montagnier. 1984. T-lymphocyte T4 molecule behaves as the
receptor for human retrovirus LAV. Nature 312:767-768.
Koenig, S., H. E. Gendelman, J. M. Orestein, M. C. Dal Canto, G. H. Pezeshkpou, M.
Yungbluth, F. Janotta, A. Aksamit, M. A. Martin, and A. S. Fauci. 1986.
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with
encephalopathy. Science 233:1089-1093.
Koga, Y., M. Sasaki, H. Yoshida, H. Wigzell, G. Kimura, and K. Nomoto. 1990.
Cytopathic effect determined by the amount of CD4 molecules in human cell lines
expressing envelope glycoprotein of HIV. J. Immunol. 144:94-102
Koka, P., K. van de Mark, and D. V. Faller. 1991. Trans-activation of genes encoding
activation-associated human T lymphocyte surface proteins by murine retroviral
sequences. J. Immunol. 146:2417-2425.
Koka, P., J. Yunis, A. L. Passarelli, D. P. Dubey, D. V. Faller, and E. J. Ynis. 1988.
Increased expression of CD4 molecules on Jurkat cells mediated by HTV Tat
protein. J. Virol. 62:4353-4357.
Konig, R., L. Y. Huang, and R. N. Germain. 1992. MHC class II interaction with CD4
mediated by a region analogous to the MHC class I binding site for CDS. Nature
356:796-798.
Konkel, D. A., J. V. Maizel, Jr., and P. Leder. 1979. The evolution and sequence
comparison of two recently diverged mouse chromosomal p-globin genes. Cell
18:865-873.
Kozbor, D., J. Finan, P. C. Nowell, and C. M. Croce. 1986. The gene encoding the T4
antigen maps to human chromosome 12. J. Immunol. 136:1141-1143.
Krensky, A. M., C. S. Reiss, J. W. Mier, J. L. Strominger, and S. J. Burakoff. 1982.
Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are
OKT4+. Proc. Natl. Acad. Sci. USA 79:2365-2369.
Krayev, A. S., D. A. Kramerov, K. G. Skryabin, A. P. Ryskov, A. A. Bayev, and G. P.
Georgiev. 1980. The nucleotide sequence of the ubiquitous repetitive DNA
sequence B1 complementary to the most abundant class of mouse fold-back RNA.
Nucleic Acids Res. 8:1201-1215.

266
Kruisbeek, A. M, M. J. Fultz, S. O. Sharrow, A. Singer, and J. J. Mond. 1983. Early
development of the T cell repertoire. In vivo treatment of neonatal mice with anti-la
antibodies interferes with differentiation of I-restricted T cells but not K/D-restricted
T cells. J. Exp. Med. 157:1932-1941.
Kruisbeek, A. M., J. J. Mond, B. J. Fowlkes, J. A. Carmen, S. Bridges, and D. L. Longo.
1985. Absence of the Lyt-2', L3T4+ lineage of T cells in mice treated neonatally
with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting
cell function. J. Exp. Med. 161:1029-1047.
Krummel, B. 1990. DNase I Footprinting, p. 184-188. In M. A. Innis, D. H. Gelfand, J.
J. Sninsky, and T. J. White (ed.), PCR Protocols: a guide to methods and
applications. Academic Press, Inc., San Diego, CA.
Kupfer, A., S. J. Singer, C. A. Janeway Jr, and S. L. Swain. 1987. Coclustering of CD4
(L3T4) molecule with the T-cell receptor is induced by specific direct interaction of
helper T cells and antigen-presenting cells. Proc. Natl. Acad. Sci. USA 84:58885892.
Kwong, P. D., S. E. Ryu, W. A. Hendrickson, R. Axel, R. M. Sweet, G. FolenaWasserman, P. Hensley, and R. W. Sweet. 1990. Molecular characteristics of
recombinant CD4 as deduced from polymorphic crystals. Proc. Natl. Acad. Sci.
USA 87:6423.
Laimins, L., M. Holmgren-Konig, and G. Khoury. 1986. Transcriptional “silencer”
element in rat repetitive sequences associated with the rat insulin 1 gene locus.
Proc. Natl. Acad. Sci. USA 83:3151-3155.
Lambastie, M. C., D. Bones, C. Chabret, J. M. Gregoire, S. Chretien, and P. H. Romeo.
1994. Structure and expression of the human GATA3 gene. Genomics 21:1-6.
Langhoff, E., E. F. Terwillinger, H. J. Bos, K. H. Kalland, M. C. Poznansky, O. M. L.
Bacon, and W. A. Haseltine. 1991. Replication of human immunodeficiency virus
type 1 in primary dendritic cell cultures. Proc. Natl. Acad. Sci. USA 88:79988002.
Ledbetter, J. A., L. K. Gilliland, and G. L. Schieven. 1990. The interaction of CD4 with
CD3/TCR regulates tyrosine phosphorylation of substrates during T cell activation.
Semin. Immunol. 2:99-106.
Ledbetter, J. A., C. H. June, P. S. Rabinovitch, A. Grossmann, T. T. Tsu, and J. B.
Imboden. 1988. Signal transduction through CD4 receptors: stimulatory vs.
inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor. Eur.
J. Immunol. 18:525-532.

267
Le Douarin, N. M, F. Dieterlen-Lievre, and P. D. Oliver. 1984. Ontogeny of primary
lymphoid organs and lymphoid stem cells. Am. J. Anat. 170:261-300.
Letvin, N. L., D. C. Linch, G. P. Beardsley, K. W. McIntyre, and D. G. Nathan. 1984.
Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea.
N. Engl. J. Med. 310:869-873.
Levelt, C. N., R. Carsetti, and K. Eichmann. 1993. Regulation of thymocyte development
through CD3. II. Expression of T cell receptor beta CD3 epsilon and maturation
to the CD4+8+ stage are highly correlated in individual thymocytes. J. Exp. Med.
178:1867-1875.
Levine, M., and J. L. Manley. 1989. Transcriptional repression of eukaryotic promoters.
Cell 59:405-408.
Lew, A. M., D. M. Pardoll, W. L. Maloy, B. J. Fowlkes, A. Kruisbeek, S. F. Cheng, R.
N. Germain, J. A. Bluestone, R. H. Schwartz, and J. E. Coligan. 1986.
Characterization of T cell receptor gamma chain expression in a subset of murine
thymoctyes. Science 234:1401-1405.
Lewin, B. 1994. Chromatin and gene expression: constant questions, but changing
answers. Cell 79:397-406.
Li, S. L., E. E. Kaaya, J. Feichtinger, P. Putkonen, C. Parravicini, D. Bottiger, G.
Biberfeld, and P. Biberfeld. 1991. Monocyte/macrophage giant cell disease in
SIV-infected cynomolgus monkeys. Res. Virol. 142:173-182.
Lipsick, J. S., and W. J. Boyle. 1987. c-myb protein expression is a late event during
T lymphocyte activation. Mol. Cell. Biol. 7:3358-3360.
Littman, D. R., and S. N. Gettner. 1987. Unusual intron in the immunoglobulin domain
of the newly isolated murine CD4 (L3T4) gene. Nature 325:453-455.
Liu, C., and R. Auerbach. 1991. In vitro development of murine T cells from prethymic
and preliver embryonic yolk sac hematopoietic stem cells. Development
113:1315-1323.
Locksley, R., S. L. Reiner, F. Hatam, D. R. Littman, and N. Killeen. 1993. Helper T cells
without CD4: control of Leishmaniasis in CD4-deficient mice. Science 261:14481451.
Loenen, W. A. M., L. A. Gravestein, S. Beumer, C. J. M. Melief, A. Hagemeijer, and J.
Borst. 1992. Genomic organization and chromosomal localization of the human
CD27 gene. J. Immunol. 149:3937-3943.

268
Lucey, D. R., D. I. Dorsky, A. Nicholson-Weller, and P. F. Weller. 1989. Human
eosinophils express CD4 protein and bind human immunodeficiency virus 1
gpl20. J. Exp. Med. 169:327-332.
Luo, K. X., and B. M. Sefton. 1990. Cross-linking of T-cell surface molecules CD4 and
CDS stimulates phosphorylation of the Lck tyrosine protein kinase at the
autophosphorylation site. Mol. Cell. Biol. 10:5305-5313.
Lusso, P., A. De Maria, M. Malnati, F. Lori, S. E. DeRocco, M. Baseler, and R. C. Gallo.
1991. Induction of CD4 and susceptibility of HIV-1 infection in human CD8+ T
lymphocytes by human herpesvirus 6. Nature 349:533-535.
Lusso, P., M. S. Malnati, A. Garzino-Demo, R. W. Crowley, E. O. Long, and R. C. Gallo.
1993. Infection of natural killer cells by human herpesvirus 6. Nature
362:458-462.
Macatonia, S. E., R. Lau, S. Patterson, A. J. Pinching, and S. C. Knight. 1990. Dendritic
cell infection, depletion and dysfunction in HIV infected individuals. Immunology
71:38-45.
MacDonald, H. K, H. Hengartner, and T. Pedrazzini. 1988a. Intrathymic deletion of self
reactive cells prevented by neonatal anti-CD4 antibody treatment. Nature
335:174-176.
MacDonald, H. R., R. Schneider, R. Lees, R. C. Howe, H. Acha-Orbea, H. Festenstein, R.
M. Zinkernagel, and H. Hengartner. 1988b. T-cell receptor V beta use predicts
reactivity and tolerance to Mlsa-encoded antigens. Nature 332:40-45.
MacDonald, R. J., G. H. Swift, C. Quinto, W. Swain, R. L. Pictet, W. Nikovits, and W. J.
Rutter. 1982. Primary structure of two distinct rat pancreatic preproelastases
determined by sequence analysis of the complete cloned messenger ribonucleic acid
sequences. Biochemistry 21:1453-1463.
Maddon, P. I, D. R. Littman, M. Godfrey, D. E. Maddon, L. Chess, and R. Axel. 1985.
The isolation and nucleotide sequence of a cDNA encoding the T cell surface
protein T4: a new member of the immunoglobulin gene family. Cell 42:93-104.
Maddon, P. J., S. M. Molineaux, D. E. Maddon, K. A. Zimmerman, M. Godfrey, F. W.
Alt, L. Chess, and R. Axel. 1987. Structure and expression of the human and
mouse T4 genes. Proc. Natl. Acad. Sci. USA 84:9155-9159.
Maniatis, T., E. F. Fritsch, and J. Sambrook. 1989. Molecular cloning: a laboratory
manual. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

269

Manor, H., B. S. Rao, and R. G. Martin. 1988. Abundance and degree of dispersion of
genomic d(GA)n • d(TC)n sequences. J. Mol. Evol. 27:96-101.
Marodon, G., and B. Rocha. 1994. Generation of mature T cell populations in the
thymus: CD4 or CDS down-regulation occurs at different stages of thymocyte
differentiation. Eur. J. Immunol. 24:196-204.
Martin, D. I. K., and S. H. Orkin. 1990. Transcriptional activation and DNA binding by
the erythroid factor GF-1/NF-E1/ Eryf 1. Genes Dev. 4:1886-1898.
Martin, D. I. K., L. I. Zon, G. Mutter, and S. H. Orkin. 1990. Expression of an erythroid
transcription factor in megakaryocytic and mast cell lineages. Nature 344:444-447.
Masuda, T.,T. Ohteki, T. Abo, S. Seki, M. Nose, H. Nagura, and K. Kumagai. 1991.
Expansion of double negative CD4'8' ocP T cells in the liver is a common feature of
autoimmune mice. J. Immunol. 147:2907-2912.
Matsumoto, K., Y. Yoshikai, Y. Moroi, T. Asano, T. Ando, and K. Nomoto. 1991. Two
differential pathways from double-negative to double-positive thymocytes.
Immunology 72:20-26.
Maxam, A. M., and W. Gilbert. 1980. Sequencing end-labeled DNA with base-specific
chemical cleavages. Methods Enzymol. 65:499-560.
McCracken, S., S. Leung, R. Bosselut, J. Ghysdael, and N. G. Miyamoto. 1994. Myb
and Ets related transcription factors are required for activity of the human lek type I
promoter. Oncogene 9:3609-3615.
McLean, M. J., and R. D. Wells. 1988. The role of sequence in the stabilization of lefthanded DNA helices in vitro and in vivo. Biochim. Biophys. Acta 950:243-254.
McPhee, D., J. Pye, and K. Shortman. 1979. The differentiation of T lymphocytes. V.
Evidence for intrathymic death of most thymocytes. Thymus 1:151 -162.
Melton, D. W., D. S. Konecki, J. Brennand, and C. T. Caskey. 1984. Structure,
expression, and mutation of the hypoxanthine phosphoribosyltransferase gene.
Proc. Natl. Acad. Sci. USA 81:2147-2151.
Melton, D. W., C. McEwan, A. B. McKie, and A. M. Reid. 1986. Expression of the
mouse HPRT gene: deletional analysis of the promoter region of an Xchromosome linked housekeeping gene. Cell 44:319-328.
Metcalf, D., and M. A. S. Moore. 1971. Haemopoietic cells, p. 172-271. In A.
Neuberger, and E. L. Tatum (ed.), Frontiers of biology. North-Holland Publishing
Co., Amsterdam/London.

270

Metcalf, D., and R. Wakonig-Vaartaja. 1964. Stem cell replacement in normal thymus
grafts. Proc. Soc. Exp. Biol. Med. 115:731-735.
Miceli, M. C., and J. R. Fames. 1993. Role of CD4 and CDS in T cell activation and
differentiation. Adv. Immunol. 53:59-122.
Milde, K. F., G. E. Conner, D. H. Mintz, and R. Alejandro. 1993. Primary structure of
the canine CD4 antigen. Biochim. Biophys. Acta 1172:315-318.
Miller, F. D., G. H. Dixon, J. B. Rattner, and J. H. van de Sande. 1985. Assembly and
characterization of nucleosomal cores on B- vs Z-form DNA. Biochemistry
24:102-109.
Minami, Y., L. E. Samelson, and R. D. Klausner. 1987. Internalization and cycling of the
T cell antigen receptor. Role of protein kinase C. J. Biol. Chem. 262:1334213347.
Mittler, R. S., S. F. Goldman, G. L. Spitalny, and S. F. Burakoff. 1989. T-cell receptorCD4 physical association in a murine T-cell hybridoma: induction by antigen
receptor ligation. Proc. Natl. Acad. Sci. USA 86:8531-8535.
Molina, T. J., K. Kishihara, D. P. Siderovski, W. van Ewijk, A. Narendran, E. Timms, A.
Wakeham, C. J. Paige, K. U. Hartmann, A. Veillette, D. Davidson, and T. W.
Mak. 1992. Profound block in thymocyte development in mice lacking p56lck.
Nature 357:161-164.
Mombaerts, P., A. R. Clarke, M. A. Rudnicki, J. lacomini, S. Itohara, J. J. Lafaille, L.
Wang, Y. Ichikawa, R. Jaenisch, M. L. Hooper, and S. Tonegawa. 1992.
Mutations in T-cell antigen receptor genes alpha and beta block thymocyte
development at different stages. Nature 360:225-231.
Moore, S. C., S. J. Anderson, and W. S. Walker. 1992. Mouse macrophages contain a
truncated CD4 transcript. J. Leukoc. Biol. 52:128-129.
Morrison, W. J., H. Offner, and A. A. Vandenbark. 1991. Ganglioside (GMl)-treated
T cells shed CD4. Immunopharmacology 22:77-84.
Moscicki, R. A., E. P. Amento, S. M. Krane, J. T. Kurnick, and R. B. Colvin. 1983.
Modulation of surface antigens of a human monocyte cell line, U937, during
incubation with T lymphocyte-conditioned medium: detection of T4 antigen and its
presence on normal blood monocytes. J. Immunol. 131:743-748.
Mosley, R. L., D. Styre, and J. R. Klein. 1990a. CD4+CD8+ murine intestinal
intraepithelial lymphocytes. Int. Immunol. 2:361-365.

271

Mosley, R. L., D. Styre, and J. R. Klein. 1990b. Differentiation and functional maturation
of bone marrow-derived intestinal epithelial T cells expressing membrane T cell
receptor in athymic radiation chimeras. J. Immunol. 1455:1369-1375.
Motojima, K., and T. Oka. 1983. 5'-terminal sequence of the mRNA of mouse whey
acidic protein contains three possible sites of interaction with 18S rRNA. Biochem.
Biophys. Res. Commun. 116:167-172.
Muglia, L., and L. B. Rothman-Denes. 1986. Cell type-specific negative regulatory
element in the control region of the rat a-fetoprotein gene. Proc. Natl. Acad. Sci.
USA 83:7653-7657.
Muller, R., D. J. Slamon, E. D. Adamson, J. M. Tremblay, D. Muller, J. Cline, and I. M.
Verma. 1983. Transcription of c-onc genes c-ras*1 and c-fins during mouse
development. Mol. Cell. Biol. 3:1062-1069.
Murosaki, S., Y. Yoshikai, A. Ishida, T. Nakamura, G. Matsuzaki, H. Takimoto, H.
Yuuki, and K. Nomoto. 1991. Failure of T cell receptor Vp negative selection in
murine intestinal intra-epithelial lymphocytes. Int. Immunol. 3:1005-1013.
Nadeau, J. H. 1989. Maps of linkage and synteny homologies between mouse and man.
Trends Genet. 5:82-86.
Nagata, S., N. Mantei, and C. Weissmann. 1980. The structure of one of the eight or
more distinct chromosomal genes for human interferon-a. Nature 287:401-408.
Nakagomi, K., Y. Kohwi, L. A. Dickinson, and T. Kohwi-Shigematsu. 1994. A novel
DNA-binding motif in the nuclear matrix attachment-binding protein SATB1.
Mol. Cell. Biol. 14:1852-1860.
Nakayama, K., R. Yamamoto, S. Ishii, and H. Nakauchi. 1993. Binding of c-myb to the
core sequence of the CD4 promoter. Int. Immunol. 5:817-824.
Naylor, L. H., and E. M. Clark. 1990. d(TG)n • d(CA)n sequences upstream of the rat
prolactin gene form Z-DNA and inhibit gene transcription. Nucleic Acids Res.
18:1595-1601.
Nickol, J., M. Behe, and G. Felsenfeld. 1982. Effect of the B--Z transition in poly(dGm5dC) • poly(dG-m5C) on nucleosome formation. Proc. Natl. Acad. Sci. USA
79:1771-1775.
Nikolic-Zugic, J., M. W. Moore, and M. J. Bevan. 1989. Characterization of the subset of
immature thymocytes which can undergo rapid in vitro differentiation. Eur. J.
Immunol. 19:649-653.

272

Norimine, J., T. Miyazawa, Y. Kawaguchi, Y. Tohya, C. Kai, and T. Mikami. 1992. A
cDNA encoding feline CD4 has a unique repeat sequence downstream of the Vlike region. Immunology 75:74-79.
Nossal, G. J. V. 1994. Negative selection of lymphocytes. Cell 76:229-239.
Offner, H., T. Thieme, and A. A. Vanderbark. 1987. Gangliosides induce selective
modulation of CD4 from helper T lymphocytes. J. Immunol. 139:3295-3305.
Ohashi, P. S., H. Pircher, K. Burki, R. M. Zinkemagel, and H. Hengartner. 1990.
Distinct sequence of negative or positive selection implied by thymocyte T-cell
receptor densities. Nature 346:861-863.
Ohmori, K., T. liai, H. Watanabe, T. Tanaka, M. Miyasaka, and T. Abo. 1993. Activation
of extrathymic T cells in the liver of mice bearing syngeneic tumors. Biomed. Res.
14:65-79.
Ohteki, T., T. Abo, S. Seki, T. Kobata, H. Yagita, K. Okumura, and K. Kumagai. 1991.
Predominant appearance of y5 T lymphocytes in the liver of mice after birth. Eur.
J. Immunol. 21:1733-1740.
Ohteki, T., R. Okuyama, S. Seki, T. Abo, K. Sugiura, A. Kusumi, T. Ohmori, H.
Watanabe, and K. Kumagai. 1992. Age-dependent increase of extrathymic T cells
in the liver and their appearance in the periphery of older mice. J. Immunol.
149:1562-1570.
Ohteki, T., S. Seki, T. Abo, and K. Kumagai. 1990. Liver is a possible site for the
proliferation of abnormal CD3+4'8‘ double-negative lymphocytes in autoimmune
MRL-lpr/lpr mice. J. Exp. Med. 172:7-12.
Ohtsuka, K., T. liai, H. Watanabe, T. Tanaka, M. Miyasaka, K. Sato, H. Asakura, and T.
Abo. 1994. Similarities and differences between extrathymic T cells residing in
mouse liver and intestine. Cell. Immunol. 153:52-66.
Okuyama, R., T. Abo, S. Seki, T. Ohteki, K. Sugiura, A. Kusumi, and K. Kumagai.
1992. Estrogen administration activates extrathymic T cell differentiation in the
liver. J. Exp. Med. 175:661-669.
Omary, M. B., D. A. Brenner, L. Y. de Grandpre, K. A. Roebuck, D. D. Richman, and M.
F. Kagnoff. 1991. HIV-1 infection and expression in human colonic cells:
infection and expression in CD4+and CD4" cell lines. AIDS 5:275-281.

273

Onishi, M, K. Nagayoshi, K. Kitamura, H. Hirai, F. Takaku, and H. Nakauchi. 1993.
CD4dull+ hematopoietic progenitor cells in murine bone marrow. Blood 81:32173225.
Oyaizu, N., T. W. McCloskey, S. Than, R. Hu, V. S. Kalyanaraman, and S. Pahwa. 1994.
Cross-linking of CD4 molecules upregulates Fas antigen expression in
lymphocytes by inducing interferon-y and tumor necrosis factor-a secretion.
Blood 84:2622-2631.
Paillard, F., G. Sterkers, G. Bismuth, E. Gomard, and C. Vaquero. 1988. Lymphokine
mRNA and T cell multireceptor mRNA of the Ig super gene family are reciprocally
modulated during human T cell activation. Eur. J. Immunol. 18:1643-1646.
Paillard, F., G. Sterkers, and C. Vaquero. 1990. Transcriptional and post-transcriptional
regulation of TcR, CD4 and CDS gene expression during activation of normal
human T lymphocytes. EMBO J. 9:1867-1872.
Paillard, F., G. Sterkers, and C. Vaquero. 1992. Correlation between up-regulation of
lymphokine mRNA and down-regulation of TcR, CD4, CDS and lek mRNA as
shown by the effect of CsA on activated T lymphocytes. Biochem. Biophys. Res.
Commun. 186:603-611.
Palacios, R., S. Studer, J. Samaridis, and J. Pelkonen. 1989. Thymic epithelial cells
induce in vitro differentiation of pro-T lymphocyte clones into TCRap/T3+ and
TCRy5/T3+cells. EMBO J. 8:4053-4063.
Panajotovova, V., J. Lastovicka, K. Sula, K. Nouza, D. Pokoma, and J. Grimova. 1989.
Thymosin fraction 5. Preclinical study. Cas. Lek. Cesk. 128:1615-1620.
Paquette, Y., L. Doyon, A. Laperriere, Z. Hanna, J. Ball, R. P. Sekaly, and P. Jolicoeur.
1992. A viral long terminal repeat expressed in CD4+CD8+ precursors is
downregulated in mature peripheral CD4'CD8+ or CD4+CD8' T cells. Mol. Cell.
Biol. 12:3522-3530.
Pardoll, D. M., B. J. Fowlkes, J. A. Bluestone, A. Kruisbeek, W. L. Maloy, J. E. Coligan,
and R. H. Schwartz. 1987. Differential expression of two distinct T-cell receptors
during thymocyte development. Nature 326:79-81.
Fames, J. R. 1989. Molecular biology and function of CD4 and CDS. Adv. Immunol.
44:265-311.

274
Patarca, R., J. Schwartz, R. P. Singh, Q. T. Kong, E. Murphy, Y. Anderson, F. Y. W.
Sheng, P. Singh, K. A. Johnson, S. M. Guamagia, T. Durfee, F. Blattner, and H.
Cantor. 1988. Rpt-1, an intracellular protein from helper/inducer T cells that
regulates gene expression of interleukin 2 receptor and human immunodeficiency
virus type 1. Proc. Nad. Acad. Sci. USA 85:2733-2737.
Patarca, R., R. P. Singh, T. Durfee, G. Freeman, F. R. Blattner, and H. Cantor. 1989.
Definition of T-cell specific DNA-binding factors that interact with a 3'-silencer in
the CD4+ T-cell gene Rpt-1. Gene 85:461-469.
Patterson, S., J. Gross, P. Bedford, and S. C. Knight. 1991. Morphology and phenotype
of dendritic cells from peripheral blood and their productive infection with human
immunodeficiency virus type 1. Immunology 72:361-367.
Pauza, C. D. 1987. Regulation of human T lymphocyte gene expression by interleukin 2:
immediate-response genes include the proto-oncogene c-myb. Mol. Cell. Biol.
7:342-348.
Pelchen-Matthews, A., J. E. Armes, and M. Marsh. 1989. Internalization and recycling of
CD4 transfected into HeLa and NIH3T3 cells. EMBO J. 8:3641-3649.
Pelchen-Matthews, A., I. Boulet, D. R. Littman, R. Fagard, and M. Marsh. 1992. The
protein tryosine kinase p56lck inhibits CD4 endocytosis by preventing entry of CD4
into coated pits. J. Cell Biol. 117:279-290.
Perelygina, L. M., N. V. Tomilin, and O. I. Podgomaya. 1987. Alu-family repeat binding
protein from Hela cells which interacts with regulatory region of SV40 virus
genome. Mol. Biol. Rep. 12:111-116.
Perno, C. F., D. A. Cooney, M. J. Currens, G. Rocchi, D. G. Johns, S. Broder, and R.
Yarchoan. 1990. Ability of anti-HIV agents to inhibit HIV replication in
monocyte/macrophages or U937 monocytoid cells under conditions of
enhancement by GM-CSF or anti-HIV antibody. AIDS Res. Hum. Retroviruses
6:1051-1055.
Petrie, H. T., P. Hugo, R. Scollay, and K. Shortman. 1990a. Lineage relationships and
developmental kinetics of immature thymocytes: CD3, CD4, and CDS acquisition
in vivo and in vitro. J. Exp. Med. 172:1583-1588.
Petrie, H. T., M. Pearse, R. Scollay, and K. Shortman. 1990b. Development of immature
thymocytes: Initiation of CD3, CD4, and CDS acquisition parallels downregulation of the interleukin 2 receptor a chain. Eur. J. Immunol. 20:2813-2815.

275

Petrie, H. T., R. Scollay, and K. Shortman. 1992. Commitment to the T cell receptoralpha beta or -gamma delta lineages can occur just prior to the onset of CD4 and
CDS expression among immature thymocytes. Eur. J. Immunol. 22:2185-2188.
Petrie, H. T., A. Strasser, A. W. Harris, P. Hugo, and K. Shortman. 1993. CD4+8' and
CD4'8+ mature thymocytes require different post-selection processing for final
development. J. Immunol. 151:1273-1279.
Pettit, G. R., C. L. Herald, D. I. Doubek, and D. L. Herald. 1982. Isolation and structure
of Bryostatinl. J. Am. Chem. Soc. 104:6846-6848.
Phillips, D. M., and A. S. Bourinbaiar. 1992. Mechansim of HIV spread from
lymphocytes to epithelia. Virology 186:261-273.
Plata, F., B. Autran, L. P. Martins, S. Wain-Hob son, M. Raphael, C. Mayaud, M. Denis,
J. M. Guillon, and P. Debre. 1987. AIDS virus-specific cytotoxic T lymphocytes
in lung disorders. Nature 328:348-351.
Portoles, P., and C. A. Janeway, Jr. 1989. Inhibition of the responses of a cloned CD4+
T cell line to different class IIMHC ligands by anti-CD4 and by anti-receptor Fab
fragments are directly related. Eur. J. Immunol. 19:83-87.
Potts, B. J., W. Maury, and M. A. Martin. 1990. Replication of HTV-l in primary
monocyte cultures. Virology 175:465-476.
Promega Corporation. 1994. CAT enzyme assay system with reporter lysis buffer. Tech.
Bull. No. 84:1-9.
Radford, I. R., R. F. Martin, and L. R. Finch. 1982. Effects of hydroxyurea on DNA
synthesis in mouse L-cells. Biochim. Biophys. Acta 696:145-153.
Radloff, R., W. Bauer, and J. Vinograd. 1967. A dye-buoyant-density method for the
detection and isolation of closed circular duplex DNA: the closed circular DNA in
Hela cells. Proc. Natl. Acad. Sci. USA 57:1514-1521.
Rahemtulla, A., W. P. Fung-Leung, M. W. Schilham, T. M. Kundig, S. R. Sambhara, A.
Narendran, A. Arabian, A. Wakeham, C. J. Paige, and R. M. Zinkemagel. 1991.
Normal development and function of CD8+ cells but markedly decreased helper
cell activity in mice lacking CD4. Nature 353:180-184.
Ramsdell, F., and B. J. Fowlkes. 1989. J. Immunol. Engagement of CD4 and CDS
accessory molecules is required for T cell maturation. 143:1467-1471.
Ratnofsky, S. E., A. Peterson, J. L. Greenstein, and S. J. Burakoff. 1987. Expression and
function of CDS in a murine T cell hybridoma. J. Exp. Med. 166:1747-1757.

276

Reason, D. C., M. Ebisawa, H. Saito, T. Nagakura, and Y. likura. 1990. Interleukin 4
induces CD47CD8 to CD87CD4' transformation of human neonatal T cells by
way of a double positive intermediate. Biochem. Biophys. Res. Commun.
168:830-836.
Reed, J. €., J. D. Alpers, P. C. Nowell, and R. G. Hoover. 1986. Sequential expression
of protooncogenes during lectin-stimulated mitogenesis of normal human
lymphocytes. Proc. Natl. Acad. Sci. USA 83:3982-3986.
Remmers, E. F., J. Q. Yang, and K. B. Marcu. 1986. A negative transcriptional control
element located upstream of the murine c-myc gene. EMBO J. 5:899-904.
Repke, H., E. Barber, S. Ulbricht, K. Buchner, F. Hucho, R. Kopp, H. Scholz, C. E.
Rudd, and W. A. Haseltine. 1992. Ganglioside-induced CD4 endocytosis occurs
independent of serine phosphorylation and is accompanied by dissociation of
p56lck. J. Immunol. 149:2585-2591.
Rich, A., A. Nordheim, and A. H. Wang. 1984. The chemistry and biology of lefthanded Z-DNA. Ann. Rev. Biochem. 53:791-846.
Richardson, B., L. Kahn, E. J. Lovett, and J. Hudson. 1986. Effect of an inhibitor of
DNA methylation on T cells. I. 5-azacytidine induces T4 expression on T8+
T cells. J. Immunol. 137:35-39.
Ritter, M. A. 1978. Embryonic mouse thymus development: stem cell entry and
differentiation. Immunology 34:69-82.
Robey, E. A., B. J. Fowlkes, J. W. Gordon, D. Kioussis, H. von Boehmer, F. Ramsdell,
and R. Axel. 1991. Thymic selection in CDS transgenic mice supports an
instructive model for commitment to a CD4 or CDS lineage. Cell 64:99-107.
Robey, E. A., B. J. Fowlkes, and D. M. Pardoll. 1990. Molecular mechanisms for
lineage committment in T cell development. Semin. Immunol. 2:25-34.
Robey, E., F. Ramsdell, J. Elliott, D. Raulet, D. Kioussis, R. Axel, and B. J. Fowlkes.
1991. Expression of CD4 in transgenic mice alters the specificity of CDS cells for
allogeneic major histocompatibility complex. Proc. Natl. Acad. Sci. USA 88:608612.
Rocha, B., P. Vassalli, and D. Guy-Grand. 1991. The VP repertoire of mouse gut
homodimeric a CD8+ intraepithelial T cell receptor a/p+ lymphocytes reveals a
major extrathymic pathway of T cell differentiation. J. Exp. Med. 173:483-486.

277
Rocha, B., P. Vassalli, and D. Guy-Grand. 1992. The extrathymic T-cell development
pathway. Immunol. Today 13:449-454.
Rojo, J. M., K. Saizawa, and C. A. Janeway Jr. 1989. Physical association of CD4 and
the T-cell receptor can be induced by anti-T cell receptor antibodies. Proc. Natl.
Acad. Sci. USA 86:3311-3315.
Romeo, P. H., M. H. Prandini, V. Joulin, V. Mignotte, M. Prenant, W. Vainchenker, G.
Marguerie, and G. Uzan. 1990. Megakaryocytic and erythrocytic lineages share
specific transcription factors. Nature 344:447-449.
Rosen, C. A., J. G. Sodroski, and W. A. Haseltine. 1985. The location of cis-acting
regulatory sequences in the human T cell lymphotropic virus type IQ (HTLVDI/LAV) long terminal repeat. Cell 41:813-823.
Rudd, C. E., J. N. Trevillyan, L. L. Wong, J. D. Dasgupta, and S. F. Schlossman. 1988.
The CD4 receptor is complexed in detergent lysates to a protein tyrosine kinase
(pp58) from human T lymphocytes. Proc. Natl. Acad. Sci. USA 85:5190-5194.
Ryu, S. E., P. D. Kwong, A. Truneh, T. G. Porter, J. Arthos, M. Rosenberg, X. Dai, N.
H. Xuong, R. Axel, R. W. Sweet, and W. A. Hendrickson. 1990. Crystal
structure of HIV-binding recombinant fragment of CD4. Nature 348:419-426.
Saffer, J. D., and S. J. Thurston. 1989. A negative regulatory element with properties
similar to those of enhancers is contained within an Alu sequence. Mol. Cell. Biol.
9:355-364.
Saggioro, D., C. Sorio, F. Calderazzo, L. Callegaro, M. Panozzo, G. Berton, L. ChiecoBianchi. 1993. Mechanism of action of the monsialoganglioside GM1 as a
modulator of CD4 expression. Evidence that GM1-CD4 interaction triggers
dissociation of p56lck from CD4, and CD4 internalization and degradation. J. Biol.
Chem. 268:1368-1375.
Saito, S., K. Nishikawa, T. Morii, M. Enomoto, N. Narita, K. Motoyoshi, and M. Ichijo.
1993. Cytokine production by CD16-CD56bnght natural killer cells in the human
early pregnancy decidua. Int. Immunol. 5:559-563.
Saizawa, K., J. Rojo, and C. A. Janeway, Jr. 1987. Evidence for a physical association of
CD4 and the CD3:a:P T cell receptor. Nature 328:260-263.
Salahuddin, S. Z., R. M. Rose, J. E. Groopman, P. D. Markham, and R. C. Gallo. 1986.
Human T lymphotrophic virus type III infection of human alveolar macrophages.
Blood 68:281-284.

278
Salmon, P., A. Giovane, B. Wasylyk, and D. Klatzmann. 1993. Characterization of the
human CD4 gene promoter: transcription from the CD4 gene core promoter is
tissue-specific and is activated by Ets proteins. Proc. Natl. Acad. Sci. USA
90:7739-7743.
Salmon, P., R. Olivier, Y. Riviere, E. Brisson, J. C. Gluckman, M. P. Kieny, L.
Montagnier, and D. Klatzmann. 1988. Loss of CD4 membrane expression and
CD4 mRNA during human immunodeficiency virus replication. J. Exp. Med.
168:1953-1969.
Sands, J. F., and J. Nikolic-Zugic. 1992. T cell-specific protein-DNA interactions
occurring at the CD4 locus: identification of possible transcriptional control
elements of the murine CD4 gene. Int. Immunol. 4:1183-1194.
Santi, D. V., A. Norment, and C. E. Garrett. 1984. Covalent bond formation between a
DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl.
Acad. Sci. USA 81:6993-6997.
Savagner, P., B. A. Imhof, K. M. Yamada, and J. P. Thiery. 1986. Homing of
hemopoietic precursor cells to the embryonic thymus: characterization of an
invasive mechanism induced by chemotactic peptides. J. Cell Biol. 103:27152727.
Sawada, M., A. Suzumura, and T. Marunouchi. 1992. Down regulation of CD4
expression in cultured microglia by immunosuppressants and lipopolysaccharide.
Biochem. Biophys. Res. Commun. 189:869-876.
Sawada, S., and D. R. Littman. 1991. Identification of characterization of a T-cell-specific
enhancer adjacent to the murine CD4 gene. Mol. Cell. Biol. 11:5506-5515.
Sawada, S., and D. R. Littman. 1993. A heterodimer of HEB and an E12-related protein
interacts with the CD4 enhancer and regulates its activity in T-cell lines. Mol. Cell.
Biol. 13:5620-5628.
Sawada, S., J. D. Scarborough, N. Killeen, and D. R. Littman. 1994. A lineage-specific
transcriptional silencer regulates CD4 gene expression during T lymphocyte
development. Cell 77:917-929.
Schans, G. P., and J. B. Aten. 1969. Determination of molecular weight distributions of
DNA by means of sedimentation in a sucrose gradient. Anal. Biochem. 32:14-30.
Schild, H., N. Mavaddat, C. Litzenberger, E. W. Ehrich, M. M. Davis, J. A. Bluestone, L.
Matis, R. K. Draper, and Y. H. Chien. 1994. The nature of major
histocompatibility complex recognition by y5 T cells. Cell 76:29-37.

279
Schmitt, D., C. Dezutter-Dambuyant, D. Hanau, H. V. Kilbe, M. P. Kieny, J. P. Cazenave,
and J. Thivolet. 1990. In vitro binding and internalization of HIV envelope
glycoproteins by human epidermal langerhans cells does not require the CD4gp 120-binding site. Res. Virol. 141:209-215.
Scoazec, J. Y., and G. Feldmann. 1990. Both macrophages and endothelial cells of the
human hepatic sinusoid express the CD4 molecule, a receptor for the human
immunodeficiency virus. Hepatology 12:505-510.
Scollay, R., A. Wilson, A. D’Amico, K. Kelly, M. Egerton, M. Pearse, L. Wu, and K.
Shortman. 1988. Developmental status and reconstitution potential of
subpopulations of murine thymocytes. Immunol. Rev. 104:81-120.
Seed, B., and J. Y. Sheen. 1988. A simple phase-extraction assay for chloramphenicol
acyltransferase activity. Gene 67:271-277.
Seki, S., T. Abo, T. Masuda, T. Ohteki, A. Kanno, K. Takeda, H. Rikiishi, H. Nagura, and
K. Kumagai. 1990. Identification of activated T cell receptor y8 lymphocytes in
the liver of tumor-bearing hosts. J. Clin. Invest. 86:409-415.
Seki, S., T. Abo, T. Oheki, K. Sugiura, and K. Kumagai. 1991a. Unusual aP-T cells
expanded in autoimmune Ipr mice are probably a counterpart of normal T cells in
the liver. J. Immunol. 147:1214-1221.
Seki, S., T. Abo, K. Sugiura, T. Ohteki, T. Kobata, H. Yagita, K. Okumura, H. Rikiishi, T.
Masuda, and K. Kumagai. 1991b. Reciprocal T cell responses in the liver and
thymus of mice injected with syngeneic tumor cells. Cell. Immunol. 137:46-60.
Seong, R. H., J. W. Chamberlain, and J. R. Parnes. 1992. Signal for T-cell differentiation
to a CD4 cell lineage is delivered by CD4 transmembrane region and/or
cytoplasmic tail. Nature 356:718-720.
Shahabuddin, M., B. Volsky, M. C. Hsu, and D. J. Volsky. 1992. Restoration of cell
surface CD4 expression in human immunodeficiency virus type 1-infected cells by
treatment with a Tat antagonist. J. Virol. 66:6802-6805.
Shapiro, B. A., R. Nussinov, L. E. Lipkin, and J. V. Maizel, Jr. 1986. A sequence
analysis system encompassing rules for DNA helical distortion. Nucleic Acids
Res. 14:75-86.
Shaw, A. S., K. E. Amrein, C. Hammond, D. F. Stern, B. M. Sefton, and J. K. Rode.
1989. The lek tyrosine protein kinase interacts with the cytoplasmic tail of the CD4
glycoprotein through its unique amino terminal domain. Cell 59:627-636.

280

Shaw, A. S., J. Chalupny, J. A. Whitney, C. Hammond, K. E. Amrein, P. Kavathas, B.
M. Sefton, and J. K. Rose. 1990. Short related sequences in the cytoplasmic
domains of CD4 and CDS mediate binding to the amino-terminal domain of the
p56lck tyrosine protein kinase. Mol. Cell. Biol. 10:1853-1862.
Sheiness, D., and M. Gardinier. 1984. Expression of a proto-oncogene ($voto-myb) in
hematopoietic tissues of mice. Mol. Cell. Biol. 4:1206-1212.
Shin, J., C. Doyle, Z. Yang, D. Kappes, and J. L. Strominger. 1990. Structural features
of the cytoplasmic region of CD4 required for internalization. EMBO J. 9:425434.
Shinkai, Y., S. Koyasu, K. Nakayama, K. M. Murphy, D. Y. Loh, E. L. Reinherz, and F.
W. Alt. 1993. Restoration of T cell development in RAG-2-deficient mice by
functional TCR transgenes. Science 259:822-825.
Simecka, J. W., R. B. Thorp, and G. H. Cassell. 1992. Dendritic cells are present in the
alveolar region of lungs from specific pathogen-free rats. Reg. Immunol. 4:18-24.
Singh, H., R. Sen, D. Baltimore, and P. A. Sharp. 1986. A nuclear factor that binds to a
conserved sequence motif in transcriptional control elements of immunoglobulin
genes. Nature 319:154-158.
Singh, K., M. Carey, S. Saragosti, and M. Botchan. 1985. Expression of enhanced levels
of small RNA polymerase III transcripts encoded by the B2 repeats in simian virus
40-transformed mouse cells. Nature 314:553-556.
Singh, L., S. G. Panicker, R. Nagaraj, and K. C. Majumdar. 1994a. Banded krait minorsatellite (Bkm)-associated Y chromosome-specific repetitive DNA in mouse.
Nucleic Acids Res. 22:2289-2295.
Singh, L., R. Wadhwa, S. Naidu, R. Nagaraj, and M Ganesan. 1994b. Sex- and tissuespecific Bkm (GATA)-binding protein in the germ cells of heterogametic sex. J.
Biol. Chem. 269:25321-25327.
Siu, G., A. L. Wurster, D. D. Duncan, T. M. Soliman, and S. M. Hedrick. 1994. A
transcriptional silencer controls the developmental expression of the CD4 gene.
EMBOJ. 13:3570-3579.
Siu, G., A. L. Wurster, J. S. Lipsick, and S. M. Hedrick. 1992. Expression of the CD4
gene requires a Myb transcription factor. Mol. Cell. Biol. 12:1592-1604.
Skowronski, J., D. Parks, and R. Mariani. 1993. Altered T cell activation and
development in transgenic mice expressing the HIV-1 Nef gene. EMBO J.
12:703-713.

281

Sleckman, B. P., M. Bigby, J. L. Greenstein, S. J. Burakoff, and M. S. Sy. 1989.
Requirements for modulation of the CD4 molecule in response to phorbol
myristate acetate. Role of the cytoplasmic domain. J. Immunol. 142:1457-1462.
Sleckman, B. P., J. Shin, V. E. Igras, T. L. Collins, J. L. Strominger, and S. J. Burakoff.
1992. Disruption of the CD4-p56lck complex is required for rapid internalization of
CD4. Proc. Natl. Acad. Sci. USA 89:7566-7570.
Smith, C. A., G. T. Williams, R. Kingston, E. J. Jenkinson, and J. J. Owen. 1989.
Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature
T cells in thymic cultures. Nature 337:181-184.
Smith, K. J., H. G. Skelton, J. Yeager, R. Ledsky, W. McCarthy, D. Baxter, and K.F.
Wagner. 1994. Cutaneous findings in HIV-1-positive patients: a 42-month
prospective study. Military Medical Consortium for the Advancement of
Retroviral Research (MMCARR). J. Am. Acad. Dermatol. 31:746-754.
Solbach, W. 1982. Tumor-promoting phorbol esters selectively abrogate the expression
of the T4 differentiation antigen expressed on normal and malignant (Sezary)
T helper lymphocytes. J. Exp. Med. 156:1250-1255.
Sorice, M., A. Pavan, R. Misasi, T. Sansolini, T. Garofalo, L. Lenti, G. M. Pontieri, L.
Frati, and M. R. Torrisi. 1995. Monosialoganglioside GM3 induces CD4
internalization in human peripheral blood T lymphocytes. Scand. J. Immunol.
41:148-156.
Sorio, C., D. Saggioro, L. Chieco-Bianchi, and G. Berton. 1993. The
monosialoganglioside GM1 induces internalisation and degradation of the CD4
antigen in U937 cells: evidence for a novel mechansim of CD4 down-modulation
in a p561ck-negative cell line, which is independent of protein kinase C activation.
Biochem. Biophys. Res. Commun. 191:1105-1110.
Sotzik, F., Y. Rosenberg, A. W. Boyd, M. Honeyman, D. Metcalf, R. Scollay, L. Wu, and
K. Shortman. 1994. Assessment of CD4 expression by early T precursor cells
and by dendritic cells in the human thymus. J. Immunol. 152:3370-3377.
Stern, J. B., and K. A. Smith. 1986. Interleukin-2 induction of T-cell Gj progression and
c-w^Z) expression. Science 233:203-233.
Stevenson, B. J., O. Hagenbuchle, and P. K. Wellauer. 1986. Sequence organization and
transcriptional regulation of the mouse elastase II and trypsin genes. Nucleic Acids
Res. 14:8307-8330.

282
Stevenson, M, C. Meier, A. M. Mann, N. Chapman, and A. Wasiak. 1988. Envelope
glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells:
mechanism for persistence in AIDS. Cell 53:483-496.
Suda, T., and A. Zlotnik. 1992. In vitro induction of CDS expression on thymic pre-T
cells. I. Transforming growth factor-beta and tumor necrosis factor-alpha induce
CDS expression on CDS' thymic subsets including the CD25+CD3'CD4'CD8' preT cell subset. J. Immunol. 148:1737-1745.
Swain, S. L. 1981. Significance of Lyt phenotypes: Lyt2 antibodies block activities of
T cells that recognize class 1 major histocompatibility complex antigens regardless
of their function. Proc. Natl. Acad. Sci. USA 78:7101-7105.
Swain, S. L. 1983. T cell subsets and the recognition of MHC class. Immunol. Rev.
74:129-142.
Sztein, M. B., W. R. Cuna, and F. Kierszenbaum. 1990. Trypanosoma cruzi inhibits the
expression of CD3, CD4, CDS, and IL-2R by mitogen-activated helper and
cytotoxic human lymphocytes. J. Immunol. 144:3558-3562.
Tae, H. J., X. Luo, and K. H. Kim. 1994. Roles of CCAAT/enhancer-binding protein and
its binding site on repression and derepression of acetyl-CoA carboxylase gene.
J. Biol. Chem. 269:10475-10484.
Takada, S., and E. G. Engleman. 1987. Evidence for an association between CDS
molecules and the T cell receptor complex on cytotoxic T cells. J. Immunol.
139:3231-3235.
Takahama, Y., and A. Singer. 1992. Post-transcriptional regulation of early T cell
development by T cell receptor signals. Science 258:1456-1462.
Takahashi, K., M. Nakata, T. Tanaka, H. Adachi, H. Nakauchi, H. Yagita, and K.
Okumura. 1992. CD4 and CDS regulate interleukin 2 responses of T cells. Proc.
Natl. Acad. Sci. USA 89:5557-5561.
Taketo, A. 1988. DNA transfection of Escherichia coli by electroporation. Biochim.
Biophys. Acta 949:318-324.
Takimoto, H., T. Nakamura, M. Takeuchi, Y. Sumi, T. Tanaka, K. Nomoto, and Y.
Yoshikai. 1992. Age-associated increase in number of CD4+CD8+ intestinal
intraepithelial lymphocytes in rats. Eur. J. Immunol. 22:159-164.
Tamura, T., J. Mizuguchi, and H. Nariuchi. 1990. Regulatory role of CD4/L3T4
molecules in IL-2 production by affecting intracellular Ca2+ concentration of T cell
clone stimulated with soluble anti-CD3. J. Immunol. 145:78-84.

283

Tatsumi, Y., A. Kumanogoh, M. Saitoh, Y. Mizushima, K. Kimura, S. Suzuki, H.Yagi,
A. Horiuchi, M. Ogata, T. Hamaoka, and J. Fujiwara. 1990. Differentiation of
thymocytes from CD3'CD4'CD8‘ through CD3 CD4'CD8+ into more mature
stages induced by a thymic stromal cell clone. Proc. Natl. Acad. Sci. USA
87:2750-2754.
Taylor, L. D., C. K. Daniels, and D. L. Schmucker. 1992. Ageing compromises
gastrointestinal mucosal immune response in the rhesus monkey. Immunology
75:614-618.
Teh, H. S., P. Kisielow, B. Scott, H. Kishi, Y. Uematsu, H. Bluthmann, and H. von
Boehmer. 1988. Thymic major histocompatibility complex antigens and the aP
T-cell receptor determine the CD4/CD8 phenotype of T cells. Nature 335:229233.
Thoenes, G., C. Soudais, F. le Deist, C. Griscelli, A. Fischer, and B. Lisowska-Grospierre.
1992. Structural analysis of low TCR/CD3 complex expression in T cells of an
immunodeficient patient. J. Biol. Chem. 267:487-493.
Thompson, C. B., P. B. Challoner, P. E. Neiman, and M. Groudine. 1986. Expression of
the c-myb proto-oncogene during cellular proliferation. Nature 319:374-380.
Thompson, S. D., A. R. Manzo, J. Pelkonen, M. Larche, and J. L. Hurwitz. 1991.
Developmental T cell receptor gene rearrangements: relatedness to the a/p and y/5
T cell precursor. Eur. J. Immunol. 21:1939-1950.
Thorey, I. S., G. Cecena, W. Reynolds, and R. G. Oshima. 1993. Alu sequence
involvement in transcriptional insulation of the keratin 18 gene in transgenic mice.
Mol. Cell. Biol. 13:6742-6751.
Tinoco, I., Jr., P. N. Borer, B. Dengler, M. D. Levine, O. C. Uhlenbeck, O. M. Corothers,
and J. Bralla. 1973. Improved estimation of secondary structure in ribonucleic
acids. Nat. New Biol. 264:40-41.
Torelli, G, L. Selleri, A. Donelli, S. Ferrari, G. Emilia, D. Venturelli, L. Moretti, and U.
Torelli. 1985. Activation of c-myb expression by phytohemagglutinin stimulation
in normal human T lymphocytes. Mol. Cell. Biol. 5:2874-2877.
Tourvieille, B., S. D. Gorman, E. H. Field, T. Hunkapiller, and J. R. Parnes. 1986.
Isolation and sequence of L3T4 complementary DNA clones: expression in T cells
and brain. Science 234:610-614.
Travers, A. A. 1992. The reprogramming of transcriptional competence. Cell
69:573-575.

284

Triebel, F., S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevee, E. ViegasPequignot, and T. Hercend. 1990. LAG-3, a novel lymphocyte activation gene
closely related to CD4. J. Exp. Med. 171:1393-1405.
Tripathi, J., and S. K. Brahmachari. 1991. Distribution of simple repetitive (TG/CA)n and
(CT/AG)n sequences in human and rodent genomes. J. Biomol. Struct. Dyn.
9:387-397.
Tschachler, E., V. Groh, M. Popovic, D. L. Mann, K. Konrad, B. Safai, L. Eron, F.
diMarzo-Veronese, K. Wolff, and G. Stingl. 1987. Epidermal Langerhans cells: a
target for HTLY-DI/LAV infection. J. Invest. Dermatol. 88:233-237.
Tucek, C. L., and R. L. Boyd. 1990. Surface expression of CD4 and Thy-1 on mouse
thymic stromal cells. Int. Immunol. 2:593-601.
Tunnacliffe, A., L. Buluwela, and T. H. Rabbitts. 1987. Physical linkage of three CD3
genes on human chromosome 11. EMBO J. 6:2953-2957.
Umiel, T. 1971. Thymus-influenced immunological maturation of embryonic liver cells.
Transplantation 11:531-535.
van Meerwijk, J. P., and R. N. Germain. 1993. Development of mature CD8+
thymocytes: selection rather than instruction? Science 261:911-915.
van Oers, N. S., A. M. Garvin, C. B. Davis, K. A. Forbush, D. A. Carlow, D. R. Littman,
R. M. Perlmutter, and H. S. Teh. 1992. Disruption of CD8-dependent negative
and positive selection of thymocytes is correlated with a decreased asociation
between CDS and the protein tyrosine kinase, p56lck. Eur. J. Immunol. 22:735743.
Veillette, A., N. Abraham, L. Caron, and D. Davidson. 1991. The lymphocyte-specific
tyrosine kinase p56lck. Semin. Immunol. 3:143-152.
Veillette, A., J. B. Bolen, and M. A. Bookman. 1989a. Alterations in tyrosine protein
phosphorylation induced by antibody-mediated cross-linking of the CD4 receptor
of T lymphocytes. Mol. Cell. Biol. 9:4441-4446.
Veillette, A., M. A. Bookman, E. M. Horak, and J. B. Bolen. 1988. The CD4 and CDS
T cell surface antigens are associated with the internal membrane tyrosine protein
kinase p56lck. Cell 55:301-308.
Veillette, A., M. A. Bookman, E. M. Horak, L. E. Samelson, and J. B. Bolen. 1989b.
Signal transduction through the CD4 receptor involves the activation of the internal
membrane tyrosine-protein kinase p56lck. Nature 338:257-259.

285

Veillette, A., and D. Davidson. 1992. Src-related protein tyrosine kinases and T-cell
receptor signalling. Trends Genet. 8:61-66.
Vidal, F., E. Mougneau, N. Glaichenhaus, P. Vaigot, M. Darmon, and F. Cuzin. 1993.
Coordinated posttranscriptional control of gene expression by modular elements
including Alu-like repetitive sequences. Proc. Nad. Acad. Sci. USA 90:208-212.
Virta-Pearlman, V. J., P. H. Gunaratne, and A. C. Chinault. 1993. Analysis of a
replication initiation sequence from the adenosine deaminase region of the mouse
genome. Mol. Cell. Biol. 13:5931-5942.
von Boehmer, H. 1986. The selection of the a,P heterodimeric T-cell receptor for antigen.
Immunol. Today 7:333-336.
von Boehmer, H. 1988. The developmental biology of T lymphocytes. Annu. Rev.
Immunol. 6:309-326.
von Boehmer, H. 1994. Positive selection of lymphocytes. Cell 76:219-228.
Wallace, V. A., J. Penninger, and T. W. Mak. 1993. CD4, CDS and tyrosine kinases in
thymic selection. Curr. Opin. Immunol. 5:235-240.
Watanabe, H., K. Obtsuka, M. Kimura, Y. Ikarashi, T. Ohmori, A. Kusumi, T. Ohteki, S.
Seki, and T. Abo. 1992a. Details of an isolation method for hepatic lymphocytes
in mice. J. Immunol. Methods 146:145-154.
Watanabe, Y., O. Mazda, Y. Aiba, K. Iwai, J. Gyotoku, S. Ideyama, J. Miyazaki, and Y.
Katsura. 1992b. A murine thymic stromal cell line which may support the
differentiation of CD4'8‘ thymocytes into CD4+8' alpha beta T cell receptor positive
T cells. Cell. Immunol. 142:385-397.
Wang, C. Y., A. G. Bassuk, L. H. Boise, C. B. Thompson, R. Bravo, and J. M. Leiden.
1994. Activation of the granulocyte-macrophage colony-stimulating factor
promoter in T cells requires cooperative binding of Elf-1 and Ap-1 transcription
factors. Mol. Cell. Biol. 14:1153-1159.
Wang, J. J., C. Hu, F. Lee, M. F. Shaio, and L. K. Chen. 1992. Internalization of CD4
molecules in human T-cells demonstrated by immuno-electron microscopy.
Histochemistry 97:51-59.
Wang, I, Y. Yan, T. P. J. Garrett, J. Liu, D. W. Rodgers, R. L. Garlick, G. E. Tarr, Y.
Husain, E. L. Reinherz, and S. C. Harrison. 1990. Atomic structure of a fragment
of human CD4 containing two immunoglobulin-like domains. Nature 348:411418.

286

Wang, P. T., M. Bigby, and M. S. Sy. 1987. Selective down modulation of L3T4
molecules on murine thymocytes by the tumor promoter phorbol 12-myristate 13acetate. J. Immunol. 139:2157-2165.
Wasylyk, B., C. Wasylyk, P. Flores, A. Begue, D. Leprince, and D. Stehelin. 1990. The
c-ets proto-oncogenes encode transcription factors that cooperate with c-fos and cjun for transcriptional activation. Nature 346:191-193.
Weinand, U., Z. Schwarz, and G. Felix. 1978. Electrophoretic elution of nucleic acids
from gels adapted for subsequent biological tests: application for analysis of
mRNAs from maize endosperm. FEBS Lett. 98:319-323.
Weiss, A. 1993. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic
protein-tyrosine kinases. Cell 73:209-212.
Weissman, I. L. 1994. Developmental switches in the immune system. Cell 76:207218.
Weissman, J. D., and D. S. Singer. 1991. A complex regulatory DNA element associated
with a major histocompatibility complex class I gene consists of both a silencer and
an enhancer. Mol. Cell. Biol. 11:4217-4227.
Wells, R. D. 1988. Unusual DNA structures. J. Biol. Chem. 263:1095-1098.
Weyand, C. M., J. Goronzy, and C. G. Fathman. 1987. Modulation of CD4 by antigenic
stimulation. J. Immunol. 138:1351-1356.
Whisler, R. L., and A. J. Yates. 1980. Regulation of lymphocyte responses by human
gangliosides: characteristics of inhibitory effects and the induction of impaired
activation. J. Immunol. 125:2106-2111.
Wilkinson, M. F., J. Doskow, R. von Borstel II, A. M. Fong, and C. L. MacLeod. 1991a.
The expression of several T cell-specific and novel genes is repressed by trans
acting factors in immature T lymphoma clones. J. Exp. Med. 174:269-280.
Wilkinson, M. F., A. M. Fong, H. Huynh, E. F. Hays, and C. L. MacLeod. 1991b. A
model system for T-lymphocyte differentiation: regulation of CD4 and CDS gene
expression in SL12.4 T-lymphoma cell clones. Mol. Immunol. 28:57-68.
Willey, R. L., F. Maldarelli, M. A. Martin, and K. Strebel. 1992. Human
immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4.
J. Virol. 66:7193-7200.

287
Wilson, A., H. T. Petrie, R. Shortman, and K. Shortman. 1989. The acquisition of CD4
and CDS during the differentiation of early thymocytes in short-term culture. Int.
Immunol. 1:605-612.
Wineman, J. P., G. L. Gilmore, C. Gritzmacher, B. E. Torbett, and C. E. Muller-Sieburg.
1992. CD4 is expressed on murine pluripotent hematopoietic stem cells. Blood
80:1717-1724.
Winoto, A., and D. Baltimore. 1989a. Separate lineages to T cells expressing the ap and
y6 receptors. Nature 338:430-432.
Winoto, A., and D. Baltimore. 1989b. ap lineage specific expression of the a T cell
receptor gene by nearby enhancers. Cell 59:649-655.
Wood, G. S., N. L. Warner, and R. A. Wamke. 1983. Anti-Leu-3/T4 antibodies react with
cells of monocyte/macrophage and Langerhans lineage. J. Immunol. 131:212216.
Wong, A. K. C., H. A. Yee, J. H. van de Sande, and J. B. Rattner. 1990. Distribution of
CT-rich tracts is conserved in vertebrate chromosomes. Chromosoma 99:344351.
Wong, G. 1991. Studies on the structure and expression of the human CD4 gene. Ph.D.
thesis. Cornell University Graduate School of Medical Sciences, New York.
Wu, J., G. J. Grindlay, P. Bushel, L. Mendelsohn, and M. Allan. 1990. Negative
regulation of the human e-globin gene by transcriptional interference: role of an
Alu repetitive element. Mol. Cell. Biol. 10:1209-1216.
Wu, L., M. Antica, G. R. Johnson, R. Scollay, and K. Shortman. 1991a. Developmental
potential of the earliest precursor cells from the adult mouse thymus. J. Exp. Med.
174:1617-1627.
Wu, L., R. Scollay, M. Egerton, M. Pearse, G. J. Spangrude, and K. Shortman. 1991b.
CD4 expressed on earliest T-lineage precursor cells in the adult murine thymus.
Nature 349:71-74.
Wurster, A. L., G. Siu, J. M. Leiden, and S. M. Hedrick. 1994. Elf-1 binds to a critical
element in a second CD4 enhancer. Mol. Cell. Biol. 14:6452-6463.
Xu, H., and D. R. Littman. 1993. A kinase-independent function of Lck in potentiating
antigen-specific T cell activation. Cell 74:633-643.

288

Yahi, N., S. Baghdiguian, H. Moreau, and J. Fantini. 1992. Galactosyl ceramide (or a
highly related molecule) is the receptor for human immunodeficiency virus type 1
on human colon epithelial HT-29 cells. J. Virol. 66:4848-4854.
Yamamoto, M., L. J. Ko, M. W. Leonard, H. Beug, S. H. Orkin, and J. D. Engel. 1990.
Activity and tissue-specific expression of the transcription factor NF-E1 multigene
family. Genes and Dev. 4:1650-1662.
Ye, J., P. Ghosh, M. Cippitelli, J. Subleski, K. J. Hardy, J. R. Ortaldo, and H. A. Young.
1994. Characterization of a silencer regulatoiy element in the human interferon-y
promoter. J. Biol. Chem. 41:25728-25734.
Yi, T., J. L. Cleveland, and J. N. Ihle. 1992a. Protein tyrosine phosphatase containing
SH2 domains: characterization, preferential expression in hematopoietic cells, and
localization to human chromosome 12pl2-pl3. Mol. Cell. Biol. 12:836-846.
Yi, T., D. J. Gilbert, N. A. Jenkins, N. G. Copeland, and J.N. Ihle. 1992. Assignment of
a novel protein tyrosine phosphatase gene (Hcph) to mouse chromosome 6.
Genomics 14:793-795.
Yoshida, H., Y. Koga, K. Nakamura, G. Kimura, and K. Nomoto. 1992. A lymphocytespecific protein tyrosine kinase, p56lck, regulates the PMA-induced internalization
ofCD4. Biochim. Biophys. Acta 1137:321-330.
Yu, M., and H. J. Edenberg. 1995. Structure and function of a long alternating purinepyrimidine sequence in the mouse alcohol dehydrogenase Adh-1 gene. Arch.
Biochem. Biophys. 316:407-412.
Yuille, M. A. R., M. Hugunin, P. John, L. Peer, L. V. Sacks, B. J. Poiesz, R. H. Tomar,
and A. E. Silverstone. 1988. HIV-1 infection abolishes CD4 biosynthesis but not
CD4 mRNA. J. AIDS 1:131-137.
Zamoyska, R., P. Derham, S. D. Gorman, P. von Hoegen, J. B. Bolen, A. Veillette, and J.
R. Parnes. 1989. Inability of CD8a‘ polypeptides to associate with p56lck
correlates with impaired in vitro and lack of expression in vivo. Nature 342:278281.
Zimecki, M., and Z. Wieczorek. 1989. Functional maturation of thymocytes: recruitment
of helper cells in the humoral immune response to SRBC in vitro by recombinant
interleukin 1 (IL-1). Arch. Immunol. Ther. Exp. 37:331-338.
Zlatanova, J. S., and K. E. van Holde. 1992. Chromatin loops and transcriptional
regulation. Crit. Rev. Eukaryot. Gene Expr. 2:211-224.

UNIVERSITY library
LOMA LINDA, CALIFORNIA

289

Zuniga-Pflucker, J. C., L. A. Jones, D. L. Longo, and A. M. Kruisbeek. 1989a. Both
TCR/MHC and accessory molecule/MHC interactions are required for positive and
negative selection of mature T cells in the thymus. Cold Spring Harbor Symp.
Quant. Biol. 54:153-158.
Zuniga-Pflucker, J. C., S. A. McCarthy, M. Weston, D. L. Longo, A. Singer, and A. M.
Kruisbeek. 1989b. Role of CD4 in thymocyte selection and maturation. J. Exp.
Med. 169:2085-2096.

